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ABSTRACT 
During synthesis Von Willebrand Factor (VWF) undergoes O-linked glycosylation 
(OLG) but the functional significance of this has not been fully explored. In this study 
the 10 OLG sites in VWF were mutated to alanine, individually and as clusters on either 
or both sides of the A1 domain: Clus-1 (N-terminal side), Clus-2 (C-terminal side) and 
double cluster (DC). All mutants demonstrated normal expression, multimeric structure 
and collagen and heparin binding functions. Furthermore, mass spectroscopy analysis 
showed that the OLG structures presented on recombinant VWF were similar in 
structure to those on plasma derived VWF including the presence of a rare disialosyl 
motif. The variants T1486 (C-terminal side of the A1 domain), Clus-2 and DC were less 
susceptible to ADAMTS13 proteolysis under static and pseudo-shear stress conditions 
and showed increased binding to ADAMTS13 when in solution. Using an optimised 
plate-based ELISA assay, it was demonstrated that mutation of the OLG sites on the N-
terminal side of the VWF-A1 domain enhanced sensitivity to ristocetin-mediated 
binding to recombinant GPIbα. Increased GPIbα binding was also observed with 
desialylated VWF and this effect was attributed to sialic acid residues on the OLGs. 
Similar results were obtained using the conventional ristocetin cofactor assay. To 
further investigate these findings, an in vitro flow assay was optimised to analyse the 
interaction of VWF and platelets under shear stress. Mutation of the OLG sites on the 
N-terminal side of the A1 domain, increased platelet rolling velocity but did not 
significantly alter the dissociation rate of the VWF-A1:GPIbα bond. However, they did 
decrease the number of transient tethering events as a function of time when VWF was 
immobilised directly on to the flow surface. Interestingly, when compared with wtVWF 
the T1255A and Clus-1 variants mediated increased platelet capture to collagen under 
high shear stress.  
The data presented in this thesis demonstrates that the OLG clustered at the C-terminal 
side of the A1 domain alter susceptibility of VWF to ADAMTS13 cleavage. Whilst 
OLGs clustered at the N-terminal side of A1 modulate its interaction with GPIbα both 
under static and shear conditions. A unifying hypothesis would be that VWF OLG alter 
conformational stability around the A1 domain and modulate its interactions with 
adjacent domains and with other molecules. However different effects may predominate 
under static and flow conditions. Importantly, VWF-platelet interaction in flow assays 
depends on the way VWF has been immobilised.  
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1 INTRODUCTION  
1.1 Overview of haemostasis 
Haemostasis is a regulated response to maintaining blood flow within the vascular 
system; preventing blood loss at sites of vessel injury but at the same time maintaining 
blood fluidity. Haemostasis is maintained by several complex interactions between 
vessel walls, platelets and plasma proteins. The first stage of the haemostatic system, 
called primary haemostasis, is initiated by exposure of blood to the subendothelium and 
results in the formation of a platelet-rich plug. Platelets adhere to the subendothelial 
matrix and temporarily limit blood loss. The platelet plug is stabilised through the 
coagulation cascade which results in the generation of thrombin, which converts 
fibrinogen into fibrin which stabilises the platelet plug into a stable haemostatic clot. At 
the same time the fibrinolytic system and healing mechanisms ares activated which 
ultimately remove they clot and repair the tissue.  
1.2 Von Willebrand factor  
Von Willebrand factor (VWF) is a multimeric plasma glycoprotein that plays a critical 
role in facilitating primary haemostasis. Firstly, VWF supports platelet adhesion and 
aggregation at sites of vascular injury.1 Secondly VWF acts as the carrier protein for 
blood coagulation Factor VIII (FVIII) being crucial for its survival in the circulation by 
protecting it from proteolytic degradation.2 VWF is synthesised and stored in 
endothelial cells and megakaryocytes and is released into the plasma as a series of 
multimers with a molecular weight ranging from 500 to 20000kDa, with the largest 
multimers being the most haemostatically active.  
1.3 VWF gene structure and transcriptional regulation  
The 178-kilo base pair (kb) gene encoding VWF is localised on the short arm of 
chromosome 12 (12p13.2). The 8.7 kb messenger RNA (mRNA) is spliced from 52 
exons.3 Exon 1 represents a 5’ untranslated sequence exons 2-18 encode signal and 
propeptide sequences and exons 19-52 encode for the mature VWF subunit.3,4 A non-
processed VWF pseudogene is located on chromosome 22 (22q11) which is ~29kb in 
length, spanning exons 23-34 of the functional VWF gene and has 97% sequence 
homology.5,6 The VWF pseudogene contains multiple stop codons, indicating that it is 
not a functional human gene.5 
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Regulation of VWF gene expression has been investigated using the promoter sequence 
linked to a reporter gene.7 The promoter sequence encompassed base pairs (bp) -487 to 
+247 (numbered relative to the transcription start site) and was able to mediate 
endothelial specific expression of the reporter gene. Deletion analysis demonstrated that 
a 112bp fragment ( -90 to +22), contained core promoter activity.7,8 A core promoter 
sequence TATA box is present at a position +30 and a CCAAT box (transcription factor 
binding site) is located +8bp downstream of the TATA box. Deletion analysis also 
established a strong silencer sequence upstream of the core promoter at base pairs -487 
to -312 that is activated by an NF-1 protein that was shown by DNA footprint analysis 
to interact with nucleotides -440 to -470.9    
The effect of the silencer sequence is counteracted by transcription factors of the GATA 
family, which bind to a positive regulatory sequence in exon 1, at bp +150 to +247.  
This positive regulatory element is able to overcome the effect of the silencer region and 
also endothelial cell (EC) specificity on the core promoter.7 DNA sequence analysis of 
the positive regulatory sequence predicted a GATA binding site at +222 and an SP1 
binding site at +180. Mutation of the SP1 site did not influence transcriptional activity, 
but mutation of the GATA site caused significant reduction of reporter gene expression, 
demonstrating the positive regulatory sequence with an intact GATA binding site is 
required to active VWF gene expression in EC.7 Finally another negatively regulatory 
element has been located in the region -89 to +244, that is able to bind the Oct-1 
transcriptional repressor.8 
1.3.1 VWF synthesis and processing  
VWF is synthesised exclusively in endothelial cells and megakaryocytes,10 with the 
majority of plasma VWF being derived from endothelial cells.11 Following transcription 
pre-pro VWF is synthesised and is composed of a 21 amino-acid N-terminal signal 
peptide, a 741 amino acid pro-peptide and a 2050 amino acid mature protein. 
Numbering of VWF is taken from the first ATG start codon of the signal peptide. Pre-
pro VWF undergoes complex co- and posttranslational modifications (Figure 1.1). The 
signal peptide directs pre-pro-VWF to the rough endoplasmic reticulum (RER) where 
the signal peptide is cleaved and 16 N-linked high mannose oligosaccharides are added 
to each pro-VWF monomer.12 VWF dimers are formed by formation of disulphide 
bonds between C-terminal subunits of VWF monomers (Figure 1.2)13,14 N-linked 
glycosylation is necessary for dimerisation to occur, since treatment of endothelial cells 
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with Tunicamycin, an antibiotic that prevents N-linked glycosylation results in the 
accumulation of pro-VWF monomers in the ER.15-17 Monomeric VWF is retained in the 
ER by binding to ER regulatory proteins, such as BiP, and is subsequently degraded.16,18 
VWF dimers are transported to the Golgi apparatus where N-linked glycans are 
modified to produce complex type carbohydrates. Mannose residues are trimmed while                                     
N-acetylgalactosamine and galactose residues are added.19 Further carbohydrate 
processing including the addition of terminal sialic acids and blood group antigens can 
take place in the trans-Golgi network (TGN) where the A, B and H blood group 
glycosyltransferases are present.20 In addition, 10 O-linked glycan chains are added to 
pro-VWF in the Golgi.12 In the trans-Golgi network (TNG) VWF undergoes sulphation, 
however inhibition of this process does not affect VWF multimerisation, storage or 
stability.21 Finally, multimerisation of pro-VWF dimers occurs in the TGN (Figure 1.2). 
Multimer assembly involves intermolecular disulphide bond formation between 
cysteines in the N-terminal part of the pro-VWF.14,22 The presence of calcium and the 
acidic pH (6.2) of the TGN 18 as well as the presence of the propeptide16 are crucial for 
multimerisation. Treatment of human umbilical vein endothelial cells (HUVEC’s) with 
chelating agents or ammonium chloride which increases pH within acidic organelles 
was demonstrated to inhibit VWF multimerisation.16,23 Co-transfection of cells with 
sequences encoding the VWF propeptide and VWF with the propeptide sequence 
deleted, resulted in the secretion of fully multimerised VWF, demonstrating that the 
propeptide does not need to be a continuous part of the VWF structure. It is 
hypothesised that the propeptide has intermolecular protein disulphide isomerase (PDI)-
like enzyme activity, acting as chaperone in a low-pH-dependent oxidoreductase 
reaction to promote disulphide bond formation.24 The VWF propeptide is cleaved in the 
TGN by the enzyme furin which recognises a positively charged sequence downstream 
of the Arg763-Ser764 cleavage site.25-27 Mutations in this region result in incomplete 
removal of the propeptide, and impaired factor FVIII binding.28 The propeptide 
(previously also known as VWF AgII) remains non-covalently associated with mature 
VWF until they are both secreted into  plasma.29 In addition, the propeptide is also 
necessary for targeting VWF to storage granules and for their formation.30-32  
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Figure 1.1. Posttranslational modifications of VWF 
Following translation VWF undergoes extensive modifications in the endoplasmic 
reticulum and Golgi network prior to being stored or released. These include 
glycosylation, including the addition of ABO blood sugars, dimerisation and 
multimerisation, and finally proteolytic cleavage of the propeptide. 
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Figure 1.2.Dimerisation and multimerisation of VWF 
Within the ER, VWF dimers are formed by formation of disulphide bonds between C-
terminal subunits of VWF monomers. Multimerisation of VWF pro-VWF dimers occurs 
in the trans-Golgi network, and involves intermolecular disulphide bond formation 
between cysteines in the N-terminal part of the pro-VWF. Subsequently the VWF 
propeptide is cleaved by furin and remains non-covalently associated with mature 
VWF.  
1.3.2 Tissue Distribution and sites of synthesis 
As discussed, VWF biosynthesis is limited to endothelial cells and megakaryocytes. 
Analysis of VWF expression in mice using quantitative RT-PCR and in-situ 
hybridisation analysis, demonstrated endothelial cells derived from the spleen, aorta and 
lung had the highest levels of VWF mRNA, while liver, gut and kidney endothelial cells 
expressed relatively less VWF mRNA. In addition, higher levels of VWF mRNA were 
detected in endothelium of larger vessels compared to microvessels, and in venous 
compared to arterial endothelial cells.33 Similarly VWF protein was predominantly 
located in the endothelium of larger vessels.34 Immunohistochemistry performed on 
porcine blood vessels detected VWF in all venous endothelium, except the pulmonary 
vein. However, VWF was absent from the majority of arterial endothelial cells, except 
the distal abdominal aorta, the vasa vasorum of the thoracic aorta and the pulmonary 
artery.35 The reason for a variable tissue distribution of VWF has not been explained 
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although it has been postulated that VWF can a play a role in controlling haemostasis in 
a vascular bed-specific manner.36,37 A porcine model with hereditary VWF deficiency 
was utilized to show that, following total body irradiation, transplantation of normal 
bone marrow restores a normal platelet count, but does not reinstate the plasma VWF 
pool.11 VWF circulates in plasma at a concentration of ~10μg/ml with a half-life of ~12 
hours.38 
1.4 VWF storage and secretion  
The endothelial mature VWF can be either secreted constitutively or stored in Weibel-
Palade bodies (WPBs),39 whereas megakaryocyte VWF is stored in the α-granules of 
platelets and is released only upon platelet activation.40,41 WPBs are large cigar-shaped, 
regulated secretory organelles that originate from the TGN.42-45 They are unique to the 
vascular endothelium but their distribution varies between endothelial beds, with 
highest numbers present in the pulmonary artery.33,46 WPBs are 100-200nm in diameter 
and 1-5µm in length, with a uniform pattern of longitudinal striations37,45 which 
represent high molecular weight VWF filaments organised into helical tubules.47,48  The 
tubular shape of the WPBs is required for the orderly secretion and haemostatic function 
of VWF.49 In addition to VWF a number of other proteins have been shown to be stored 
in WPBs: Factor VIII, P-Selectin, Endothelin, CD36/lamp3, Interlukin-8, α1,3-
Fucosyltransferase VI, tissue-type plasminogen activator, angiopoietin-2 and 
osteoprotegerin,29,50-56 suggesting that secretion from these organelles can contribute to 
the regulation of haemostasis, inflammation and angiogenesis.  
 
VWF is essential for WPB formation, since in its absence endothelial cells do not form   
WPBs.57,58 What is more, the expression of VWF in cell lines that normally do not 
express VWF such as human embryonic kidney 293 cells (HEK293) can result in the 
generation of organelles that are identical to WPBs.31,49 Likewise, endothelial cells 
isolated from a type 3 VWD dog that lack WPBs, were able to re-establish WPB 
formation when transfected with VWF.58 The propeptide is essential for WPB formation 
32 and WPB-like tubules can be assembled in vitro from VWF propeptide and dimeric 
N-terminal domains of VWF only.47 Interestingly, the VWF propeptide is also able to 
target unrelated proteins to storage granules.59  In addition to VWF, clathrin associated 
adaptor protein complex AP-1 is another factor crucial for the formation of WPBs.60  
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Endothelial exocytosis is one of the earliest reactions to vascular injury and plays an 
important role in thrombosis and inflammation. Regulated secretion from WPBs 
involves their translocation from the cytoplasm and fusion with the plasma membrane. 
The exocytosis of VWF generally requires an intra-endothelial rise in Ca2+ or cAMP 
and can be induced by number of secretagogues including thrombin, histamine, vascular 
endothelial growth factor (VEGF), vasopresin, epinephrine or serotonin.61-66 For 
example, following vascular injury, thrombin induces a rapid, local response involving 
elevation of intracellular Ca2+ levels that results in WPB exocytosis,67 whilst 
epinephrine induces cAMP-dependent release of VWF following physical activity and 
other acute stresses.68,69 Additionally, factors such as shear stress or hypoxia have also 
been shown to trigger VWF secretion.70,71 What is more, secretion from WBP can be 
induced artificially, for instance, the vasopressin analogue DDAVP (1-deamino-8-D-
arginine vasopressin) is used in the clinical treatment of VWD and several other 
bleeding disorders to increase the pool of circulating VWF.72 A variety of diverse 
agonists can trigger exocytosis, whilst the only factors described to inhibit WPBs 
exocytosis are nitric oxide (NO)73,74 and hydrogen peroxide.75 By limiting exocytosis 
those two factor can inhibit vascular inflammation and their roles might be important in 
haemostasis since excessive endothelial exocytosis has been linked to inflammatory and 
thrombotic disorders such as atherosclerosis and acute coronary syndromes.74,76,77 
Vascular inflammation and atherosclerosis were more severe in mice strains lacking 
endothelial NO synthase(eNOS),78,79 and the inability to synthesise NO is a risk factor 
for the development of atherosclerosis.80,81 Moreover, it has been shown that deficiency 
of eNOS and therefore lack of NO in mice results in endothelial VWF release and leads 
to development of thrombotic microangiopathy.82 
Several pathways have been proposed to facilitate release of WPB contents under 
different pathophysiological conditions such as injury or inflammation.  Initially it has 
been demonstrated that WPBs can employ two types of exocytosis; full-collapse and a 
slow form of ‘kiss-and-run’ (‘lingering kiss’), with the second type allowing for the 
selective release of small molecules other than VWF.83 However, in a recent study 
another type of exocytosis, multigranular exocytosis, has been identified and proposed 
as a key pathway of VWF secretion. In this study, a novel membrane surrounded 
structure (‘secretory pod’) was identified as the site of WPB’s coalescence and VWF 
exocytosis. In addition, small cytoplasmic vesicles were shown to mediate the fusion of 
WPBs with these secretory pods prior to VWF secretion. The authors suggest this 
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homotypic fusion of secretory granules prior to regulated exocytosis may facilitate 
VWF string formation by pooling the content of multiple WPBs.84 
To date it has been generally accepted that majority of newly synthesised VWF is 
spontaneously released from non-stimulated endothelial cells through a constitutive 
pathway and only 5-10% of VWF is stored in WPBs.38,85-87 However a recent study has 
shown that blocking the constitutive secretion has only a minor effect on the 
spontaneous release of VWF, suggesting that majority of VWF was sorted into WPBs 
and subsequently secreted without the requirement for cell stimulation. This 
spontaneous release of VWF that has been firstly sorted into the regulated secretory 
pathway is called basal secretion.88 It has been demonstrated that 80% of VWF 
spontaneously released from cultured human umbilical vein endothelial cells (HUVEC) 
was via the basal secretion pathway. This data suggests that VWF is sorted to the 
regulated secretory pathway in endothelial cells more efficiently than previously 
reported.88 
1.5 VWF structure and function 
Mature VWF is assembled from 250kDa subunits into haemostatically active multimers 
of variable size ranging from 500 to 20000kDa, with the larger multimers having the 
greatest haemostatic potential. Each pro-VWF monomer is comprised of four types of 
homologous repeating domains arranged in the sequence:  
                       NH2-D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK-COOH  
 
 
 
33 
 
 
Figure 1.3. Domain structure of VWF 
VWF is comprised of four homologous repeating domains: four D domains, a truncated 
D’ domain, three A domains, three B domains, two C domains and a cysteine knot (CK) 
domain arranged as shown. Binding sites for platelet receptors, collagen, and other 
ligands as well as the ADAMTS13 cleavage site are indicated. VWF dimers are formed 
by intramolecular disulphide bonds at the C-terminus and multimers are form by 
intramolecular disulphide bonds at the N terminus. 
 
1.5.1 VWF tertiary structure  
Electron microscopy and atomic force microscopy techniques have been used to 
visualise the overall structure of VWF and two conformations of multimeric VWF were 
identified. Firstly in the absence of shear VWF appears as a loosely coiled mass of 
VWF multimers (‘ball of yarn’ or globular VWF conformation). However, when 
subjected to the critical shear stress of 35dyn/cm2 VWF multimers undergo 
conformational change from a globular state to an extended conformation and appear as 
uncoiled filamentous structures- (elongated VWF).89,90 As will be discussed later this 
structural transition is essential for exposure of various binding sites and VWF 
interactions with receptors, therefore for VWF physiological functions.89 The 
unravelling effect of shear stress on VWF structure can be imitated in vitro by 
denaturants such as urea and guanidine-HCl or modulators such as the antibiotic 
ristocetin or the snake venom botrocetin; however it is unlikely that these fully 
reproduce the conditions in vivo.  
Numerous studies using electron90-92 and atomic force89,93,94 microscopy demonstrate 
that VWF multimers are flexible strands of various sizes containing globular domains 
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joined by rod-like connecting structures. A multimeric strand encompasses several 
dimeric core units or protomers, which are linked by N-terminal disulphide bonds. The 
protomeric dimers represent two VWF monomers connected end-to-end via the C-
terminal disulphide bond. Tapping mode atomic force microscopy was recently used to 
visualise and compare the structure of recombinant and plasma derived (r & pd) VWF.94  
The minimum multimer size of pd and rVWF was determined to be 53 and 25nm 
respectively, while the maximum size was 693nm for pdVWF and 910mm for rVWF. 
Approximately 70% of multimers analysed were in the range from 100 to 300nm. 94 The 
diameters of the globular core repeating subunits of pdVWF and rVWF multimers were 
shown to be around 18.6nm and 20.3nm respectively. The diameter of the globular core 
of VWF dimer, was shown to be in the same range (~22.3nm) as that of multimeric 
VWF. In addition, the elongated rVWF structure was analysed following exposure to 
shear stress. Completely extended molecules lengths were in the range of 2300 to 
28000nm, and the diameter of the core was around 19.3nm. The length of elongated 
rVWF was similar to the length of extended pdVWF determined in another EM study.90  
Elongated pdVWF reaching 15µm was previously described, however this probably 
corresponded to the VWF aggregates rather than individual multimers, since the study 
used a low-resolution fluorescence microscopy.95 Interestingly, hydrophobicity of the 
surface was shown to influence the structure of VWF. On hydrophobic surfaces, VWF 
displayed a compact tertiary structure, while on hydrophilic surface it appeared in an 
extended structure.93  
1.5.2 The D domains  
VWF has four D domains, each comprised of 360 amino acids, as well as the D’ domain 
which is 97 amino acids long.96 D domains have a significant sequence homology and 
all are rich in cysteine residues.1,97 The position of the majority of the cysteine residues 
is conserved, suggesting that D domains have a similar tertiary structure.96  
The propeptide D1 and D2 domains (residues R34-S746) are essential for the formation 
of multimers as well as for VWF direction to storage 18,30-32 and they are removed from 
the mature VWF as previously described. Furthermore, the highly cysteine-rich VWF 
propeptide has internal protein disulphide isomerase activity and functions as an 
intramolecular chaperone by positioning VWF into the correct orientation, thereby 
enabling proper intermolecular disulphide bond formation. 98 The integrity of the 
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propeptide is essential for its functional activity and deletion of either the D1 or D2 
domain prevents VWF multimerisation30. In addition, several naturally occurring 
mutations in the VWF propeptide, impair its function and result in defective VWF 
multimerisation (T87S,98 R273W,99 N528S,100 G550R,101 C623W102 and 625insG102).  
The D' and D3 (residues P769-L1242) form the N-terminal portion of mature VWF 
subunit and contain binding sites for FVIII 103 and P-Selectin55 and are crucial for 
multimer formation, as deletion of either the D' or D3 domain results in the production 
of un-multimerised VWF.22 Moreover, VWF comprised of propeptide, D' and D3 
domains only was able to form intermolecular disulphide bonds, showing that it is the 
only part of VWF involved in multimerisation and that this process is independent of 
dimerisation.22  
What is more, as supported by a number of studies, the VWF D3 domain contains the 
cysteine residues essential for multimer formation.22 For example, when plasma VWF 
was digested with V8-protease and trypsin a dimeric fragment spanning residues 1036-
1491 was generated, while with the flanking regions were monomeric. This illustrated 
that all the intersubunit disulphide bonds must occur within these residues.104 Moreover, 
cysteine residues C1142, C1130, C1149, C1157 and C1234 have been shown to be 
requisite for VWF multimerisation to occur.105-107 In addition, Purvis et al., 
demonstrated that two cysteines at position 1099 and 1143, are essential for the 
oxidoreductase mechanism of VWF multimerisation and may form intersubunit 
disulphide bonds.108 Conversely, the D' domain does not contain cysteine residues 
involved in an intersubunit disulphide bonding, but its correct folding and integrity are 
essential for multimerisation, suggesting it may act as a molecular chaperone in VWF 
multimerisation.109,110 
1.5.2.1 Factor VIII binding  
As mentioned previously, VWF acts as the carrier protein for FVIII, which circulates in 
blood at a concentration of 0.3-0.7nM, non-covalently associated with VWF.2,111  FVIII 
binds VWF with a KD of 0.2 -0.3 nM,112 independently of VWF multimeric size,113 
although the affinity decreases following VWF binding to collagen (KD=5nM).114 FVIII 
is the critical factor in the coagulation cascade, as its deficiency leads to impaired 
generation of activated factor X and results in the severe bleeding disorder haemophilia 
A.111 The survival and the consequent plasma concentration of FVIII are significantly 
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reduced in the absence of VWF,115 since VWF stabilizes the FVIII heterodimeric 
structure,116 protects it from proteolytic degradation by phospholipid-binding proteins 
such as activated protein C,117 inhibits FVIII binding to activated factor IXa118 and stops 
FVIII cellular uptake.119 As will be discussed later it has been demonstrated that FVIII 
can accelerate cleavage of VWF by ADAMTS13 under conditions of shear stress.120  
1.5.2.2  P-selectin binding  
P-selectin is a membrane protein expressed on the surface of activated endothelial cells 
and platelets, stored together with VWF in WPBs.50,121 It has been demonstrated that P-
selectin interaction with D’D3 domains of VWF facilitates its recruitment to WPBs.55 A 
study by Paddila et al., revealed that P-selectin expressed on the apical membrane of 
endothelial cells mediates adhesion of ULWF multimers to the vascular endothelium.122 
which then bind circulating platelets and could support leukocyte tethering and 
rolling.123  
1.5.3 The A domains  
VWF contains three A domains that share ~ 30% homology and span residues 1260-
1874, (A1 domain 1260-1453, A2 domain 1498-1668, A3 domain 1691-1874).124. The 
crystal structures of all three VWF A domains have been determined.125-127 Both the A1 
and A3 domains contain an intramolecular disulphide bond that forms loops of 
approximately 187 residues, the A2 domain lacks this disulphide bond, thus its structure 
is more flexible, which has hindered its crystallisation (Figure 1.4). Nevertheless 
interesting evolutionary adaptations of the A2 domain have been deduced from its 
crystal structure, suggesting it acts as a force-sensing domain.127  In addition the 
intrinsic thermodynamic stability of the VWF A domains against unfolding was studied 
in the presence of urea and the A2 domain was shown to be the least stable and most the 
most susceptible to unfolding.128 
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Figure 1.4 The A domains structure 
In contrast to the A2 domain, both the A1 and A3 domain contain an intramolecular 
disulphide bond between cysteine residues (indicated in yellow), resulting in the 
formation of a loop composed of 187 amino acids. The crystal structures of the three A 
domains have been resolved as shown. Binding sites for GPIbα located in the A1 
domain (in red), collagen type III localised in the A3 domain (in brown), and the 
ADAMTS13 cleavage site (Y1605- M1606) present in the A2 are shown. 
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The A1 domain contains the binding sites for Glycoprotein (GP) Ibα, heparin, cell 
surface sulfatides, and collagens type VI,129-131 type I132 and putatively type III.133 Its 
homologous A3 domain has been shown to bind only to collagens type I and III.134 The 
A2 domain contains the single ADAMTS13 (A Disintegrin And Metalloproteinase with 
ThromboSpondin type-1 repeats 13), cleavage site and the linker region between A1 
and A2 is involved in leukocyte binding.135  
The A1 domain contains, as will be discussed further, the only known VWF binding site 
for platelet glycoprotein receptor GPIbα.136,137 Interaction of VWF with platelets is 
controlled by various mechanisms which are necessary to avoid premature formation of 
platelet aggregates which could occlude the vasculature. In normal conditions in the 
circulation there is no interaction between platelets and VWF, partially due to the fact 
that the platelet binding site within A1 domain is shielded by the adjacent D’-D3 
domains.138 Shear stress and immobilization of VWF both induce conformational 
changes in VWF and lead to exposure of functional sites which enables VWF to bind 
circulating platelets via the GPIb/IV/X complex.14,89,129 To mimic this interaction in 
vitro VWF needs to be treated with modulators such as ristocetin or botrocetin.  
The A1 domain mediates heparin binding,129,139-141 with residues K1362 and R1395 and 
clusters K1332-R1336 and K1405-K1408 being essential for this interaction.142 A 
second minor heparin binding site has been found within the N-terminal residues (M1-
E272) of VWF.92 It has been established that heparin binding is largely independent of 
the multimeric composition of VWF.143 Presence of a heparin binding site may indicate 
that VWF can interact with matrix proteoglycans that contain sulphated carbohydrates. 
Indeed, VWF was reported to bind decorin, a proteoglycan that plays role in the vessel 
wall matrix assembly.144  
VWF can bind to sulfated glycosphingolipids (sulfatides) that are present on cellular 
membranes and may support VWF localisation on injured tissues.145,146 The sulfatide 
binding site has been localised to the A1 domain, and was shown to be different from 
the GPIbα binding site.147,148 Conversely sulfatides have been shown to block ristocetin 
dependent platelet aggregation and platelet adhesion under flow conditions.149  
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1.5.4 The D4 and B domains  
Limited research has been performed to elucidate the role of the D4 and B domains. 
Expression of recombinant VWF with the D4 domain deleted did not alter VWF 
multimeric structure or binding to type III collagen.150 Interestingly, the VWF region 
spanning residues G1874 to K2813 which includes the D4 domain was shown to 
contain a low affinity (KD=86nM) ADAMTS13 binding site.151,152 However, this 
binding site was exposed only when VWF was in globular conformation with the A2 
domain buried.151  
1.5.5 The C domains and the cysteine knot 
The C1, C2, and cysteine knot domains comprise the C-terminal part of the VWF 
monomer. The C1 and C2 domains span residues C2255-L2645 and have sequence 
homology to cysteine rich domains found in thrombospondin and alpha-procollagen 
types I and III.153 The C1 domain contains the RGDS (Arginine-Glycine-Asparagine-
Serine) sequence which is essential for binding to the platelet GPIIb/IIIa receptor 
(integrin α2bβ3) and also to the HUVEC vitronectin receptor (αvβ3).154 In addition, a 
peptide antagonist that binds to the VWF C-terminal domains, specifically inhibiting 
VWF binding to collagen, and consequently suppressing platelet adhesion and 
aggregation, has been identified using a phage display method.155 
The cysteine knot (CK) domain spans the final C-terminal residues of VWF (2724-
2813) and contains the cysteine residues involved in the formation of VWF 
dimers.13,14,156 Given that recombinant VWF with the mutations C2771A and C2773R 
cannot dimerise, these residues are thought to be significant for the dimerisation 
process. What is more, mutations of these residues have been found in some patients 
with type 2A VWD who cannot assemble large multimers.157  
1.6  Collagen binding 
The first step in haemostasis is the interaction of platelets with the exposed extracellular 
matrix at the sites of vascular injury. Collagen is the main component  of the 
subendothelial matrix158 as it accounts for up to 40% of the vessel wall protein contents, 
and provides a scaffold for attachment of other matrix proteins and endothelial cells. 
Several types of collagen have been identified in the human vasculature: types I, III-VI, 
VIII and XII-XIV; with fibrillar collagens type I and III being the major components of 
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blood vessels, and type IV localised in the basement membrane.159,160 Furthermore, 
collagen type III is present in the subendothelium and is exposed following limited 
injury to the vessel wall, while collagen type I is localised deeper in the vessel wall and 
becomes exposed only as a result of an extensive injury. It is well documented that 
platelet recruitment to the site of vascular injury under high shear (>600s-1) requires 
VWF, that binds to exposed collagen and mediates platelet adhesion and activation.159 
VWF binds preferentially to collagen type III and displayed lower affinity for collagens 
type I, II, IV and V under static conditions.161 The VWF A1 and A3 domains have been 
shown to mediate collagen binding, and their respective roles may differ depending on 
the type of collagen engaged, and the shear stress of blood flow.131,133  The VWF-A1 
domain was shown to interact with collagen types I and III162 and contain a major 
binding site for collagen type VI ,130,131 whilst the A3 domain encompasses the principal 
collagen type III binding site134 and can also mediate interaction with collagen type I.162 
Furthermore, the VWF A3 domain was shown to be vital and sufficient for VWF 
binding to fibrillar collagens in vitro since VWF protein lacking the A3 domain showed 
minimal residual collagen binding, with a normal multimeric pattern.134,163,164 
Additionally, mutagenic studies of the VWF A3 domain demonstrated that residues 
N1742, S1783 and H1786 are essential for collagen binding; also residues I1738, 
T1740, V1760, E1764, R1726 and R1779 are important for collagen binding, as their 
alteration decreases collagen binding at least 10 fold.165,166 Together these residues 
define a flat hydrophobic collagen binding site at the front face of the A3 domain.166-168 
Moreover, the analysis of the VWF A3 domain crystal structure suggests that its 
negatively charged residues interact with positively charged residues on collagen.126  
Of note, VWF multimeric size directly correlates with its affinity to collagen, with the 
higher molecular weight VWF multimer exhibiting greater collagen binding affinity, 
with  KD values of 1-7nM on a subunit basis*,150,169 while the recombinant A3 domain 
alone exhibits a weak binding with much higher KD of 2µM.168 Based on the crystal 
studies of the A3 domain its interaction with collagen is achieved due to interaction of 
negatively charged residues on the A3 domain and positively charge residues on 
collagen. The size of the isolated A3 domain limits the number of residues of collagen 
that can interact with the putative collagen interaction surface and the absence of  
                                                          
* To determine the KD for the interaction of VWF with collagen, the monomeric weight of VWF was 
taken as 270kDa 
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pronounced binding grove, which precludes a large van der Waals surface and 
interaction between the A3 domain and collagen and is consistent with low affinity for a 
single A3 domain.126  
It has been demonstrated that the VWF A1 domain can play an important role in VWF 
binding to the injured vascular wall, by interacting with collagen type VI.170 In addition, 
a study has shown that under shear stress the A1 domain can substitute for the A3 
domain in platelet recruitment to collagen fibres.133 Moreover, Morales et al., in their 
studies suggest that binding to collagen via the A3 domain causes a conformational 
change that exposes a cryptic collagen binding site in the A1 domain that increases the 
affinity of VWF for collagen.132 In summary, the synergistic action of A1 and A3 
domains can be crucial to support VWF binding to exposed subendothelial matrix 
containing various collagen types and their roles might vary depending on the shear 
conditions.  
1.7 ADAMTS13   
The VWF A2 domain contains the cleavage site for the VWF cleaving metalloprotease, 
ADAMTS13 (A Disintegrin And Metalloproteinase with ThromboSpondin type-1 
repeats),171 a Zn2+ and Ca2+dependent enzyme and a member of the “the disintegrin and 
metalloprotease with thrombospondin repeats” family.172,173 It is a large multidomain 
glycoprotein, and starting at the N-terminus it is composed of a metalloprotease domain, 
a disintegrin-like domain, a thrombospondin-1-repeat (TSR), a cystein-rich and a spacer 
domains, seven tandem TSRs and two CUB domains [complement components 
C1r/C1s, Uegf (epidermal growth factor-related sea urchin protein) and bone 
morphogenetic protein-1] that are unique for ADAMTS13 (Figure 1.5). ADAMTS13 is 
primarily synthesized in hepatic stellate cells, but also by endothelial cells, and 
megakaryocytes or platelets 174-177 and its plasma concentration in healthy individuals is 
~1μg/ml (5nM)178-180 and the estimated half life is 2-3 days.181 
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Figure 1.5 ADAMTS13 domain structure 
Schematic diagram showing the ADAMTS13 domain structure. ADAMTS13 has a 
signal peptide (S), which is removed upon entry into ER and a propeptide (P). Mature 
ADAMTS13 consists of an N-terminal metalloprotease domain (MP), followed by a 
disintegrin-like domain (Dis), a thrombospondin-1-repeat (TSR), a cystein-rich (Cys-
rich) and a spacer domains (spacer), seven tandem TSRs and two CUB domains.  
 
1.7.1 ADAMTS13 role in the haemostasis 
ADAMTS13 regulates VWF multimeric size and hence its activity by proteolytic 
cleavage of the Y1605- M1606 bond located in the VWF A2 domain.171,182 Although 
ADAMTS13 is constitutively active,183 VWF can be proteolysed only once it undergoes 
substantial changes in its secondary structure that expose the cryptic cleavage site.182 A 
fundamental function of ADAMTS13 is cleavage of hyperactive ultra large (UL)VWF 
multimers anchored at the cell surface following endothelial secretion. This proteolysis 
results in the formation of smaller multimers that have lost the ability to spontaneously 
bind platelets and therefore are no longer prothrombotic but still haemostatically 
active.184,185 The proteolysis of UL-VWF takes place very rapidly and requires      
low,184-186 or almost no shear stress187,188 and once released cleaved VWF fragments 
become inaccessible for ADAMTS13. 
In addition to controlling the size of newly secreted UL-VWF, ADAMTS13 can also 
regulate the size of VWF at the sites of haemostatic plug formation. During platelet plug 
formation VWF binds to the exposed collagen and subsequently unravels due to the 
shear stress exerted by flowing blood. This conformational change of VWF is not only 
essential for platelet capture but also exposes ADAMTS13 cleavage site. However, 
other process involved in primary and secondary haemostasis such as fibrin and platelet 
GPIIbIIIa interaction with fibrinogen, platelet-platelet binding, and fibrin deposition 
also stabilise plug formation and therefore the effect of VWF proteolysis is limited. 
ADAMTS13 can act only at the edges of the developing plug, limiting its growth. This 
mechanism has been confirmed in vivo as increased platelet binding to the 
subendothelium and accelerated thrombus formation were observed following arterial 
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injury in ADAMTS13 deficient mice strain or when ADAMTS13 activity was blocked 
by antibody in wild type animals. This effect was observed to decrease when 
recombinant ADAMTS13 was infused into knockout animals.189 
ADAMTS13 cleaves UL-VWF preferentially due to their greater susceptibility to 
deformation which results in exposure of multiple binding sites within the A domain 
when endothelial bound. Furthermore, UL-VWF multimers are able to bind platelets 
more tightly than smaller multimers and since VWF-platelet complexes are the 
preferred substrates of ADAMTS13 under fluid shear-stress, ULVWF multimers are 
more prone to proteolysis.190  
Another rationale for increased ADAMTS13 proteolysis of endothelial cell-anchored 
UL-VWF emerged when ADAMTS13 was shown to bind to the endothelial cell plasma 
membrane.191 Studies established that ADAMTS13 pre-bound to HUVECS exhibited 
increased proteolysis of VWF when compared to ADAMTS13 present in solution. 
ADAMTS13 binding to endothelial cells was specific, reversible, concentration and 
time dependent, with KD of 58nM. In addition, the interaction required presence of the 
C-terminal TSP1 repeats of the protein, and was inhibited by heparin and trypsin.191  
1.7.2 ADAMTS13 associated disorders 
UL-VWF multimers are biologically hyper-active because compared to small multimers 
they have higher affinity towards the extracellular matrix 192 and platelet GPIbα. 193 As 
pointed out their size needs to be controlled in order to prevent formation of platelet rich 
thrombi in the microcirculation (pathogenic thrombosis). Absence or severe reduction in 
ADAMTS13 is associated with systemic thrombosis, mainly thrombotic 
thrombocytopenic purpura (TTP). TTP is clinically characterised by microvascular 
thrombosis, haemolytic anemia, thrombocytopenia, neurological abnormalities, fever, 
and renal dysfunction.194,195 Mutations in ADAMTS13 gene cause a congenital form of 
TTP,196 while an acquired form results from the development of autoantibodies against 
ADAMTS13.197  
On the other hand, mutations in VWF that prematurely destabilise it can increase its 
susceptibility to ADAMTS13 cleavage. The significant decrease in VWF multimeric 
size and thereby haemostatic potential at the sites of injury is associated with a 
congenital bleeding disorder VWD type 2A.198,199 Moreover, patients with aortic 
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stenosis which generates high shear in circulation have increased VWF proteolysis and 
reduced multimer size as compared with healthy individuals.200,201 
ADAMTS13 activity has been shown to be crucial in vivo to protect the brain from 
ischemia-reperfusion injury by ameliorating post-ischemic hypoperfusion.202 The 
possible neuroprotective effect of ADAMTS13 is possibly due to proteolysis of VWF 
on the surface of thrombi formed on the ischemic endothelial cells since VWF was 
shown to play a role in the development of ischemic brain injury, however the specific 
mechanism of its action remains unclear.184,202-204 Moreover, it has been demonstrated 
that VWF deficient mice were protected from ischemic brain injury,205 while mice 
deficient in ADAMTS13 displayed larger stroke infarction,206-208 when compared to 
wild type animals. It has been subsequently demonstrated that interaction of VWF with 
collagen and GPIbα are critical steps in stroke development in mice, while interaction of 
VWF with GPIIb/IIIa is not essential.209 
Interestingly it has been suggested that ADAMTS13 activity can not only down-
regulate thrombosis but also inflammation. Firstly, VWF levels were shown to be 
increased while ADAMTS13 level were reduced in both acute and chronic 
inflammation.210 In addition, it has been demonstrated that by cleaving endothelial UL-
VWF, ADAMTS13 prevents excessive leukocyte rolling in unstimulated veins and 
leukocyte adhesion and extravasation under inflammatory conditions.211-213 
Platelets play a crucial role in thrombus formation in normal haemostasis by adhering to 
exposed endothelium at sites of vascular insult and participating in thrombus formation, 
however, this physiological defence mechanism can also lead to thrombotic diseases 
such as heart attack and stroke. Rupture of an atherosclerotic plaque exposing 
underlying fibrous matrix can lead to thrombus formation mediated by GPIb-IX-
V/VWF and/or GPVI/collagen interactions. On the other hand pathological shear stress 
in an atherosclerotic coronary or cerebral artery can induce platelet-VWF interaction 
leading to thrombus formation, which obstructs the blood flow and consequently leads 
to heart attack or a stroke.214,215 Many studies have been performed to elucidate whether 
high plasma concentration of VWF are associated with an increased risk of thrombosis, 
and some evidence was provided that high VWF levels are associated with a moderately 
increased risk of arterial thrombosis. Studies in pigs with VWD and in VWF deficient 
mice have revealed a reduced tendency to develop artherosclerosis.216 On the other hand 
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no difference in the size of atherosclerotic plaque has been shown between VWD type 3 
patients and healthy individuals, suggesting that VWF does not play a role in the 
atherosclerotic process but only in the occlusive arterial thrombosis.217,218  
1.7.3 ADAMTS13 role in proteolysis of VWF  
The specificity of ADAMTS13 for proteolysis of VWF is facilitated by multiple 
cooperative contacts that bind ADAMTS13 to VWF.151,219,220 ADAMTS13 binds to 
unfolded VWF with high affinity and the apparent KD was calculated to be ~14nM.174,183 
The N-terminal ADAMTS13 domains are required and sufficient for recognition of and 
proteolysis of denatured multimeric VWF, since ADAMTS13 truncated after the spacer 
domain still efficiently proteolysed VWF whereas ADAMTS13 truncated before the 
spacer domain did not.221,222 It has been demonstrated that the spacer domain of 
ADAMTS13 (in particular residues R568, R660, Y661 and Y665) binds the exosite 
E1660-R1668 at the C-terminal side of the A2 domain which helps approximate the two 
proteins.223-226 Subsequent interaction between the ADAMTS13 disintegrin-like domain 
with amino-acids close to the VWF A2 cleavage site was shown to be crucial for the 
proteolysis to occur.227 Furthermore the ADAMTS13 disintegrin-like domain was 
shown to assist in proteolysis via an interaction between ADAMTS13 R349 residue and 
the D1614 residue in VWF helping to position  the scissile bond within the active site of 
ADAMTS13.227 Once ADAMTS13 is bound to the elongated VWF, its metalloprotease 
domain can catalyse hydrolysis of the Y1605-M1606 within A2 domain. The 
metalloprotease domain contains a conserved active site sequence motif 
HEXXHXXGXXH and adjacent Met-turn that provide Zn2+ binding pocket. The bound 
zinc ion and the active site residue GE225 coordinate a water molecule that impels the 
hydrolysis of the scissile bond.228 In addition, a high affinity Ca2+ binding site, near the 
active site is vital for efficient VWF proteolysis.229  
In vivo ADAMTS13 proteolysis of VWF is initiated by high shear stress that induces 
unfolding of the cryptic ADAMTS13 cleavage site.230 To observe ADAMTS13 
proteolysis in vitro VWF has to be unfolded by mild denaturation with urea171 or 
guanidine hydrochloride182,231 followed by barium or calcium activation of 
ADAMTS13.173,182 Cleavage of VWF in vitro using denaturants may require long 
incubation times,171 whereas cleavage of VWF under flow conditions occurs in 
minutes.184 To investigate the interaction of ADAMTS13 with VWF, short recombinant 
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substrates can be used to avoid the need for denaturants or shear stress. The shortest 
substrate that can be cleaved by ADAMTS13 is a 73 amino acid fragment (VWF73) 
spanning residues 1596-1668 of the A2 domain.173 Other studies have used a VWF115 
substrate, spanning residues 1554-1668 of the A2 domain.232  
It has been suggested that ADAMTS13 distal domains modulate its activity, however, 
their role has not yet been fully elucidated. Under conditions of high shear stress, Feys 
et al., did not observe any difference in VWF cleavage or binding for ADAMTS13 
recombinant variants truncated after the TSR-8 (delCUB) or the spacer domain 
(MDTCS), while Zhang et al. reported that delCUB and MDTCS had minimal activity 
against VWF, and that removal of CUB domains reduces VWF binding 5 to 7 fold. 
152,174 In addition, the MDTCS variant was able to cleave UL-VWF released form 
endothelial cells in a parallel flow chamber based assay226 and had unaltered activity 
when assayed in the presence of urea or guanidine.221,222  Interestingly, transgenic mice 
that expressed ADAMTS13 truncated after the TSR6 domain were reported to have 
increased thrombogenicity compared to wild type animals, while the plasma VWF 
multimeric pattern was normal.233 This could suggest that distal domains of 
ADAMTS13 are important for VWF cleavage under high shear. Alternatively, altered 
thrombus formation could be due to removal of ADAMTS13 domains interacting with 
globular WVF, therefore limiting the amount of ADAMTS13 immediately available at 
the site of thrombus formation. 
1.7.4 Factors modulating ADAMTS13 proteolysis  
At the site of vascular injury, VWF can adhere to exposed collagen and this 
immobilisation under high shear flow allows VWF to unravel, bind platelets, and 
undergo ADAMTS13 proteolysis. Consequently as described previously, both 
hydrodynamic forces and immobilisation change the conformation of VWF and the way 
it interacts with ADAMTS13. Interestingly cleavage is activated by shear when A2 is 
present in large VWF multimers, but not when present as a much smaller isolated 
domain, probably because the tensile forces acting on the protein under shear flow 
increase with protein size.171,182,200,234 In addition, domains adjacent to A2 as well as 
VWF ligands can exert a differential effect on ADAMTS13 cleavage. For example, it 
has been demonstrated that binding of platelet GPIbα to the A1 domain stimulates the 
cleavage of the A2 domain by ADAMTS13. Recombinant VWF A2A3 was cleaved ~10 
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fold faster than recombinant A1A2A3, indicating that the A1 domain inhibits cleavage, 
however this inhibition can be relieved by binding of the A1 domain to GPIbα or 
heparin.235 As mentioned earlier, FVIII binding to VWF can also accelerate 
ADAMTS13 cleavage of VWF under conditions of shear stress.120 Further analysis 
demonstrated that binding of both platelets and FVIII to VWF synergistically enhances 
its proteolysis by ADAMTS13 under mechanically induced shear stress.236 Furthermore 
glycosylation status of both VWF (discussed in section 1.14) and ADAMTS13 was 
suggested to modulate their interaction. ADAMTS13 undergoes both O-and N-linked 
glycosylation. Preventing O-fucosylation in the TSP-1 repeats resulted in reduced 
secretion from HEK293T237 cells while the N-linked glycans were shown to modulate 
both ADAMTS13 secretion and proteolytic activity.238 
1.7.5 Mechanism of ADAMTS13 multistep binding to VWF  
Recently it has been reported that apart from binding to elongated VWF, ADAMTS13 
is able to bind with different affinity to VWF in its native conformation.  ADAMTS13 
was shown to bind to globular VWF with an apparent KD of 79nM when the interaction 
was studied using immunoprecipitation experiments152 and with a KD of 90nM when 
binding to VWF captured via a monoclonal antibody was analysed by an ELISA based 
plate assay.239 Additionally, a similar KD of 86nM was calculated for interaction of 
immobilised ADAMTS13 and globular VWF in solution.151 Distal ADAMTS13 
domains are required for its binding to globular VWF; however their exact role is not 
yet clear. Zanardelli at al. suggested the involvement of TSP5- CUB domains, and Feys 
et al.152 reported that deletion of CUB domains did not alter native VWF binding and 
suggested that TSR2-8 are important for the interaction. Nevertheless, the distal 
ADAMTS13 domains interact with the C-terminal region of VWF, as suggested both by 
surface plasmon resonance (SPR) experiments and plate binding assays using a series of 
VWF deletion mutants.151 Significantly, ADAMTS13 binding to globular VWF does 
not lead to VWF proteolysis in the absence of shear stress therefore binding of 
ADAMTS13 to VWF in globular conformation is suggested to be an early step of a 
multistep interaction that ultimately leads to VWF proteolysis (Figure 1.6). In addition, 
it has been suggested that globular VWF and ADAMTS13 in plasma may be able to 
form complexes, as ADAMTS13 and presumably native VWF were co-purified from a 
commercial factor VIII/VWF concentrate by size exclusion chromatography, 240 while 
Feys et al. were able to detect ADAMTS13 binding to plasma VWF152.  
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Figure 1.6 Putative two step binding interaction between ADAMTS13 and VWF 
Illustration of the proposed initial binding interaction mechanism between ADAMTS13 
and VWF that eventually leads to VWF proteolysis. A) Diagram of ADAMTS13 
domain structure and VWF in globular conformation. The ADAMTS13 cleavage site 
within the VWF A2 domain is buried. C-terminal domains of VWF can interact with 
distal ADAMTS13 domains. It is not clear yet exactly which domains participate in the 
binding. However this step is not necessary for VWF proteolysis to occur B) Under 
conditions of shear stress, VWF unravels and its A2 domain interacts with high affinity 
with ADAMTS13 spacer domain and C) metalloprotease domain can access and cleave 
the Y1605-M1696 bond in the VWF A2 domain. Figure reproduced from Zanardelli et 
al., 2009.151 
1.8 Thrombospondin I cleavage  
VWF multimeric size can also be regulated, however to a significantly lesser extent, by 
a protein disulphide bond reductase, identified as thrombospondin-1 (TSP-1).241 VWF 
and TSP-1 incubated together can form thiol dependent complexes, which results in the 
generation of free thiols in VWF, and a decrease in VWF multimeric size. Furthermore 
an inverse relationship was observed between the plasma molar ratio of VWF/TSP-1 
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and VWF multimeric size. Additionally, administration of TSP-1 to mice resulted in a 
decrease in VWF multimeric size. 241 However, it has also been demonstrated that the 
average multimer size of plasma VWF in TSP-1 null mice was significantly smaller 
than in wild type mice.242 Interaction between VWF and TSP-1 was shown to be 
mediated by the VWF A3 domain.241,242 Since ADAMTS13 was also shown to interact 
with the A3 domain185 it has been suggested that TSP-1 and ADAMTS13 may compete 
for binding to the A3 domain, which would limit degree of ADAMTS13 proteolysis. 
TSP-1 is stored in the α-granules of platelets. Following platelet lysis and activation 
reduced multimeric size of platelet VWF was observed in wild type but not in TSP-1 
null mice. Increased collagen and platelet binding was observed upon platelet lysis and 
activation only in TSP-1 null mice.242 This suggests that TSP-1 influences plasma 
derived and platelet derived VWF differently and may be more relevant to platelet 
derived VWF. 
1.9 VWF and platelet binding  
Under physiological conditions platelets and VWF do not interact. Vascular injury leads 
to exposure of subendothelial matrix i.e. collagen, fibronectin and laminin that initiates 
VWF and platelet adhesion. The type of interaction depends on the rheological 
conditions. At low shear conditions platelets can bind directly to collagen via integrin 
α2β1,243,244 or to fibrinogen via integrin αIIbβ3.245 At conditions of high shear rates 
(exceeding 500-800s-1246), shear rates that are normally present in the human arterial 
circulation, VWF is required to mediate platelet adhesion to the damaged 
endothelium.247 
Under conditions of elevated shear stress VWF binds to the subendothelium principally 
via collagen. This enables VWF to assume an extended conformation and results in 
exposure of its A1 domain to interact with the platelet membrane glycoprotein (GP) Ib-
IX complex and mediates platelet capture. The largest VWF multimers support platelet 
adhesion most efficiently, since they expose repeating functional sites supporting 
multiple and more efficient adhesive interactions.192 This is the first step in a sequence 
of signalling and adhesion events that generate a haemostatic plug at the site of vessel 
injury.  
The platelet GPIb-IX-V complex is composed of transmembrane leucine rich 
glycoproteins:  GPIbα and GPIbβ that are disulphide linked and non-covalently 
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associated with GPIX and GPV  with minimal stoichiometry of 2:4:2:1 on the platelet 
surface.248,249 The VWF binding site lies within the N-terminal 293 residues of GPIbα. 
250 The A1 domain contains the only known VWF binding site for GPIbα.104,137,141 A 
study using a synthetic VWF peptides showed that  the residues D1277-E1305 
encompass the major GPIbα binding site.136 Moreover specific mutations R1287S, 
G1324S, H1326T, T1357S/E1359A, Q1367R, S1370R251and E1260A, N1274A252 
reduced binding between VWF A1 domain and platelets in the presence of ristocetin 
and botrocetin. The GPIb domain also contains non-identical but overlapping binding 
sites for other adhesive ligands (e.g. thrombospondin), counter-receptors (e.g. P-selectin 
and leukocyte integrin αMβ2), and coagulation Factors XI and XII, kininogen, and 
thrombin.253-256 Therefore GPIb-IX-V also takes part in the adhesion of platelets to 
activated endothelial cells, in leukocyte recruitment to the sites of vascular damage and 
in thrombin induced platelet activation. Interaction between the A1 domain and GPIbα 
is crucial for haemostasis in arterioles and arterial capillaries, and participates in 
thrombosis in larger arteriessuch as coronary arteries at the sites of stenosis caused by 
artherosclerotic plaques.257-260  
Recombinant isolated A1 domain binds to GPIbα but in contrast to the entire molecule 
does not initiate stable platelet adhesion.104,261 Binding of GPIbα to VWF facilitates the 
initial transient tethering of platelets to the vessel wall that can be visualized, both in 
vivo and in vitro, as platelet rolling or slow translocation. The interaction between 
GPIbα and the A1 domain has fast association (“on”)262-264  and dissociation           
(“off”)262,264,265 rates and by itself cannot provide irreversible adhesion. The torque 
imposed by flowing blood causes platelets to translocate over immobilized VWF but the 
interaction between GPIbα and the A1 domain slows the platelet velocity down 
allowing establishment of additional bonds through other receptors on activated 
platelets. Those receptors have an intrinsically slower rate of bond formation, but 
mediate stable interaction and result in definitive arrest of platelets and thrombus 
formation. The mechanism by which GPIbα-VWF binding produces platelet activation 
has not been yet fully elucidated. It has been shown that GPIbα interaction with VWF 
triggers elevation of intracellular Ca2+, phosphoinostide metabolism, protein 
phosphorylation (PLCγ2, ERK-1/2); activation of myosin light chain kinase and 
cytoskeletal actin filament rearrangements leading to platelet spreading. Upon activation 
the platelets undergo a change in morphological shape becoming more spherical and 
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extrude long pseudopods that enhance interaction with adjacent platelets. The platelet 
membrane also exposes more negatively charged phospholipids to provide an optimal 
surface for binding of coagulation factors. Furthermore, platelet granular contents are 
released (i.e., ADP, platelet derived growth factors, adhesion molecules and coagulation 
factors).266,267 This allows the recruitment of additional platelets from the flowing blood. 
Eventually the activation of platelets leads to activation of platelet receptor GPIIb/IIIa 
(integrin αIIbβ3) that interacts with fibrinogen and the RGDS sequence in the VWF C1 
domain and to P-Selectin expression on the platelet surface, thus mediating stable 
platelet adhesion, spreading and aggregation.164,245   
Binding between VWF and GPIb-IX-V has to be strictly regulated to ensure that platelet 
plug formation is restricted to the site of vascular injury, since inadvertent binding can 
lead to both thrombosis and bleeding. For instance gain of function mutations in the 
VWF-A1 domain affect its conformation and promote spontaneous GPIbα binding. 
Enhancement of adhesion in the normal circulation can lead to the loss of high 
molecular weight VWF multimers and a reduction in platelets numbers, resulting in the 
bleeding disorder, von Willebrand disease (VWD) type 2B.11,268 The type 2B mutations 
are clustered in a small region within the lower surface of VWF-A1 domain which is 
remote from the GPIbα binding site but they were showed to cause a significant change 
in the crystal structure of the A1 domain, altering the positions of residues implicated in 
GPIbα binding.269,270 Platelet-type pseudo-VWD is caused by mutations in the amino 
terminal region of GPIbα region that increase its affinity for VWF resulting in a 
phenocopy of type 2B VWD.271,272 In addition, binding studies of VWD mutants have 
indicated that both type 2B and platelet type VWD mutation increase platelet adhesion, 
in part by reducing the GPIbα-A1dissociation rate.262,265 Lack or dysfunction of the 
GPIb-IX-V complex causes Bernard-Soulier syndrome (BSS), a rare congenital 
bleeding disorder characterised by thrombocytopenia, giant platelets, and decreased 
ristocetin-induced agglutination.273,274 
The crystal structure of the unaligned VWF A1 domain 125 and extracellular domain of 
GPIbα275and the crystal structure of the VWF A1-GPIbα complex have been solved.276 
The A1 domain with the type 2B gain of function mutation R1306Q and GPIbα with the 
gain of function mutation M239V were used to facilitate crystallization of their 
complex.276  Furthermore, a complex comprised of the extracellular domain of GPIbα 
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and wild type VWF-A1 domain was crystallised.277 Conformational rearrangements 
occurring within the regions directly involved in the GPIbα-A1 binding were suggested 
by comparing the crystal structures of wild type and mutated protein complexes. 
The VWF binding fragment of GPIbα (H1-E282) is elevated from the platelet plasma 
membrane by a mucin stalk and is composed of an N-terminal disulfide-looped capping 
sequence (residues 1-35), a leucine rich repeat sequence (residues 36-200), a C-terminal 
disulphide-looped flanking sequence (residues 201-268), and an anionic/sulphated 
sequence (residues 269-282).278(Figure 1.7) The GPIbα central fragment forms an 
elongated curve that is composed of eight tandem leucine-rich repeats (LRRs); while the 
N-terminal sequence forms a 14-residue β-hairpin motif defined by a disulfide bond. 
The tip of the β-hairpin, named a β-finger, protrudes from the protein surface .The C-
terminal flanking sequence has a more complex structure with two cysteine bonds and a 
highly protruding flexible loop between the cysteine bonds named a β-switch.276 The A1 
domain interacts with the concave surface of GPIbα with two main areas of high affinity 
interaction: the C-terminal β-switch of GPIbα binds near the top of the A1 domain while 
the β hairpin binds near the base of the A1 domain (Figure 1.7). Upon binding to the 
VWF A1 domain, the β-switch region undergoes a conformational change forming a β-
hairpin that aligns with the central β sheet of the A1 domain forming the major interface 
of the complex.276,277 The GPIbα gain of function mutations are located in the β-switch 
region and are predicted to stabilize the β-hairpin, enhancing the binding affinity. 
Comparison of the wild type and mutant complex shows that the GPIbα gain of function 
mutant adopts a more stable β-hairpin conformation, nucleated by a strong γ-turn, while 
wild type GPIbα has the same β-hairpin structure but a weak γ-turn.276,277 The gain of 
function mutations in type  2B VWD are clustered in the bottom face of the A1 domain 
next to the interaction site with the β-finger of GPIbα. In the free A1 domain the 
sequence at the N-terminal side of the disulphide bond shields the binding site for the β-
finger and this N-terminal extension is displaced when GPIbα binds.276 The N-terminal 
extension is inhibitory because recombinant A1 domains lacking this extension bind 
GPIbα with 5-10 fold higher affinity.137 The type 2B mutants that are localized within 
the N-terminal extension are likely to destabilize its interactions with the bottom face of 
the A1 domain, thereby making the GPIbα β-hairpin binding site accessible. Shear 
stress induces GPIbα activation by inducing a conformational transition of the β-switch 
loop to the β-hairpin, thus stabilizing it and facilitating the interaction with the central β-
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sheet of the A1 domain, thereby promoting VWF binding.279,280 VWD type 2B 
mutations and platelet-type pseudo VWD gain of function mutations affect distinct 
binding sites and their effect on binding is additive.276  
 
Figure 1.7 GPIbα structure and model of interaction with the VWF-A1 domain 
A) GPIbα structure-ribbon representation; N-terminal β-finger region shown in blue, 
leucine rich repeats region in green, and C-terminal β-switch in red. B) Cartoon 
illustration of VWF interaction with the N-terminal part of GPIbα. Leucine-rich repeats 
of GPIbα wrap around one side of the A1 domains but do not directly contact it. The N-
terminal β-finger region of GPIbα contacts the N-terminal extension of the A1 domain 
(in pink), and the β-switch region of GPIbα contacts the top of the A1 domain. Binding 
requires the amino–terminal extension of A1 to move, and induces transformation of the 
β-switch to a β-strand (figure adapted from Sadler, 2002281). 
 
From the crystal structure analysis it appears that interface of the A1-GPIbα complex is 
characterised by presence of large patches of opposite charges, however charge residues 
at the interface are not involved in direct contacts between two proteins but are either 
fully or partially solvated. This suggests that GPIbα and the A1 are attracted by long-
range electrostatic interactions, therefore avoiding the energetically adverse de-
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solvation of charged residues in the formation of final complex.276,282 The efficiency of 
platelet adherence is also dependent on the strength of the tethering force between the 
VWF-A1 domain and GPIbα, which was shown to be strongly correlated with the 
stability of the A1 domain.283 
The isolated A1 domain used for crystallization lacks key structural elements that 
inhibit GPIbα binding in multimeric VWF. Binding studies using Surface Plasmon 
Resonance (SPR) in the absence of modulators demonstrated that the isolated A1 
domain has notably higher affinity for  GPIbα with KD of 30nM compared to a Kd of 
more than 1µM determined for multimeric VWF , suggesting that other domains have 
inhibitory effect on the binding.276 In addition, it has been demonstrated that the binding 
strength between GPIbα and the isolated A1 domain is identical to that determined for 
UL-VWF, in the absence of modulators, e.g ristocetin and botrocetin while plasma 
VWF bound GPIbα only in the presence of modulators. This suggested that changes in 
UL-VWF multimer conformation are more significant than their size for capture of 
platelets and that the intrinsic conformation of the A1 domain remains intact during the 
structural change of VWF.193 Furthermore, several studies have shown that GPIbα 
binding affinity varies between A1 domains depending on the length of  regions 
flanking the cystein bond.137,284,285 
In multimeric VWF the accessibility of the A1 domain might be limited by the shielding 
effect of the D'-D3, since the D'-D3 region has been shown to have a negative 
regulatory role on the VWF-GPIb-IX-V interaction. It has been shown that deletion of 
the D'-D3 region in VWF results in increased GPIbα binding, while the isolated D'D3 
region inhibits binding of platelet receptor GPIb to VWF. Moreover, using a panel of 
anti-VWF monoclonal antibodies it was shown that the D'D3 region is in close 
proximity with the A1 domain in soluble but not immobilised VWF.138  The A2 domain 
might also participate in regulating the A1 domain activity. It has been demonstrated 
that the purified bacterial A2 domain binds to the A1  domain when VWF is 
immobilised or activated by ristocetin and prevents VWF interaction with GPIbα under 
high-flow conditions.286  
Binding between GPIbα and VWF can be induced in vitro by modulators such as the 
antibiotic ristocetin and the snake venom protein botrocetin. Ristocetin and botrocetin 
interact with two distinct regions of VWF and GPIbα, and induce GPIbα binding 
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through different mechanisms. Ristocetin is an antibiotic from Nocardia lurida, that 
fluctuates many proteins, binds to platelets at high concentration (>1mg/ml) and 
mediates VWF dependent platelet agglutination (< 1mg/ml ristocetin).287 Two regions 
have been implicated in its interaction with VWF: the C1237- P1251 region of VWF at 
the N-terminal site of the A1 domain288,289 and the proline-rich sequence, E1463 to 
N1472, C-terminal to the disulphide bond in the VWF A1 domain.288-291 Botrocetin is a 
venom coagglutinin isolated from the rattlesnake Bothrops jararaca that specifically 
binds to VWF and can interact with GPIbα only in the presence of the A1 domain. The 
botrocetin binding site is localised within the A1 domain (engaging helices α5 and α6 
on one side of the VWF-A1) in the close proximity to the GPIbα binding site.270,292 In 
contrast to ristocetin, botrocetin does not induce any conformational change in the A1 
domain but could provide an additional binding surface for GPIbα.293,294 It has been 
demonstrated that botrocetin first binds to the A1 domain but not GPIb and than 
subsequently slides around the A1 surface to form a new interface. Botrocetin decreases 
the A1-GPIbα disassociation rate two fold without affecting the association rate.293,294 
Moreover, within the GPIbα receptor, leucine-rich repeats 2 to 4 are critical for 
ristocetin dependent VWF binding, whereas the sulfated-tyrosine cluster between Asp-
269 and 287 is more important for botrocetin dependent VWF binding.295-298 It is 
accepted that ristocetin dependent rather than botrocetin dependent VWF-GPIbα 
binding closely correlates with shear-dependent interaction between VWF and 
GPIbα.299 For example, studies showed that the ability of the anti-GPIbα and anti-VWF 
antibodies to inhibit GPIbα dependent adhesion under flow correlated with their 
capability to inhibit ristocetin, but not botrocetin dependent VWF binding.299 In 
addition, VWF-A1 containing type 2M-VWD mutations were able to support shear 
induced platelet aggregation in the presence of botrocetin.300 This thought to reflect the 
fact that only ristocetin induces conformational change in the A1 domain. 
1.9.1 Platelet aggregation  
Once platelets have adhered to the site of vascular injury they release VWF stored in    
α-granules and bind to VWF and fibrinogen, and further platelets are recruited to the 
site to form the primary platelet plug. This process is mediated, depending on the fluid 
dynamic, conditions by VWF interacting with GPIbα and integrin αIIbβ3 in the same 
way as described above and/or fibrinogen interacting with αIIbβ3.301-303 In addition, 
immobilised fibrinogen and fibrin can mediate immediate irreversible adhesion of 
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flowing non-activated platelets via integrin αIIbβ3 at the lower shear stress rates. At low 
wall shear stress fibrinogen interacting with integrin αIIbβ3 forms the predominant link 
between aggregated platelets,304 although VWF competes with fibrinogen for integrin 
αIIbβ3.305,306 However at high shear flow, fibrinogen alone is unable to support platelet 
aggregation and VWF is required to form the platelet aggregate.302,307,308 The presence 
of both VWF and fibrinogen is important for the development of stable thrombi as 
shown by both ex vivo studies and knock-out mice309,310 and supported by observation 
of altered haemostatic properties of platelets from individuals with isolated congenital 
deficiency of either fibrinogen or VWF311,312.  
Interestingly, it was demonstrated that GPIbα can mediate activation-independent 
platelet adhesion and aggregation under very high shear rates above 10000s-1.313 
Importantly, this process depends on the presence of both soluble and immobilised 
VWF and can occur without any need for platelet activation or integrin function.  
Platelet VWF can also be involved in the formation of the platelet plug. However, since 
it is released from the α-granules of activated platelets it is unlikely to be involved in the 
initial adhesion of platelets to the site of vascular injury. Platelet VWF has been shown 
to mediate platelet aggregation at high shear stress and therefore is involved in the 
extension of the platelet aggregate after the initial adhesion of platelets to the exposed 
subendothelium.308 
Collagen can also directly bind activated platelets receptors; integrin α2β1 
(GPIa/IIa)314,315 and glycoprotein VI (GPVI),316-318 however their relative importance 
remains debated. The type of binding is dependent on shear stress. Under high shear 
only previously activated platelets can bind to collagen via their GPVI receptor or via 
integrin α2β1 to collagen type III. 164,319 It has been suggested that at low shear, platelets 
bind mainly type I collagen, through integrin α2β1, which is followed by binding via the 
GPVI receptor and subsequent platelet activation. GPVI is a low-affinity collagen 
receptor but is very effective in initiating signalling once it is cross-linked by binding to 
collagen.320 The integrin α2β1 conformational activation increases its affinity for 
collagen, and possibly requires inside-out signalling generated by either interaction of 
GPVI with collagen or activation of integrin α2β3.321 GPVI has been shown to influence 
platelet aggregation and thrombus formation on fibrillar collagen type I coated surface 
under flow conditions.322-324 Combined deficiency of GPVI and integrin α2β1 in mice 
results in complete inhibition of thrombus formation, compared to a minor reduction in 
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thrombus formation resulting from deficiency of only one of the receptors.316 
Interestingly GPVI or integrin α2β1 deficiency in humans does not cause a strong 
bleeding phenotype.315,325,326 Nevertheless genetic polymorphism in both GPVI and 
integrin α2β1 has been suggested as a predisposition to thrombosis and targeting those 
receptors is considered a potential antithrombotic strategy.327 
1.10 Mechanism of transient platelet adhesion under flow 
Platelets are disc shaped, anulceate blood cells derived from megakaryocytes that are 
activated to initiate thrombosis only in certain physiological or pathological conditions. 
As described previously, at the sites of vascular injury, under high shear, VWF is 
essential to the initiation of platelet adhesion and therefore subsequent plug formation, 
since it is able to resist hydrodynamic forces and provide a rapid link between 
extracellular matrix and platelets. As mentioned above, platelet adhesion is initiated by 
transient interaction between the VWF-A1 domain and platelet receptor GPIbα, though 
only when both proteins are subjected to high fluid shear stress which exerts a 
hydrodynamic force on the GPIbα-VWF bonds.215 Interestingly, flow enhances rather 
than impedes platelet adhesion, despite the dislodging forces.245 This unique feature of 
the interaction between GPIbα and VWF-A1 enables activation-independent platelet 
tethering to injured vessel wall even when the velocity of blood is elevated whilst at the 
same time preventing inappropriate platelet agglutination in the normal circulation. 
Bonds between adhesion molecules are often mechanically stressed. It used to be 
assumed that the tensile mechanical force acting on a biological adhesive bond increases 
the detachment rate and shortens bond lifetimes, since work done by the force could 
overcome the energy barrier between the bound and free states.328 However in recent 
years, several receptor-ligand pairs have been shown to form ‘catch bonds’ whose 
lifetimes are actually extended by force. Examples of such force-enhanced bonds 
include the bacterial protein FimH binding to its ligand mannose,329 leukocyte selectins 
and sialyl LewisX containing ligands330 and myosin-actin motor protein interaction.331 
The interaction between GPIbα and VWF under conditions of increasing shear stress 
was proposed to follow this mechanism with binding observed under high flow 
conditions and showing a dual response to the force of the flowing blood.  
Applied force affects lifetimes of catch bonds in two distinct ways depending on the 
degree of shear applied. Initially, as force increases, bond lifetime increases until a 
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maximal value is reached (catch regime). Increased bond life time results in decreasing 
cell rolling velocity. As the force increases further, bond lifetimes decrease and as a 
result rolling velocities increase (slip regime).330 It has been shown that disassociation 
of the bond is governed by the force that is applied to the bond as a result of the 
hydrodynamic force acting on the cell. The key property of adhesive catch bonds 
distinguishing them from slip bonds is their ability to resist applied force. This 
mechanism allows many adhesive molecules to resist forces in the body that would 
normally break cell-cell contact. 332,333  
Mechanical properties of individual catch bonds in response to mechanical force (shear) 
have been analysed using atomic force microscopy,334,335 optical tweezers,336 a 
biosurface force probe,337,338  and a microneedle cantilever.339 In these experiments, 
surfaces coated with receptor and ligand are touched together and then pulled apart 
while recording forces, and rupture events are analysed. Force can be either; loaded at a 
constant level and held until the bond breaks-to measure bond life time; or increased 
steadily until the bond ruptures-to measure the probability of bond rapture and bond 
strenght.340-342 A bond can be described as a slip bond when the bond lifetime is shorter 
at higher forces and the bonds rupture more frequently (Figure 1.8 a,c) A bond can be 
called a catch bond if the bond lifetime increases with force up to a critical force (this 
region is called catch regime), and then it enters a slip regime where force shortens the 
lifetime (Figure 1.8 b). A catch bond has two peaks corresponding to increased 
probability of bond rapture, that are below and above the critical force (Figure 1.8, d). 
The proportion of ruptures in each of the peaks is determined by the pace at which the 
loading force is increased, as bonds only break below the critical force if given enough 
time. If the force is increased too fast, a bond could be described as slip, which was 
probably why these bonds were not always detected.  
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Figure 1.8 Schematic representation of bond mechanics 
A) The mean life time of a slip bond decreases, and ligand rolling velocity increases 
with shear stress. B) Mean lifetimes of catch bonds increases with force below a critical 
force and decreases with force above the critical force. In addition, strength of a slip 
bond (C) and catch bond (D) when force is increased until rapture. Slip bonds have one 
peak at higher forces (shear stress) corresponding to highest chance of rapture and 
lowest lifetime. Catch bonds have to peaks, above and below critical force, where the 
bonds break most frequently.  
 
Interestingly, a number of mutations in VWF that result in type 2B VWD can modify 
the mechanical regulation of the GPIbα-A1 catch bond. Recently single molecule 
experiments have shown that the mutation R3106 and R1450 linked to type 2B VWD 
change the properties of the bond by prolonging the bond lifetime at low shear and 
lowering or eliminating the shear threshold requirement for bond formation and platelet 
rolling: thus eliminating catch bond behaviour.335 This may explain the ability of 
globular VWF with type 2B mutations to induce platelet agglutination in the circulating 
blood. 343 As mentioned previously, the domains neighbouring A1 and the flanking N-
terminal region, have beenshown to inhibit GPIbα binding. It is not clear if this 
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inhibition is due to allosteric or masking effects, since these parts of VWF were not 
included in the A1 construct used to examine the catch bonds.138,286,335  
1.11 Blood flow dynamics and kinetics 
Platelets perform their function in the blood under constant fluid motion and the type of 
flow influences platelet function. Blood is a viscous fluid suspension comprised of a 
continuous part (plasma) and a suspended part (cells) that may become separated by the 
action of shear stress, as gravity has a negligible effect in the flowing blood.344,345 In 
addition when the cell count is normal, red blood cells constitute majority of the 
circulating mass and occupay the center of the vessel where the velocity of blood is the 
highest. As the consequence of lateral migration under shear and erratic motion,260,346 
they occupy most of the lumen, pushing leukocytes and platelets to the sides increasing 
the platelet concentration adjacent to the vessel wall.347-349 This distribution facilitates 
adhesive interactions of platelets with the vessel wall.  
 
 
Figure 1.9 Schematic representation of blood flow in a vessel 
Blood flow in a vessel follows a laminar model, and can be visualised as a series of 
fluid layers (laminae) moving at different velocity. It is the difference in the velocity 
between laminae of the flowing blood that generates shearing forces. The blood has 
greater velocity at centre of the vessel than near the wall, while the shear rate value is 
minimal in the centre and increases toward the vessel wall.  
 
A Newtonian fluid is one that has a constant viscosity at all shear rates (i.e. irrespective 
of velocity fields). Blood has a pulsatile flow in arteries and non-Newtonian behaviour 
at lower shear rates. However, blood flowing in a vessel wall at shear rates above 200s-1 
can be considered a Newtonian fluid,260,350 therefore the velocity profile of blood 
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moving steadily in the vessel with a constant cross-sectional is assumed to follow the 
laminar flow model. This means that at a given flow rate, blood in the centre of the 
vessel has maximal velocity which decreases toward the wall.(Figure 1.9) The changing 
velocity of blood which increases with distance from the vessel wall creates shearing 
flow, which is a sliding motion between two adjoining laminae moving at different 
speeds. Shear rate (γ) is the difference in flow velocity as a function of a distance from 
the wall, and is expressed in cm/s per cm or usually as inverse second (s-1). Shear rates 
in flowing blood are small at the centre of the vessel, and increase near the vessel wall 
as a result of drag215. Shear stress (τ) is the tangential force per unit area of contact 
between laminae resulting mainly from pressure differences within the vascular system 
and can be expressed either in pascals (Pa; 1Pa=N/m2) using the International System of 
Units or as dyn/cm2 (1Pa=10dyn/cm2) in CGS system. In an ideal Newtonian fluid shear 
stress and shear rate are linear. Shear stress is a function of shear rate and the viscosity 
(µ) of the fluid. Fluid viscosity is expressed in Pa·s or dyn/cm2·s the latter equivalent to 
Poise (P) where 1P= 0.1Pa·s. Examples of shear rates in vivo are given in Table 1.1. 
Several specific models have been suggested to describe the effect of the force on 
association and disassociation of adhesive proteins,351,352 and VWF-GPIbα interaction, 
similarly to selectins, is principally described by the Bell model. The Bell model is used 
to describe the force dependence of the off rate of a receptor-ligand interaction and is 
expressed as an exponentially increasing function of force. According to this model two 
mechanisms can regulate rolling velocities in flow. First it may be controlled by the 
intrinsic kinetics of bond disassociation (koff0), i.e in the absence of force. Secondly, 
rolling could be modulated by the relative compliance (σ), which is the susceptibility of 
the bond disassociation to applied force.333 Engineering principles have been used to 
design models to reproduce blood flow ex vivo in injured, narrowed, or branched 
arteries. However it has to be mentioned that the assumption of laminar flow may not be 
completely relevant in vivo where blood flow is more complex and rheological variables 
related to eddy formation, pulsatility and dynamic constriction may predominate under 
some physiological and pathological conditions.  
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Blood vessel Shear rate (s-1) 
wall shear stress 
(dyn/cm2) 
Large arteries 300-800 11.4-30.4 
Arterioles 500-1600 19.0-60.8 
veins 20-200 0.76-7.6 
Stenotic vessels 800-10000 30.4-380 
Table 1.1 Average wall shear rates and wall shear stresses, in various vessels types 
Viscosity of blood assumed to be 3.8,miliPoise. (Reproduced from Kroll et al., 1996)215 
 
Viscosity is a very important factor in shear flow as it relates the kinematics of fluid 
movement (shear rate, units of time -1) to shear stress (units of force per area, the 
product of shear rate and viscosity) and therefore the hydrodynamic forces that are 
experienced by objects in contact with the fluid. It has been demonstrated that bond 
formation is a function of shear rate and therefore the kinematics of receptor and ligand 
movement, but not shear stress. The formation of the bond is limited by the separation 
distance of the receptor and ligand and the time that the receptor and ligand are in 
proximity to each other, rather than by the force applied on the bond. Shear rate is a 
limiting factor in tether formation, because when the velocity of the cell relative to the 
substrate is too high, it provides insufficient time for a collision to take place between 
the receptor and the ligand and thus to allow bond formation.332,353 Dissociation of the 
bond on the other hand, is a function of shear stress and consequently the force on the 
bond.  
For cells (platelets) in the flow, the formation of an adhesive receptor-ligand interaction 
is termed ‘transient tethering’ and can be detected as an abrupt arrest in the movement 
of cell previously free in the flow, while bond disassociation can be distinguished as the 
subsequent recommencement of the hydrodynamic movement of the cell.354 Transient 
tethers have been shown to take place when the density of the receptor is very sparse, so 
that it cannot support rolling, therefore they represent a single receptor-ligand 
bond.333,354,355 This has been confirmed for the P - and L- selectin by comparing the koff 
calculated from the Bell model333,354 at the absence of force and koff measured using 
SPR.356,357  
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Mody at al, investigated the mechanics of platelets tethering to surface immobilised 
VWF-A1 domain under hydrodynamic flow, and developed a two-dimensional model to 
calculate the motion of platelets.358 Through the comparison of theoretical analysis and 
experimental observation, they have estimated that the tether bond formation between 
the A1 domain and platelet could take place only in situations where a hydrodynamic 
compressive force is predicted to act along the platelet length (compressive force), 
pushing it against the surface, in that way initiating platelet adhesion.358 They have 
suggested that the compressive force promotes bond formation by bringing the surfaces 
into close molecular contact and helping to overcome repulsive long range interactions 
between surfaces358,359   
1.12 VWF self aggregation 
It has been shown that shear forces can induce VWF lateral self-association in solution. 
VWF multimers are thought to form fibres, which are organised in a spider web-like 
structure and therefore have significantly increased platelet capture potential. This 
property of VWF was first observed by Savage at al., when properties of VWF lacking 
its A1 domain where investigated in a parallel flow chamber under conditions of high 
shear flow.  VWF lacking the A1 domain and therefore the ability to interact with non-
activated platelets, immobilised on a flow slide was able to support platelet adhesion 
when whole blood containing VWF was perfused over the slide, but did not when 
plasma free blood used.360 This implies that VWF present in whole blood, was able to 
associate with VWF lacking the A1 domain immobilised on the slide, and mediate 
platelet capture. Subsequently Choi at al. showed that some plasma VWF multimers 
contain surface exposed free thiols, and that shear stress can promote the formation of 
disulphide bonds utilising these free thiols. Based on that data and additional 
experiments using a cone-plate viscometer361 it has been proposed that the VWF self-
association is mediated by the formation of new intermolecular disulphide bonds under 
high shear.362 Furthermore, VWF with its free thiols blocked had decreased ability to 
interact with VWF secreted from endothelial cell under shear up to 250s-1.363 
Interestingly VWF self assembly was also observed under static conditions. A plate 
binding assay demonstrated that the interaction between immobilised and soluble VWF 
involves multiple domains but none has been identified as essential.360,364 In addition 
VWF self-aggregation has been detected in a solution under static conditions when 
conformation of the protein was altered by ristocetin.365   
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1.13 Von Willebrand disease 
Von Willebrand disease (VWD) is the most common congenital bleeding disorder 
caused by defects in the concentration, structure, or function of VWF. The disease was 
first identified by Dr Erik Von Willebrand in 1924 in families from the Aland Islands 
who suffered bleeding problems distinct from haemophilia. Symptoms vary according 
to severity of the disease and include epistaxis, gingival bleeding, menorrhagia, 
prolonged bleeding from minor wounds, skin bruises and haematomas and 
gastrointestinal bleeding in more severe cases. VWD is a heterogeneous disorder and is 
classified into three primary categories. Type 1 is a partial quantitative deficiency, type 
2 results from qualitative defects, and type 3 results from a total deficiency of VWF.  
Type I is the most frequent VWD type (70% of all VWD patients). It is defined as a 
bleeding disorder resulting from as a simple quantitative deficiency of VWF. However 
it appears that when analysed in detail VWF from individuals with type 1 VWD 
frequently shows subtle abnormalities in multimer composition and distribution. This is 
more consistent with the dominant-negative effect of many type 1 VWD associated 
mutations.Type I VWD subtype Vicenza is characterised by low plasma VWF levels 
resulting  from the accelerated clearance of VWF.366-368 
VWD type 2 that results from functional defects of VWF is further divided into four 
secondary categories: 2A, 2B, 2M, 2N.  
Type 2A refers to VWF mutants with decreased platelet adhesion caused by a selective 
deficiency of the most haemostatically active high and intermediate molecular weight 
VWF multimers. Two distinct molecular mechanisms can cause the type 2A VWD 
phenotype and the corresponding causative mutations are subdivided into group I and 
group II. Group I refers to VWF with mutations localised in the propeptide, the cysteine 
knot domain or the D3 domain, resulting in defective assembly and secretion of VWF 
multimers.  VWF mutants that are classified to group II undergo normal processing and 
secretion but loss of large and intermediate molecular weight multimers takes place in 
plasma, due to increased ADAMTS13 proteolysis caused by mutations in the A2 
domain.  
Type 2B refers to VWF mutants with increased affinity for platelet GPIbα.  The 
responsible mutations are cluster within or near the A1 domain, which contains the 
GPIbα binding site. Mutated VWF shows an increased ristocetin-induced platelet 
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aggregation (RIPA) at abnormally low concentrations of ristocetin. Paradoxically, 
patients with VWD type 2B do not suffer from thrombosis but bleeding. This can be 
explained by the increased clearance of both VWF and platelets, leading to absence of 
haemostatically effective high molecular weight multimers in plasma and a variable 
thrombocytopenia. 
Type 2M refers to VWF mutants with decreased platelet adhesion but normal VWF 
multimer distribution. The functional defect is caused by mutations in the GPIbα 
binding site in the A1 domain, which disrupt VWF binding to platelets.  
Type 2N refers to mutants with markedly decreased affinity for factor VIII, and 
consequently low FVIII levels due to enhanced clearance. Mutations that lead to type 
2N VWD are localised within the FVIII binding site of VWF domains. Since VWF is 
physiologically in excess of FVIII the phenotype is autosomal recessive.  
1.14 VWF glycosylation  
Protein glycosylation is exceptionally abundant and structurally diverse 
posttranslational modification. A large proportion of proteins and lipids in biological 
systems are glycosylated. Carbohydrate chains attached to extracellular proteins can act 
as ligands for receptors and mediate recognition and also modify biochemical properties 
of proteins, such as charge, folding, solubility and sensitivity towards proteases.369,370 
Moreover, many nuclear and cytoplasmic properties in eukaryotes undergo dynamic 
glycosylation, which may be an important regulatory modification, reciprocal to 
phosphorylation, modulating biological processes.371 Glycosylation can also be used as 
a way to expand the information of a small genome. For instance, a single gene product 
such as tissue plasminogen activator (tPA) can be a foundation for over 100 discrete 
protein glycoforms with different enzymatic activities and plasma clearance.372 The 
complexity and heterogeneity of glycans, as well as their template-independent 
biosynthesis has made it difficult to characterise them or modulate their function.  
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Figure 1.10 Types of glycans 
Examples of linear and branched glycans are illustrated. A) Glycosaminoglycans 
(GAGs) are the major category of linear polysaccharides comprised of disaccharide 
repeat units of alternating uronic acids linked to hexosamines, attached to a core 
tetrasaccharide. B) Branched glycans include N- and O-linked oligosaccharides. N-
linked glycans can by divided into high mannose, hybrid, and complex. O-linked 
glycans are further subdivided by core type.   
 
Glycans are categorised into two broad groups: branched and linear (Figure 1.10). 
Linear glycans are represented by glycosaminoglycans(GAGs) such as heparin sulphate 
chondroitin or dermatan sulphate373 while branched glycans are further divided into N- 
linked and O-linked oligosaccharides.374 VWF undergoes posttranslational 
modifications resulting in addition of N- and O-linked glycan chains which comprise 
18.7% of the total molecular weight12 (with N-linked glycans accounting for 70% of the 
carbohydrate component and O-linked glycans accounting for 30%)(Figure 1.11)375,376.  
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Figure 1.11 VWF glycosylation 
VWF contains a predicted 16 N- and 10 O-linked glycosylation sites. 4 potential N-
linked glycan sites are present in the propeptide (D1, D2) and 12 are distributed 
throughout the mature protein. Conversely 8 O-linked glycans are clustered in the A1 
domain flanking regions. One O-linked oligosaccharide is present in the A3 domain and 
one in the D4 domain. 
 
1.14.1 N-linked glycosylation  
N-linked glycosylation is one of the most common co/posttranslational modifications. 
N-linked glycosylation is initiated in the ER by en bloc attachment a 14-saccharide 
moiety (‘core’ oligosaccharide) onto a nascent polypeptide chain.19 This core structure 
(Glc3 Man9GlcNAc2) is linked via an N-acetylglucosamine residue to an asparagine 
residue in the sequence NXS/T (or in some cases NXC) where X is any amino acid 
except proline.  Subsequently the terminal glucose residues are removed by Glucosidase 
I and II. The resulting monoglucosylated structure associates with  ER lectin chaperones 
calnexin and calreticulin, and protein disulphide isomerases including ERp57. When the 
glycoprotein has folded correctly, the final glucose residue is removed by Glucosidase 
II, allowing release from calnexin and calreticulin, and transit to the Golgi apparatus. 
Mannosidases further process the carbohydrate structure. Additional GlcNAc or 
galactose or N-acetylneuraminic acid residues are added to Man3GalNAc2 structure to 
form complex N-linked glycans.377-380 Endothelial cells can also add terminal fucose 
residues in an α1-2 linkage to a precursor glycan chain creating the H-antigen , which 
can be further modified to blood group A or B antigens by addition of GalNAc or 
galactose residues respectively.381 
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VWF presents sixteen N-linked oligosaccharides; four are predicted to be in the 
propeptide (N99, N156, N211 and N666) and twelve are present in the mature subunit 
N1515, N1574, N2223, N2290, N2357, N2400, N2546, N2585, N2790.12 (Figure 1.11) 
In a number of initial studies VWF glycan structures were isolated and sequenced. A 
detailed study of VWF N-linked glycans was performed by Matsui, Titani and 
Mizuochi. All studies demonstrated that VWF carries a mixture of complex glycans, 
with variable number of branches as well as number and identity of terminal sugar 
residues. A bi-antennary, glycan was shown to be a major N-linked glycan type 
presented by VWF (~70%).20,382,383 
N-linked glycans fulfil several important functions; for instance they assist in protein 
folding, disulphide bond formation, prevent aggregation, enhance thermal and kinetic 
stability of  proteins and protect them from proteolysis.380,384,385 The role of N-linked 
glycans on VWF function and structure has been studied extensively. N-linked 
glycosylation is necessary for dimerisation of VWF since treatment of endothelial cells 
with Tunicamycin that blocks N-linked glycosylation results in the accumulation of 
VWF monomers within the cell.16,17 Castanospermine, that prevents initial trimming of 
glucose residues, was also shown to inhibit VWF secretion, suggesting that interaction 
with ER chaperones in required to assist in processing of N-linked oligosaccharides.17 
Furthermore, presence of certain N-linked glycan chains was shown to be important for 
the proper intracellular processing as well as storage and secretion of VWF, as their 
removal resulted in protein retention within the ER.17 Furthermore prevention of 
glycosylation at individual sites resulted in increase in free thiol reactivity. This 
suggests that VWF N-linked glycans can modulate inter- and intra-molecular disulphide 
bond formation.17 
The effect that removal of terminal sialic acid and/or terminal galactose residues from 
oligosaccharide chains, has on VWF structure and function is not clear. A number of 
studies have suggested that removal of those residues results in the loss of high 
molecular weight multimers,386-388 while others reported that it does not have an effect 
on VWF multimeric composition. However it is possible that the results from the earlier  
studies were confounded by the use of impure PNGase enzymes.389 A recent study 
clearly demonstrated that removal of the entire N-linked glycan chains by PNGaseF 
does not alter VWF multimeric structure.239 
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VWF N-linked glycans have been shown to present ABO group determinants.20,239 
Interestingly, ABO group structures influence the plasma level of VWF, with VWF 
levels 25% lower in group O than non-O individuals.376,390,391 In addition, within non-O 
blood group VWF levels were highest in AB individuals, followed by group B, group A 
and lowest levels were observed in group O individuals.392 ABO antigens also influence 
VWF susceptibility to ADAMTS13 proteolysis, with the O group being the most 
susceptible.393 
Finally, removal of N-linked glycans increased susceptibility to ADAMTS13 cleavage 
and allowed cleavage under static conditions in the absence of denaturants.239 Two N-
linked oligosaccharides flank the ADAMTS13 cleavage site (N1515 and N1574). 
Mutation of N1574, to prevent glycosylation at this site, results in increased sensitivity 
to ADAMTS13 proteolysis. This suggests N-linked glycans modulate the interaction 
between VWF and ADAMTS13.239  
1.14.2 O-linked glycosylation  
The most common form of O-linked glycosylation in eukaryotes is mucin-type 
glycosylation, which is initiated by α-O-linking of N-acetylgalactosamine (GalNAc) to 
the β-hydroxyl group of either a serine or a threonine of the polypeptide chain.394-396 
Following addition of the first residue, O-linked glycans are synthesised by sequential 
addition of monosaccharides using specific transferases. Other types of O-linked 
glycosylation are rare or restricted to certain species, tissues or proteins. Examples of 
alternative types of O-linked glycans attached to Ser/Thr include: β-O-xylose found on 
proteoglycans, α-O-fucose on epidermal growth factor (EGF)-like domains397 and α-O-
mannose in yeast and mammalian glycoproteins. Moreover, the structure Galβ-O-
hydroxyLys is found in collagens398 and Araβ-OhydroxyPro on plant cell wall 
proteins.399 Finally, nuclear and cytoplasmic eukaryotic proteins can be glycosylated at 
multiple sites by single O-linked N-acetylglucosamine (O-GlcNAc) residues.400,371 
Mucins are high molecular weight polymeric glycoproteins present in the mucous gel 
that protects the mucous epithelium, or cell surface-bound molecules which can take 
part in cell adhesion. Mucins glycoproteins are very heterogeneous at mRNA, protein, 
as well as carbohydrate levels. The characteristic property of mucins is the presence of 
tandem repeat domains that contain identical or similar sequences rich in serine, 
threonine and proline residues and are highly glycosylated.401 Mucins are glycoproteins 
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with dense clusters of O-linked sites bearing up to 20 monosaccharides per glycan; 
however mucin type glycosylation can also take place at singular positions on non 
mucin proteins.  
1.14.2.1 Synthesis of O-linked glycans  
The biosynthesis of mucin-type glycosylation takes place in the Golgi apparatus, 
following N-linked glycosylation, protein folding, and oligomerisation. As mentioned 
above, O-linked glycosylation is initiated by the transfer of GalNAc residue from a 
nucleotide sugar donor (UDP-αGalNAc) to serine or  threonine.402 This process can be 
mediated by at least 15 UDP-GalNAc:polypeptide N-acetyl-galactosaminyltransferases 
that have overlapping but different specificities and are expressed differently  among 
tissues.403-406  GalNAc transferases are membrane glycoproteins located in variable 
regions of the Golgi, which may also govern their specificity.404  
No consensus sequence has yet been determined, but the likelihood of O-linked 
glycosylation occurring can be predicted from comparative studies, basing on the amino 
acid sequence surrounding the Ser/Thr residue (NetOglyc server 
www.cbs.dtu.dk/services/netoglyc).369 O-glycosylation will only occur on exposed 
Ser/Thr residues which are mostly on β-turns of the secondary structure and other 
regions with extended conformations i.e. rich in proline residues and regions with low 
hydrophobicity and it will not occur near large amino acid residues. It is suggested that 
the mucin type glycosylation of multisite substrates occurs in a hierarchical manner, 
since some of the transferases can only glycosylate peptides which are already 
glycosylated.407-409 In addition, studies have showed that the density and glycosylation 
pattern can affect the activity of transferases; for instance addition of galactose residue 
to the GalNAc-Ser/Thr moiety can affect the extent of activity on neighbouring 
sites.396,410 
The α-O-GalNAc-Ser/Thr structure is a foundation for various ‘core’ structures, which 
are generated by addition of other monosaccharides to the C-3 and/or C-6 hydroxyl 
groups of GalNAc. To date, eight core structures have been identified  with core 1 and 2 
being the most common among both mucin and non-mucin glycoproteins.411 
Unmodified α-O-GalNAc-Ser/Thr structures are seldom found in glycoproteins in 
normal tissues but are abundant in mucins from cancer cells and are termed Tn 
antigens.412  The core structures can be further modified by sialylation, sulphatation, 
72 
 
acetylation, fucosylation, and polylactosamine-extension, and form complex structures 
such as sialyl LewisX and blood group antigens. The core 1 structure is normally 
substituted with sulphate, sialic acid or other sugars, but in cancer remains often 
unsubstituted and constitutes the T antigen.412 The synthesis, extension and termination 
of O-linked glycans is regulated by transcriptional and translational control, transport of 
substrates through the Golgi apparatus, concentration of cofactors, as well as interaction 
of glycosyltransferases (GTs) with other proteins.412-414   
 
 
Figure 1.12 Pathways specific for the assembly of the O-linked glycans 
Schematic illustration of the O-linked glycans biosynthesis. Mucin type glycosylation is 
initiated by addition of N-acetylgalactosamine (GalNac) residue to serine or threonine 
of the polypeptide, and then specific transferases (above the arrows) catalyze sequential 
addition of monosaccharides creating a number of different glycan structures.  
 
More than 80GT families have been identified. Importantly each GT is specific for both 
the sugar donor and the acceptor substrate. Functions of transferases can be altered by 
hormones, cytokines and other external factors. Organ specific suppression of specific 
GTs and up regulation of others results in the formation of cancer-associated changes in 
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O-linked glycans as demonstrated for breast and colon cancer.396,415 Changes in the 
elaboration of O-linked glycan chains are associated with a range of diseases, for 
instance Wiskott-Aldrich syndrome, haematological disorders, cystic fibrosis and 
cancer.412,416,417 
1.14.2.2 Function of O-linked glycans 
O-linked glycans can constitute 80% of the mucin mass and confer viscous, gel-
forming, and adhesive properties, thus providing lubrication and a protective barrier for 
various body tissues.401,418,419 Extensively O-glycosylated regions of mucins can block 
accessibility of the peptide backbone to proteases therefore protecting it from 
degradation. 420 Mucin type O-linked glycans can also regulate the serum half-life of 
chemokines and hormones, and mediate intracellular trafficking of proteins.421-424 
Moreover, it has been shown that mucin glycans can determine the aggregation state of 
membrane bound glycoproteins (e.gCD45) thereby modulating signalling and 
interaction with receptors.425 Apart from modulating protein function, O-linked glycans 
are often ligands for cell surface receptors and play important roles in the immune 
system. They have been shown to interact with natural killer cells, lymophocytes, 
dendritic cells, and other leukocytes. For instance the sialyl-Lewisx structure is a ligand 
for selectins (E-, L-, P) and mediates leukocyte adhesion to sites of inflammation as 
well as the rolling of leukocytes along the endothelial surface.426-428 In addition, O-
linked glycans were demonstrated to play roles in cell-adhesion events during sperm-
egg interaction,429 host-microbe contacts430 and viral infections431. In vitro experiments 
showed that O-linked glycans on cancer cells can bind to selectins and endothelial cells, 
which can contribute to the invasive and metastatic properties of tumours. 
432,433Glycosylation with an O-GlcNAc moiety of nuclear and cytoplasmic proteins such 
as c-myc, p53, RNA polymerase II, and tau, is reciprocal to phosphorylation. It is highly 
dynamic and responsive to changes in cellular stages and signalling and may have a 
reverse function to phosphorylation, thus is thought to take part in regulation of 
transcription, nuclear transport and cytoskeletal assembly.371,434-437  
O-linked glycosylation may also influence the secondary, tertiary, and quaternary 
structure of the folded protein. Glycans introduce steric hindrance, and the polypeptide 
they are attached to can adopt a rigid, extended conformation, with length up to 
hundreds of nanometers in length as demonstrated by AFM, light scattering and nuclear 
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magnetic resonance studies438-445 For example, removal of O-linked glycans from the 
ovine submaxillary mucin causes change of its structure from elongated filamentous to 
globular.446-448  
Another interesting aspect of glycosylation is the presence of the O-glycosylated 
Ser/Thr/Pro rich domains, for example in the hinge regions of immunoglobulins IgD 
and IgA. The O-linked glycan chains in this region can extend the peptide chain, due to 
repulsion between the charge sugars, and protect the region from protease cleavage. O-
linked glycans in the hinge also mediate the IgA and IgD binding to a lectin site on T-
lymphocytes in vitro.449,450 In individuals with IgA nephropathy the O-linked glycans in 
the IgA hinge region express less sialic acid and/or galactose residues, which results in 
the kidney deposition of immunoglobulins.451  
1.14.3 VWF O-linked glycans structure and function 
Ten O-linked oligosaccharides are added to each VWF molecule. Eight of the O-linked 
oligosaccharides are clustered in the A1 domain flanking regions (T1248, T1255, 
T1256, S1263, T1468, T1477, S1486, T1487 aa), one is present between the A2 and A3 
domains (T1679 aa) and one is attached within the D4 domain (S2298 aa)12 (Figure 
1.11). A major structure of O-linked glycan has been determined as a di-sialylated core 
1 structure known as the sialylated T-antigen12,452,453 (Figure 1.13).  
 
 
Figure 1.13 Major tetrasaccharide structure of the O-glycans of VWF 
VWF is predicted to contain 10 O-linked glycan sites with the major structure to be 
disialyated core 1 also known as the T-antigen. Two sialic acid residues are linked to C-
3 of galactosyl and C-6 of N-acetylgalactosaminitol residues. (NeuAc- N-
acetylneuramic acid, GalNAc- N-acetylgalactosamine) 
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The VWF region containing the A domains is particularly enriched in glycan side 
chains. 8 of 10 O-linked glycans are positioned near regions designated as important for 
platelet binding suggesting they might be part of mechanisms regulating the exposure of 
the GPIbα binding site.289 Four O-linked glycans are clustered in the N-terminal 
extension of the A1 domain which interacts with the β-finger of GPIbα, therefore the 
presence and composition of the O-linked glycans might alter the binding between 
VWF and GPIbα. As mentioned beforehand O-linked glycans can provide rigidity to a 
peptide backbone and stabilize otherwise flexible regions.439 O-linked glycan clusters in 
VWF might stabilise the potentially flexible linker regions flanking the A1 domain and 
thus modulate A1 domain interactions. In addition interactions between the A1 and the 
A2 domains could be affected by glycan residues in the vicinity of these domains. 
The properties of recombinant VWF lacking O-linked glycosylation have been 
previously investigated, however often with conflicting results. VWF expressed in 
Chinese hamster ovary cells with a defect in carbohydrate synthesis (CHO ldl-D), 
therefore lacking O-linked oligosaccharides, was shown to be synthesized, multimerised 
and secreted in the same way as fully glycosylated form.454 Moreover, when devoid of 
O-linked glycans, VWF bound heparin and collagen type I with normal affinity but 
exhibited diminished reactivity with GPIbα, and platelet agglutination in the presence of 
ristocetin. However platelet binding potential was normal in the presence of 
botrocetin.454 
Conversely, the isolated VWF-A1 domain expressed in COS-7 cells under O-
glycosylation blocking conditions exhibited increased platelet aggregation potential 
compared to the fully glycosylated protein. Simultaneous mutation of S1253, T1255 and 
T1256 residues to prevent predicted O-linked glycosylation of these sites resulted in 
increase platelet aggregatory responses. However, deletion of only one O-linked 
oligosaccharide (T1468) led to decreased platelet aggregation.455  
There are limited data regarding the correlation between VWF levels and its O-linked 
glycosylation profile. Firstly, recombinant VWF expressed under glycosylation 
blocking conditions displayed a reduced half-life when administered in rats. 456 More 
recent studies examined the association between VWF levels and the presence of the 
major VWF O-linked oligosaccharide sialylated core 1 structure (T antigen; Gal-
GalNAc-Ser/Thr). To investigate that, an immunosorbent assay has been developed, in 
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which peanut agglutinin (PNA) binds to core 1 structure of desialylated VWF. 
Interestingly, an inverse nonlinear association between PNA binding and VWF plasma 
levels was observed, suggesting that variations in glycosylation of VWF with O-linked 
sialylated T antigen are associated with its plasma levels. In addition, a linear 
correlation between PNA binding and propeptide/VWF ratios has been demonstrated, 
suggesting a putative relationship between the extent of VWF O-linked glycosylation 
and VWF survival. Moreover, VWF released from WPBs following treatment with 
DDAVP, exhibited a decrease in PNA binding, implying that the O-linked glycosylation 
pattern of VWF stored in WPBs differs from VWF that circulating in plasma.457   
1.15 Sialic acid  
Sialic acids are a family of electronegatively charged monosaccharides including around 
50 members, which are derivatives of neuraminic acid (Neu Neu 5-amino-3,5-dideoxy-D- 
glycerol-D-galacto-non-2-ulopyranosonic acid).  The most common sialic acid is N-
acetylneuraminic acid (NeuAc). Sialic acids are essential in higher organisms because 
inhibition of their biosynthesis (by inactivation of the key enzyme of sialic acid 
biosynthesis UDP-N-acetlyglucosamine-2-epimerse/N-acetylmannosamine kinase) 
during early development of mice is lethal.458 Glycans can be terminated with the sialic 
acid in α2-3 and 2-6 linkage to Gal residues or α2-6 to GalNAc. Sialylation typically 
stops chain growth and further branching; however in some cells sialic acid polymers, 
where sialic acid residues are connected via α2-8 linkages are formed.402 Three families 
of sialyltransferases have been identified; α3-sialyltransferse -ST3Gal, α6-
sialyltransferse ST6GalNAc-I and II, and ST6GalNAc-III and IV. Sialyltransferases 
have various specificities towards both the acceptor glycan and the type of sialic acid 
linkage formed.459 All ST3Gal enzymes can add sialic acid to Galactose residues, while 
ST3Gal-I and IV can sialylate the Galβ1-3 residue attached to GalNAc-Thr. 
ST6GalNAc acts on the GalNAc or Galβ1-3GalNAc residues.460,461  The sialic acid-
containing glycans can exhibit a dual role, as they can either shield underlying antigens, 
or become ligands and determinants for cell adhesion molecules like lectins or bacteria 
and viruses.462 Desialylation can lead to recognition of macromolecules and cells by the 
complement and immune system, and targeting cells to specific sites often for 
degradation.414,463 It has been recognised for a long time that removal of terminal sialic 
acid and exposure of Gal residues leads to increased clearance of various plasma 
glycoproteins and cells (ceruloplasmin, fetuin, hormones, erythrocytes, prothrombin and 
77 
 
bacteria.463-466 Therefore hypersialylation is often used as a protective mechanism, as 
observed for bacteria. 
Both the N- and O-linked glycan chains of VWF contain terminal sialic acid       
residues,20,375,452 and enzymatic removal of these residues can alter glycoprotein 
conformation.452 It has been shown that the removal of sialic acid from the carbohydrate 
chains of VWF by treatment with neuraminidase results in increased sensitivity to 
proteolysis by trypsin, chymotrypsin and plasmin, within the N-terminal region.467 
Therefore it clear that sialylation is important in protecting VWF against plasma serine 
and cysteine proteases. A different study has demonstrated that desialylation of 
VWF/VIII leads to decrease in ristocetin dependent platelet aggregation and facilitates 
its rapid clearance.468  Even though sialic acid protects VWF from proteolytic 
degradation by plasma proteases it was shown it specifically enhances proteolysis by 
ADAMTS13.469 Specifically, expression of α2-6 linked sialic acid, predominantly on 
the N-linked glycans appears to mediate this effect. 20,383,469  
1.16 VWF clearance, role of carbohydrates 
The mechanism by which VWF is cleared from plasma is not well understood. Several 
parameters have been shown to influence VWF clearance such as glycosylation and a 
number of VWF missense mutations. For example, accelerated VWF clearance is a 
pathophysiological mechanism in some cases of VWD type I (VWD Vicenza). 
However, no dominant clearance receptors that mediate the cellular uptake of VWF 
have been characterised.  
As pointed out before ABO blood groups greatly influence circulating VWF levels, with 
the group O individuals having the lowest VWF values and the mechanism underlying 
variation has been extensively investigated.470 A number of studies suggest that ABO 
groups influence VWF survival but not its synthesis or release from endothelial cells. 
Firstly, the VWF propeptide to VWF antigen ratio, which is used for predicting an 
increase VWF clearance was shown to be significantly higher in the O than non- O 
subjects. In addition, the elimination half-life of VWF following DDAVP treatment was 
significantly shorter in individuals with blood group O when compared to non-O. 471  
Furthermore, it has been suggested that different susceptibility to ADAMTS13 
proteolysis,393 possibly mediated by the ABO antigen structures on the N-linked 
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glycans, particularly H-antigen expression390 may be one of the reasons for variability in 
VWF levels between blood groups. To support this, in a study using Duch Kookier dogs 
with VWF deficiency, HMW VWF was demonstrated to have a  longer high life than 
LMW VWF.472 The opposite effect was observed in a study using rats, in which HMW 
VWF were shown to be cleared from circulation faster than VWF dimers.456 On the 
other hand, a recent study on VWF knock-out mice model demonstrated that high and 
low molecular weight multimeric VWF have a similar survival.368 and another study 
found no difference in the survival and clearance between the wtVWF and a 
proteolysis-sensitive VWF variant in the rat model.456 Therefore, to date, no convincing 
difference in the clearance of intact VWF and VWF cleaved by ADAMTS13 has been 
shown. Furthermore, no association between ADAMTS13 levels and the survival of 
post-desmopressin VWF from patients with VWD type 1 or haemophilia could be 
detected, further implying that VWF cleavage by ADAMTS13 is not involved in its 
survival.473 Finally, mice strains deficient in ADAMTS13 and/or deficient in VWF were 
used to look at endothelial and hepatocyte derived-VWF clearance.474 In this study, 
clearance of endogenous VWF in both the wild type ADAMTS13 and ADAMTS13 
deficient mice was equivalent. Moreover, VWF expressed by hepatocytes following 
hydrodynamic tail injection in VWF deficient mouse strain, was eliminated from the 
circulation at the same rate in the ADAMTS13 deficient and wild type mice.474 These 
results demonstrate that ADAMTS13 proteolysis of VWF is not associated with VWF 
clearance, at least in an in vivo mice model.  
In order to establish the role of various domains VWF in its clearance, a VWF knock-
out mouse model has been used to examine the survival of truncated VWF variants. To 
begin with, studies using this animal model demonstrated that clearance rates of the 
recombinant A1A2A3 were comparable to FL-VWF suggesting that major receptor site 
for clearance could be located in the A1A2A3 domains.368 Moreover, deletion of D'-D3 
region resulted in increased VWF clearance, suggesting that this region is important in 
preventing VWF clearance.368 Interestingly, mutation of R1205S localised in the D3 
domain caused accelerated clearance, suggesting that this mutation abrogated the 
protective role of the D’D3 domains. In addition, deletion of the C-terminal D4-CK 
domains resulted in markedly reduced clearance, whereas simultaneous deletion of 
D’D3 and D4-CK regions had no effect.368 Another study utilised the same mice model 
to demonstrate increased clearance of VWF with mutations of cysteine residues at 
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positions C1130, C1149 and C2671, further emphasizing the role of D’D3 domains in 
VWF clearance.106  
O-linked glycans could also play a role in VWF clearance, since expression of VWF 
under O- glycosylation blocking conditions results in expression of VWF with a notably 
reduced half-life: whether the effect was due to removal of terminal residues or entire 
oligosaccharide remains to be established.456  
The clearance of various plasma glycoproteins has been shown to be influenced by both, 
glycan chains and their terminal sialic acid residues.464,475 Therefore it has been 
considered that carbohydrate status might modify VWF clearance. For example, VWF 
with terminal sialic acid residues enzymatically removed has been cleared more rapidly 
from the circulation in the rabbit model, and the clearance was inhibited by 
simultaneous infusion of asialo-α-1-acid glycoprotein that binds to the 
asialoglycoprotein-receptor (ASGPR).468 Moreover, in vitro assays demonstrated that 
desialylated VWF was able to bind ASGPR with similar affinity to asialo-α-1-acid 
glycoprotein, while wt VWF showed negligible interaction with the receptor.468 VWF 
with both sialic acid and then galactose residues removed was not able to bind the 
ASGPR, indicating that Galβ1-4GalNAc is the carbohydrate structure recognised.476 In 
addition, ASGPR can also recognise glycans terminating with sialic acid α2-6 
GalNAc.477 
Sialic acid is attached to VWF by one of six sialyltransferases (ST3Gal I-VI). ST3Gal-
IV and ST6Gal-I can produce α2-3 and α2-6 sialic acid linkages respectively that can 
block recognition of VWF by asialoglycoprotein receptors (ASGPR) that recognise 
exposed Gal and GalNAc residues.476,478 Interestingly no change in PNA binding was 
observed in mice deficient in ST6Gal-I suggesting that this enzyme is not crucial for 
VWF sialylation of O-linked glycans.468 Subsequently, in order to study the role of 
sialic acid in VWF clearance, a murine model was established in which expression of 
ST3Gal-IV has been inhibited, to produce VWF with decreased α2-6 sialic acid content 
and as result increased exposure of Gal residues. Interestingly, mice with ST3Gal-IV 
deficiency had the half-life of VWF reduced 2-fold and reduced VWF and platelets 
levels were detected.478 This observation suggested that VWF sialic acid averts VWF 
clearance via ASGPR receptor. Additionally, to support this theory, in a group of 
patients with bleeding disorder, reduced sialylation and increased exposure of β-linked 
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Gal or GalNAc was observed and shown to be associated with reduced plasma VWF 
levels.478  Furthermore it has been established that the RIIIS/J mice with naturally 
reduced plasma VWF levels, expresses N-acetylgalactosaminyltransferase in the 
vascular endothelial cells instead of intestinal epithelial cell as happens in normal 
humans and animals. Expression of this transferase resulted in modification of VWF 
glycan structure, with increased GalNAc presentation. This atypically glycosylated 
VWF was then showed to be cleared via ASGPR significantly faster than the wild type 
VWF. 479-482 
Several studies have investigated which routes and which types of receptors participate 
in the removal of VWF from the circulation. The VWF knockout mouse model has been 
used to investigate in vivo VWF clearance and identify cells that contribute to the 
uptake of VWF. It has been suggested that VWF binds to macrophages in both the liver 
and the spleen. Bound VWF is subsequently rapidly internalised and degraded 
suggesting that macrophages in the liver and the spleen have the capacity to remove 
VWF from the circulation.483 In addition, VWF was demonstrated to be a ligand for the 
Ashwell receptor, which is a major lectin of hepatocytes, responsible for removal of 
sialo- and asialo-glycoproteins from circulation, implying that hapatocytes are also 
involved in the clearance of VWF.484 Furthermore, it has been shown that Man/GlcNAc, 
Fuc, phosphomannosyl residues can be recognised by other carbohydrate receptors in 
the liver, therefore recognition via these residues could also contribute to VWF 
clearance.475 Despite a great deal of circumstantial evidence, the structural basis for 
VWF clearance remains obscure and it is not clear which of the possible or which 
combination of mechanisms is most important or whether the pathological examples use 
these or other clearance mechanisms. 
1.17 Mass spectrometry 
Mass spectrometry (MS) is an analytical technique used to determine masses of 
particles, elemental composition of samples and to elucidate the chemical structure of 
molecules such as peptides or oligosaccharides. Mass spectrometers generate ions, and 
separate them according to their mass to charge (m/z) ratio and measure their respective 
abundance. They consist of three main components; an ionisation source, one or more 
mass analysers and a detector. In this project a matrix assisted laser desorption 
ionisation (MALDI) was used as a source of ionisation. Other sources are electrospray 
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ionisation (ESI) or electron ionisation/impact (EI). In MALDI-MS, the sample is co-
crystallised with a low molecular weight matrix on a metal target and introduced into 
the high vacuum MALDI source. Irradiation by laser pulses induces desorption of the 
sample and its ionisation by proton transfer between the photo-excited matrix and the 
analyte. Charged molecules can then be accelerated by an electrical field and send into 
the analyser.  
The two most common analysers are quadrupole and time-of-flight (TOF) analysers. 
The tandem mass spectrometry techniques (MS/MS) combine two or more analysers. In 
quadrupole analysers, ions are separated according to their (m/z) ratio using the stability 
of their trajectories in oscillating electrical fields. In TOF analysers, the separation and 
measurement of ions are based on the kinetic energy relation (Ek = ½ mv2 , then m = 
2Ek / v2 = 2Ek / [dd/dt], where Ek is the kinetic energy, m is the mass and v the velocity 
of the analyte, d being the distance and t the time of flight). According to the equation 
when the kinetic energy as constant, ions of different mass travel through a field-free 
region at different velocities. Ions formed in the source are simultaneously accelerated 
into a linear flight tube and reach the detector after travelling a known distance. The 
(m/z) ratios are determined by based on the time it takes for ions to travel through the 
field-free region. In the tandem MS, the first mass analyser allows only selected (m/z) 
precursor ion to pass through and become fragmentised and then resulting fragment ions 
are re-analysed in the second analyser. 
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2 AIMS OF THESIS 
The aim of this thesis is to fully characterise the role of VWF O-linked glycans on the 
function of the VWF molecule. Initially I will produce recombinant VWF O-linked 
glycan variants and determine if these have altered expression and function o using a 
wide range of assays. Additionally, detailed mass spectroscopy analysis will be 
performed to determine the nature of the O-linked glycans presented on recombinant 
VWF and how similar they are to plasma derived material. Specifically, this thesis will 
then focus on two important aspects of VWF biology; firstly the effect of O-linked 
glycans and their terminal sialic residues in mediating susceptibility to proteolysis by 
ADAMTS13 and secondly, the role that O-linked glycans play in mediating VWF 
interaction with platelets. To investigate the interaction of VWF with platelets I will 
develop a static plate binding assay to provide a reproducible measure of the interaction 
of VWF with GPIbα. Subsequently I will then optimise an in vitro flow based assay to 
investigate the functional role of VWF O-linked glycans under conditions of 
physiological shear stress. This assay will be used to investigate the role of O-linked 
glycans and sialic acid on the ability of VWF to capture platelets and mediate platelet 
translocation, and to determine kinetic parameters for the interactions such as the koff 
and kon rate constants. 
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3 MATERIAL AND METHODS 
3.1 General molecular biology techniques  
3.1.1 Site-directed mutagenesis  
Mutations were introduced into VWF cDNA using the QuickChange® XL site-directed 
mutagenesis kit (Stratagene) in accordance with manufacturers’ instructions. The 
polymerase chain reaction (PCR) reaction mixture consisted of 2.5U high fidelity Pfu 
ultra DNA polymerase, 125ng of complementary primers containing the desired 
mutation, 10ng of dsDNA template, 1X reaction buffer, 10mM dNTP’s and 3µl of 
QuickSolution in a final volume of 50µl. The primers used in each amplification 
reaction are shown in Appendix A. The PCR amplification consisted of an initial 
denaturation (95ºC, 1 min); 18 cycles of: denaturation (95ºC, 50 sec), annealing (60ºC, 
50 sec) and extension (68ºC, 1 min for 1kb); and final extension (68ºC, 7 min). 
PCR products were digested with 10 U of DpnI for 1 hour at 37ºC to digest the 
methylated template DNA. The mutagenesis reactions were transformed into XL-10 
gold cells as described in section 3.1.5. 
3.1.2 Restriction endonuclease digestion of plasmid DNA 
Restriction endonucleases recognise specific sequences in double stranded DNA and 
induce strand breaks, creating cohesive or blunt ends.  Restriction digests were 
performed using New England Biolabs restriction enzymes and buffers. Reaction 
mixtures consisted of ~5ng DNA, 20U of the appropriate enzyme and buffer. The 
reaction mixture was than incubated at the optimum temperature for 1 hour.  After 
cleaving the DNA, digestion products were analysed and separated with agarose gel 
electrophoresis (see section 3.1.4) and purified using the gel extraction kit (Qiagen, 
UK).  
3.1.3 Ligation of plasmid vector and insert DNA 
DNA ligase catalyzes the formation of a phosphodiester bond between the 5' phosphate 
of one strand of DNA and the 3' hydroxyl of another. Ligation reactions were carried 
out after both insert and vector DNA had been digested with the appropriate enzymes to 
generate compatible ends for cloning (see section 1.2). The standard ligation mixture 
contained vector and insert DNA at the ratio of 1:3, 2μl 5X ligase buffer, 0.5μl T4 DNA 
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ligase and sterile water to final volume of 10μl. The mixture was incubated overnight at 
4°C and then used for transformation (section 3.1.5). 
 
3.1.4 Agarose gel electrophoresis of DNA 
Horizontal agarose gel electrophoresis was the technique used to separate DNA 
molecules depending on their size (according to the methodology of Sambrook et al., 
1989).  To prepare a gel, agarose powder was mixed with Tris-borate-EDTA buffer 
(TBE- 40 mM Tris base-40nM boric acid, 1 mM EDTA, pH 8.0) to the desired 
concentration and then heated in a microwave oven until completely melted.  The 
solution was cooled and SYBRTM was added to facilitate visualization of DNA after 
electrophoresis (final concentration in gel 5 μg/ml).  Gels were then poured and allowed 
to polymerise for 20mins at 4°C. Samples were prepared by mixing with 6X gel loading 
buffer (40% (w/v) sucrose in deionised water containing 0.1% bromophenol blue) and 
loaded into the wells. Electrophoresis was carried out for approximately 1 hour at a 
constant voltage of 75V.  DNA ladder molecular weight markers (NEB) were run 
alongside the samples in order to determine the molecular size of DNA fragments.  The 
gel was examined on a Bio-Rad FluorS machine equipped with a UV filter to enable 
visualization of the DNA fragments.  
3.1.5 Transformation of competent bacterial cells 
20µl of competent cells [XL10-Gold ultra competent E.coli cells (Stratagene); NEB 
Turbo; One Shot®Top10 (Invitrogen)] were thawed on ice and 0.5-2µl of ligation or 
plasmid samples were added and then incubated on ice for 30 min.  Heat shock was 
performed at 42ºC for      30sec and then the cells were incubated on ice for 2 min at 
4ºC.  200μl SOC media (Invitrogen) was added to each transformation reaction and then 
incubated for 1 h at 37ºC in shaking incubator. Following this they were plated onto LB 
agar plates containing the appropriate antibiotic, and incubated overnight at 37ºC. 
3.1.6 Isolation of plasmid DNA 
Isolation of plasmid DNA was performed using; plasmid Miniprep kits (Qiagen,UK) for 
small scale plasmid isolation (up to 20μg DNA) and plasmid endo-free Maxiprep kits 
(Qiagen, UK) for large scale plasmid isolation (up to 500μg DNA), both according to 
manufacturers’ instructions. Both kits operate on a principle of bacterial cell lysis, 
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followed by precipitation of denatured proteins, chromosomal DNA and cellular debris 
and then elution of plasmid DNA. 
3.1.7 Agar Plates and Luria-Bertani (LB) Media ± Ampicillin, Kanamicin  
Laura-Bertani media or agar were dissolved in distilled water according to 
manufacturer’s instructions (Invitrogen,UK) and subsequently autoclaved. Once the 
temperature of the media was below 55°C, either sterilised Ampicillin or Kanamicin 
were added to a final concentration of 100µg/ml and 50µg/ml respectively. For agar 
plates, 20ml of molten LB agar was poured into a 10cm2 petri dish and allowed to set. 
LB media and LB agar was stored for a maximum of 2 weeks at 4°C. 
3.1.8 Gel extraction 
After electrophoresis the bands of interest were excised from agarose gels and purified 
using the QIAquick gel extraction kit (QIAgen, UK) as per manufactures instructions. 
Briefly, bands of interest were excised from the gel using a clean razor blade, weighed 
and solubilised with 3 volumes buffer QG for 10mins at 50°C. Subsequently 1 x volume 
of isopropanol was added to the dissolved bands and the sample applied to the silica-gel 
column and centrifuged for 1min at 13000rpm to bind DNA. Flow through was 
discarded and 0.5ml Buffer QG was applied to the column and centrifuged for 1min to 
remove traces of agarose, then the 0.75ml Buffer PE was applied to the column and 
centrifuged to wash the DNA. The column was centrifuged for an additional 1min to 
remove all traces of wash buffer. Finally, DNA was eluted by the addition of 30μl 
Buffer EB and centrifugation for 1min at 13000rpm 
3.1.9 Cloning and expression vectors 
pcDNA3.1/Myc-His (A+) 
The pcDNA3.1 (Invitrogen) is a 5.5kb vector that contains the following elements: a 
human cytomegalovirus (CMV) and immediate-early promoter/enhancer that permits 
efficient, high level gene expression in mammalian cells; a multiple cloning site; pUC 
origin that allows high-copy number replication and growth in E.coli; an SV40 early 
promoter and origin that allows episomal replication in cells expressing SV40 large T 
antigen and ampicillin and neomycin resistance genes, to allow selection in E.coli and 
mammalian cells respectively.(Figure 3.1) The pcDNA vector used also contained a 
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myc epitope to facilitate immunodetection, and a 6xHis C-terminal tag to allow 
purification. However these were not needed for expression of full length VWF. 
 
 
 
 
 
 
 
 
 
Figure 3.1  pcDNAA3.1/myc-His A(+) mammalian expression vector 
 
 pBlueScript 
The pBlueScript® II SK Phagemid vector (Stratagene), is a 3 kb, high copy cloning 
vector. The MCS, T7 and T3 RNA polymerase promoter sequences are present in the 
N-terminal portion of a lacZ gene fragment (Figure 3.2). A β-galactosidase coding 
sequence is interrupted by the large polylinker (MCS), which allows screening for 
bacterial colonies that contain the desired insert because these have the lacZ gene 
interrupted and will appear white instead of blue. The vector also contains the pUC 
origin that enables high-copy number replication in E.coli and an ampicillin resistance 
gene to allow for selection.   
(Invitrogen)
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Figure 3.2pBlueScript cloning vector 
 
pGEM-7Zf(+) 
pGEM-7zf(+) (Promega) is a 3kb cloning vector that shares the same features as the 
pBS vector.  
3.1.10 Generation of human and murine VWF glycan mutants  
The ~2.kb Xho1-KpnI fragment of VWF was cloned into the 3kb cloning pGEM-7Zf(+) 
vector and used for site-directed mutagenesis of VWF. The XhoI-KpnI fragment 
contained the VWF sequence between amino acid residues 786-1584, encompassing the 
putative eight O-linked glycan sites T1248, T1256, T1256, S1263, T1468, T1477, 
S1486, T1487. This vector was therefore used to mutate the threonine or serine residues 
to alanine residues, to prevent glycosylation at these sites. The A2-CK fragment of 
VWF was cloned into the pcDNA3.1 vector and used for site directed mutagenesis of 
two putative O-linked glycan sites T1679 and T2298 by mutating the threonine residues 
to alanine residues. Ten single mutations and two cluster mutations (Cluster 1: T1248A, 
T1256A, T1256A, S1263A; Cluster 2: T1468A, T1477A, S1486A, T1487A) were 
generated using Quick QuikChange® XL site-directed mutagenesis kit (Stratagene), as 
described (section 3.1.1).The cluster mutants were produced by successive mutagenesis 
reactions. The sequence of the mutants was verified and fragments of VWF containing 
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mutations were subcloned into a vector containing full length VWF. Briefly pGEM 
(XhoI-KpnI) vector and pcDNA 3.1 with sequence coding full length VWF cloned into 
multiple cloning site (MCS) and with one KpnI restriction site removed, (FL-VWF-KpnI) 
were digested with BamHI and KpnI. The digested BamHI–KpnI DNA fragment was 
ligated into a vector containing FL-VWF that had been digested with the same enzymes.  
For mutations in pcDNA3.1-A2-CK, the KpnI-AgeI fragment was digested from this 
vector and subcloned into pcDNA 3.1 FL-VWF-KpnI that had been digested with the 
same enzymes.(Figure 3.3) 
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Figure 3.3 Outline of cloning steps used to generate VWF glycosylation mutants 
Subcloning of mutated BamHI- KpnI fragment from pGEM VWF (A) or mutated KpnI- 
AgeI fragment from pcDNA A2-CK (B) into full length VWF in pcDNA FL-VWF-KpnI. 
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3.1.11 Sequencing  
All the vectors and mutations generated were verified by sequencing to ensure the 
absence of any unwanted PCR-introduced errors and to check the presence of mutations 
introduced by site-directed mutagenesis. DNA sequencing was performed at the 
Imperial College-MRC Genetics Core Facility using an ABI 3700 DNA analyser 
(Perkin-Elmer). 
 
3.2 Cell culture  
3.2.1 General Tissue Culture 
All tissue culture was performed in a class II flow cabinet (FASTER BHG 2004, 
JENCONS-PLS) in a separate laboratory designated specifically for tissue culture. 
Aseptic technique was used at all times. Cells lines were grown in humidified 
incubators (BIOHIT, Biological Instrumentation Service, Lancashire, UK) at 37ºC, in 
5% CO2. Frozen cells were kept in a liquid nitrogen container, at a temperature around -
180ºC. Cultured cells were visualised under an inverted microscope CK2 (Olympus, 
Japan). 
3.2.2 Cell revival   
HEK293T and HEK293 cells stored in 10% DMSO in liquid nitrogen were thawed at 
37ºC, then placed in a T75 tissue culture flask (Nunc) with 4ml of growth media 
[Minimal Essential Medium (MEM) (Sigma), supplemented with 10% Fetal Bovine 
Serum (FBS) (Biosera), 5mM Penicillin/Streptomycin (Invitrogen), 5mM L-Glutamine 
(Invitrogen) and 1 x non-essential amino acids (NEAA) (Sigma).] Cells were allowed to 
attach for 2 hours, then the media was changed to remove residual DMSO and dead 
cells.  
3.2.3 Cell passage 
Once cells had reached 80-100% confluency they were passaged into larger culture 
flasks or split into more flasks. Cells were washed twice with autoclaved phosphate 
buffer saline (PBS) then detached from the flask surface with 0.5-1ml 0.25% 
trypsin/EDTA (Sigma). Trypsin was inactivated by the addition of growth media and 
cells seeded appropriately. 
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3.2.4 Transient transfection of HEK293T cells 
Transient transfection is used to produce recombinant protein without integrating DNA 
into the cell genome. HEK293T cells express high levels of SV40 large tumour (T) 
antigen, which allows episomal replication of SV-40 origin-containing plasmids (i.e. 
pcDNA 3.1). HEK293T cells at ~70% confluency were transfected using 10mM 
polyethyleneimine (PEI). A control transfection was also performed using an empty 
pcDNA3.1 vector. 2-3µg/ml of DNA and PEI at the ratio of 2.25:1 (PEI: DNA) were 
diluted in sterile 150mM NaCl to a required volume. The PEI solution was then added 
drop-wise to the DNA solution and allowed to incubate for 20mins at room temperature. 
During the incubation, growth media was removed from the cells and they were washed 
once with sterile PBS and then Optimem conditioned medium (Invitrogen) was added. 
The DNA:PEI mixture was then applied to the cells and they were incubated for 3 days 
at 37ºC, 5% CO2. The conditioned medium was collected, filtered and if required, 
concentrated using 100kDa cut off spin filters (Amicon) or a Tangential flow filtration 
(TFF) apparatus.  
3.3 General protein techniques  
3.3.1 Protein determination using the Bicinchoninic acid (BCA) assay 
The Bicinchoninic acid (BCA) assay is a biochemical assay for determining the total 
level of protein in a solution. This method is based on the ability of proteins to reduce 
Cu+2 to Cu+1 (cuprous ion) in an alkaline medium. The purple-coloured  reaction 
product is formed by the chelation of two molecules of bicinchoninic acid (BCA) with 
one cuprous ion. The colorimetric intensity correlates with the protein concentration. 
The assay was performed in flat bottomed uncoated 96 well plates.  BCA reagent was 
prepared immediately before use by adding 1 ml cupric sulphate pentahydrate to 50ml 
of bicinchoninic acid.  Bovine serum albumin (BSA) was used as a standard and a series 
of dilutions of known concentrations (range 15-2000µg/ml) were prepared. Serial 
dilutions of the unknown sample were prepared simultaneously. 25µl of each standard 
or unknown sample were applied in duplicate to the wells of a plate. 200µl of the BCA 
reagent were added to each well and incubated at 37°C for 30 minutes on a plate shaker. 
The absorbance was measured at 540 nm using a plate reader (Biotek). The protein 
concentration of the unknown sample was determined by reading from the BSA 
standard curve. 
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3.3.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Different sizes of NuPAGE Bis-Tris precast polyacrylamide gels (Invitrogen) were used 
to resolve proteins of different molecular weights using SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples to be analysed under non-reducing conditions 
were diluted with 4 X SDS loading buffer, (200mM Tris, 8%SDS, 0.4% Bromophenol 
blue, and 50% glycerol). Samples to be analysed under reducing conditions were diluted 
with the same buffer containing 4% w/v β-mercaptoethanol. A pre-stained molecular 
weight protein marker (Invitrogen) was run in parallel with all samples. Samples were 
heated for 15mins at 90ºC,and loaded onto a gel. Electrophoresis was then performed at 
a constant voltage of 200V for approximately 40mins. 
3.3.3  Coomassie staining of SDS-PAGE gels 
Following SDS-PAGE the gel was removed from the apparatus washed with ddH2O, 
then placed in SimplyBlue™ SafeStain (Invitrogen, UK) for 1 h at room temperature.  
The background was destained with ddH2O overnight at room temperature. Gels were 
dried using a gel Dryer 583 (Biorad, UK) for two hours. 
3.3.4 Western Blot 
Proteins were transferred from the polyacrylamide gels to nitrocellulose membranes 
(Amerham Pharmacia, UK) using Transfer buffer [0.2M glycine, 0.02M Tris, 20 (v/v) 
methanol] prepared  in advance and chilled at 4˚C. Transfer was carried out for 60 min 
at a constant 35V. After washing in phosphate buffered saline with 0.1 % (v/v) Tween 
(PBST), membranes were incubated in blocking buffer containing 2.5% (w/v) non-fat 
milk powder in PBST for either 1 hour on a shaker at room temperature (RT) or 
overnight at 4ºC. They were washed 3 times for 10 min with PBST and incubated in 
relevant horseradish peroxidise (HRP) conjugated antibody diluted in PBST on a shaker 
at RT for 1 hour. Excess antibody was removed by extensive washing with PBST. If the 
primary antibody was not HRP conjugated the membranes were washed 3 times for 10 
min in PBST and incubated with HRP-conjugated secondary antibody, diluted in PBST 
for 1 hour at RT.  Antibodies used in this study are listed in Table 3.1.After washing, 
protein was detected with an ECL chemiluminescence kit (Immobilion, Milliopore). 
Briefly, equal amounts of solutions A and B are applied to the membrane for 5 min then 
the membrane is exposed to Hyper-Film (Amersham Pharmacia, UK) and developed. 
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Primary Antibody Concentration Secondary Antibody Concentration 
Rabbit polyclonal 
Anti-VWF-HRP (Dako) 1/1000 N/A N/A 
Mouse Anti-myc 
(Invitrogen) 1/5000 
Goat Anti-mouse-
HRP (Dako) 1/2000 
Goat polyclonal anti-
CD42b (SantaCruz) 1/1000 
Anti-goat HRP 
(Dako) 1/5000 
Anti-His -HRP 1/5000 N/A N/A 
Table 3.1 Primary and secondary antibodies and their concentrations used for 
western blotting 
HRP horse-radish peroxidise 
 
3.3.5 Purification of VWF from Haemate P® 
3.3.5.1 Gel filtration 
Gel filtration or size exclusion chromatography which separates proteins on the basis of 
size was used to remove large quantities of albumin and factor VIII and isolate high 
molecular weight VWF from Haemate P®. A Sepharose 2B-CL gel filtration column 
(Amersham Pharmacia, UK) (600mm × 26mm, 318.5ml volume) was pre-equilibrated 
overnight with 2 column volumes of buffer A (100mM NaCl, 20mM Tris-HCl, pH7.4). 
Haemate P® was resuspended in water and  the sample was loaded onto a column at a 
flow rate of 0.7ml/min, then eluted at flow rate 1ml/min and 5ml fractions were 
collected. VWF concentration was determined by VWF antigen ELISA, multimeric 
composition was analysed by VWF multimer gels and collagen binding assay and used 
for functional assays or VWF containing fractions were pooled for further purification. 
3.3.5.2 Heparin Sepharose affinity chromatography 
VWF purification was carried out by affinity chromatography using a heparin column 
(Heparin-Sepharose 6 fast flow) equilibrated with 2 column volumes of a 20 mM Tris, 
100 mM NaCl pH 7,4 buffer. Briefly, mixed gel filtered fractions were loaded at a flow 
rate of 0.4 mL/min. The column was washed until the UV280nm absorbance had returned 
to zero. VWF was then eluted using a 20 mM Tris, 300 mM NaCl pH 7,4 buffer then 
dialysed into a 20 mM Tris pH 7,4 buffer for 24 h at 4ºC and quantified. 
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3.3.6 Purification of recombinant VWF 
3.3.6.1 Ion exchange chromatography  
An SK-16 chromatography column (Amersham Pharmacia, UK) was packed with 30ml 
of Fractogel-EMD-TMAE+ (Merck) according to manufacturer’s instructions. Briefly, 
the empty SK-16 column was washed with ddH2O and the bottom outlet tube connected 
to an AKTA FPLC machine. The Fractogel resin was prepared by removing ethanol 
from the slurry by repeated centrifugation and washing. After decanting the last wash 
the slurry was resuspended in an equal volume of 300mM NaCl. The column was 
flushed with 20mM Tris-HCl pH 7.4, and then 35ml of Fractogel-EMD-TMAE+ fast 
flow was poured into the column chamber with a smooth continuous motion. The 
remaining column space was filled with 20mM Tris-HCl, 150mM pH 7.4 and the 
plunger inserted into the top of the column. The Fractogel was allowed to settle for 
1min, before a flow rate of 10ml/min was applied to the column for 20 min to ensure 
the resin was fully packed. The plunger was then pushed ~5mm into the top of the resin. 
The final column had a volume of 30ml and a maximum flow rate of 4ml/min. VWF 
expression medium was filtered through a 0.4μm filter and applied to the previously 
equilibrated column at a flow rate of 1.5 ml per minute. Next, the column was washed 
until the UV280nm absorbance had returned to zero. The VWF was then eluted using  
20mM Tris, 500mM NaCl, pH 7.4 and dialysed into 20mM Tris, 150mM NaCl, ph.7.4 
buffer for 24 hours at 4°C quantified and further purified an a Heparin-Sepharose 
column.  
3.3.6.2 Heparin Sepharose affinity chromatography  
This was performed as described before in section 3.3.5.2 
3.3.7 Nickel affinity chromatography 
The recombinant protein (VWF-D’A3, ADAMTS13, and GPIbα) containing culture 
media was subjected to nickel affinity chromatography using Nickel charged columns 
that bind His-tagged proteins allowing contaminants to be removed. The media was 
dialysed into 20mM Tris-HCl, 500mM NaCl, 20mM imidazole, pH 7.8 and was passed 
over a 5ml Ni2+ His trap chelating column (Amersham Pharmacia, UK). The column 
was then washed, and bound protein eluted with 20mM Tris-HCl, 500mM NaCl, 
500mM imidazole, pH 7.8 using an isocratic elution. Eluted fractions were dialysed into 
20mM Tris-HCl (pH 7.8) using a 10kDa molecular weight cut-off dialysis membranes 
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(Pierce, UK). Protein concentration was assessed using ELISA, or BCA (section 3.3.1), 
purity was assessed using SDS-PAGE in 4-15% gels followed by Coomassie staining 
(section 3.3.2). 
3.3.8 Botrocetin purification 
Snake venom from Bothrops jararaca (Sigma) was resuspended in 20mM NaH2PO4, 
150mM NaCl, pH 7.35 and at centrifuged to pallet debris. Supernatant was loaded on a 
anion exchange column-Source 15Q (GE Healthcare) previously equilibrated with 
20mM NaH2PO4, 150mM NaCl, pH 7.35 at a flow rate of 0.5ml/min. The column was 
then washed and by applying a gradient of 1M NaCl in 20mM NaH2PO4, pH 7.35: first 
150 to 400nM of NaCl for 20 min and than 40nM to 1M NaCl for 10 minutes. All 
fractions were collected and analysed by SDS-PAGE followed by Coomassie Blue 
Stain. Fractions containing botrocetin was dialysed into 20mM Tris-HCl, and amount of 
protein estimated using a BCA assay.  
3.4 VWF Analysis 
3.4.1 VWF ELISA 
VWF antigen (VWF:Ag) was measured by sandwich enzyme-linked immunosorbent 
assay (ELISA). 96 well microtitre plates (MaxiSorp, Nunc) were coated by overnight 
incubation at 4˚C with 100 µl per well of rabbit polyclonal anti-human VWF antibody 
(Dako) diluted in 50mM sodium bicarbonate buffer, pH 9.6 to a final concentration of 
7.5μg/ml. Following the incubation, the plates were washed with PBST. Next the plates 
were blocked for 1 hour at RT with 2.5% BSA-PBST. Following washing, wells were 
incubated with serial dilutions of recombinant protein and reference plasma; each 
dilution was assayed in duplicate. After 2 hours incubation at RT, the plate was washed 
to remove any unbound protein. Bound protein was detected with anti- rabbit polyclonal 
anti-VWF HRP diluted to a final concentration of 5µg/ml at RT for 1 hour. After a final 
wash step, to detect bound antibody, 180µl substrate solution (Sigma colour fast OPD 
tablets) was added to the wells, the reaction stopped with 50µl of 1M H2SO4, and the 
absorbance measured at 492nm using a plate reader. Concentration of VWF in each 
sample was determined using standard curve generated using reference plasma (VWF 
concentration 10µg/ml). A standard curve was generated plotting VWF concentration 
on the x-axis against absorbance on the y-axis. The concentration of reference plasma 
was taken as being 10µg/ml and diluted serially 1:10 to 1:1280. 
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Graphs were plotted in Microsoft Excel and the equation-of-the-line and R2 values were 
calculated using the “add trendline” function. The equation-of-the-line was given in the 
format: 
y = mx + c 
Where: y is the absorbance value, m is the gradient of the slope, x is concentration of 
VWF  y intercept. To calculate the VWF of unknown samples the equation was 
rearranged to: 
x = (y - c) / m  
Absorbance values (y) of the unknown samples were substituted into the equation and 
returned a VWF value. Unless stated, all VWF concentration were expressed in µg/ml. 
 
3.4.2 VWF Multimer Analysis  
The multimeric pattern of VWF may be visualised by analysis in agarose gels under 
non-reducing conditions. VWF multimer analysis was performed using a method 
optimised by Dr. McKinnon. Low resolution (0.8%) and high resolution (1.4%) agarose 
gels (1.5mm diameter) were prepared by dissolving respectively 0.8g and 1.4g high 
gelling temperature agarose (Seakem) in 100ml of gel buffer [200mM Tris, 100mM 
glycine, 0.1% sodium dodecyl sulphate (SDS), pH 9.0] and cast using a Bio-Rad mini-
gel casting system. Samples were diluted with sample buffer (10mM Tris, 1mM EDTA, 
2% SDS, 8M urea, 0.01% bromophenol blue, pH 8.0) and incubated for 30 min at 60°C. 
Gels were assembled in a Bio-Rad mini-gel electrophoresis tank and chilled running 
buffer (100mM Tris, 150mM glycine, 0.1% SDS, pH 8.4) applied to the tank placed in 
an ice box. 10µl of each sample was applied and electrophoretic separation performed 
first at 60V for 20 min and than at 35V until the tracking dye had reached the end of the 
gel. After electrophoresis, Western Blot and immuno-staining with HRP-conjugated 
polyclonal anti-human VWF antibody was performed (section 3.3.4). 
3.4.3 Collagen binding assay 
Collagen binding activity (VWF:CB) is recognised as a sensitive measure of high-
molecular weight VWF (HMV-VWF). The highest molecular weight multimers bind 
collagen with the greatest affinity. VWF:CB of recombinant VWF was analysed using 
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an ELISA based collagen binding assay (CBA). Type III collagen prepared from human 
placenta by trypsin digestion (Sigma) was dissolved for 16 hours at 4°C in 0.2M acetic 
acid to final concentration of 0.1mg/ml. A 96 well microtitre plate was coated with 
100µl per well of 0.5µg/ml collagen in 50mM sodium bicarbonate buffer, pH 9.6. 
Following an overnight incubation at room temperature plates were washed with PBST 
and blocked with 2.5% BSA-PBST for 1 hour at RT. Following washing, wells were 
incubated with serial dilutions of reference plasma and recombinant VWF. Each 
dilution was assayed in duplicate. After incubation for 2 hours at RT, wells were 
washed and rabbit anti-human VWF –HRP polyclonal-antibody added as described 
above (section 3.4.1). 
3.4.4 Nanobody binding assay 
The interaction between a nanobody AU/VWF a-11 and VWF was investigated using a 
modified ELISA based plate assay. The AU/VWFa-11 is a Llama-derived antibody 
fragment that recognises VWF in its active conformation. To investigate VWF binding, 
microtiter plates were coated overnight at 4°C with 5µg/mL AU/VWFa-11 in 50mM 
sodium bicarbonate buffer, pH9.6. Following washing with PBST, wells were blocked 
with 2.5% BSA PBST for 1 hour at room temperature. Recombinant VWF was prepared 
in the absence or presence of ristocetin (500µg/mL). All VWF samples were diluted in 
PBST to reach a concentration between 4 and 0.5nM, and 100µl of sample was loaded 
into each well and incubated for 1 hour at 37°C. To determine the effect of ristocetin 
concentration on nanobody binding, VWF at a concentration of 0.5nM was incubated 
with ristocetin at concentrations between 0 and 500µg/ml. After incubation, bound 
protein was detected with HRP-conjugated polyclonal rabbit anti-human VWF antibody 
as described above (section 3.4.1). 
3.4.5 Plate binding assay between the bacterial A2 domain and VWF variants 
The interaction between the purified bacterial VWF A2 domain (expressed in E. coil, 
kindly donated by Dr Alain Chion) and immobilised or globular VWF was investigated 
using a modified ELISA based plate assay. To investigate the binding of the A2 domain 
to immobilised VWF, microtitre plates were coated by overnight incubation at 4˚C with 
100 µl per well of VWF variants diluted in 50mM sodium bicarbonate buffer, pH 9.6 to 
a final concentration of 1μg/ml. Following the incubation, the plates were washed with 
PBST. Next the plates were blocked for 1 h at RT with 2.5% BSA-PBST. Following 
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washing, wells were incubated with increasing concentrations of the A2 protein (0-
5µm); each dilution was assayed in duplicate. After 1 hour incubation at RT, the plate 
was washed to remove any unbound protein. Bound protein was detected with anti-
Xpress antibody (Invitrogen) diluted in 1 in 1000 at room temperature for 1 hour 
followed by washing and 1 hour incubation with HRP conjugated polyclonal goat anti-
mouse IgG antibody (Dako). After a final wash step OPD substrate solution was added 
and reaction stopped with H2SO4 and the absorbance measured at 492nm using a plate 
reader.  
A modified version of the assay was used to assess the binding of globular VWF to 
immoblised VWF-A2 domain. Briefly, the microtitre wells were coated with bacterial 
A2 domain at 5μg/ml. After blocking with 2.5%BSA PBST, soluble VWF (0-35nM) 
was added for 2 hours and bound VWF was detected using an HRP-conjugated 
polyclonal anti-VWF antibody as described previously.   
3.4.6 Immunosorbent assay for VWF-linked T antigen–Peanut agglutinin 
binding (PNA) binding assay 
Peanut agglutinin (PNA) is a lectin that recognises a desialylated core 1 structure of O-
linked glycans (T-antigen) and thus can be used to determine the presence of this 
structure on VWF. The interaction between VWF and PNA (Dako) was investigated 
using a modified ELISA plate binding assay. Briefly, microtitre plates were coated with 
polyclonal anti-VWF antibodies at final concentration of 7.5 μg/ml diluted in 50mM 
sodium bicarbonate buffer, pH 9.6 overnight at incubation 4°C.  Wells were then 
washed with PBST and blocked with 2.5 % BSA-PBST for 1 hour at RT. Following 
washing wells were incubated with serial dilutions of reference plasma and recombinant 
VWF. Each dilution was assayed in duplicate. To remove terminal sialic acid residues 
from oligosaccharide chains VWF samples applied to the wells were incubated in 
advance with the α 2-3, 6, 8 neuraminidase (from Clostridium perfringens, New 
England BioLabs, UK) at a final concentration of 5mU/ml, for 2 hours at 37ºC. 
Following incubation with VWF wells were washed and biotinylated.  PNA (5μg/mL) 
was added in Tris buffered saline (50mM Tris, 150mM NaCl) with 0.1mM CaCl2, 1mM 
Mg Cl2, 1mM MnCl2 and incubated for 1 hour at 37ºC. Following washing wells were 
incubated with HRP-conjugated streptavidin. Bound PNA was detected by measuring 
HRP activity using OPD as the substrate, as described previously (section 3.4.1) 
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3.4.7 Heparin binding 
VWF binds to heparin via its A1 domain, allowing the binding between two proteins to 
be  investigated using heparin-SepharoseTM(GE Healthcare, Sweden). Firstly, Heparin-
Sepharose agarose was washed with PBS. Briefly, resin was centrifuged at 800g for 5 
min and supernatant discarded, PBS was then added, mixed thoroughly, centrifuged, 
and supernatant was discarded. Once the resin was washed 200 µl of  each VWF variant 
diluted with PBS to a final concentration of 2µg/ml was added to 100µl of Sepharose 
and incubated on up an over mixer for 30 min at RT. Samples were then centrifuged at 
800g for 5 min and supernatant containing unbound VWF was collected. The 
concentration of VWF before and after incubation with heparin-Sepharose was 
measured using VWF-ELISA (as described in section 3.4.1) and percentage of binding 
calculated for each of the variants.  
3.4.8 Glycoprotein Ibα binding assay  
To investigate binding between recombinant GPIbα fragment and VWF an ELISA 
based binding assay was optimised. 96 well microtitre plates were coated by overnight 
incubation at 4°C with 100µl per well of goat polyclonal antibody raised against a 
peptide mapping to the N-terminus of human CD42b (GPIbα). Antibody was diluted to 
a final concentration of 5µg/ml in 50mM sodium bicarbonate. Following washing with 
PBST wells were blocked with 2.5% BSA PBST for 1 hour at room temperature. 
Following washing, 100µl of recombinant purified GPIbα diluted in PBST at a 
concentration of 1µg/ml was added to each well and incubated for 1 hour at RT. VWF 
samples were diluted in PBST to a concentration of 1µg/mL in the absence or presence 
of ristocetin (0.3-1mg/ml; Helena Labs) to investigate the GPIbα binding at various 
ristocetin concentrations. To investigate GPIbα binding kinetics, VWF was diluted in 
PBST to a concentration between 5-0.125µg/ml and 1mg/ml of ristocetin was added to 
each sample. Samples were applied to the wells and incubated for 1 hour at 37°C. 
Following washing, bound protein was detected with rabbit polyclonal anti human 
VWF antibody (final concentration 5µg/ml in PBST) as described above (section 3.4.1). 
Binding curves were fitted to the one-site binding model using GraphPad Prism 4.0 
software, to determine KD(app). 
Given that two modulators; ristocetin and botrocetin, induce binding VWF-GPIbα via 
different mechanisms, GPIbα binding assays were also performed in the presence of 
botrocetin. Briefly, VWF was diluted serially in PBS starting at 5µg/ml and 4 µg/ml of 
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purified botrocetin was added to each sample. Samples were applied to GPIbα coated 
and blocked wells and plates were incubated at 37°C for 2 hours. Following washing, 
bound protein was detected with rabbit polyclonal anti-human VWF as described above 
(section 3.4.1). 
3.5 ADAMTS13 analysis 
3.5.1 ADAMTS13 ELISA  
To determine the concentration of ADAMTS13, 96 well microtitre plates were coated 
by overnight incubation at 4˚C with 100 µl per well of 100ng rabbit polyclonal anti-
ADAMTS13 antibody depleted of antibodies against the TSP2-4 domains, diluted in 50 
mM sodium bicarbonate buffer, pH 9.6. Following the incubation, the plates were 
washed with PBST. Next the plates were blocked for 2 hours at RT with 2.5% BSA-
PBST. Following washing wells were incubated with serial dilutions of rADAMTS13 
protein and reference plasma; each dilution was assayed in duplicate. After 2 hours 
incubation at room temperature, the plate was washed to remove any unbound protein. 
Biotinylated anti-ADAMTS13 polyclonal antibody directed against TSP2-4 domains 
was added to each well at a final concentration of 0.1µg/ml and incubated at 37˚C for 
1hour. Bound antibodies were detected by 1 hour incubation with HRP-conjugated 
streptavidin (at a final concentration 5µg/ml).  Hence ADAMTS13 was quantitated  by 
measuring HRP activity using OPD as the substrate. Astandard curve was plotted as 
described for the VWF:Ag ELISA(section 3.4.1). Reference plasma diluted 1:10 was 
taken to be 1µg/ml ADAMTS13. 
3.5.2 ADAMTS13 activity assays under static conditions 
To investigate the cleavage of FL-VWF by ADAMTS13 in vitro, purified (section 
3.3.7) recombinant ADAMTS13 was used. VWF was unfolded into a conformation 
suitable for cleavage, by exposing the ADAMTS13 cleavage site in the A2 domain with 
urea. ADAMTS13 was activated by pre-incubation with calcium. Recombinant FL-
ADAMTS13 or was preincubated without substrate at 37° C for 45 minutes in reaction 
mixture containing 5mM CaCl2, 150 mM NaCl and 20mM Tris-HCl (pH 7.8). 
Activated ADAMTS13 was then used to digest 15µg/ml of recombinant full length 
VWF or D’A3 VWF fragment, in the presence of 1.5M urea. Subsamples were removed 
at designated time points and the reaction stopped with 5mM EDTA. Full length VWF 
proteolysis was analysed using collagen binding (section 3.4.3) and multimer pattern 
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(section 3.4.2). Cleavage of D’A3 was analysed using SDS-PAGE followed by western 
blot (section 3.3.2&4) and detection of the. C-terminal cleavage product by 
immunostaining with a murine anti- c-myc antibody and a secondary HRP conjugated 
anti-mouse IgG antibody.  
3.5.3 ADAMTS13 activity assays under pseudo-shear conditions 
Cleavage of FL-VWF by ADAMTS13 was also investigated without the presence of 
denaturants but under pseudo shear stress. VWF at final concentration of 15µg/ml was 
added to preincubated ADAMTS13 at a concentration of 15nM in 20nM Tris-HCl 
buffer containing 0.25% BSA, 5mM CaCl2, and  NaCl2 (total volume, 20 µL) in a 
0.2mL thin walled PCR tube with domed caps (Fisherbrand). The reaction mixture was 
placed on a vortex at a fixed rotation rate of approximately 2500rpm. Subsamples were 
removed from the vortex at designated time points. The VWF proteolysis was analysed 
using collagen binding assay (section 3.4.3) and multimer gel electrophoresis 
(section3.4.2).  
3.5.4 Assay of ADAMTS13 binding to extended VWF 
VWF variants, 30nM each, in 50mM sodium bicarbonate buffer (pH9.6) were 
immobilised onto a 96-well microtitre plate by overnight incubation at 4°C. Wells were 
washed with PBST, and blocked with 2.5% BSA-PBST for 2 hours at RT. Following 
washing, increasing concentrations of purified wild-type ADAMTS13 (0-300nM) in 
PBST in the presence of 10mM EDTA, were applied for 2 hours at 37°C. Bound 
ADAMTS13 was detected as described for ADAMTS13 ELISA in section 3.5.1. 
Binding curves were fitted to the one-site binding model using GraphPad Prism 4.0 
software, to determine KD(app). 
3.5.5 Assay of ADAMTS13 binding to globular VWF 
ADAMTS13 binding to soluble VWF was investigated using an immunoprecipitation 
method. Binding reactions were prepared in 0.2ml PCR tubes (Fisherbrand, UK) and 
contained 10μg/ml of recombinant VWF, 30nM inactive ADAMTS13 (E225Q) variant 
in PBS, and incubated for 30 min at 37°C. Subsequently binding reactions were 
incubated for 30 min on the up and over mixer with 30µl magnetic beads (Dynabeads 
Protein G, Invitrogen) coupled according to manufacturer’s instructions to anti-VWF 
CK antibody diluted to 5μg/ml in PBS. The magnetic beads were separated from the 
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supernatant using a magnetic rack and washed with PBS. The protein coupled to beads 
was then eluted by heating the beads with 2x reducing buffer (200mM Tris, 8%SDS, 
0.4% Bromophenol blue, and 50% glycerol, l4% w/v β-mercaptoethanol) at 60°C, for 
20 minutes. Immunoprecipitated proteins were resolved SDS-PAGE, followed by 
western blotting, and immunostaining with polyclonal anti-VWF antibodies and anti-c-
myc antibodies to detect ADAMTS13.  
3.6  Generation of GPIbα-myc/His construct 
Dr Tom Mckinnon has previously established a clone of GPIbα spanning the first 290 
amino acids by PCR from cDNA isolated from HUVEC lysate and reverse transcription 
of mRNA. This has been verified by DNA sequencing and is present in the cloning 
vector pCR TOPO4  flanked by EcoRI and XbaI restriction sites. GPIbα was cloned 
into pBluescript II SK (+/-) vector, and was than subcloned into a pcDNA3.1/ myc-His 
vector in frame with the myc-his tag.  Briefly, the GPIbα fragment was inserted into a 
pBluescript II SK (+/-) vector using a site directed insertion method. The first step was 
amplification of GPIbα sequence (918bp) from pCR-Topo by PCR using ultra high-
fidelity KOD polymerase. The PCR reaction mixture consisted 0.5µl KOD DNA 
polymerase, forward and reverse primers with 0.75µl of dsDNA template, 10X reaction 
buffer, 2.5µl dNTP’s and 1.5µl of 25mM MgSO4 in a final volume of 25µl. The PCR 
amplification consisted of an initial denaturation (95ºC, 2 min); 27 cycles of: 
denaturation (95°C, 20 sec), annealing (55°C, 10sec), extension (70° C, 14 sec); and 
final extension (70°C, 4 min). Following PCR, the reaction mixture was subjected to 
agarose gel electrophoresis. Amplified GPIbα sequence was purified from the agarose 
gel using Gel Extraction Kit and quantified on a gel. Next, PCR with Pfu Turbo DNA 
polymerase was used to insert the DNA fragment encoding GPIbα into the pBluescript 
vector. The PCR reaction mixture consisted of 1µl Pfu Turbo polymerase, 5µl dNTP’s, 
3µl QuickSolution, 10X reaction buffer, ~100ng pBluescript (template DNA), and 
200~300ng GPIbα sequence (used as primer for this reaction) and ddH20 in the final 
volume of 50µl. The PCR reaction consisted of an initial denaturation (95°C, 1 min); 18 
cycles of: denaturation (95°C, 30 sec), annealing (55°C, 35 sec) extension (68°C, 4 
min); and final extension (68°C, 7 min). PCR products were digested with 10 U of DpnI 
for 1 hour at 37ºC to digest methylated template DNA that did not contain the GPIbα 
insert.   
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Following sequencing, GPIbα was subcloned into a pcDNA3.1/myc-His vector in frame 
with a myc-His tag. Briefly, the GPIbα sequence was excisedusing EcoRI and XbaI 
enzymes. This fragment was then ligated into a pcDNA3.1 containing a myc-His tag 
digested with the same enzymes. Ligation reactions were used to transform competent 
cells, colonies were selected plasmids DNA was isolated and sequenced. The vector 
containing GPIbα with the myc-His tag was amplified, purified and GPIbα-myc-His 
protein expressed in HEK293T as described (section 3.2.4), purified (section 3.3.7) and 
used for functional assays.  
 
Step1. Primer design- primers for GPIbα amplification, including flanking sides for 
insertion into the pBluescript vector 
 
Step2. GPIbα amplification by PCR  
 
 
Step3. Fragment purification and quantification 
Amplified fragment-primer for next PCR 
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Step4. Mutagenesis to insert GPIbα fragment into pBluescript 
PCR primer                                              Template DNA 
 
PCR 
 
 
PCR product  
 
 
 
Step5. Subcloning EcoRI-XbaI fragment form pBluescript/GPIbα into pcDNA3.1/ 
myc-His 
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Final construct 
Figure 3.4 Cloning steps used to generate GPIbα-myc-His construct in expression 
vector 
 
3.7 Interaction of platelets and VWF variants under conditions of 
flow  
3.7.1 Platelets and erythrocytes isolation and labelling 
Whole blood was collected from healthy donors into an anticoagulant solution; 1:6 
sodium citrate (ACD; 85mM sodium citrate, 111 mM glucose, 71nM citric acid, pH 
4.5). All the centrifugation steps were performed without a brake at 20-25°C, and a 10 
min rest-period was taken before each spin. Moreover all used solutions were pre-
warmed to room temperature.  In order to eliminate potential effects of VWF and other 
plasma proteins in performed experiments blood cells were prepared as followed. 
Firstly, erythrocytes and platelet rich plasma (PRP) were separated by centrifugation at 
120g for 15min. The top phase containing PRP was placed into a separate tube and 10% 
v/v ACD, 100mU Apyrase garde VI (Sigma) and 100nM prostaglandin E1 (PGE1; 
Sigma) were added to prevent platelet activation and centrifuged for 15 min at 1200g to 
isolate platelets. Next the platelet poor plasma in the supernatant was discarded or 
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stored for further analysis and the pellet containing platelets was re-suspended in 500µl 
of platelet wash buffer (36mM Citric acid, 5mM glucose, 5mM KCl, 1mM MgCl2, 
100mM NaCl, 2mM CaCl2, pH 6.5) containing 100mU Apyrase, 100nM PGE1 and 3.5 
mg/ml BSA. The re-suspended platelets were incubated in the dark for 15min with 4nM 
calcein-AM, an acetoxymethyl ester, which is fluorescent once cleaved with nonspecific 
esterases inside the cell. Subsequently 14 ml of wash buffer was added to the 
fluorescently labelled platelets; the sample was mixed by inverting the tube and 
centrifuged for 12 min at 1200g. Supernatant was than discarded and pelleted platelets 
re-suspended in HEPES/Tryodes buffer (10mM HEPES, 137mM NaCl, 2.68mM KCl, 
0.42mM NaH2PO4 1.7mM MgCl2, 11.9mM NaHCO3, 5mM glucose, pH7.4) 
supplemented with 3.5mg/ml BSA. Red blood cells were prepared as follows. 
Following PRP removal 50% v/v of 0.9% saline was added to erythrocytes containing 
fraction, gently inverted to mix and centrifuged at 1200g for 15 minutes. The 
supernatant was removed and erythrocytes were re-suspended 50% v/v of 0.9% saline 
and centrifuged as previously described, this washing procedure was repeated two 
further times. After the final centrifugation, the supernatant was discarded and 
erythrocytes re-suspended with HEPES/Tryodes buffer supplemented with 3.5mg/ml 
BSA to the original starting volume of blood, to maintain a normal hematocrit and the 
required amount of labeled platelets were added. 
3.7.2 Flow chamber and digital image processing 
Plasma free blood substituted with fluorescently labelled platelets was perfused through 
a flow slide (Ibidi) placed on an inverted epifluorescent microscope (Olympus-CKX41).  
All experiments were recorded in real time using a QImaging camera (Rollera XR) and 
Q Capture pro software. The digitalised images were collected, processed and analysed 
using ImageJ software (MacMaster Biophotonics) and Virtual Dub utility.  Uncoated μ-
Slides as well as fitting tubing and adapters manufactured by Ibidi were used for 
parallel perfusion assays. Desired flow rates were achieved by adjusting the diameter of 
syringe and flow rate depending on a slide size according to conversion tables provided 
by the manufacturer. Slides were connected to a syringe pump Aladdin-1000 (World 
Precision Instruments) to generate a continuous laminar flow at specific wall shear 
rates.  
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3.7.3 Preparation of flow slides  
The slide channels were coated with purified D’A3-VWF constructs diluted in sodium 
bicarbonate buffer, pH 9.6 to 30µg/ml for rolling and 2µg/ml for tethering experiments 
and incubated for 1 hour at RT. Subsequently the coating solution was aspirated 
completely and channels were rinsed carefully 3 times with PBS (10 times channel 
volume), and blocked for 15 min with 1.5% BSA in PBS, and washed with PBS. To 
compare coating efficiency with immobilised D’A3 variants, the solution containing 
unbound protein was recovered after coating as were three successive aliquots of PBS 
used to rinse the slide. The amount of each VWF variant coated was compared by 
calculating the difference between the total amount added for coating and that recovered 
in the coating and wash solutions. 
To investigate VWF mediated platelet adhesion to collagen, flow slides were coated 
with collagen type III (Sigma). Collagen was diluted with acetic acid (25mM) to a final 
concentration of 5µg/ml. And applied to a flow well, and slides incubated overnight at 
4°C. As described above slides were washed, blocked with 1.5% BSA in PBS and 
washed again before use.  
3.7.4 Measurements of platelet interaction and rolling velocities in flow 
To investigate the ability of VWF variants to support GPIbα dependent platelet rolling, 
plasma free blood substituted with platelets was passed over D’A3 VWF immobilised 
onto flow slides at a coating concentration sufficient to saturate the surface. The platelet 
count in reconstituted blood was lowered to aproximately14000 platelet per μl. Platelet 
attachment and translocation were analysed at a range of shear rates (125-5000s-1) and 
movies were recorded after 4 min of flow. Subsequently movies were processed and the 
number of platelets that remained attached per unit area throughout 3 frames (0.15 s) 
was measured using Image J software. The number of adherent platelets at a given shear 
rate was counted for three separate experiments, at 3 fields of view for each experiment. 
Rolling velocities were measured by tracking an individual platelet frame by frame at an 
interval of 0.05s, in the direction of flow and mean velocity was calculated by Image J. 
The time that one platelet spent continuously moving while mainlining contact with 
VWF coated surface is defined as the rolling duration, and rolling velocity was 
calculated by Image J from the distance that the platelet translocated during this period. 
For each D’A3 variant, approximately 25-40 platelets were tracked in 3 random fields 
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of views, and 3 separate experimental runs were completed for each flow rate. The data 
from all experiments was pooled, plotted and used to calculate the mean velocity and 
variance of velocity for each VWF variant at a range of shear rates.  
3.7.5 Measurement of platelet tethering 
The duration of tether bonds, the smallest unit of adhesion observable in flow was 
investigated for platelets and the D’A3 domains. The lowest coating concentration of 
D’A3 capable of supporting these brief adhesive events was determined by determining 
the percentage of platelets that paused but did not roll. Only one tethering event per 
platelet (in the field of view) was counted during the observation period. A transient 
tether was defined as a flowing platelet that suddenly arrested, without evidence of 
translocation and then resumed a velocity equivalent to that of a non-interacting platelet. 
The dissociation rate constants of transient tethers were calculated for coating 
concentrations of protein that only supported these transient tethers i.e. interaction of an 
individual platelet with a single VWF-A1 domain.  The duration of tethers was 
determined by recording images at a rate of 22 frames per second and measuring a time 
each platelet remained bound to the surface at a given shear rate. The dissociation rate 
constants were then determined by plotting the natural log of the number of platelets 
that interacted as a function of time after the initiation of tethering. For first-order 
dissociation kinetics, the resultant plot is a straight line, and the slope of the line = -koff   
The video data was analysed using Virtual Dub utility. On average, 150 tethering events 
were measured to determine koff in each independent experimental run. In addition, the 
number of transient tethering events per 5s was calculated for each variant, at a range of 
shear rates. Measurements were taken at 3 random fields of view on three separate 
occasions.   
3.7.6 Measurement of platelet binding by VWF bound to collagen 
The interaction between platelets and full length VWF mutants bound to collagen was 
investigated as follows. Plasma free blood substituted with full count of washed labelled 
platelets and recombinant VWF variants, at final concentration of 10µg/ml was perfused 
over collagen coated slides for 5 minutes at a shear rate of 1500s-1. Short movies (1s) 
were recorded every 30 seconds of flow, and experiment was repeated 3 times on 
separate occasions. The number of accumulated platelets at each time point assessed as 
surface coverage (%) was measured using Image J programme.   
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3.8 Statistical analysis  
Analysis of data was performed using the Prism software package (GraphPad {Prism 
version 4.0 Software for Science, San Diego,USA. All data are expressed as mean with 
SD. Data were analysed using a t-test and analysis of variance (ANOVA). P values 
≤0.05 were considered significant. 
3.9 Mass spectrometry techniques  
3.9.1 Reductive elimination  
O-linked glycans were released from PNGase F digested VWF glycopeptides by 
reductive elimination. Firstly samples were incubated with 55 mg/ml potassium 
borohydrate (KBH4) and 0.1M potassium hydroxide solution for 24 hours at 45°C. The 
reaction was stopped by drop-wise addition of glacial acetic acid. Released O-linked 
glycans were purified via an ion-exchange 50W-X8 Dowex® column previously 
equilibrated in 5% (v/v) acetic acid. Samples were eluted with 5% (v/v) acetic acid and 
dried using a Savant Speed-Vac. Surplus borates from the reductive elimination were 
eliminated by successive co-evaporations using 10% (v/v) acetic acid in methanol 
solution and dried under a stream of nitrogen and lyophilised.  
3.9.2 Chemical derivatisation-permethylation  
O-linked glycans were permethylated using a sodium hydroxide procedure on purified 
and lyophilised glycans. Briefly, sodium hydroxide pellets were crushed with dimethyl 
sulfoxide to form a slurry which was then added to glycans with 1mL of methyl iodide. 
The mixture was vigorously mixed on an automatic shaker for 10 min at RT. and the 
reaction was stopped by addition of water. Permethylated glycans were recovered by 
chloroform extraction and washed several times with water, and chloroform was 
evaporated under a stream of nitrogen.  
Permethylated glycans were subsequently purified using a reverse-phase C18 Sep-Pak 
column. The Sep-Pak cartridge was attached to a glass syringe and conditioned 
successively with methanol (5ml), water (5ml), acetonitrile (5ml), and water (3x5ml). 
The sample was dissolved in 1:1 (v/v) methanol/ water, loaded onto the cartridge, 
washed with water and eluted with 3ml of 15%, 35%, 50% and 75% (v:v) aqueous 
acetonitrile solution. The organic solvent was removed by on a Savant Speed-Vac and 
samples were lyophilised.  
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3.9.3 MALDI-MS and MS analysis 
Matrix assisted laser desorption ionisation MS (MALDI-MS) and MS/MS data on 
permethylated samples was acquired in a reflector positive ion mode using a 4800 
MALDI-time-of-flight (TOF) TOF/TOF (Applied biosystems) mass spectrometer. The 
instrument was calibrated using the 4700 calibration standard, calmix, as the external 
calibrant for the MS mode and human [Glu1]-fibrinopeptide G was used as the external 
calibrant for the MS/MS mode. The collision energy was set to 1 kV, and argon was 
used as collision gas. Samples were dissolved in 20µl of methanol, and 1 µl was mixed 
at a 1:1 ratio (v/v) with 2,5-dihydrobenzoic acid (20 mg/ml)1 in 50% (v/v) methanol in 
water) as the matrix. Data was acquired using 4000 Series Explorer Instrument Control 
Software and were processed using Data Explorer MS processing software. MS/MS 
spectra were assigned and annotated with the help of the GlycoWorkbench tool.485 
3.9.4 Data analysis  
The mass of the glycans was determined based on the monoisotopic from of each 
monosaccharidic constituent (Table 3.2). The reducing and non-reducing extremities of 
the glycan (e.g a molecule of water and the replacement of two hydrogens by methyl 
group) and the addition of a sodium atom have to be considered when calculating the 
mass of permethylated glycan.   
Family Monosaccharide examples 
Monoisotopic mass (Da) 
Native    Permethylated                   
Hexose Glucose, galactose, mannose 162 204 
Hexosamine 
N-acetylglucosamine, 
N-actylgalactosamine 
203 245 
Sialic acid N-acetylneuraminic acid 291 361 
Deoxy-
hexose fucose 146 174 
Table 3.2 Native and permethylated masses of common monosaccharide 
constituents of glycans 
 
 
111 
 
4 ANALYSIS OF VWF O-LINKED GLYCAN STRUCTURE 
4.1 Introduction 
A significant proportion, ~20%, of the molecular weight of VWF is comprised of N- 
and O-linked glycan chains. Based on the primary amino acid sequence and the original 
sequencing of the VWF protein, VWF contains 16 N-linked and 10 O-linked 
glycosylation sites. 
An  analysis of the N-linked glycan structures of VWF was first  performed by Matsui 
et al on de-sialyated fragments using chemical techniques.20 A more detailed mass 
spectrometric study was recently performed on N-linked glycans released from plasma 
derived VWF by digestion with PNGase F (unpublished data by Dr. K. Canis). Firstly, 
an additional thirteenth N-linked glycosylation site suggested to be unoccupied by 
Titani, was found to be consistently glycosylated. From these studies, it has been 
demonstrated that the VWF N-linked glycome comprises a large variety of structures (at 
least 300 distinct structures), the majority of which are multi-antennary complex 
glycans, with bi-antennary structures being the most common (~80%). Moreover, most 
structures terminated in sialic acid or fucose residues. In agreement with previous 
studies the ABH blood group antigens were detected. Interestingly a proportion of the 
VWF N-linked glycan population was shown to have sulphate groups, which are 
important for recognition in other proteins. VWF N-linked glycans have been studied 
extensively, whilst O-linked glycan function is still poorly characterised and a detailed 
study regarding the VWF O-glycome composition was only recently published.486 It has 
been demonstrated that the pdVWF O-glycome encompasses a heterogeneous 
population of 18 structures. Both the core 1 and core 2 structures were identified, with 
the core 1 family being the most abundant. The majority of the structures were 
sialylated and the di-sialyl core 1 accounted for about 75% of the overall population in 
accordance with previous studies.452,486 Interestingly a proportion of core 1 structures 
(~40%) contained one or two disialosyl motifs; that is two sialic acid residues linked via 
an α2-8 linkage (NeuAcα2-8NeuAc). In addition, some core 1 structures were show to 
carry atypical N-glycolylneuraminic acid residues. Strikingly, the majority of core 2 
structures were shown to carry ABH blood group antigens (~1% of the O-linked 
glycom). Therefore it can be suggested that similarly to N-glycans, O-linked glycans, by 
carrying ABO blood group antigens, could have an influence on VWF plasma 
levels.390,392,470     
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The pdVWF glycome has been characterised, however no information regarding the 
structure and composition of O-linked glycans of recombinant VWF is available. Since 
in this project rVWF expressed in non-endothelial cell line was used to study the 
function of O-linked sugars, it was necessary to characterise its O-linked glycom and 
compare it to that of pdVWF. 
To begin with the glycan structure of VWF, the primary VWF protein sequence was 
analysed using neural network algorithms to predict the probability of potential 
glycosylation sites being occupied. Furthermore, parts of the human VWF protein 
sequence were aligned with the VWF sequence of other species and with other proteins 
sharing homologous domains.  
Importantly a purification method of rVWF was optimised. Finally purified VWF 
expressed in HEK293T cells was sequenced and analysed by state-of-the art Mass 
Spectrometry methods previously optimised for pdVWF.  
4.2 In silico analysis of VWF 
4.2.1 Sequence alignment of the VWF-A1 domain flanking regions 
In order to elucidate whether O-linked glycans are functionally important to VWF, I 
decided to examine if the sequences that enclose them are conserved across species. To 
investigate if the O-glycosylation sites are conserved, a protein sequence alignment was 
performed to align the sequences of linker region between the D3-A1 domains and A1-
A2 domains of human VWF against other species with known VWF A1 domain 
flanking sequences. Sequences were obtained from the Swiss-Prot protein database,  
(http://www.expasy.org/cgi-bin/sprot-search- de?von%20willebrand%20factor) 
 and were aligned using AliBee Multiple Alignment (available at: 
http://www.genebee.msu.su/services/malign_reduced.html)  
Both linker regions flanking the A1 domain appear to be conserved. In the D3-A1 linker 
region the three O-glycosylation sites: T1248, T1255, T1256 are highly conserved 
throughout the species analysed. Interestingly, the S1263 site is not conserved with all 
the species analysed, with the exception of the Indian elephant, having a proline residue 
instead of a serine at position 1263. However, in these species, there is a threonine 
residue at position 1262 which could potentially be glycosylated. The A1-A2 linker 
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region contains another cluster of 4 O-linked glycan chains in human VWF. The O-
glycosylation sites T1468 and T1477 are highly conserved, whilst the sites S1486 and 
T1487 appear to be less conserved amongst organisms. (Figure 4.1b) The high 
conservation of O-linked glycosylation sites could suggest their functional importance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next page- 
Figure 4.1 Protein sequence alignment of the VWF A1domain linker regions from 
various species 
The amino acid sequence of the VWF A1domain flanking regions from 10 different 
species was aligned using a protein sequence alignment programme. (A) Illustration of 
sequences of the D3-A1 linker region. The human VWF O-linked glycosylation sites 
T1248, T1255, T1256 are conserved among other species (red boxes). The S1263 
residue is present only in the Indian elephant, other organisms have a proline in this 
position (green box). However in those organisms the position 1262 is occupied by 
threonine (arrow). (B) Illustration of sequences of the A1-A2 linker region. The human 
VWF O-linked glycosylation sites T1468 and T1477 are highly conserved (red boxes). 
The S1486 and T1487 are conserved in majority of species (green box).
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4.3 Experimental analysis of VWF O-linked glycans structure 
4.3.1 Purification of VWF from Haemate P 
To determine the O-linked glycome of both plasma derived and recombinant VWF 
(rVWF), high purity VWF was required. Plasma derived VWF was purified from a 
commercial VWF-FVIII concentrate: Haemate P. Haemate P has been shown to contain 
a high proportion of high molecular weight multimers and has a multimer pattern 
resembling normal human plasma.487,488 Lyophilised Haemate P was re-suspended in 
ddH2O, then gel filtered through a Sephacryl 400 gel filtration column and 5ml fractions 
were collected. Protein began to elute from the column typically at fraction A10 (Figure 
4.2a). Early eluted fractions and selected later fractions were analysed by SDS-PAGE 
under reducing conditions followed by Coomassie staining. Fractions A10-B3 
demonstrated a major 250kDa band, consistent with monomeric VWF (Figure 4.2b). To 
remove contaminating proteins and to concentrate the VWF samples, fractions A10-B3 
were pooled and further purified using Heparin-Sepharose affinity chromatography. 
Purified, fully multimeric pdVWF was used as a control in the MS studies and was also 
used in several other assays described throughout this thesis. 
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Figure 4.2 Gel filtration of Haemate P 
Haemate P was gel filtered through a Sephacryl 400 gel filtration column and 5ml 
fractions were collected. (A) As demonstrated on chromatogram protein began to elute 
from the column typically at fraction A10 (B) Early eluted fractions and selected later 
fractions were analysed using reducing SDS-PAGE followed by Coomassie staining. 
Fractions B6-D12, contained a major 250kDa band corresponding to a monomeric 
VWF, were pooled and VWF was further purified by Heparin-Sepharose 
chromatography. 
 
4.3.2 Purification of recombinant VWF 
In order to analyse the glycan content of rVWF, large scale transient transfections of 
HEK293T cells were performed. Approximately 250ml of expression media was 
collected and filtered and VWF purified by ion exchange chromatography using a 
previously equilibrated Fractogel-EMD-TMAE+ column. VWF was eluted with 
500mM NaCl (Figure 4.3) and all fractions were collected and analysed by SDS-PAGE 
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under reducing conditions followed by Coomassie staining. The elution fraction 
contained a band of ~250kDa corresponding to monomeric VWF, however other 
proteins were still present (Figure 4.4b, lane 1). Some of the bands were detected with 
ant-VWF antibody, suggesting they correspond to VWF degradation product. To 
remove contaminating proteins the elution fraction was therefore dialysed against 
20mM Tris and further purified using Heparin-Sepharose affinity chromatography 
(Figure 4.4a). Bound protein was eluted using 500mM NaCl. Gel filtered pdVWF was 
purified via Heparin affinity chromatography in the same way. Purity of the eluted 
material was analysed using SDS-PAGE under reducing conditions, followed by 
Coomassie staining while the multimeric pattern was determined by agarose multimer 
gel electrophoresis, and the concentration determined by VWF-ELISA. As illustrated on 
Figure 4.4b (lane 2) a single ~250kDa, band consistent with monomeric VWF, was 
present in the eluted fraction, indicating a high level of purity. Moreover purified VWF 
exhibited a normal multimeric pattern, when compared to the non-purified material 
(Figure 4.4c). The typical VWF recovery after the first purification was 85-90% and 
44% after the second.  
 
 
Figure 4.3 FPLC purification of rVWF by ion exchange chromatography 
A representative chromatogram of a typical rVWF purification using an ion exchange 
chromatography. Filtered condition media was loaded onto a Fractogel column. Some 
proteins pass through the column and did not bind (flow through fraction). Column was 
washed extensively with 100mM NaCl/20mM Tris to ensure that majority of 
contaminant proteins were removed from the column with (wash fraction) prior to 
elution with 500mM NaCl/20mM Tris. Column was recovered with 2M NaCl.  
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Figure 4.4 Purification of rVWF by heparin affinity chromatography 
(A) A representative chromatogram of a typical rVWF purification using a Heparin-
Sepharose column. Dialysed elution fraction from the ion-exchange chromatography 
was passed through a column, which was then washed with 100mM NaCl/ 20mM Tris 
and bound protein was eluted with 500mM NaCl. (B) The elution fraction was analysed 
for purity by reducing SDS-PAGE followed by Coomassie staining. As illustrated only 
one band of 250 kDa corresponding to monomeric VWF was detected (lane 2) which is 
in contrast to elution fraction from ion-exchange purification only (lane 1) which had 
additional bands present. (C) Multimeric pattern was determined using a VWF 
multimer analysis. Purified VWF (lane 2) has comparable multimeric composition as 
VWF from expression media (lane 1). 
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4.3.3 O-glycome profile of rVWF 
State-of-the-art mass spectrometry was used to determine the O-linked glycan structures 
present on purified rVWF. Initially, rVWF purity was further assessed using a mass 
spectrometry (MS) based proteomic technique by Dr. K. Canis using an off-line nano-
LC MALDI-TOF/TOF and data interrogated using the MASCOT program. This 
analysis confirmed a high level of purity with only trace levels of contaminating 
peptides present.  
The approach used to characterise the rVWF O-glycom is illustrated on Figure 4.5 and 
had been previously optimised for pdVWF.486  Briefly, VWF was subject to a reduction 
and carboxymethylated and was then digested with trypsin. Next the N-linked glycans 
were release by incubation with PNGase F and separated from the peptides and O-
glycopeptides by reverse phase chromatography. (These experiments were performed 
by Dr. Canis) The O-linked glycans were then released from the post-PNGase F 
glycopeptides by reductive elimination. They were subsequently purified by ion-
exchange chromatography, permethylated and purified using a reverse-phase 
chromatography. The O-glycans were finally subject to the matrix-assisted laser 
desorption and ionization-time of flight (MALDI-TOF) profiling.  
  
Figure 4.5 Schematic representation of glycomic strategy used to describe VWF O-
linked glycome 
Protocols I have performed are described in Material and Methods section.  
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As demonstrated on Figure 4.6 six relevant molecular ions were identified, including 
both core 1 and core 2 moieties, with the core 1 structure being the most abundant. The 
majority of structures appeared sialylated. Moreover, the major signal corresponded to a 
di-sialylated core 1 moiety (HexNAc1 HexNeuAc2 ; m/z 1256) but mono (m/z 895, 
1286) species were also present. Strikingly an uncommon tri-sialylated core 1 structure 
was also detected (m/z 1617). This structure carries a disialosyl group in which two 
sialic acids are linked together. In addition, a monosialylated core 1 structure and core 2 
structures with an unusual sugar N-glycolylneuraminic acid were detected (m/z 1286 
and m/z 1736 respectively). All VWF O-linked glycans appear to be processed, as core 
1 and core 2 precursors (Hex1HexNAc1 and Hex1HexNeuAc2) were not detected. 
 
 
Figure 4.6 MALDI-TOF mass spectrum of permethylated VWF O-linked glycans 
MALDI-TOF analysis showed VWF O-linked glycans contain both core 1 and core 2 
structures. The profile is dominated by sialylated core 1 structures (m/z 895, 1256, 
1617) but also shows presence of core 2 structures (m/z 1344, 1706). In addition a core 
1 and core 2 structures with a terminal N-glycolylneuraminic acid were detected (m/z 
1286 and 1736 respectively) No relevant molecular ion has been observed below m/z 
895. 
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The ion at m/z 1617 suggest the presence of a core 1 structure with a disialosyl group, to 
further confirm this,  MALDI-TOF/TOF analysis of that ion was performed (Figure 
4.7). The MS/MS fragmentation of the 1617 parent ion revealed the presence of 
characteristic fragment ions m/z 384, 759, 1020, confirming the presence of disialosyl 
groups. In addition, it is clear that this motif is carried by the 6-arm as indicated by the 
presence of m/z 1020 and absence of m/z 981 ion.  
 
 
Figure 4.7 MALDI-TOF/TOF mass spectrum of the tri-sialylated O-linked glycan 
(m/z 1617) 
MALDI-TOF/TOF analysis was performed to further investigate the molecular ion at 
m/z 1618 suggestive of tri-sialylated core 1. Fragmentation of the parent ion provided 
fragment ions at m/z 759, 1020 which allowed characterisation as a core 1 with the tri-
sialylated O-linked glycan structure that contains an unusual disialosyl motif. 
Diagnostic m/z.1020 fragment ion revealed that disialosyl group is carried by the 6 arm. 
In the spectrum all fragment ions carry sodium except the sialic acid residue at mz/ 376 
which is an oxonium ion.    
 
Also the parent ion m/z 1256 was subject to fragmentation by MALDI-TOF/TOF 
MS/MS analysis. This was done in order to elucidate whether the di-sialylated core 1 
structure (m/z 1256) carries a single sialic residue on each arm, or a disialosyl group on 
one arm, or if the signal corresponds to both isoforms. As illustrated on Figure 4.8 the 
rVWF O-glycome contains only a di-sialylated core 1 structure, which carries a terminal 
sialic acid on each arm. This was revealed by presence of fragment ions at m/z 506, 620 
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and 659. The absence of core 1 structures with a disialosyl motif was inferred from the 
absence of characteristic fragments ions at m/z 759 (corresponding to two sialic acids 
linked together) and ions m/z 520 and 1020.  
 
 
Figure 4.8 MALDI-TOF/TOF MS/MS spectrum of the [M+ Na]+ parent ion at m/z 
1256 
The fragmentation of m/z 1256 parent ion confirms the presence of di-sialylated core 1 
structure. The characteristic fragment ions at m/z 506, 620 and 659 allow the 
characterisation of the structure as core 1 with a sialic acid residue on each arm. In the 
spectrum all fragment ions carry sodium except the sialic acid residue at m/z 376 which 
is an oxonium ion.    
 
Finally, as an example for core 2 structure the fragmentation pattern of the parent ion at 
m/z is graphically illustrated on Figure 4.9 .  
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Figure 4.9 MALDI-TOF/TOF MS/MS spectrum of the [M+ Na]+ parent ion at m/z 
1705 
The fragment ions at m/z 620, 660, 881, 921 and 1143 allow a full characterisation of 
the structure as being a core 2 O-linked glycan. .In the spectrum all fragment ions carry 
sodium except the sialic acid residue at m/z 376 which is an oxonium ion.    
 
4.4 Discussion    
The VWF oligosachcarides account for approximately 15-20% of its total molecular 
weight. N-linked glycans comprise 70% of the carbohydrate and O-linked chains the 
remaining 30%.375 In contrast to N-linked glycans there is no consensus sequence for O-
linked glycosylation. Nevertheless, the likelihood of O-linked glycosylation occurring 
can be predicted from comparative studies, basing on the amino acid sequence 
surrounding the Ser/Thr residue. Titani.12  The prediction of O-linked glycosylation 
sites has to be taken with a degree of caution, but might be more useful to identify the 
glycosylated regions in a protein rather than specific sites. 
Since the two O-linked glycan clusters are localised in the linker regions flanking the 
A1 domain I have aligned the human sequence of the linker regions against known 
sequences from 10 other species. The protein alignment shows that three O-
glycosylation sites in the D3-A1 linker are highly conserved. Interestingly, most 
organisms lack the glycosylation site at position S1263 however they have a vicinal 
 124 
threonine residue which could potentially undergo glycosylation. Furthermore, the 
protein alignment of the A1-A2 linker region shows that two O-glycosylation sites most 
proximal to the A1 domain (T1268 and T1477) are highly conserved while the other 
two residues (S1486 and T1487) appear conserved in the majority of analysed 
organisms. The highly conserved nature of the O-glycosylation sites could suggest that 
both sites are important and are required for proper VWF structure/function. 
Interestingly it has been previously suggested that glycosylated threonine or serine 
residues are less likely to be precisely conserved than a non-glycosylated ones.369 It has 
been suggested that O-linked glycosylation would be conserved more as a bulk 
property, as O-glycans functions are not highly dependent on the exact number or 
position of glycosylated residues.369 However these studies have been mostly performed  
on heavily glycosylated mucin type proteins where the exact position of S and T 
residues is not likely to be important as long as they abundant. The individual mucin-
type glycosylation sites can be highly specific and highly conserved between species. 
The fact the VWF O-linked glycosylation sites are highly conserved further confirms 
their importance. 
We have recently determined and published the O-linked glycan profile of pdVWF.486 
However since the majority of the experiments described in this thesis were performed 
on recombinant VWF, in collaboration with Prof Anne Dell and Dr Kevin Canis I 
characterised the rVWF O-glycome profile.  In order to achieve this, rVWF was first 
purified from HEK293T expression media by a combination of ion exchange and 
Heparin-Sepharose chromatography. Heparin-Sepharose affinity chromatography 
exploits the ability of VWF to bind to heparin.139 By combination of two purification 
steps I have successfully obtained highly pure rVWF in quantities large enough for the 
MS profiling.  
The O-glycome of rVWF was subsequently analysed using MS techniques previously 
optimised for pdVWF. Firstly it has been demonstrated that similarly to pdVWF,452,486 
the major O-linked glycan moiety of rWVF is a desialylated core 1 structure. Moreover, 
akin to pdVWF, the rVWF O-glycome mostly consisted of sialylated core 1 structures. 
In addition, core 2 structures were also detected.  In contrast to pdVWF, rVWF did not 
contain any fucosylated O-linked oligosaccharides, therefore no ABO- blood group 
antigens are presented on rVWF O-glycans. In addition, both core 1 and core 2 
structures with an unusual sugar N-glycolylneuraminic acid were detected, which was 
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also observed for pdVWF. Humans are not able to synthesise N-glycolylneuraminic 
acid, however traces level of this monosaccharide were observed on several human 
proteins and it has been shown that the incorporation can occur from dietary sources. In 
the case of recombinant VWF the fetal calf serum present in the HEK293T tissue 
culture media could be the source of N-glycolylneuraminic acid. 
Interestingly it has been demonstrated that similarly to pdVWF, the rVWF O-linked 
glycans carry a rare disialosyl motif. However in contrast to pdVWF, rVWF glycans 
presented only tri-sialylated core 1 structures, with no tetra-sialylated core 1 structure 
detected. Therefore a single core 1 glycan carries only one disialosyl group, which we 
detected primarily on the 6 arm of the structure. The α2-8 linkage of the two sialic acid 
residues is mediated by a specific α2,8-sialyltransferase (ST8Sia), which can synthesise 
polysialic structures of more than 100 residues as observed in the Neural cell adhesion 
molecule (NCAM).489,490 The expression of polysialic acid is significantly upregulated 
during brain development, and modulates the adhesion properties of NCAM and affects 
neuronal and glial cell migration, outgrowth and sprouting of axons.491 Interestingly in 
the case of proteins such as vitronectin and plasminogen or MUC1492,493  as well as 
VWF, the number of connected sialic acid residues does not exceed two. Since the 
disialosyl motif appears to be very specific it could be inferred that it is important for 
VWF function. Interestingly a recently published review494 suggests that VWF can 
interact with Siglec 7 protein, which is expressed on monocytes and NK cells. Since 
Siglec 7 has been shown exhibit a high affinity for the disialosyl epitope,495 it is 
suggested that VWF O-linked glycans could play a role in the interaction of VWF with 
Siglec expressing cells. 
In addition, sialic acid residues confer a negative charge to glycoproteins and since they 
are abundant on the O-linked glycans clustered in the A1 domain flanking regions they 
could mediate the interaction of the A1 domain with vicinal domains. It has been 
previously demonstrated that D’D3 domains modulate the accessibility of GPIbα 
binding site within the A1 domain138 therefore it is hypothesised that sialic acid residues 
or the entire O-linked glycans in the D3-A1 linker region could modulate this 
interaction.  In addition, interaction between the A1 domain and isolated A2 domain has 
been documented, suggesting those domains interact with each other.286 Consequently 
the terminal sialic acid residues on O-linked glycans clustered in the A1-A2 linker 
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region could influence the accessibility of the ADAMTS13 cleavage site by determining 
rigidity of the linker region and proximity of the A1, A2 domains.  
In conclusion, the O-glycome profile of rVWF appears very similar to the profile of 
pdVWF. The only major, but expected difference is absence of ABO blood group 
antigens. Moreover, compared to pdVWF, O-linked glycans of rVWF lack the tetra-
sialylated structures, nevertheless those were quite infrequent in pdVWF O-glycome 
and the rVWF O-linked glycans still present the rare disialyl motif.  
The functional implications of mutating the O-linked glycocyslation site in rVWF are 
investigated in the subsequent chapters. 
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5 EXPRESSION AND CHARACTERISTION OF VWF O-LINKED 
GLYCOSYLATION MUTANTS  
Current data regarding the role of VWF O-linked glycans are limited and often 
contradictory; therefore the aim of this study was to establish the importance of O-
linked glycans in modulating VWF expression, structure and function. Since there is no 
universal enzyme for the release of O-linked glycans from the protein backbone, 
recombinant VWF lacking O-linked glycans was produced. As demonstrated in the 
previous chapter, the types and  relative abundance of O-linked sugars was similar on 
plasma derived VWF and recombinant VWF expressed in HEK293T cells, therefore 
this cell line was chosen to express wtVWF and VWF lacking O-linked 
oligosaccharides. As described, the VWF monomer contains 10 O-linked glycosylation 
sites; therefore VWF variants were generated to prevent glycosylation at one or more of 
these sites (T1248A, T1255A, T1256A, S1263A, T1468A, T1477A, S1486A, T1487A, 
T1679A and T2298A) (Figure 5.1). Firstly, the expression and secretion of proteins 
lacking only one O-linked glycan chain or lacking all four of the glycans flanking each 
(N- or C-terminal) or both sides of the A1 domain was investigated.  In order to assess 
the multimeric composition of expressed VWF variants, multimer gel analysis and 
collagen binding assays were used. Subsequently VWF functions; collagen type I and 
III and heparin binding were assessed.  Also the impact of the removal of O-linked 
sugars on the conformation of the VWF was probed using a Llama derived nanobody, 
and isolated VWF A2 domain. In addition, the lectin peanut agglutinin was employed to 
examine presence of core 1 O-linked glycan structure on VWF variants.The interaction 
of O-linked glycosylation variants with ADAMTS13 and platelets was also investigated 
and is going to be discussed in following chapters.  
5.1 Generation of O-linked glycosylation variants 
To determine the individual roles of VWF O-linked glycan chains, specific Thr/Ser 
residues were mutated to prevent glycosylation. The VWF cDNA encoding for full 
length (FL) VWF has been previously cloned into the mammalian expression vector 
pcDNA3.1 by Dr Tom McKinnon. A silent mutation at G100 was introduced to remove 
the KpnI site within the D1 domain leaving a unique KpnI site within the A2 domain to 
facilitate efficient subcloning of the VWF cDNA. To aid mutagenesis the XhoI – KpnI 
fragment of VWF (sequence for residues 768-1590) has also been previously sub-
cloned into the cloning vector pGEM Z(+). This vector was used to mutate the 8 O-
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linked glycan sites located either side of the A1 domain; T1248, T1255, T1256, S1263, 
T1468, T1477, S1486, T1487, changing the Serine or Threonine residue to Alanine. 
Following confirmation of the desired mutations by DNA sequencing, the XhoI–KpnI 
fragment was sub-cloned back into pcDNA FL-VWF. In addition, three cluster variants 
were constructed mutating all of the four sites either side of the A1 domain or all eight 
sites around the A1 domain. These were designated cluster 1(Clus 1, N-terminal), 
cluster 2 (Clus 2, C-terminal) or double cluster (DC) respectively. 
To generate O-linked glycan mutants at sites T1679 and T2298 the KpnI–Age I 
fragment of VWF (residues 1590–end) was digested from pcDNA FL-VWF and sub-
cloned into pcDNA3.1 and used for mutagenesis. All the mutants were successfully 
generated and the sequences verified by DNA sequencing.  
 
 
Figure 5.1 VWF O-linked glycosylation sites 
VWF contains 10 O-linked glycosylation sites.12 Eight glycans are clustered around the 
A1 domain, four on each side. One oligosaccharide is present in the A3 domain and one 
in the D4 domain.  
5.1.1 Mammalian expression of recombinant VWF 
Wild type and mutated recombinant VWF variants were transiently expressed in 
mammalian HEK293T cells using PEI as the transfection agent. Initial transfections to 
investigate whether any of the O-linked glycan chains play a role in the effective 
secretion of VWF were performed in 6 well plates. The concentration of each VWF 
variant in the conditioned media and cell lysate was than compared by VWF ELISA. 
All VWF variants including the cluster mutants were expressed and secreted into the 
conditioned medium at similar levels to wild type VWF (wtVWF), also the media to 
lysate ratio was comparable for all the variants (Figure 5.2a and Figure 5.3b).  Co-
transfection with enhanced green fluorescent protein (eGFP) was used as a control of 
transfection efficiency. Conditioned media was subject to SDS-PAGE under reducing 
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conditions and western blotting with anti-eGFP antibody. Similar eGFP expression was 
observed for each VWF variant, indicating similar transfection efficiency (Figure 5.2c). 
In addition, in all transfection experiments control cells were transfected with empty 
pcDNA3.1 vector, and no VWF expression was observed. The expression of the VWF 
O-linked glycan variants was then scaled up and expressed proteins were concentrated 
or purified for functional analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next page : 
Figure 5.2 Expression of wtVWF and its glycosylation variants - VWF ELISA 
To study the effect of O-linked glycosylation on the secretion of VWF, VWF antigen 
levels in condition media (A) and cell lysate (B) were analysed using VWF ELISA. 
Similar amounts of each VWF variant and wtVWF protein was expressed and retained 
within the cell. (Values shown here are SEM of 3 separate transfections performed in 
duplicate). (C) Media to lysate ratio was determined to be similar for wtVWF and each 
VWF variant. (D) In addition, conditioned medium from each transfection was 
subjected to SDS-PAGE under reducing conditions followed by western blot with anti-
eGFP antibody, showing equal effectiveness of transfection. (p>0.05) 
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Figure 5.3 Expression of O-linked glycosylation cluster variants 
To investigate the effect of O-linked glycan cluster on the secretion of VWF, VWF 
antigen levels in the conditioned media (A) and cell lysate (B) were measured by VWF 
ELISA. Similar amounts of each VWF variant and wtVWF protein were expressed and 
retained within the cell. (Values shown here are SEM of 3 separate transfections 
performed in duplicate). (C) Media to lysate ratio was determined to be similar for 
wtVWF and each VWF cluster variant.(p>0.05). 
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5.2 Characterisation of VWF mutants  
5.2.1 Multimer analysis 
The multimeric composition of expressed VWF was analysed by agarose gel 
electrophoresis followed by Western Blotting. Equal amounts of VWF were loaded on 
to the gel and the multimeric composition of the VWF glycosylation variants was 
compared to that of recombinant wtVWF and plasma derived VWF (pdVWF). All 
cluster variants and single glycosylation mutants demonstrated multimeric patterns 
similar to that of wtVWF (Figure 5.4). Compared to pdVWF, rVWF has a different 
multimeric composition, with the multimer pattern skewed towards medium and lower 
molecular weight multimers. 
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Figure 5.4 Multimer distribution of VWF glycosylation variants 
The multimeric pattern of VWF single and cluster glycosylation variants was visualised 
on in 1.4 % agarose gels. The multimeric patterns of VWF O-linked glycosylation 
variants are indistinguishable from that of recombinant wtVWF. (RP-reference plasma). 
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5.2.2 Collagen binding activity 
The collagen binding function of VWF is highly sensitive to VWF multimeric size with 
high molecular weight multimers binding collagen with greater affinity. Since all the 
VWF variants were shown to have a similar multimeric pattern, any alterations in 
collagen binding are likely to reflect changes in binding affinity rather than an effect of 
multimerisation.  The effect of mutations on binding to collagen types III and I was 
assessed by an ELISA based collagen binding assay. Immobilised collagen type III was 
incubated with increasing concentrations of rVWF to generate binding.  Binding curves 
were calculated using a one site binding model which has been previously shown to 
give appropriate fitting curves. The KD,app was ~2nM for wtVWF* and all the VWF O-
linked glycan variants demonstrated similar binding affinity demonstrating that they do 
not affect collagen binding.(Figure 5.5) The VWF collagen type I and III binding 
function was also investigated as a ratio of collagen binding to VWF antigen 
(VWF:CB/VWF:Ag). The normal observed ratio for pdVWF is >0.7. WtVWF had a 
VWF:CB/VWF:Ag ratio of 0.4. This difference in collagen binding is due to differences 
in multimeric pattern, with plasma derived VWF having more high molecular weight 
multimers. All single and cluster glycosylation variants showed collagen type III and I 
binding similar to that of wtVWF confirming that the O-linked glycans do not alter 
binding to collagen (Figure 5.6). 
 
 
 
 
 
 
 
 
*To determine the KD for the interaction of VWF with collagen, the monomeric weight of rVWF was 
taken as 270kDa 
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Figure 5.5 Binding isotherms of VWF variants to collagen type III 
Collagen type III binding affinity of VWF O-linked glycosylation variants was analysed 
using an ELISA based plate assay. KD, app values were calculated by fitting the data to 
the one site binding equation and compared to that of wt VWF. Collagen binding curves 
for glycosylation variants located on the N-terminal side of the A1 domain (A) on the 
C-terminal side of the A1 domain and double cluster (B) and the T1679A and T2289A 
(C) variants were shown to be similar to wtVWF. (D) The calculated KD values for all 
glycosylation variants are listed in the table and are similar collagen binding affinity 
obtained for wtVWF. Values shown here are SEM of 3 separate experiments performed 
in duplicate. 
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Figure 5.6 Analysis of VWF binding to collagen types III (A) and I (B) 
VWF O-linked glycosylation variants were tested for their ability to bind collagen. 
Results from three separate ELISA experiments on VWF samples demonstrate that all 
variants bound to immobilized collagen types III (A) and I (B) with the same affinity as 
wt VWF. (Values shown here are SEM of 3 separate experiments performed in 
duplicate; p>0.05).  
 
5.3 Functional characteristics of VWF variants  
5.3.1 Heparin binding 
The major heparin binding site of VWF is localised to the A1 domain, and therefore, 
removal of the O-linked glycans chains that flank both sides of the A1 domain 
disulphide loop could potentially influence the ability of VWF to interact with heparin. 
Moreover, since I planned to purify recombinant VWF using heparin affinity 
chromatography I investigated the ability of the VWF O-linked glycan variants to bind 
to Heparin. The heparin-binding properties of the VWF variants were investigated by 
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incubating a fixed quantity of VWF or its variants with Heparin-Sepharose beads and 
measuring the amount of VWF remaining unbound by VWF ELISA. It has been 
established that heparin binding is largely independent of the multimeric composition of 
VWF.143 The concentration of VWF was low enough to prevent saturation of the beads. 
As demonstrated in Figure 5.7 no significant difference in heparin binding between 
wtVWF and the VWF variants was observed, indicating that removal of O-linked 
glycans does not influence heparin binding.  
 
 
Figure 5.7 Binding of wtVWF and VWF glycosylation variants to heparin 
Effect of VWF O-linked glycans on the interaction with heparin was investigated using 
heparin-Sepharose resin and  unbound VWF was detected using VWF ELISA. Results 
are expressed as the percent of heparin unbound, when for each variant the 
concentration of VWF prior incubation with heparin-Sepharose beads was taken as 
100%. The heparin binding capacity for each O-linked glycosylation variant was similar 
to that for wtVWF. (Values shown here are SEM of 3 separate experiments performed 
in duplicate; p>0.05). 
 
5.3.2 Nanobody binding 
VWF circulates in plasma in a globular inactive conformation, which is unable to 
spontaneously interact with platelets. Transition from the non-binding to the GPIbα-
binding form of the A1 domain is necessary to induce formation of the VWF-GPIbα 
complex. This physiological activation occurs when VWF elongation is induced 
following its binding to collagen or under conditions of high shear stress.  The presence 
of ‘activated’ VWF (i.e. VWF in its GPIbα-binding conformation) in solution can be 
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detected using a nanobody (AU/VWFa-11), which is a homodimer of a Llama derived 
immunoglobin heavy chain.496 Although the nanobody binds a site within VWF distinct 
from the GPIbα binding site itself, it can detect VWF in its activated form, which is, for 
instance, induced by immobilization, ristocetin, or VWD type 2B mutations.  
I postulated that removal of the O-linked glycans that flank the A1 domain could alter 
VWF or the A1 domain conformation and therefore enable nanobody binding. To 
investigate the influence of O-linked glycans on VWF conformation and nanobody 
binding an immunosorbent binding assay in the presence and absence of ristocetin was 
used. Firstly, in the absence of ristocetin only minimal nanobody binding was observed 
for wtVWF when compared to wtVWF incubated with 250 µg/ml of ristocetin (Figure 
5.8). Similarly, with the exception of the double cluster mutant, no substantial nanobody 
binding was observed for any of the VWF glycosylation variants in the absence of 
ristocetin. However, when compared with wtVWF, a slight increase in nanobody 
binding in the absence of ristocetin was detected for the double cluster variant. (Figure 
5.8)  This would suggest that removal of all the O-linked glycans flanking the A1 
domain partially increases the ability of VWF to interact with the nanobody without the 
need for ristocetin, however it does not appear to fully ‘activate’ the A1 domain, since 
the extent of interaction is still minimal compared to ristocetin activated VWF. 
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Figure 5.8 Binding isotherm of wtVWF and DC variant to nanobody AU/VWFa-11  
in the absence of ristocetin  
Binding of wtVWF and all glycosylation variants to nanobody in the absence of 
ristocetin was determined. Apart from the double cluster all VWF variants showed 
binding similar to that of wtVWF; for simplicity graph illustrates binding curves for 
wtVWF and the DC variant only. Inset is with larger scale ordinate. In the absence of 
ristocetin, wtVWF in solution weakly interacted with the nanobody, and slightly 
increased binding was observed for the double cluster however accurate binding curves 
or KD values could not be derived. For comparison, the much greater binding observed 
for wtVWF activated with ristocetin is shown. 
 
Subsequently the interaction between ristocetin-activated VWF and the nanobody was 
investigated. Since maximal binding to the nanobody for wtVWF was reached at a 
ristocetin concentration of 250µg/ml this concentration was used to compare binding of 
the nanobody to the VWF variants. The double cluster variant displayed a slight 
increase in binding, consistent with the slightly increased binding in the absence of 
ristocetin, while the cluster 2 variants demonstrated a slight decrease in nanobody 
binding in the presence ristocetin when compared with wtVWF (Figure 5.9). None of 
the other glycosylation variants showed a significant change in ristocetin dependent 
nanobody binding in this static assay. To further examine this, the binding parameters of 
ristocetin activated VWF to nanobody were quantified. Briefly nanobody coated plates 
were incubated with various concentrations of rVWF (0.5-4nM) in the presence of 
250µg/ml ristocetin. Binding isotherm and binding parameters were estimated by fitting 
the data to the one site binding equation using GraphPad Prism. Figure 5.10 shows 
binding data from a representative experiment. It was determined that wtVWF bound 
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the nanobody with a KD,app~1.2±0.1nM The T1477A, S1486A, T1487A, Clus2 and the 
DC showed somewhat decreased nanobody binding in the presence of ristocetin when 
compared to wtD’A3 and all other glycosylation variants showed similar binding 
variants were shown to bind with a similar KD,app suggesting that the removal of O-
linked glycans does not significantly affect VWF-nanobody binding. 
 
Figure 5.9 Binding of wt and mutated VWF to AU/VWFa-11 nanobody in the 
presence of 250 μg/ml ristocetin 
The concentration of ristocetin that induced maximum binding of VWF to nanobody 
was determined to be 250μg/ml and this concentration was chosen for the binding 
assays. The double cluster exhibited increased and cluster 2 decreased nanobody 
binding while all other mutants have binding similar to that of wtVWF. Each value 
represents SEM of three independent sets of duplicate determinations.   
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Figure 5.10 Binding isotherm of ristocetin activated VWF to AU/VWFa-11 
nanobody 
Nanobody coated plates were incubated with various concentrations of rVWF (0.5-
4nM) in the presence of 250µg/ml ristocetin. Binding isotherm and binding parameters 
were estimated by fitting the data to the one site binding equation. (A,B) Representative 
binding curves illustrated. (C) The calculated KD,app values for all variants are listed in 
the table. (Standard error values are given) Estimated nanobody binding KD,app for 
wtVWF was approximately 1.2nM. The T1477A, S1486A, T1487A, Clus2 and the DC 
showed somewhat decreased nanobody binding in the presence of ristocetin and all 
other glycosylation variants showed similar binding. 
 
5.3.3 Binding of bacterial expressed VWF A2 domain to VWF 
It has been previously reported that isolated VWF A2 domain expressed in bacterial 
cells can bind to the VWF A1 domain when the A1 domain in its ‘active’ conformation 
and that this blocks the interaction with GPIbα under high shear.286 The data obtained 
from the nanobody binding assays suggested that the double cluster and cluster 2 
variants may have an altered conformation. Therefore, I investigated whether the 
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removal of O-linked glycans clustered around the A1 domain could affect the 
interaction between bacterial expressed A2 domain and the A1 domain of the VWF O-
linked glycosylation variants. 
To begin with, binding of the VWF variants to immobilised bacterial A2 domain was 
studied as a function of VWF concentration in the absence of ristocetin using an ELISA 
based plate assay. As previously reported, no binding to the A2 domain was detected for 
wtVWF in solution. However, ristocetin activated wtVWF was able to bind to the 
isolated A2 domain with high affinity (Figure 5.11). Similarly to wtVWF, none of the 
glycosylation variants, when in solution, were able to bind to the isolated A2 domain. 
(Binding for selected mutants illustrated on Figure 5.11) Subsequently the interaction 
between the isolated A2 domain and immobilised VWF variants was studied.  In 
agreement with the previous study, the isolated A2 domain binds to wtVWF in a 
concentration dependent and saturable manner, with half-maximal binding observed at 
0.5µM. Consequently VWF variants were also assayed and showed a similar interaction 
with the immobilised isolated A2 domain, comparable to the wild type protein. Binding 
curves for selected VWF variants are shown on Figure 5.12. This further confirmed that 
absence of O-linked oligosaccharides flanking the A1 domain does not alter the 
interaction between multimeric VWF and the bacterial isolated A2 domain.  
 
Figure 5.11 VWF binding to immobilised bacterial A2 domain 
The wtVWF in solution did not bind to the purified A2 domain even at the highest 
concentration (10µg/ml). Conversely wtVWF in the presence of ristocetin therefore in 
an ‘active’ (GPIbα binding conformation) was able to interact with the bacterial A2 
domain with half-maximal binding at a concentration of ~ 1µg/ml. Moreover none of 
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the O-linked glycosylation variants in solution bound to the A2 domain. (For clarity 
only selected variants shown) 
 
Figure 5.12 Binding of the bacterial A2 domain to immobilised multimeric VWF 
variants 
Effect of the O-linked glycans on the binding of the isolated A2 domain was examined 
using an ELISA based plate assay. Binding isotherm and binding parameters were 
estimated by fitting the data to the one site binding equation. Half maximal binding was 
observed at 0.5µm for wtVWF and comparable KD,app values were detected the for O-
linked variants. For simplicity selected variants are shown on the graph. 
 
 
Since bacterial expressed proteins do not undergo glycosylation I tested the ability of 
the purified A2 domain expressed in HEK293T cells, to interact with VWF. In contrast 
to the bacterial form, the glycosylated mammalian A2 domain was unable to interact 
with the immobilised FL-VWF. However a notable increase in binding was observed 
for the A2 domain when the N-linked glycans were removed by incubating with 
PNGase F (Figure 5.13). In addition, VWF appeared to bind to the de-glycosylated 
mammalian A2 to a lesser extent than to the bacterial A2. This suggests that the N-
linked glycosylation of the A2 can prevent the interaction that was previously shown to 
occur between the A1 domain and the bacterial A2 domain devoid of glycans.  
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Figure 5.13 Binding of the mammalian glycosylated and de-glycosylated VWF-A2 
domain to multimeric immobilised VWF 
Interaction between immobilised VWF and the A2 domain expressed in HEK293T cells 
was assessed using an ELISA base plate assays. No binding of the fully glycosylated 
VWF-A2 domain was detected (mA2, in black). De-glycosylation of the A2 domain, by 
treatment with PNGase F resulted in a considerable increase in the binding to the 
immobilised multimeric VWF (+PNG mA2, in purple). 
5.3.4 Peanut agglutinin binding  
The majority of O-linked glycans terminate with the sialylated core 1 structure (also 
termed the T-antigen), and variations in the extent of glycosylation of VWF with this 
structure have been suggested to correlate with VWF plasma levels.457 The core 1 
structure can interact with the lectin peanut agglutinin (PNA), therefore this lectin was 
used in an immunosorbent assay to assess the relative amount of core 1 structure on the 
VWF cluster variants compared to wtVWF.  In this assay VWF-linked carbohydrates 
are desialylated using neuraminidase, which allows subsequent detection of the core 1 
structure by PNA. No PNA binding was detected when neuraminidase treatment was 
omitted, confirming specificity of PNA for desialyted core 1 structures. As shown on 
Figure 5.14, PNA binding was detected for desialylated wtVWF, confirming it contains 
T-antigen structures. Furthermore a marked decrease in PNA binding was observed for 
the DC variant that lacks eight of the ten O-linked glycan. PNA binding was reduced to 
a similar level for the Clus 1 variant that has 4 glycans flanking the N-terminal side of 
the A1 domain missing. The Clus 2 VWF variant, devoid of 4 O-linked glycan chains 
on the C-terminus of the A1 domain exhibited decrease in PNA binding compared to 
wtVWF, however the reduction in binding was less than for Clus 1 and DC.  
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Figure 5.14 Binding of peanut agglutinin to VWF cluster variants 
Serial dilutions of neuraminidase (Neu) treated VWF were added to microtiter plates 
coated with anti-VWF antibodies, and peanut agglutinin (PNA) binding was detected. 
WtVWF that was not incubated with neuraminidase, therefore with terminal sialic acid 
residues present was used as a negative control and this did not bind PNA (wtVWF no 
Neu). In contrast, PNA was able to bind to wtVWF and cluster VWF following removal 
of terminal sialic acids with neuraminidase. When compared to wtVWF all the cluster 
variants exhibited diminished PNA binding. A marked reduction in PNA binding was 
observed for Clus 1 and DC variants while the Clus 2 demonstrated smaller reduction in 
PNA binding. Data represents the mean of 3 independent experiments.  
 
5.4 Discussion  
The properties of recombinant VWF lacking all O-linked glycans have been previously 
investigated, however, often with conflicting results. VWF produced in Chinese 
Hamster Ovary (CHO) cells that lacked the ability to synthesize O-linked glycans was 
shown to be secreted and multimerised in the same way as the fully glycosylated 
form.454 Therefore in this project VWF mutants were made to prevent O-linked 
glycosylation at the ten identified sites and their properties studied in more detail. In 
addition to this, three cluster variants were constructed  by mutating all of the 4 sites 
either side of the A1 domain (cluster 1 and cluster 2) or all 8 sites around the A1 
domain (double cluster). Mutations deleting the remaining two sites were also prepared 
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separately. Threonine or serine residues were mutated to alanine since it the typically 
used change to prevent O-linked glycosylation at specific side and it is the most 
conservative change one could apply. Alanine amino acid has a similar size as threonine 
and serine, and has a hydrophobic side chain instead a polar uncharged side chain, 
which should not significantly interfere with the conformation of the peptide. As 
described these were expressed in HEK293T cells and expression and function 
analysed. The expression and secretion analysis of VWF O-glycosylation variants 
created in this project confirm that absence of O-linked glycans does not affect VWF 
expression and secretion with all the individual point mutations and the cluster 
mutations being synthesized and secreted to a similar extent. Variations in the extent of 
glycosylation of VWF with O-linked sialylated T-antigen have previously been shown 
to affect VWF plasma levels.457 However, the similar expression of VWF O-linked 
glycosylation variants in this study suggests this effect is not due to changes in VWF 
secretion.   
Furthermore, I have confirmed that the removal of O-linked glycans has no effect on 
VWF multimeric structure, with all recombinant variants exhibiting a full range of 
multimers, similar to wtVWF. The distribution of multimers for recombinant VWF 
expressed in HEK293T cells was slightly different from that of pdVWF, with the 
multimeric composition of rVWF being skewed towards the medium and small 
multimers that are less haemostatically active and as a result having reduced collagen 
binding per unit antigen. However, wtVWF and all glycosylation variants had a similar 
affinity for collagen with KD,app ~2nM and VWF:CB/VWF: Ag ratio of 0.4. The value 
for the KD,app refers to the monomeric concentration of VWF and was calculated based 
on a VWF monomeric weight of 250kDa, and was in keeping with previously published 
values. 150 These results suggest that O-linked glycans does not affect either multimeric 
structure or collagen binding affinity.  
Heparin binding function, mediated by the VWF-A1 domain, was also examined with 
all the mutants showing normal heparin binding. Therefore the O-linked glycans of 
VWF do not affect the interactions with heparin, allowing the use of heparin-Sepharose 
chromatography as a second step of VWF purification.  
In order to bind GPIbα, VWF requires a conversion from its resting state into an active 
GPIbα binding conformation. A previously described llama-derived nanobody can 
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distinguish between resting and activated VWF.496 In this study the binding between the 
immobilised nanobody and rVWF variants in solution was investigated first in the 
absence of ristocetin. Neither wtVWF, nor any of the glycosylation variants (with the 
exception of the DC variant) were able to bind appreciably to the nanobody in the 
absence of ristocetin, showing that those mutations do not induce a conformational 
change that renders the VWF-A1 domain constitutively active. For the double cluster 
variant, slightly increased nanobody binding in the absence of ristocetin was detected. 
This observation could suggest that removal of all O-linked glycans flanking the A1 
domain alters VWF configuration at least partially, allowing nanobody binding. In the 
presence of ristocetin the nanobody binding was increased for the double cluster variant 
and slightly decreased for the Clus 2 variant when compared to wtVWF. The reason for 
this effect is not fully explained. Removal of glycan chains from the A1 domain N-
terminal flanking region could introduce flexibility into the peptide backbone and this 
could induce a conformational change or alter stability of the A1 domain or the way the 
A2 or D’D3 domains interact with the A1 domain. This change in conformation could 
enhance the exposure of either the nanobody binding site or ristocetin binding site 
allowing more VWF to bind. To further examine the effect of O-linked glycans flanking 
the A1 domain on its interaction with vicinal domains, a previously described A2 
binding assay was employed. 
A previous study has shown that bacterial expressed VWF A2 domain is able to bind to 
the A1 domain of VWF when the A1 domain is in its active conformation. In addition it 
has been shown that the R1405A gain-of function mutation that results in increased 
platelet binding in the isolated A1 domain diminishes its interaction with the isolated 
bacterial A2 domain.132,335,497  Moreover, denaturation and differential scanning 
calorimetry experiments performed on mammalian wild type and mutated (R1405A) 
A1A2A3 tri-domain protein have shown that the destabilisation of the A1 domain 
results in a reduced interaction between the three domains and enhances the binding to 
GPIbα.497 However a direct association between the A1 and A2 domain has not been 
demonstrated in the context of full-length VWF. In the view of these data I used 
bacterial expressed VWF A2 domain as a tool to investigate if the removal of VWF O-
linked glycans could alter the conformation of the A1A2A3 complex, resulting in 
“activation” of the A1 domain. In keeping with previous work, wtVWF did not bind to 
immobilised bacterial A2 domain in the absence of ristocetin and binding was only 
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induced when ristocetin was included in the assay. Similar to wtVWF, none of the 
tested VWF O-linked glycosylation mutants bound to bacterial A2 domain in the 
absence of ristocetin suggesting that either they are not in an “active” conformation or 
the removal of the O-linked glycosylation is unable to produce a significant 
conformational change to allow binding to bacterial derived VWF A2 domain in the 
absence of ristocetin. Similarly, when wtVWF or the O-linked glycan variants were 
immobilised and incubated with soluble VWF A2 domain, the A2 domain bound with 
equal affinity to wtVWF and the mutant proteins. This confirms that immobilisation of 
VWF to microtitre plates “activates” the molecule and furthermore suggests that the 
extent of activation (or at least activation detected by isolated A2 domain) by 
immobilisation is not altered by removal of the O-linked glycan chains. Bacterial 
derived VWF A2 domain is not routinely used in our laboratory due to aggregation of 
the protein (McKinnon and Chan unpublished observations) and we prefer to express 
VWF A2 domain in HEK293T cells. Importantly, the VWF A2 domain contains 2 N-
linked glycan sites, one of which, N1574, has been shown to be crucial for VWF 
function.239 In light of this, I determined the ability of mammalian VWF A2 domain to 
interact with active VWF. Interestingly, unlike its bacterial counterpart, mammalian 
VWF A2 domain failed to bind to immobilised full length VWF. Following PNGase F 
digestion to remove the two N-linked glycan chains, the mammalian A2 domain was 
again able to interact with immobilised VWF. These data suggest that the N-linked 
glycan chains present on the A2 domain may influence the way it interacts with the 
VWF–A1 domain and warrants further investigation. Furthermore this data also 
highlights differences between proteins expressed in bacterial and mammalian systems 
A basic view of O-linked glycan structure of the VWF cluster variants was determined 
by lectin analysis. Lectins are proteins (usually derived from plants) that specifically 
recognise and reversibly bind carbohydrate moieties. The lectin Peanut agglutinin 
(PNA) that binds to the core 1 (galactosyl β-1,3 N-acetylgalactosamine) glycan 
sequence was used, since the majority of VWF O-linked glycans are composed of 
sialylated core 1 structures.452 As demonstrated by PNA analysis, compared to wtVWF, 
the DC variant demonstrated greatly reduced PNA binding consistent with the loss of 8 
O-linked glycan chains. Some PNA binding capacity was retained with the DC variant, 
implying that the O-linked glycan/s at position T1679 and S2298 could be core 1 
structures. Consistent with the loss of 4 O-linked glycans, the Clus2 variant had less 
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PNA binding then wtVWF, but more binding than the DC variant. Curiously, the Clus1 
variant demonstrated PNA binding similar to the DC variant. The reason for this is not 
fully understood, however it may be suggested that the O-linked glycans on the N-
terminal side of the A1 domain are composed of mainly Core 1 structures and the O-
linked glycans on the C-terminal side are mainly core 2 structures. As such, when the 
four N-terminal glycans are not present (as with the Clus1 variant) PNA binding is 
reduced to the same extent as the DC variant. Further detailed mass spectroscopy 
analysis will be required to confirm the exact structure of the O-linked glycan clusters. 
Alternatively, the C-terminal glycans may be more inaccessible that the N-terminal ones 
to PNA binding, further structural analysis will be required to confirm this. 
In summary, O-linked glycans have no influence on VWF expression, secretion or 
multimeric structure. Moreover, they do not alter the ability of VWF to bind to collagen 
or heparin. In addition, VWF O-linked glycans have a marginal effect on binding to a 
nanobody designed to recognise the GPIb binding conformation of the A1 domain, but 
no influence on the interaction of VWF with isolated bacterial A2 domain. In the next 
chapter the role of O-linked glycans in the interaction of VWF with ADAMTS13 is 
going to be discussed.  
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6 INTERACTION OF VWF O-LINKED GLYCOSYLATION 
VARIANST WITH ADAMTS13                                                                                                                                                                                                                                                                                                                                                                                                                                     
6.1 ADAMTS13 cleavage of VWF O-linked glycosylation variants  
 
6.1.1 ADAMTS13 proteolysis of full length VWF variants under static and 
pseudo-shear conditions  
To investigate the influence of VWF O-linked glycans on the interaction with 
ADAMTS13, cleavage assays were performed initially under static conditions. This 
assay required the presence of 1.5M urea to denature VWF and cause a conformational 
change that allows ADAMTS13 access to the otherwise buried cleavage site. The extent 
of proteolysis was determined by multimer gel analysis and CBA. 
The multimeric pattern for the single glycosylation mutants before and after 
ADAMTS13 proteolysis in the presence of urea is shown in Figure 6.1. At time point 
zero, all the single glycosylation VWF variants have similar multimeric composition.  
After 4 hours incubation with ADAMTS13, the HMW multimers are lost, with only the 
medium to low molecular weight multimers remaining, however the extent of the loss 
of HMW multimers was noticeably less for the S1486A variant than for the others 
variants. This suggests that VWF-S1486A is less susceptible to ADAMTS13 cleavage 
compared to wtVWF. To provide a more quantitative measure of VWF proteolysis, 
cleavage assay samples were analysed using the collagen binding assay to detect the 
reduction in multimer size. Supporting the multimer gel analysis, the CBA showed that 
the S1486A variant was cleaved appreciably slower than wtVWF with less reduction in 
collagen binding at all time points. Furthermore, cleavage of the Clus 2 (which contains 
S1486) and DC variants was also assessed in this way. Interestingly the Clus 2 variant 
was also cleaved to a similar extent to VWF-S1486A and the DC variant was 
proteolysed by ADAMTS13 to an even lesser extent (Figure 6.2). All other variants 
exhibited unaltered susceptibility to ADAMTS13 proteolysis (data not shown). 
. 
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Figure 6.1 Multimer gel analysis of ADAMTS13 cleavage 
Multimer gel electrophoresis was used to assess the extent of VWF proteolysis of single 
glycosylation variants by ADAMTS13. (A) VWF multimeric content prior to 
ADAMTS13 proteolysis. (B) VWF multimeric pattern after four hour incubation with 
ADAMTS13 in the presence of 1.5M urea. Single glycosylation variants were 
proteolysed very similarly to the wtVWF, with the exception of S1486A (red box) that 
was proteolysed at a markedly slower rate. The T1477A variant might also seem to be 
cleaved more slowly, however CBA analysis and cleavage assays showed that it to be 
the same as wtVWF. RP-reference plasma (no ADAMTS13). 
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Figure 6.2 Collagen binding analysis of wtVWF, S1486A and Clus 2 and DC 
variants proteolysis by ADAMTS13 in the presence of urea 
VWF variants were subject to ADAMTS13 proteolysis in the presence of urea and the 
extent of cleavage was analysed by collagen binding assay. Results are expressed as 
percentage reduction of collagen binding from baseline. The results show that the 
S1486A, cluster 2 and double cluster variants are cleaved significantly slower than the 
wtVWF.  (Values shown are SEM of 3 separate experiments performed in duplicate). 
 
The requirement for denaturants is a major limitation of static cleavage assays since it 
does not accurately reflect conditions in vivo. To examine the cleavage of VWF under 
more physiological conditions, experiments were repeated using a simple shear-stress 
based assay.120 In this assay a bench top vortex mixer is used to generate mechanical 
shear stress that results in exposure of the ADAMTS13 cleavage site without the need 
for urea. As with the static assays, cleavage was assessed by multimer gels and CBA. In 
keeping with the data obtained under static conditions all of the single O-linked glycan 
variants with the exception of S1486A were proteolysed to a similar extent by 
ADAMTS13 in the vortex assay. As illustrated by multimer gel analysis, after 2 minutes 
incubation on the vortex mixer, the loss of HMW multimers is greater for the wtVWF 
than the S1486A variant indicating slower proteolysis and supporting the data obtained 
under static conditions (Figure 6.3).  
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Figure 6.3 Multimer gel analysis of wt and S1486A VWF proteolysis by 
ADAMTS13 in pseudo shear assay 
Multimer gel electrophoresis of VWF variants subjected to ADAMTS13 proteolysis 
under pseudo shear to show the extent of VWF proteolysis. Single glycosylation 
variants were proteolysed at very similar extent to the wtVWF, with the exception of 
S1468A that was cleaved more slowly.  Before the start of the assay both wtVWF and 
S1486A variant have similar multimeric pattern, while after 2 minutes incubation with 
ADAMTS13 under pseudo-shear conditions the S1486A sample still contains high 
molecular weight multimers while the wtVWF samples has been reduced to medium 
weight multimers.   
 
Subsequently, the extent of cleavage under pseudo shear stress was assessed by collagen 
binding analysis (Figure 6.4). VWF-S1486A, the cluster 2 and the double cluster 
mutants were shown to exhibit more collagen binding potential than wtVWF after 2 
minutes incubation on the vortex mixer, indicating that have decreased susceptibility to 
ADAMTS13 proteolysis, again corroborating the observations seen under static 
conditions. However it should be noted that the double cluster variant showed 
substantially decreased susceptibility to ADAMTS13 cleavage when compared to 
wtVWF in the presence of urea while the decreased in proteolysis under pseudo-shear 
conditions was not as significant.  
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Figure 6.4 Collagen binding analysis of VWF proteolysis by ADAMTS13 in pseudo 
shear-vortex assay 
Bar graph illustrates the reduction in collagen binding following 2 minute incubation 
with ADAMTS13 on a vortex used to generate shear stress. The extent of cleavage was 
analysed by CBA. The S1486A, Clus 2 variants are cleaved significantly slower when 
compared to wtVWF as demonstrated by the lesser reduction in collagen binding 
activity. Also DC variant exhibited moderate decrease in ADAMTS13 proteolysis. 
Other single glycosylation variants and cluster 1 have the same susceptibility to 
ADAMTS13 proteolysis as wtVWF (data not shown). (Error bars are SEM of 3 separate 
assays performed in duplicate) 
6.1.2 Cleavage of D’-A3 VWF with ADAMTS13  
In order to establish if the effects of the O-linked glycans on ADAMTS13 cleavage are 
due to alterations in the local conformation of the VWF monomer, ADAMTS13 
cleavage assays were also performed on VWF from the  D’ to A3 (i.e. D’D3A1A2A3) . 
Experiments were performed in the presence of urea on purified wtD’A3-VWF and 
D’A3 containing either S1486A, Clus 2 or DC mutations, since these variants in full 
length VWF  had altered  susceptibility to ADAMTS13 cleavage.  
The D’A3 protein contained a C-terminal c-myc/his tag and therefore the C-terminal 
cleavage product at specific time points was visualised with mouse anti c-myc 
antibodies. The intensities of the bands produced by the cleavage products of wtVWF, 
S1486A, Clus 2 and DC at specified time points were compared. There was found to be 
no significant reduction in cleavage between wtVWF and the S1486A variant, but a 
marked reduction in cleavage between wtVWF and the cluster 2 and double cluster 
variants (Figure 6.5). This suggests that removal of all O-linked glycan chains form the 
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linker region between the A1 and A2 domain alters the susceptibility of D’A3 to 
ADAMTS13 proteolysis. 
 
 
 
Figure 6.5 Cleavage of  wt-, S1486A-, Clus 2- and DC- D’A3 by ADAMTS13, 
analysed by western blotting 
Purified VWF-D’A3 fragments containing either S1486A, Clus 2 or DC mutations were 
incubated with activated ADAMTS13 in the presence of urea and the extent of 
proteolysis over time was examined by SDS-PAGE and Western blotting. C-terminal 
end cleavage products were detected with anti-c-myc antibodies as illustrated above. 
Prior to incubation (time point 0) and after 0.5 hour incubation with ADAMTS13, there 
are no cleavage products for any of the VWF samples. After 1 hour, weak bands for 
cleavage products for both wtD’A3 and the S1486A-D’A3 could be detected but no 
appreciable band for Clus 2-D’A3 or DC-D’A3. The cleavage of Clus 2 was detected 
after 2 hours. The first visible band for the DC-D’A3 variants was only visible after 2.5 
hours and is still weaker in comparison to that of wtVWF and other variants. This 
suggests that the cleavage of Clus 2- and DC-D’A3 in the presence of urea is 
significantly slower than that of wt D’A3 and S1486A-D’A3. 
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6.2 Characterisation of binding between ADAMTS13 and S1486A, 
Clus 2 and DC VWF variants 
6.2.1 Binding between ADAMTS13 and elongated VWF 
In order to further elucidate the changes in proteolysis identified, I proceeded to 
investigate they were associated with altered ADAMTS13 binding to VWF in either its 
elongated or globular conformation. 
First, I assessed the efficiency of VWF at coating microtitre plates. To do this the 
purified recombinant wtVWF, S1486A, Cluster 2 and double cluster glycan variants 
were directly coated onto a plate and bound VWF was detected with polyclonal rabbit 
anti-human VWF.  The results showed that the wild type protein and all glycosylation 
variants analysed were immobilised at similar level (Figure 6.6a) therefore binding 
assays could be performed. Subsequently, binding of ADAMTS13 to elongated full 
length VWF was carried out by immobilising wtVWF, S1486A, Clus 2 and DC variants 
on a microtitre plate and incubation with serial dilutions of full length E225Q-
ADAMTS13 mutant is proteotyically inactive. The E225 residue participates in water 
molecule coordination that impel the hydrolysis of the scissile bond and the inactive 
ADAMTS13 has been previously created and expressed in our lab (provided by Dr 
S.Zanardelli). Immobilisation of VWF leads to exposure of exosites in VWF that 
interact with ADAMTS13 allowing subsequent proteolysis. As shown on (Figure 6.6b) 
no appreciable difference in binding between wtVWF and the glycosylation variants 
was observed and the KD,app values were all within the same range.  
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Figure 6.6 Binding of ADAMTS13 to elongated VWF 
Binding between elongated VWF and ADAMTS13, was investigated by a plate binding 
assay. (A) Firstly coating efficiency of wtVWF and mutated proteins was compared and 
as shown on the graph all recombinant protein coated with the same effectiveness. (B) 
Binding of ADAMTS13 to the immobilised VWF variants was studied as a function of 
ADAMTS13 concentration. Binding isotherm and binding parameters were estimated 
by fitting the data to the one site binding equation. ADAMTS13 shows no difference in 
binding to full length wtVWF when compared to S1486A, Cluster 2 and DC glycan 
mutants. The insert table shows KD estimations and standard error, which are within the 
same range. 
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6.2.2 Binding between ADAMTS13 and VWF in globular conformation 
ADAMTS13 has been shown to bind weakly to VWF in its globular conformation     
(KD ~80nM) with the A2 domain buried, and the binding is mediated by C-terminal 
parts of both proteins. In the view of the decreased susceptibility to ADAMTS13 
proteolysis but normal binding of elongated S1486A, Cluster 2 and double cluster to 
ADAMTS13 observed I proceeded to investigate if the removal of O-linked glycans can 
influence binding of VWF in solution (i.e. globular VWF) to ADAMTS13. This was 
assessed by co-immunoprecipitation essentially as previously described.152 E225Q-
ADAMTS13 was incubated with wtVWF and S1486A-, Clus1- and DC-VWF variants 
and immunoprecipitated with anti-VWF-CK antibodies. Magnetic beads with bound            
VWF-ADAMTS13 complexes were washed to remove unbound proteins. The VWF 
and ADAMTS13 were then eluted, and subject to SDS-PAGE under reducing 
conditions followed by Western Blotting. As shown on Figure 6.7b bands of ~260kDa 
corresponding to VWF were detected with generally the same intensity for all the 
samples apart from the sample with VWF omitted, indicating equal 
immunoprecipitation of VWF by the anti-VWF antibody. Interestingly as shown on 
Figure 6.7a the glycan variants S1486A- Cluster 2 and DC-VWF (lanes 2, 3, 4 
respectively) showed increased ADAMTS13 co-precipitation when compared to 
wtVWF (lane1), apparent in reduced band strength. No ADAMTS13 was detected when 
ADAMTS13 (lane 5) or VWF (lane 6) were omitted in the immunoprecipiated mix. 
These results indicate that S1486A- Cluster 2 and DC-VWF variants in globular 
conformation have increased ability to bind ADAMTS13. 
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Figure 6.7 Binding between ADAMTS13 and globular VWF 
ADAMTS13 binding was studied for wtVWF, S1486A, Clus 2 and DC variants in 
solution using an immunoprecipitation method. Solutions containing wtVWF and VWF 
variants and E225Q-ADAMTS13 were immunoprecipitated with anti-VWF-CK domain 
antibody. Immunoprecipitated proteins were eluted and analysed by SDS-PAGE under 
reducing conditions and western blotting with (A) anti-c-myc (tagged to ADAMTS13) 
(B)or anti-VWF antibodies. Molecular weight markers are indicated. As shown in panel 
(A) less ADAMTS13 was bound to wtVWF (lane 1) than to S1486A-VWF (lane 2), 
Clus2-VWF (lane 3) or DC-VWF (lane 4). As a control no ADAMTS13 protein was 
detected when VWF (lane 5) or ADAMTS13 (lane 6) were excluded from the mix. As 
shown on panel (B) similar amounts of wtVWF (lane1) and S1486A, Clus 2 and DC  
VWF glycosylation variants (lanes 2-4 respectively) were immunoprecipitated with 
anti-VWF antibody. No ADAMT13 was immunoprecipitated when VWF was omitted 
(lane 5). 
 
To further confirm this results, binding between wtVWF and the S1486A variant in 
solution to ADAMTS13 was assessed by an ELISA based plate assay as previously 
described.151 As illustrated on Figure 6.8 wtVWF weakly bound to immobilised 
ADAMTS13 with a KD,app value of 91 ±30nM, which was in accordance with previously 
published values (85.6± 8nM).151 Interestingly, the S1486A variant exhibited markedly 
increased ADAMTS13 binding with KD,app values of 14±5nM. This result further 
confirms the observation that the absence of an O-linked glycan chain at a position 
S1486 increases binding between VWF in its globular conformation and ADAMTS13. 
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Figure 6.8 Binding isotherms of soluble wtVWF and S1486A variant to 
ADAMTS13 
Binding between ADAMTS13 and globular wtVWF or S1486A-VWF, was investigated 
as a function of VWF concentration. Binding isotherm and binding parameters were 
estimated by fitting the data to the one site binding equation. The S1486A-VWF variant 
in globular conformation had an increased affinity to ADAMTS13 as indicated by a 
KD,app value of 14nM when compared to KD,app of 91nM estimated for the 
wtVWF.(Error bars are the SEM of 2 separate assays performed in duplicate). 
 
6.3 Discussion 
Cleavage of wild type and mutant rVWF by ADAMTS13 in the presence of urea was 
assessed by collagen binding and multimer analysis and demonstrated that the S1486A, 
cluster 2 and double cluster variants were proteolysed slower than wtVWF. In the 
absence of urea no cleavage was observed, and all samples retained 100% collagen 
binding when incubated without ADAMTS13, indicating that preparations were stable 
over the duration of the reaction and that no other contaminating proteases were present. 
Since the inclusion of urea in this assay to induce a conformation change in VWF is not 
physiological, the ability of ADAMTS13 to proteolyse VWF was investigated using a 
bench top vortex mixer to generate shear stress and obviate the need for urea. It is 
questionable whether this assay generates a shear stress that accurately reflects the shear 
forces encountered by VWF in the circulation because VWF is not anchored at any 
point in this assay.  The effect is most likely mechanical shear that induces a 
conformation change in the VWF molecule. Nonetheless, this assay has been 
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successfully used in several studies and provides a useful alternative to standard in vitro 
assays. Interestingly, the results obtained using the vortex assay demonstrated similar 
results to those obtained under static conditions, in that the S1486A, Cluster 2 and DC 
variants were less susceptible to ADAMTS13 proteolysis.  
Intriguingly even though the S1486 and T1487 glycosylated residues are next to one 
another, only the mutation of the S1486 residue has an effect on the ADAMTS13 
cleavage. This may be explicable when one considers the specificity of N-
acetlygalactosaminyltransferases (GalNAcTs) that initiate glycosylation by attachment 
of GalNAc to Seronine or Threonie residues. It has been previously demonstrated that 
the initial O-linked glycosylation of the peptide can influence the subsequent 
glycosylation events by inducing conformational changes in the peptide backbone and 
adjusting the accessibility of particular glycosylation sites for GalNAcTs.409,410,423,498,499 
For example it has been shown that complete glycosylation of MUC1 tandem repeat 
peptide is dependent on several transferases that act in a highly ordered and hierarchical 
manner and can have highly restricted acceptor substrates.500 A similar observation; that 
prior glycosylation of a peptide backbone with GalNAc has a positive effect on 
subsequent glycosylation of nearby residues, was shown for the MUC5AC motif 
peptide501 and may explain the formation of clustered O-linked glycans on mucins. An 
analogous mechanism can be postulated for VWF O-linked glycosylation: mutation of 
S1486A preventing addition of GalNAc sugar to this residue may then prevent 
glycosylation of the adjacent T1487 residue.   Conversely, the lack of a GalNAc residue 
at T1487A may not be necessary for the glycosylation of S1486. We have attempted to 
clarify this by mass spectrometry analysis however to date it has not proved possible.  
Decreased susceptibility to ADAMTS13 cleavage observed for the cluster 2 and the 
double cluster proteins could therefore either be a result of the loss of a single O-linked 
oligosaccharide at S1486 or from a cumulative response resulting in loss of the whole 
C-terminal glycan cluster. The removal of O-linked glycans from the N-terminal 
flanking region of the A1 domain does not alter susceptibility to ADAMTS13 cleavage. 
Therefore diminished proteolysis of the double cluster variant is only a consequence of 
loss of O-linked glycans from the C-terminal cluster.  
The exact mechanism by which O-linked glycosylation can influence susceptibility of 
VWF to cleavage by ADAMTS13 is unknown. It could be hypothesised that the altered 
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susceptibility to ADAMTS13 cleavage is due to a change in accessibility to the A2 
domain, which in turn reflects a change in VWF conformation.  
O-linked glycans are known to provide rigidity to a peptide backbone and stabilize 
otherwise flexible regions thus stabilising protein conformation.439 Glycans introduce 
steric hindrance, and the polypeptide they are attached to can adopt a rigid, extended 
conformation, with length up to hundreds of nanometers in length as demonstrated by 
AFM, light scattering and nuclear magnetic resonance studies438-445 Clustering of 
GalNAc-based glycans linked by α-linkages to Ser/Thr induces a stable and extended 
structure to glycopeptides. Importantly, it has been shown that the attachment of a first 
GalNAc residue by α-linkage to Ser/Thr has a profound effect on the overall 
conformation of peptide backbone, in which specific interactions between the peptide 
and the sugar moiety play a crucial role. It has been suggested that stereochemical 
constraints imparted by the α linkage place the first sugar moiety in close proximity to 
the peptide backbone.400,502 The GalNAc residues stabilises the peptide via hydrogen 
bonding between the amide proton of the GalNAc residue and the oxygen atom of the 
carbonyl group of the amino acid it is attached to.438,503 However, a study on the MUC7 
protein demonstrated that hydrogen bonding does not occur in serine glycosylated 
peptides, and therefore they  have more rotational freedom around the glycosidic bond 
and assume a more apical position.502 In addition, the peptide structure is stabilised by 
close association of several methyl groups. It has been proposed that the N-acetyl 
methyl groups of GalNAc interact with methyl groups of nearby amino acids, shielding 
the hydrophobic surfaces. Rigid and extended O-glycosylated peptide have been 
identified for glycophorin A and it has been suggested the GalNAc residues are located 
alternatingly on opposite sides of the peptide backbone, further reducing its 
flexibility.504 Ovine submaxillary gland mucin (OSM) is another protein whose structure 
is controlled by O-linked glycans. OSM has a highly extended conformation when in its 
native from, asialo OSM has a somewhat less extended structure, but protein with the 
O-linked glycans removed looses its linear structure and becomes globular. 441O-linked 
glycans clusters are also present in the hinge regions of the IgA or IgD proteins, where 
they extend the peptide chain, due to repulsion between charged sugars such as sialic 
acids, and protect the region from protease cleavage.450,451 
It could be suggested that removal of glycans from the linker region between the A1 
domain and the A2 domain may change flexibility of this region, altering any potential 
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interactions between the A1 and the A2 domains, and as a result, altering the 
accessibility of ADAMTS13 cleavage site. In addition, it is known that terminal sialic 
acid confers a negative charge to glycoproteins due to its carboxyl group dissociating a 
proton at physiological pH.505 The removal of O-linked glycan(s) and therefore sialic 
acid may decrease the charge on the A1-A2 linker region and allow VWF to adopt a 
more tightly folded conformation making it more difficult for ADAMTS13 to access the 
cleavage site within the A2 domain. It has been previously suggested that the A2 
domain is mechanically stabilised by the A1 and A3 domains,506 therefore I propose that 
O-linked glycans might participate in this stabilisation.   
The reason why mutation of only one glycosylation site (S1486A) in the glycan cluster 
at the C-terminal side of the A1 domain has an effect on ADAMTS13 cleavage may 
also become better understood when a model of the proposed structure of the VWF 
A1&A2 domains is analysed. As illustrated on Figure 6.9 when VWF is in its globular 
conformation, threonine residues 1468 and 1477 are exposed on the surface of the A1 
domain while residues S1486 and T1487 are buried within the A2 domain in the 
vicinity of ADAMTS13 cleavage site. However, this model needs to be interpreted with 
a degree of caution, since the crystal structures of the A1 and predicted structure of the 
A2 domains do not include the linker region between the two domains. Indeed, only the 
crystal structures of the A1 domain obtained by Huizinga et al.,276  included the O-
linked glycan site S1468 and this was derived from bacterial cells and thus would not 
have been O-linked glycosylated in any case. 
In addition, it is surprising that the two glycosylation sites T1486 and T1487 could be 
buried within the A2 domain, since these sites have been shown to occupied by O-
linked glycans. O-linked glycosylation occurs once the protein is folded therefore it 
would be difficult for galactosyltransferases to access the glycosylation site if they were 
indeed buried. However, the predicted model of the VWF A1A2A3 domains based on 
the crystal structures is still a valuable model.   
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Figure 6.9 Model of the A1 and A2 domain in solution with O-glycosylation sites 
indicated 
Model is based on the crystal structure of the A1 domain and predicted crystal structure 
of the A2 domain and was provided by Wei Chen  (A) Two O-linked glycosylation sites 
in the A1-A2 linker region mapped to the  surface of the A1 domain are indicated, the 
T1468 residue in orange and the T1477 amino acid in black. (B) Ribbon representation 
of the A1 and A2 domains, the S1486 (in green) and the T1487 (in blue) glycosylation 
site appear to be buried within the A2 domain, close to the ADAMTS13 cleavage site 
(Y1605-M1606, in red). 
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As discussed, the VWF O-linked glycans are potentially responsible for maintaining 
rigidity of the A1-A2 linker region and could prevent excessive shielding of the A2 
domain by the A1 domain. Alternatively, O-linked glycans can have a more local effect 
on the stability of the ADAMTS13 cleavage site, since as suggested by the VWF 
A1A2A3 structural model, the glycans attached to the S1486 and T1487 residues are 
positioned next to the Y1605-M1606 cleavage site in the partially unfolded A2 domain 
(Figure 6.10). O-linked glycans have been shown to increase stability of various 
proteins,385,507-510 and it has been suggested that rather than stabilising the folded state of 
the protein, they destabilise the unfolded state by increasing its enthalpy. (e.g. by 
breaking some residual structural elements).508 Moreover, presence of O-linked glycans 
can prevent aggregation of unfolded or partially unfolded proteins.508 Furthermore it has 
been demonstrated that the degree of stabilisation depends on the position of the 
glycosylation sites and their number, but only very weakly on the type or a size of the 
glycan.385,508 Therefore it is postulated that the O-linked glycans can force the unfolded 
VWF-A2 domain to adopt a more extended conformation allowing efficient exposure of 
the ADAMTS13 cleavage site. Furthermore, they could prohibit the formation of 
residual interactions within the A2 domain and allow exposure of residues that interact 
with ADAMTS13 allowing for subsequent proteolysis of the Y1605-M1606 bond. The 
absence of O-linked glycans might induce more flexibility into the structure and allow 
formation of nonspecific interactions within the A2 domain, therefore impeding 
ADAMTS13 binding and cleavage as observed for the S1486A, cluster 2 and double 
cluster variants. Moreover absence of O-liked glycans chains could alter the 
arrangement of the metalloprotease domain in the binding pocket, subsequently 
impairing the catalytic efficiency of metalloprotease domain.  
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Figure 6.10 Proposed crystal structures model of the A1 the A2 unfolded domains 
with the O-linked glycosylation sites indicted 
Model is based on the crystal structure of the A1 domain and predicted crystal structure 
of the A2 domain and was provided by Wei Chen. Unfolding of the A2 domain results 
in the exposure of ADAMTS13 cleavage site (in red) and O-linked glycosylation sites 
S1486 and T1487 (green and blue respectively) Suggesting that two oligosaccharides 
attached to these amino acids, will be present in vicinity of the scissile bond. The other 
glycosylation sites are T1468 in orange and T1477 in black. 
 
In order to investigate if removal of VWF O-linked glycans has a more local effect the 
susceptibility to ADAMTS13, cleavage reactions were also performed using a shorter 
substrate D’A3 fragment of VWF. This fragment of the protein was chosen for number 
of reasons. Firstly it is unable to form dimers or multimers, but contains VWF regions 
that can influence ADAMTS13 proteolysis. It encompasses both O-glycosylated linker 
regions flanking the A1 domain, as well as all three A domains that are thought to 
interact with each other. In addition, it contains the D’D3 domains that have been 
shown to shield the A1 domain. Finally D’A3-VWF was successfully and efficiently 
expressed and secreted in HEK293T cells. 
Interestingly, ADAMTS13 cleavage of the D’A3 cluster 2 and double cluster variants 
showed significantly reduced cleavage in comparison to wtVWF, whereas the D’A3 
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S1486A VWF mutant did not show any appreciable difference. The reason for the why 
the absence of a single glycan chain at position S1486 has an effect on cleavage of full 
length VWF but not the D’A3 fragment is not obvious. It is hypothesised that in the full 
length protein, the C-terminal end of VWF may be exerting an effect on the 
conformation or stability of the A2 domain and the removal of only a single glycans 
chain from this VWF fragment does not modify this.  
To further assess how O-linked glycans affect the susceptibility of VWF to 
ADAMTS13 cleavage, the binding interaction between the two proteins was 
investigated. It has been previously shown that when VWF is coated onto microtitre 
plates it undergoes a conformational change that exposes the ADAMTS13 binding site 
within the A2 domain and allows high affinity binding of ADAMTS13 to VWF. 
Interestingly, the VWF S1486A, Clus2 and DC variants, which were all cleaved to a 
lesser extent by ADAMTS13, bound ADAMTS13 in this assay with similar affinity.  
The binding of ADAMTS13 to elongated VWF is a multistep interaction that engages 
different exosites in the A2 domain. The ADAMTS13-VWF binding interaction is 
initiated by the binding of the ADAMTS13 spacer domain with VWF residues E1660-
R1668 which helps to approximate two proteins.223-226 As illustrated on Figure 6.11a the 
ADAMTS13 spacer domain binding site is positioned near the O-linked glycosylation 
sites when VWF is in its globular conformation. However, in the unfolded VWF-A2 
domain, residues E1660-R1668 are distant from the glycosylated A1-A2 linker region 
(Figure 6.11b). The spacer domain binding allows for subsequent vital interaction 
between the ADAMTS13 disintegrin-like domain residue R349 and the VWF-A2 
domain D1614 residue, which helps to position the scissile bond within the active site of 
ADAMTS13.227 Interestingly D1614 is close to the O-linked glycans and the 
ADAMTS13 cleavage site when the VWF A2 domain is partially unfolded (Figure 
6.11b), but is distant from the linker region in the folded VWF (Figure 6.11a). Based on 
the predicted model of the VWF A1A2A3 domain complex the remoteness of the 1660-
1668 spacer binding site and O-linked glycans in the elongated conformation could 
explain why the O-linked glycans did not influence ADAMTS13 binding in this 
situation. However since O-linked glycans are located close to D1614 residue they 
could have an effect on downstream binding by the ADAMTS13 disintegrin-like 
domain, which may not be detected by the binding assay used in this study. 
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Figure 6.11 Predicted model of the A1A2A3 domains complex  
Legend next page: 
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Model is based on the crystal structure of the A1 and A3 domains and predicted crystal 
structure of the A2 domain and was provided by Wei Chen (A) Illustration of the 
unfolded A domains complex surface. Exposed O-linked glycan sites are indicated 
T1468 in orange and T1477 in black. The ADAMTS13 cleavage site indicated in red 
(Y1605-M1606) is buried within the A2 domain. Residues crucial for VWF binding to 
ADAMTS13 spacer domain, E1660 to R1668 are shown in light green. The D1614 
residue that interacts with the disintegrin like domain is labelled in dark green. (B) 
Unfolding of the A2 domain results in the exposure of ADAMTS13 cleavage site and 
two additional O-linked glycosylation sites S1468 and T1487 (green and blue 
respectively). In addition ADAMTS13 exosites become exposed. With the D1614 
residue positioned near the cleavage site and O-liked glycosylation sites.  
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In addition, it may be implied that the observed differences in the interaction of the 
VWF variants with ADAMTS13 are due to the amino acid change and not the absence 
of O-linked oligosaccharides, however this is unlikely to be the case. Firstly, change of 
alanine to threonine is typically used to prevent glycosylation at specific sites since it 
the most conservative change one could apply. Alanine has a similar size as threonine 
and serine, and has a hydrophobic side chain instead of a polar uncharged side chain, 
which should not significantly interfere with the conformation of the peptide. Moreover, 
no change in ADAMTS13 cleavage is observed for the T1487A mutation which is 
adjacent to the S1486A mutation. 
Recently it has been reported that apart from binding to elongated VWF, ADAMTS13 
is able to bind with low affinity to VWF, when VWF in its native globular 
conformation,152,232  the effect of O-linked glycans on this interaction was therefore 
studied. Intriguingly, the mutations that resulted in decreased susceptibility to 
ADMATS13 proteolysis enhanced binding of VWF in solution to ADAMTS13. It is not 
unfeasible, as to our knowledge binding between globular VWF and ADAMTS13 is not 
necessary or linked to VWF cleavage in the presence of urea. It is hypothesised that the 
improvement in binding is due to a change in overall conformation of VWF due to 
removal of O-glycan chains. As discussed beforehand absence of O-linked glycan chain 
can induce flexibility of the A1-A2 linker region thus alter the position of both domains 
in relation to not only each other but also towards other domains. Therefore it is 
suggested that change in local conformation can alter the exposure of binding sites, on 
all other domains in globular VWF. 
 
In summary, it has been demonstrated O-linked glycans alter VWF interaction with 
ADAMTS13, possibly by modifying the interface and stability of the A1 and A2 
domains. In the next chapter the role of O-linked glycans on the interaction of VWF 
with GPIbα is going to be discussed. 
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7 EFFECT OF O-LINKED GLYCANS ON THE INTERACTION 
OF VWF WITH PLATELET RECEPTOR GLYCOPROTEIN Ibα 
UNDER STATIC CONDITIONS 
7.1 Introduction 
The O-linked glycans clustered around the A1 domain are positioned near regions 
designated as important for platelet binding, suggesting they may be part of mechanisms 
regulating the exposure of the GPIbα binding site.289 Indeed, it has been reported that 
VWF lacking O-linked glycans exhibits reduced binding to GPIbα and limited ability to 
agglutinate platelets in the presence of ristocetin.454 Conversely, VWF A1 domain 
(residues 1236-1476) expressed in E.coli, or under O-linked glycosylation blocking 
conditions exhibited increased platelet aggregatory responses when compared with the 
fully glycosylated forms.261,455  It is obvious that the existing data is contradictory, 
therefore the aim of this study was to fully characterise the influence of O-linked 
glycans on the VWF A1 domain interaction with platelets.  
Traditionally the interaction of VWF with platelets (via GPIbα) is investigated using the 
ristocetin cofactor assay and this assay was first used to examine platelet agglutination 
by O-linked glycosylation variants. However, a number of studies have recently utilised 
a recombinant fragment of GPIbα, spanning the first 290 amino acids to investigate the 
interaction between GPIbα and the VWF-A1 domain. Consequently I have expressed 
and purified this recombinant GPIbα fragment (rGPIbα) and a subsequently optimised 
its use in an ELISA based plate binding assay. This assay was then used to explore the 
role of O-linked glycans in the GPIbα-VWF interaction under static conditions in the 
absence and presence of various ristocetin concentrations and also in the presence of 
botrocetin. 
VWF sialylation status has also been previously shown to influence platelet 
aggregation, with several studies suggesting that desialylated-VWF (dsVWF) can 
induce spontaneous platelet aggregation in the absence of ristocetin and increase 
ristocetin mediated aggregation.511,512 However, other studies have detected decreased 
ristocetin mediated platelet aggregation by dsVWF,468,476 or have not shown any 
difference in ristocetin mediated or independent platelet aggregation by 
dsVWF.386,387,513 Again, the results of previous studies are conflicting and because the 
O-linked glycans terminate predominantly in negatively charged sialic acid residues, the 
role of sialic acid on the VWF interaction with GPIbα was also investigated. 
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7.2 Expression of recombinant GPIbα 
7.2.1 GPIbα construct 
The N-terminal part of GPIbα has been shown to mediate the interaction between 
platelets and VWF; therefore Dr TAJ Mckinnon has previously established a clone of 
GPIbα spanning the first 290 residues and cloned this into the cloning vector 
pCRTOPO4. In this study the GPIbα fragment from pCRTOP4 was cloned into a 
pBluescript II SK (+/-) vector using site directed insertion PCR. This fragment was then 
subcloned into the mammalian expression vector pcDNA3.1/myc-his vector in frame 
with a myc-his tag as described in detail in section 3.6. 
7.2.2 GPIbα/myc-his protein expression and purification 
In initial experiments pcDNA-GPIbα/myc-his was transiently expressed on a small 
scale in HEK293T cells. Western blot analysis of the expression media demonstrated a 
band of ~45kDa when probed with anti-myc and anti-GPIb antibodies indicating the 
presence of recombinant GPIbα. To provide sufficient quantities of protein for further 
assays, rGPIbα was transiently expressed on a large scale in HEK293T cells and 
purified by Nickel affinity chromatography (Figure 7.1). Eluted fractions were analysed 
by SDS-PAGE followed by Coomassie staining to determine the purity and presence of 
rGPIbα (Figure 7.2). The protein was successfully eluted from the column with 250mM 
imidazole and visible as a single band of 45kDa; however some contaminants were still 
present in the GPIbα positive fraction (Figure 7.2, lane 3), indicating this purification 
method provides partial purification of GPIbα. To improve purity and purification was 
repeated on the eluted material. As shown on the chromatogram (Figure 7.1) some 
protein was eluted with 10 and 100nM imidazole and those elution fractions were 
analysed by SDS-PAGE followed by Coomassie staining and immunoblotting using 
anti-myc antibody to determine their purity. Fusion protein was detected by a Western 
Blot as a single band of 45kDa in the fraction eluted with 100nM imidazole. As shown 
on SDS-PAGE gel (Figure 7.2, lane 4), all contaminants were successfully removed and 
only one band of 45kDa corresponding to GPIbα-myc/His was visible.  
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Figure 7.1 FPLC purification of GPIbα-myc/his using a Ni2+-chelating HiTrap 
column 
A representative chromatogram of a typical GPIbα purification.  The His tag of the 
protein was exploited in the purification. Filtered and concentrated condition media was 
loaded onto a column. Some proteins pass through the column and did not bind (flow 
through fraction). Columns were washed extensively with 20mM Tris, 100mM and 
2mM imidazole to ensure that majority of contaminant proteins are washed from the 
column (wash fraction) prior to isocratic elution (20mM Tris-HCl, 500mM NaCl, 
500mM imidazole, pH 7.8). Protein was eluted with 10 and 100nM imidazole. All the 
fractions were collected and analysed with SDS-PAGE and Western Blotting. 
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Figure 7.2 SDS-PAGE gel showing the expression and purification of rGPIbα 
GPIbα-myc/his protein was expressed in HEK293T cells and purified using Nickel 
affinity chromatography. Fractions from purification were analysed by SDS-PAGE 
followed by Coomasie blue staining. Lane 1, total mixture of proteins in the culture 
medium. Lane 2, flow through- material that did not bind to the column X1 fraction on 
chromatogram), demonstrates presence of contaminant proteins. Lane 3, rGPIbα -
myc/His containing elution fraction from the first purification, with some contaminants 
still present.  This elution fraction (A2) was re-purified and as shown in Lane 4: pure 
GPIbα-myc/His protein was eluted. 
 
7.3 GPIbα binding assay  
The rGPIb fragment was used to establish a plate based assay to investigate the binding 
of VWF to GPIbα. In brief, microtitre plates were coated with a polyclonal anti-GPIb 
antibody (anti-CD42b) and this was then used to capture rGPIbα at concentration of 
1µg/ml. The microtitre plates were then incubated with VWF in the absence or presence 
of ristocetin or botrocetin.  
7.3.1 GPIbα binding and VWF multimeric size  
In order to validate the assay, I initially assessed the effect of VWF multimerisation on 
the interaction with GPIbα. It has been previously reported that larger VWF multimers 
bind GPIbα with the greatest affinity. To this end, different VWF fractions with 
decreasing multimeric size were purified from Haemate P by gel filtration, and were 
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incubated with immobilised GPIbα in the presence of ristocetin (1mg/ml). Multimer 
size was determined by VWF multimers analysis and CBA, with the largest multimers 
(fractions 1 and 2) having a CBA/VWF:Ag ratio of 2.2 and the smallest multimers 
(fraction 6), a CBA/VWF:Ag ratio of 0.2. In keeping with published data, there was a 
direct relationship between VWF multimer size and GPIbα binding, with the greatest 
GPIbα binding observed with the fraction containing the largest VWF multimers. 
(Figure 7.3) This confirms sensitivity of the assay to VWF molecular weight. 
 
Figure 7.3 VWF multimeric size and ristocetin dependent GPIbα binding 
Microtitre plates coated with GPIbα were incubated with different multimeric size 
pdVWF in the presence of 1mg/ml of ristocetin. PdVWF multimeric size was 
previously assessed by CBA. Collagen binding corrected for VWF antigen levels 
(CBA/VWF) of 2.2 corresponded to highest molecular weight multimers and collagen 
binding of 0.2 to low molecular weight multimers. Calculated CBA/ VWF for sample 1 
– was 2.2, sample 2 -1.8, sample 1.6, sample 3- 1, sample 4-0.5, sample 5- 0.5 and 
sample 6-0.2.  GPIbα binding gradually decreases with VWF multimeric size 
 
7.4 GPIbα binding and VWF O-linked glycosylation  
Since eight of the VWF O-linked glycan chains are clustered around the A1 domain 
they could potentially affect the interaction of VWF with GPIbα. Using the GPIbα plate 
binding assay I investigated the effect of the O-linked glycan variants on the binding of 
VWF to GPIbα in the absence and presence of ristocetin.  
GPIbα coated plates were incubated with 4nM VWF in the absence or presence of 
1mg/ml ristocetin. As expected no GPIbα binding was detected for wtVWF when 
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ristocetin was omitted. (Figure 7.4) In contrast, notable binding was detected following 
addition of ristocetin (wtVWF +R; Figure 7.4). GPIbα binding assay in the absence of 
ristocetin was repeated for all glycosylation variants, in order to determine whether 
removal of any of the glycans results in VWF conformational change that would allow 
spontaneous GPIbα binding. None of analysed VWF variants could bind VWF without 
addition of ristocetin (Figure 7.4). 
 
Figure 7.4 GPIbα binding by VWF variants in the absence of ristocetin 
wtVWF and VWF variants were applied onto a microtitre plate coated with recombinant 
GPIbα in the absence of ristocetin. As expected no GPIbα binding was observed for 
wtVWF. Similarly all O-linked glycosylation variants were unable to bind to GIbα 
without ristocetin. As a control, wtVWF was shown to bind to GPIbα. in the presence of 
1mg/ml ristocetin (wtVWF +R). 
Since removal of O-linked oligosaccharides had no effect on GPIbα binding in the 
absence of ristocetin, the influence of O-linked glycans on ristocetin dependent binding 
was examined. For this, microtitre plates were coated with GPIbα as beforehand 
incubated with VWF variants at a concentration of 4nM in the presence of ristocetin. 
The concentration of 1mg/ml ristocetin was used in this assay as it is used in the 
traditional Ristocetin Cofactor activity assay and previously described plate assay514. 
Interestingly, compared to wtVWF markedly increased GPIbα binding was detected for 
the T1255A variant which is localised in the D3-A1 linker region. (Figure 7.5) 
Furthermore an even greater increase in ristocetin dependent GPIbα binding was 
detected for the Clus 1 variant, devoid of all O-linked glycan chains flanking the N-
terminal side of the A1 domain. Moreover, enhanced GPIbα binding was detected for 
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the DC variant. Conversely, the T1468A and T1477A variants demonstrated reduced 
binding to GPIbα in the presence of 1mg/ml ristocetin (Figure 7.5), however, despite the 
Clus2 variant encompassing both of these mutations, its binding to GPIb was unaltered. 
Mutation of the other O-linked glycosylation sites did not alter the ability of VWF to 
bind GPIbα in the presence of ristocetin.  These data suggest that the O-linked glycans 
clustered at the N-terminus of VWF-A1 domain can have a negative effect on the 
interaction of VWF with GPIbα, at least in the presence of saturating concentrations of 
ristocetin. In contrast the lack of O-linked sugars at positions T1468 and T1477 in the 
C-terminus of VWF-A1 domain can decrease the ability of VWF to interact with GPIbα 
in the presence of ristocetin.  
 
 
Figure 7.5 Interaction between GPIbα and VWF glycosylation variants in the 
presence 1mg/ml ristocetin 
GPIbα coated plate was incubated with 4nM wtVWF and VWF variants and 1mg/ml of 
ristocetin, and bound VWF was detected. No binding was detected for wtVWF without 
the modulator. When compared to wtVWF the T1255A variant, the Clus 1 variant and 
the DC variant showed increased, whilst the T1468A and the T1468A demonstrated 
somewhat decreased GPIbα binding potential in the presence of ristocetin. All other O-
linked glycans exhibited similar ristocetin dependent GPIbα binding to wtVWF.  
 
The changes in the capability of VWF to bind to GPIbα following removal of certain 
glycan chains were observed in the presence of saturating concentrations of ristocetin. 
To further elucidate the effect of O-linked glycans on the VWF interaction with GPIbα, 
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binding was tested using a range of ristocetin concentrations between 0 and 1mg/ml. 
wtVWF binding to GPIbα was evident in the presence of 0.6 mg/ml ristocetin and 
thereafter the amount of bound VWF increased with increase in ristocetin concentration. 
(Figure 7.6) 
All single N-terminal glycosylation variants apart from the T1255A showed similar 
sensitivity to ristocetin mediated GPIbα binding as wtVWF. The T1255A variant 
exhibited increased binding to GPIbα at any ristocetin concentration as shown in Figure 
7.6. Moreover, distinctly enhanced GPIbα binding was observed for the T1255A variant 
in the presence of 0.5mg/ml ristocetin. This is a striking result as wtVWF and the 
adjacent mutant T1256A were unable to bind GPIbα when incubated with ristocetin 
concentrations below 0.6mg/ml.  
 
 
Figure 7.6 Binding between VWF O-glycosylation variants (N-terminal side) and 
recombinant GPIbα in the presence of various ristocetin concentrations 
A GPIbα coated plate was incubated with 4nM wtVWF and VWF variants with a range 
of ristocetin concentrations (0-1mg/ml), and bound VWF was detected. Single 
glycosylation variants T1248A, T1256A and S1263A and wtVWF showed comparable 
GPIbα binding in the presence of ristocetin. The T1255A, showed increased GPIbα 
binding at any ristocetin concentration when compared to wtVWF and in contrast to 
wtVWF was able to bind to GPIbα at a ristocetin concentration of 0.5mg/ml. (Values 
shown here are mean ± SEM of 4 separate experiments performed in duplicate). 
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As illustrated on Figure 7.7a, two single glycosylation variants S1486A and T1487A 
that flank the C-terminal side of the A1 domain showed similar sensitivity to ristocetin 
mediated GPIbα binding as wtVWF at any ristocetin concentration. The other two 
variants T1468A and T1477A demonstrated reduced GPIbα binding at concentrations of 
ristocetin above 0.6mg/ml when compared to wtVWF, however the difference in 
binding was not so significant at 1mg/ml of ristocetin (Figure 7.7b). 
A 
 
B 
 
Figure 7.7 Binding between VWF O-glycosylation variants (C-terminal side) and 
recombinant GPIbα in the presence of various ristocetin concentrations 
A GPIbα coated plate was incubated with 4nM wtVWF and VWF variants with a range 
of ristocetin concentrations (0-1mg/ml), and bound VWF was detected. The S1486A 
and T1487A variants showed similar GPIbα binding; while the T1468A and T1477A 
variants showed decreased GPIbα when compared to wtVWF (Values shown are mean 
± SEM of 4 separate experiments performed in duplicate). 
 
 180 
Intriguingly, the cluster 2 variant bound GPIbα in an identical manner as wtVWF 
(Figure 7.8b). This result is surprising given that the Cluster 2 variant includes the 
T1468A and T1477A mutations which resulted in decreased sensitivity to ristocetin 
mediated GPIbα binding. Furthermore, significantly enhanced sensitivity to ristocetin 
mediated GPIbα binding was observed for both the Clus 1 and DC variants when 
compared to wtVWF (Figure 7.8a). Importantly, notable binding for those mutants was 
observed at ristocetin concentrations of 0.5mg/ml, which was too low to induce GPIbα 
binding by wtVWF. On the basis of this data, it is apparent that the glycans clustered at 
the N-terminal side of the A1 domain have a major influence on ristocetin mediated 
GPIbα binding.  
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Figure 7.8 Binding between O-linked glycosylation cluster variants and 
recombinant GPIbα in the presence of various ristocetin concentrations 
A GPIbα coated plate was incubated with 4nM wtVWF and VWF cluster variants with 
a range of ristocetin concentrations (0-1mg/ml), and bound VWF was detected.(A) The 
Clus 1 and DC variants showed significantly increased GPIbα binding compared to 
wtVWF at any ristocetin concentration. (B) The Clus 2 variant exhibited unaltered 
ristocetin dependent GPIbα binding. (Values shown here are mean ±SEM of 4 separate 
experiments performed in duplicate) 
 
Finally the single glycan variants T1679A and T2298A localised in the A3 and D4 
domains respectively were analysed and showed unaltered sensitivity to ristocetin 
mediated GPIbα binding (Figure 7.9 ). This suggests that glycan chains remote from the 
A1 domain have no influence on the VWF sensitivity to ristocetin mediated GPIbα 
binding. 
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Figure 7.9 Binding between T1679A and T2289A variants and recombinant GPIbα 
in the presence of various ristocetin concentrations 
A GPIbα coated plate was incubated with 4nM wtVWF and VWF variants with a range 
of ristocetin concentrations (0-1mg/ml), and bound VWF was detected.  Both T1679A 
and T2298A variants showed similar GPIbα binding as the wtVWF. (Values shown 
here are mean ± SEM of 4 separate experiments performed in duplicate) 
 
In summary, the T1255A, cluster 1 and double cluster variants were demonstrated to 
have enhanced sensitivity to ristocetin mediated GPIbα and required lower 
concentrations of ristocetin for the interaction to occur. This indicates that O-linked 
glycans flanking the N-terminal side of the A1 domain have an inhibitory effect on 
ristocetin mediated GPIbα binding. Strikingly, the absence of only one O-linked glycan 
chain from T1255 residue has a similar effect on ristocetin mediated GPIbα binding as 
the absence of the entire cluster of glycans flanking the A1 domain. 
Interestingly, elimination of a single O-linked glycan from either threonine residue 1468 
or 1477 resulted in diminished sensitivity of VWF to ristocetin mediated GPIbα 
binding. Paradoxically, the Clus 2 variant that included these two mutations showed 
unaltered capacity to interact with GPIbα in the presence of ristocetin. 
Finally a type 2B VWD-mutant V1316M was analysed in the plate assay. It has been 
demonstrated that similarly to the T1255A, Clus1 and DC variants the V1316M variant 
exhibited an enhanced sensitivity to ristocetin mediated GPIbα binding (Figure 7.11). 
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Figure 7.10 Binding between VWF O-glycosylation variants and recombinant 
GPIbα in the presence of various ristocetin concentrations 
Summary of mutants with altered sensitivity to ristocetin mediated GPIbα binding. The 
T1255A, cluster 1 and double cluster variants showed increased sensitivity while the 
T1468A and T1477A variants showed reduced sensitivity to ristocetin mediated GPIbα 
binding when compared with wtVWF at any ristocetin concentration from 0.6mg/ml. 
All other mutants have similar sensitivity to ristocetin mediated GPIbα as wtVWF 
(results not shown). 
 
 
Figure 7.11 Comparison of ristocetin mediated GPIbα binding for wtVWF, VWF 
O-glycosylation variants and type 2B VWD variant 
When compared to wtVWF, the type 2B-VWD variant V1316M shows increased 
sensitivity to ristocetin mediated GPIbα binding. The increase in binding is comparable 
to that observed for the T1255A, Clus1 and DC variant.  
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7.5 GPIbα binding and VWF sialylation 
Although previous studies have been conflicting, some studies have suggested that 
VWF devoid of sialic acid is able to interact with GPIbα in vitro without the need for 
ristocetin. Since O-linked glycans predominantly terminate in sialic acid residues any 
effect of sialic acid on GPIbα binding is likely to be mediated by sialic acid residues 
present on the VWF O-linked glycans. 
Firstly GPIbα binding to VWF was investigated after the enzymatic removal of sialic 
acid by treatment with neuraminidase in the absence and presence of ristocetin. In 
contrast to some previously published reports no spontaneous binding of desialylated 
wtVWF (+Neu-wtVWF) to GPIbα was observed in the absence of ristocetin (Figure 
7.12). However, in the presence of 1mg/ml ristocetin, Neu-wtVWF demonstrated 
appreciably increased GPIbα binding compared to wtVWF, suggesting a role for sialic 
acid in the interaction of VWF with GPIb. However this procedure will have removed 
sialic acid from both N and O-linked glycans. 
 
Figure 7.12 GPIbα binding for wtVWF and desialylated wtVWF in the absence 
and presence of ristocetin 
Microtitre plates coated with GPIbα were incubated with wtVWF or desialylated VWF 
(+Neu-wtVWF) in the absence or presence of 1mg/ml ristocetin. No binding was 
detected for either sialyated or neuraminidase treated VWF without ristocetin. 
Desialylated VWF displayed markedly increased sensitivity to ristocetin mediated 
GPIbα binding in the presence of 1mg/ml when compared to sialylated VWF. 
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Following on from this, GPIbα binding by desialylated plasma derived (pd) and 
recombinant VWF was investigated at increasing ristocetin concentrations (0-1 mg/ml) 
(Figure 7.13). For both pdVWF and rVWF, GPIbα binding was detected first in the 
presence of 0.6mg/ml ristocetin and gradually increased with increasing concentration 
of ristocetin. Subsequently, GPIbα binding was compared before and after removal of 
sialic acid residues. It was observed that more pdVWF (Figure 7.13a) and rVWF 
(Figure 7.13b) bound to GPIbα following neuraminidase treatment. The increase in 
binding was observed at ristocetin concentrations above 0.6mg/m. These results clearly 
indicate that removal of sialic acid residues from VWF results in increased sensitivity to 
ristocetin mediated GPIbα binding. 
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Figure 7.13 Interaction between GPIbα and sialyated and desialyated plasma 
derived and recombinant VWF 
GPIbα binding affinity was investigated for pdVWF (A) and rVWF (B) in the presence 
of various ristocetin concentrations (0-1mg/ml). Both pdVWF and rVWF start to bind to 
GPIbα at 0.6mg/ml of ristocetin. In addition GPIbα binding was compared for sialyated 
and desialyated VWF (+Neu). More GPIbα binding was detected for desialyated (+Neu) 
pdVWF and rVWF at each ristocetin concentration (above 0.6mg/ml). +Neu- 
neuraminidase treated desialyated VWF. 
 
 187 
7.5.1 Desialylation of O-linked glycosylation variants  
Since an increase in sensitivity to ristocetin dependent binding to GPIbα was observed 
for the Clus 1 and DC variants and for Neu-VWF, I investigated the combined effect of 
removing sialic acid from these variants on ristocetin mediated GPIbα binding. 
Confirming my previous observations, Neu-VWF demonstrated increased GPIbα 
binding at and above ristocetin concentrations of 0.6mg/ml. The Clus2 variant bound 
GPIbα in similar fashion to wtVWF. Interestingly, removal of sialic acid from the     
Clus 2 variant did not enhance its binding to GPIbα, with binding at all ristocetin 
concentrations similar to wtVWF (Figure 7.14b). In contrast, the Clus1 variant, that has 
increased GPIbα binding, demonstrated a similar binding profile to Neu-VWF and 
binding of the Clus1 variant was further enhanced by the removal of sialic acid, with the 
Neu-Clus1 variant showing interaction with GPIbα at a ristocetin concentration of 
0.4mg/ml. (Figure 7.14a). This is a remarkable result as neither wtVWF, single cluster 
mutants or desialylated VWF were able to interact with GPIbα at such a low 
concentrations of ristocetin.  
Finally, the DC variant demonstrated markedly increased GPIbα binding compared to 
desialylated wtVWF (+Neu-wtVWF) at any ristocetin concentration (above 0.5 mg/ml). 
Significantly, the DC variant bound to GPIbα in the presence of as little as 0.4mg/ml of 
ristocetin in a manner comparable to the +Neu-Cluster 1 variant. Intriguingly, removal 
of sialic acid residues from the double cluster did not alter its GPIbα binding.(Figure 
7.15a) Since the DC variant  has only 2 more O-linked glycan chains left, 
neuraminidase treatment in this case will have resulted in removal of terminal sialic acid 
mainly from the N-linked glycans. Consequently it seems highly probable that the loss 
of sialic acid from the O-linked glycans is responsible for the increased sensitivity to 
ristocetin mediated GPIbα binding.  
To further confirm this conclusion and to assess the role of sialic acid from the O-linked 
but not N-linked glycans in GPIbα binding, neuraminidase with highly specific activity 
towards α2-3 linked sialic acid was used in contrast to general neuraminidase that 
removes α2-3,6,8,9 sialic acid. This assay was performed based on the fact that the 
terminal sialic acid residues on the N-linked glycans are predominantly α2-6 linked to 
penultimate galactose residues,20,383 whilst sialic acid on O-linked glycans may be either 
α2-3 or α2-6 linked452 As shown in Figure 7.15b the wtVWF with majority of α2-3 
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linked sialic acid removed, exhibited identical ability to bind GPIbα in the presence of 
ristocetin as the wtVWF with α2-3,6,8,9 sialic acid residues removed and the fully 
sialylated wtVWF. This tends to confirm the conclusion that it is loss of sialic acid 
primarily from the O-linked glycans which lead to increased sensitivity to ristocetin 
dependent GPIbα binding.  
 
Figure 7.14 GPIbα binding by desialyted wtVWF, Clus 1 and Clus 2 variants in the 
presence of various ristocetin concentrations 
A microtitre plate was coated with rGPIbα fragment via an antibody, and incubated with 
4nM sialylated and desialylated wtVWF and VWF cluster variants in the presence of 0-
1mg/ml ristocetin. (A) Cluster 1 bound to GPIbα similarly to desialylated wtVWF, and 
even greater increase in binding was observed for neuraminidase treated cluster 1. (B) 
No change in GPIbα binding was observed following removal of sialic acid form the 
Clus 2 variant.  
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Figure 7.15 Binding between GPIbα and desialylated DC variant in the presence of 
a range of ristocetin concentrations 
A microtitre plate was coated with rGPIbα fragment via an antibody and incubated with 
4nM sialylated and neuraminidase treated wtVWF and DC variant in the presence of 0-
1mg/ml ristocetin. (A) The DC variant bound to GPIbα significantly more readily than 
desialylated wtVWF, no additional increase in binding was observed for desialylated 
double cluster.(B) WtVWF was incubated with the α2-3 neuraminidase to specifically 
remove α2-3 linked sialic acid. The same amount of ristocetin dependent GPIbα binding 
was detected for wtVWF devoid of all sialic acid residues (+Neu wtVWF) and VWF 
lacking only α2-3 linked sialic acid (α2,3 Neu VWF).  
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7.6 Binding between GPIbα and wtVWF in the presence of botrocetin  
To obtain more information regarding the role of O-linked glycans flanking the A1 
domain of VWF in its interaction with GPIbα, plate binding assays were performed for 
wtVWF and double cluster in the presence of botrocetin since the mechanism by which 
botrocetin supports platelet binding and aggregation is different from that of ristocetin. 
However due to time constraints only preliminary data for the DC cluster variant was 
obtained.  
rGPIbα was immobilised onto a plate via anti-GPIb antibody and incubated with 
increasing concentrations of VWF in the presence of 5µg/ml purified botrocetin. As 
shown on Figure 7.16 botrocetin dependent GPIbα binding was detected for wtVWF. 
Interestingly no difference in binding was detected for double cluster variant, 
suggesting that O-linked glycans have no influence on GPIbα binding in the presence of 
botrocetin.  
 
 
Figure 7.16 Binding of wtVWF and double cluster variant to GPIbα in the 
presence of botrocetin 
A microtitre plate was coated with rGPIbα via anti-CD42b antibody and incubated with 
increasing concentrations of wtVWF or DC variant in the presence of 5µg/ml 
botrocetin. Interestingly, both wtVWF and double cluster exhibit similar botrocetin-
dependent GPIbα binding. 
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7.7 Ristocetin co-factor activity assay- Influence of O-linked glycans 
on platelet aggregation 
The ristocetin co-factor activity assay (VWF:RCo) is used in the diagnosis of patients 
with suspected VWD as it reproduces, in vitro, the ability of VWF to interact with 
platelets. The original method for this assay was described by MacFarlane and is based 
on the property of ristocetin to agglutinate formalin-fixed platelets in the presence of 
VWF.515 Recombinant wild type and mutated VWF were sent to a diagnostic laboratory 
and their ristocetin co-factor activity analysed. (Assays performed by Ms Gillian Angus, 
Hammersmith hospital, London and Dr Anne Riddell, Royal Free hospital, London). 
The results from two separate assays performed on proteins expressed at different times 
are shown on Figure 7.17. It was demonstrated that all single glycosylation mutants 
localised on the N-terminal side of the A1 domain (T1248A, T1255A, T1256A) and 
their cluster (Clus 1) showed an increase in ristocetin dependent platelet aggregation 
when compared with wtVWF. The T1468A variant, on the C-terminal side of the A1 
domain, had significantly diminished ristocetin co-factor activity. Interestingly the 
cluster 2 variant had the same capability to agglutinate platelets in the presence of 
ristocetin as wtVWF. 
The results from the VWF:RCo assays generally correlate with the results obtained with 
the static GPIbα binding assays. The VWF variants that demonstrated increased 
ristocetin dependent binding to GPIbα  also demonstrated enhanced platelet aggregation 
(e.g. T1255A, Cluster 1). Furthermore, the S1468A mutant showed both decreased 
R:Co activity and GPIbα binding, while the cluster 2 variant performed  like wtVWF in 
both assays. However the T1248 and T1256A variants showed increased platelet 
aggregation, in contrast to results obtained in the plate assay where they showed similar 
GPIbα binding as wtVWF. 
 192 
 
Figure 7.17 Ristocetin co-factor activity assay of recombinant VWF variants 
Platelet agglutination in the presence of 1mg/ml ristocetin was analysed for wtVWF and 
VWF glycosylation variants. When compared with wtVWF the Cluster 2 shows the 
same VWF:RCo activity while decrease in activity is observed for the T1468A variant. 
The T1248A, T1255A, T1256A and Cluster 1 demonstrate increased platelet 
aggregation in the presence of ristocetin. All other single glycosylation variants showed 
unaltered platelet ristocetin dependent platelet aggregation.  
7.8 Discussion  
Existing published data regarding the function of VWF O-linked glycans in mediating 
the VWF-platelet interaction are conflicting and inconclusive; therefore in this project 
the role of O-linked glycans flanking the VWF-A1 domain on GPIbα binding has been 
investigated. 
Traditionally, the ristocetin cofactor activity assay (VWF:RCo) has been used to 
investigate the platelet aggregatory potential of VWF; however this assay is known to 
have a high intra-assay coefficient of variation (CV) and is often not highly 
reproducible.516 Recent attempts to improve the assay have made use of a plate based 
ELISA assay that utilises a recombinant fragment of GPIbα.514 Therefore in this project 
I have constructed an expression vector for recombinant GPIbα, and used purified 
rGPIbα to establish a more reliable, reproducible and sensitive plate based assay to 
examine the interaction of VWF with GPIbα. In this assay GPIbα is captured to an anti-
GPIbα antibody that doesn’t affect the VWF-GPIbα interaction and then VWF is 
applied in the presence or absence of ristocetin.  
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Consistent with previous reports, I confirmed that larger VWF multimers bind more 
readily to GPIbα and since the O-linked glycosylation mutants analysed have similar 
multimeric patterns, any changes in GPIbα binding will not be due to variations in 
multimer distribution. In the absence of ristocetin, no GPIbα binding was detected for 
wild type or mutated VWF demonstrating that removal of even all the O-linked glycans 
flanking the A1 domain does not allow VWF to bind platelets spontaneously, or at least 
not in the assay used. Subsequently, I have analysed the ability of the VWF variants to 
bind GPIbα in the presence of 1mg/ml ristocetin. Interestingly, compared to wtVWF, 
markedly increased sensitivity to ristocetin mediated GPIbα binding was detected for 
the T1255A, Clus 1 and DC variants. Conversely, the T1468A and T1477A variants 
demonstrated slightly reduced binding to GPIbα; however, despite the Clus2 variant 
encompassing both of these mutations, its binding to GPIbα was unaltered. The changes 
in the ability of VWF to bind to GPIbα following removal of certain glycan chains were 
observed in the presence of saturating concentrations of ristocetin, therefore binding 
was investigated using a range of ristocetin concentrations. Ristocetin response curves 
generated for the O-linked glycan mutants on the N-terminal side of the A1 domain 
demonstrated that the T1255A, the cluster 1 and double cluster variants exhibited an 
increased response to ristocetin compared to wtVWF. These results indicate that O-
linked glycans clustered at the N-terminal side of the A1 domain have an inhibitory 
effect on GPIbα binding at least in the presence of ristocetin, however the mechanisms 
of this effect are likely to be complex.  
The crystal structure of the A1-GPIbα complex demonstrates that the N-terminal A1 
flanking region interacts with the β-finger of GPIbα, and is displaced when GPIbα 
binds.276 Moreover, recombinant A1 domain lacking the N-terminal extension has 
significantly enhanced GPIbα binding and the N-terminal flanking region is dislocated 
away from the interaction site in the type 2B VWD gain of function R1306Q 
mutant.276,137 These data suggest that the N-terminal A1 flanking region has an 
inhibitory effect on GPIbα binding and that dislocation of the N-terminal extension, for 
example by shear stress may be a crucial mechanism physiologically allows GPIbα 
binding. Therefore, it may be hypothesised that dislocation of the N-terminal flanking 
region can also occur following removal of O-linked glycans, reducing its inhibitory 
properties and enhancing platelet binding. In addition, the N-terminal O-linked glycan 
cluster could modulate the interaction of the A1 domain with the D’-D3 domains. A 
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recent study suggested that when VWF is in a globular conformation the D’-D3 region 
shields the A1 domain, preventing GPIbα binding.138 As discussed in the previous 
chapter, O-linked glycans provide rigidity to peptide backbones and for that reason it is 
suggested that the A1-N-terminal O-linked glycan cluster can stabilize the linker region 
between the D3 and A1 domains.439  Consequently, loss of O-linked glycans can 
potentially increase the flexibility of the linker region and decrease any shielding effect 
of the D’D3 domains which would in turn result in increased exposure of the GPIbα 
binding site and augmented GPIbα binding. Change in the rigidity of the linker region 
and the interaction between the D’D3 and A1 domain might also result from the loss of 
negative charges associated with terminal sialic acid residues present on VWF O-linked 
glycans.  
Alternatively, it could be hypothesised that the T1255A, cluster 1 and double cluster 
variants have an altered structure and as a result less ristocetin is required to promote an 
adequate conformational change required for interaction with GPIbα. In the nanobody 
binding assay, discussed in the previous chapter, a lower concentration of ristocetin was 
required to activate VWF and allow binding, as only partial activation of the VWF A1 
domain is required for nanobody binding. The conformational change following 
removal of all the O-linked glycans flanking the A1 domain allows VWF to weakly 
bind to the nanobody in solution suggesting that the A1 domain is partially activated, 
however this activation is not large enough to result in spontaneous GPIbα binding. In 
addition removal of both clusters resulted in increased GPIbα binding at various 
ristocetin concentrations suggesting increased availability of the GPIbα binding site. 
The effect observed for the double cluster variant is possibly attributed to the removal of 
O-linked glycans from the N-terminal cluster, as removal of cluster 2 alone does not 
influence GPIbα binding. 
In contrast, the S1468A variant (C-terminal side of A1) showed decreased GPIbα 
binding and platelet aggregation. These results are in keeping with previous data in 
which membrane-expressed A1 domain, devoid of  O-glycan at position T1468, showed 
decreased platelet aggregatory potential.455 It is hypothesised that the reduction in 
GPIbα binding is either due to destabilisation of the GPIbα or the ristocetin binding 
sites. Two regions have been implicated in VWF interaction with ristocetin the C1237- 
P1251 region at the N-terminal site of the A1 domain288,289 and the proline-rich 
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sequence, E1463 to N1472, C-terminal to the disulphide bond in the VWF-A1 
domain.288-291 (Figure 7.18) 
 
Figure 7.18 The A1 domain diagram 
Schematic illustration of the A1 domain and its flanking regions with O-linked glycan 
sites indicated in green. Disulphide bond in yellow; sites implicated in ristocetin binding 
red boxes; GPIb binding site in blue box.  
On the basis of that data, the N-terminal ristocetin binding site encompasses the 
glycosylated T1468 residue.291,517,518 Cationic ristocetin would be expected to interact 
with a region of VWF having a net negative charge; therefore removal of T1468 glycan 
with its putative sialic acid terminus would reduce ristocetin binding. Moreover, as 
graphically illustrated on a predicted model of the folded A1-A2 domain complex, the 
ristocetin binding site and the T1468 glycosylation site are positioned on the surface of 
the A1 domain, while the putative GPIbα binding site is located on the opposite face of 
the A1 domain (Figure 7.19). On the basis of this observation I propose that the absence 
of an O-linked glycan at the T1468 residue alters ristocetin binding, rather than having 
any direct effect on the GPIbα binding site. However, as discussed in the previous 
chapter the proposed model needs to be interpreted with a degree of caution, as neither 
the crystal structures of the A1 or the predicted structure of the A2 domain519 include 
the linker region between the two domains. The crystal structure of the A1 domain 
obtained by Emsley et al.,125  included only the O-linked glycan sites S1263 and S1468 
however the A1 protein was expressed in E.coli and therefore would not have been O-
linked glycosylated in any case. 
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Figure 7.19 Predicted model of the A1-A2 domain complex based on the A1 
domain crystal structure and predicted A2 domain structure with sites implicated 
in GPIbα and ristocetin binding 
Surface model is based on the crystal structure of the A1 domain125 and predicted 
crystal structure of the A2 domain519 and was provided by Wei Chen (A) Two O-linked 
glycosylation sites in the A1-A2 linker region mapped to the  surface of the A1 domain 
are indicated, the T1468 residue in black and the T1477 amino acid in orange. S1263 
glycosylation site located in the N-terminal A1 domain flanking region marked in 
purple. The putative C-terminal ristocetin binding site is showed in red.(B) The major 
GPIbα binding site is indicated in blue and positioned on the opposite side of the A1 
domain than the ristocetin binding site (in red). 
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Surprisingly, removal of all the C-terminal cluster O-linked glycans does not alter 
GPIbα binding even though it includes the T1468A mutation. This discordance is as yet 
unexplained. As discussed in the previous chapter O-linked glycans provide rigidity and 
stability to peptide backbones, therefore it is likely that removal of a whole glycan 
cluster from the A1-A2 linker increases flexibility of the peptide backbone enhancing 
the interaction between the A1 and A2 domains. Increasing the proximity (folding) 
between the A domains due  to removal of O-linked glycans could limit the exposure of 
the C-terminal ristocetin binding site, but could at the same time enhance the exposure 
of the ristocetin biding site at the N-terminus of the A1 domain, and thus the cluster 2 
variant  would retain its GPIbα binding ability. Conversely, the removal of single 
glycan from this region may not alter the flexibility of the linker region enough to 
change the availability of ristocetin binding sites but could still limit the VWF 
interaction with ristocetin by removing the negative charge. It needs to be stated 
however that the sites implicated in ristocetin binding are not necessarily the only ones 
and are were not precisely mapped. In addition, it is not known how and if putative O-
linked glycosylation sites are occupied in the recombinant O-glycosylation variants. 
Inhibition of glycosylation at the T1468 might modify utilisation of other sites within 
the cluster, and this could alter GPIbα binding. 
Increased platelet aggregation in the presence and absence of ristocetin was previously 
observed for desialylated VWF (Neu-VWF).512 In this study I have shown that 
desialylated recombinant and plasma derived VWF did not bind GPIbα in the absence 
of ristocetin but exhibited increased ristocetin dependent GPIbα binding. It has been 
previously shown that VWF sialic acid is decreased in patients with primary pulmonary 
hypertension (PPH).520,521  PPH is characterised by presence of defective VWF, lacking 
large multimers and of chronic endogenous platelet activation. The authors of the study 
suggested that the presence of only lower molecular weight multimers in PPH patients 
is due to the increased consumption of VWF due to increased platelet binding and/or 
increased cleavage of VWF. This hypothesis is consistent with the observations made in 
this study that desialylated VWF has increased GPIbα binding and that larger VWF 
multimers exhibit greater GPIbα binding in the presence of ristocetin.  
Furthermore, the Cluster 1 variant had similar binding to GPIbα Neu-wtVWF at various 
ristocetin concentrations and a further increase in binding was observed following 
removal of sialic acid residues. Interestingly Neu-Cluster 2 bound GPIbα in a similar 
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manner to wtVWF, suggesting that loss of entire O-linked oligosaccharide chains in the 
N-terminal cluster, not just terminal sialic acids is responsible for the increased binding 
observed for Cluster 1. However, it has to be also considered that removal of sialic acid 
from the N-terminal glycan cluster can have a different effect on VWF conformation 
and GPIbα binding than removal of both the C-terminal glycan cluster and sialic acid 
from the N-terminal glycan cluster. No additional increase in GPIbα binding was 
observed for the desialylated double cluster variant, which implies that removal of sialic 
acid from O-linked oligosaccharides not N-linked glycans is responsible for the 
increased GPIbα binding detected for Neu-wtVWF. Is has been shown that the terminal 
sialic acid on the N-linked glycans are predominantly α2-6 linked to penultimate 
galactose residues,20,383 whilst sialic acid on O-linked glycans may be either α2-3 or    
α2-6 linked.452 This property was used to further assess the role of sialic acid on the           
O-linked but not N-linked glycans. The wtVWF was treated with α2-3 neuraminidase 
which resulted in reduction of sialic acid mainly on O-linked glycans. Interestingly no 
difference in GPIbα binding was observed between wtVWF with no terminal sialic acid, 
and wtVWF with no α2-3 linked sialic acid, with all both having increased binding 
when compared to wild type VWF. Consequently it seems highly probable that the loss 
of sialic acid from the O-linked glycans is responsible for the increased GPIbα binding.  
It needs to be considered, however, that the static GPIbα binding assay described in this 
thesis looks only at the first stage of the interaction with platelets. The VWF:RCo assay 
utilises ristocetin as an in vitro agonist to stimulate VWF-platelet interactions. 
Therefore the ability of the O-linked glycan variants to bind and agglutinate platelets 
was investigated using the traditional Ristocetin Cofactor Assay. Results obtained from 
the VWF:RCo assay were generally consistent with the results obtained using the  
GPIbα plate binding assay, with the T1255A, Clus1 and DC variants showing increased 
and the T1468A variant showing decreased ristocetin dependent platelet aggregation. 
However the T1248A and T1256A single glycosylation variants showed increased 
VWF:RCo, which contradictory to results from the plate assay were the variants had 
similar sensitivity to ristocetin mediated GPIbα binding. The exact reason why T1256A 
and T1248A have increased VWF:RCo but do not demonstrate increased ristocetin 
mediated GPIbα binding is not clear. However it is widely viewed that the VWF:RCo 
assay has a high intra-assay coefficient of variation (CV) and is often not highly 
reproducible.516 Additionally, the high concentration of ristocetin (1mg/ml) used in the 
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assay, can precipitate plasma proteins, including VWF, and can bind platelets directly, 
thus further confounding the data.  
In order to further elucidate if the changes in GPIbα binding where due to altered 
interaction with the O-linked glycan mutants I have attempted to investigated the 
binding with a different modulator; botrocetin. The snake venom protein botrocetin  
promotes the VWF-GPIbα interaction in vitro, however it interacts with distinct region 
of VWF and GPIbα (Figure 7.20), and induces GPIbα binding through different 
mechanisms compared to ristocetin.270,292 In contrast to ristocetin, botrocetin does not 
induce any conformational change in the A1 domain but can provide an additional 
binding surface for GPIbα.293,294 It has been demonstrated that botrocetin first binds to 
the A1 domain but not GPIbα and than subsequently slides around the A1 surface to 
form a new interface. Unlike ristocetin which is readily purchased as a ready to use 
reagent, botrocetin is only available as crude venom from Bothrops jararaca and 
requires purification prior to use. It has only recently been possible to optimise a 
purification protocol and only a small quantity of purified botrocetin was obtained. Thus 
the data I have obtained with botrocetin is very limited. 
Nevertheless I have demonstrated that interestingly, in the presence of botrocetin, the 
DC variant bound to GPIb in a similar fashion to wtVWF. This could imply that the 
increase in binding observed for the DC variant in the presence of ristocetin reflects an 
enhanced response to ristocetin, not the accessibility of the GPIbα binding site. 
Furthermore, it is suggested that the double cluster variant could bind ristocetin more 
readily and less ristocetin would be required to induce conformational change in VWF. 
Alternatively VWF with O-linked glycans removed could be less stable and more 
susceptible to deformation.  
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Figure 7.20 The A1 domain crystal structure 
The A1 domain crystal structure125 with the main GPIbα binding site in blue.  Residues 
implicated in ristocetin binding are coloured in red. Residues implicated in polar 
interaction with botrocetin binding are also indicated (in grey).294 The O- glycosylated 
residues S1263 (purple) and T1468 are also indicated in the A1 N-and C-terminal 
flanking region respectively. 
 
In conclusion, the data presented in this chapter demonstrates that the O-linked glycans 
flanking the N-terminal side of the A1 domain have a negative effect on sensitivity to 
ristocetin mediated GPIbα binding in the plate assay and platelet aggregation in the 
VWF:RCo assay. In addition the absence of T1486A and T1477A glycans appears to 
impair VWF sensitivity to ristocetin mediated GPIbα binding and platelet aggregation. 
However these effects have all been observed under static conditions in the presence of 
artificial modulators. To assess the role of VWF O-linked glycans under more 
physiological conditions an in vitro flow assay was optimised and used to investigate 
the interaction of VWF with platelets under shear stress conditions. 
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8 VWF O-LINKED GLYCANS ROLE IN VWF-PLATELET 
INTERACTION UNDER CONDITIONS OF FLOW  
8.1 Introduction  
It is evident from the previous chapter that the O-linked glycans clustered around the 
VWF A1 domain alter the ability of VWF to interact with GPIbα in the presence of 
ristocetin. In vivo, platelets bind to VWF under conditions of physiological blood flow, 
thus the limitation of the assays performed in the previous chapter are the requirement 
for ristocetin and the absence of shear stress. To more effectively analyse the interaction 
of VWF with platelets, I have developed an in vitro flow based assay system to assess 
the VWF-platelet interaction under conditions of physiological flow. The developed 
flow assay allows direct visualization of the VWF-platelet interaction in real time, 
negating the need for ristocetin and providing a more physiological setting in which to 
investigate the role that VWF O-linked glycans play in mediating this interaction. In 
this chapter I will firstly discuss the optimisation of the flow assay and then its 
application to investigate the effect of VWF sialic acid and O-linked glycosylation on 
the ability of VWF to capture platelets under conditions of shear stress.  
8.2 Expression and purification of D’A3  
In majority of the flow assays performed a VWF fragment spanning the D’ to A3 
domains was used. The D’A3 construct, (designated VWF-D’A3) had been previously 
cloned in our laboratory and was chosen for several reasons; firstly the construct 
encompasses both clusters of O-linked glycans and domains vicinal to the A1 domain 
which could influence the A1 domain exposure and GPIbα binding (e.g. it contains the 
D’D3 domains that have been shown to shield the A1 domain138); secondly, it is readily 
expressed and purified at high levels and thirdly, for kinetic analysis of the VWF-GPIbα 
bond under flow conditions a monomeric fragment of VWF was required because 
spatial separation of VWF A1 domains is critical for these assays. 
The O-linked glycosylation mutations were inserted into VWF-D’A3 by sub-cloning 
from the pcDNA3.1-FL-VWF construct using KpnI and BamHI restriction sites. D’A3 
proteins which contained a C-terminal c-myc/His tag, were transiently expressed in 
HEK293T cells and purified by Nickel affinity chromatography. Eluted fractions were 
analysed by SDS-PAGE followed by Coomassie staining to determine the presence and 
purity of D’A3-VWF. In the fraction eluted with 25mM imidazole a band of ~115kDa 
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corresponding to D’A3 protein was present, with very little other contaminating 
proteins (Figure 8.1). 
 
Figure 8.1 SDS-PAGE gel showing the expression and purification of           
wtD’A3-VWF 
VWF-D’A3-myc/his protein was expressed in HEK293T cells and purified using a Ni2+-
chelating HiTrap column. Fractions from the purification were analysed by SDS-PAGE 
followed by Coomasie blue staining. Lane 1 - total mixture of proteins in the culture 
medium. Lane 2 - flow through material that did not bind to the column, Lane 3 - 
column wash fraction. Lane 4 - material eluted with 25mM imidazole.  
 
8.3 Flow assay optimisation  
8.3.1 Experimental setup  
A schematic overview of the components used in the flow assay system is presented in 
Figure 8.2. The system comprises a syringe connected to a syringe driver that is set to 
predefined flow rates and is used to pump fluids through the flow slides. The flow slides 
are mounted under an Olympus U-TV1X-2 inverted stage fluorescent microscope that is 
coupled to a high speed RoleraXR digital camera and the camera is connected to a PC 
system to allow real-time visualisation and recording of fluorescently labelled platelets. 
StreamPix 6 software was used to capture images at a rate of 20-30 frames per second, 
these were then processed using VirtualDub software (freely available from 
http://www.virtualdub.org) and analysed using ImageJ software (freely available from  
http://www.ibidi.de). 
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Figure 8.2 Experimental setup for flow assays 
 
8.3.2 Flow slides 
Previous work using physiological flow assays have generally utilised parallel plate 
flow chamber systems. This normally involved coating glass coverslips with proteins 
(or cells) and mounting the coverslip on a glass or plastic slide; this would then be 
covered with a rubber gasket and then a second slide on top. This was subsequently 
clamped and sealed tight with a vacuum source to prevent leakages. While these 
systems were effective, they could be cumbersome to assemble and the glass coverslips 
were often prone to breakage or the whole system prone to leakage. Recently, a number 
of products have become commercially available that have simplified the normal 
parallel plate system. These flow chamber slides are normally made of disposable 
plastic and are constructed to comprise a narrow channel with a low chamber height 
through which fluid can be perfused. The slides used in this project are manufactured by 
ibidi® and are made of hydrophobic plastic that has been optimised for efficient protein 
coating and fluorescent microscopy. Two types of ibidi slide were used, µ-slides 
VI0.1and VI0.4. As shown in Figure 8.3a these slides contain 6 separate flow channels 
with an inlet and outlet reservoir at either end, the inlet port is connected via plastic 
tubing to the syringe, while the outlet port is put to waste. The 0.1 and 0.4 refer to the 
channel heights of 100 and 400µm respectively, with the smaller channel height and 
volume of the µ-slide VI0.1 resulting in a low pump speed to high shear ratio, thus 
minimising the amount of blood required for each experiment. The desired shear rate 
was obtained by setting the syringe driver to pump at a flow rate defined by the slide 
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manufacturer and as shown in Figure 8.3b, the recommended observation area is the 
central portion of the each channel which gives the greatest area of homogenous shear 
stress.           
A 
 
B 
 
Figure 8.3 Flow slide-design and setup 
Images acquired from Ibidi® web-site http://www.ibidi.de/ 
 
8.3.3 Platelet preparation  
In this project flow assays were performed using purified and fluorescently labelled 
platelets and washed erythrocytes. Platelets were isolated by centrifugation from whole 
blood collected form healthy donors into ACD anticoagulant. Since in this project only 
the interaction between the platelet receptor GPIbα and the VWF-A1 domain was 
investigated, platelet activation was inhibited by the addition of prostaglandin E1, 
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apyrase and EDTA. Apyrase was used as it rapidly metabolizes ADP and ATP released 
from platelets thereby reducing platelet activation and recruitment whilst EDTA inhibits 
integrin receptor function. Isolated platelets were labelled with Calcein 
acetoxymethylester (AM) fluorescent dye. Calcein AM is cell permeable compound that 
is hydrolyzed by intracellular esterases enabling calcein to readily bind intracellular 
calcium, resulting in a green fluorescence (excitation and emission maxima ~494 and 
517nm respectively). In parallel, erythrocytes were washed to remove any plasma VWF. 
As illustrated on Figure 8.4 erythrocytes require four saline washes to eliminate all 
plasma VWF. Washed erythrocytes were re-suspended with HEPES/Tyrodes buffer 
supplemented with 3.5mg/ml BSA to the original starting volume of blood, to maintain 
a normal hematocrit and the required amount of labelled platelets were added. In the 
assays where slides were coated with collagen the full platelet count was perfused 
(~200000 platelets per μl), while in the assays with immobilised VWF 14000 platelets 
per μl were used. 
 
Figure 8.4 Preparation of plasma free blood – washing erythrocytes 
Erythrocytes were separated from plasma and platelets, and washed with NaCl (by 
repeating re-suspension and centrifugation) to remove any residual VWF. Levels of 
VWF after the washes were measured by VWF ELISA. After the first wash majority of 
VWF was removed, but VWF free RBCs suspension was obtained only after the fourth 
wash. 
8.3.4 Coating VWF concentration  
Since the majority of experiments were to be performed with immobilised VWF and 
platelets in solution, preliminary experiments were performed to determine the optimal 
concentration of VWF to coat onto the flow slide surface.  
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Initially, the coating concentrations of full length VWF and VWF-D’A3 that would 
support platelet attachment and rolling were determined. No platelet attachment was 
seen when plasma free blood was perfused over a BSA blocked channel, indicating that 
platelets do not interact directly with the flow surface or the BSA used to block the 
surface (Figure 8.5). When channels were coated with 10µg/ml FL-VWF, minimal 
platelet interaction was observed and the platelets that did interact were observed to  
translocate rapidly across the surface in the direction of the flow (Figure 8.5). When 
coated at 25µg/ml or above, FL-VWF was able to capture large numbers of platelets 
(~500 per field of view, 0.4x0.3mm), with higher coating concentrations of VWF 
capturing similar numbers of platelets, indicating that at 25µg/ml the surface of the slide 
is saturated with VWF (Figure 8.5). Based on these results, in all subsequent assays full 
length VWF was immobilised at a concentration of 25µg/ml. No dose response was 
observed as the aim was to determine the saturating concentration. One would see a 
dose response if concentrations between 10 and 25μg/ml were used. 
 
 
Figure 8.5 Optimal FL-VWF coating concentrations for the flow assay 
Full length VWF was diluted in carbonate buffer, coated directly onto the flow slides at 
specified concentrations and blocked with BSA. Platelets reconstituted with 
erythrocytes were passed over at a shear rate of 1500 s-1 for 4 minutes. The number of 
residual platelets was determined for each VWF coating concentration and control lane 
coated with BSA per field of view-0.4x0.3mm. No non-specific binding was observed 
and VWF concentrations above 25μg/ml bound similar platelets numbers.  
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Similarly, the concentration of wtD’A3 required to saturate the slide surface was 
determined.  Appreciably less platelet capture was detected for the slides coated with 15 
and 20μg/ml of protein when compared with slides coated with 30 and 40 µg/ml of 
VWF-D’A3 (Figure 8.6). Since comparable platelet capture was observed when VWF-
D’A3 was immobilised at 30μg/ml and 40μg/ml, the lower concentration of protein was 
used in all subsequent assays in which the platelet attachment and rolling were assessed. 
In addition, the coating concentration of VWF-D’A3 that would support only transient 
tethering events was established and will be discussed later. 
 
Figure 8.6 Optimal D’A3 coating concentration saturating the flow sides 
WtD’A3 -VWF was diluted in carbonate buffer, coated directly onto the flow slides at 
specified concentrations and blocked with BSA. Platelets reconstituted with 
erythrocytes were passed over at a shear rate of 1500 s-1 for 4 minutes. The number of 
residual platelets was determined for each D’A3 coating concentration and control lane 
coated with BSA. No non-specific binding was observed. Slides were saturated with 
wtD’A3 at a concentrations above 30μg/ml. 
 
8.3.5 Optimal collagen source 
Following vessel injury VWF binds to exposed collagen, unravels and binds flowing 
platelets. This can be replicated in flow assays by coating the flow chamber surface with 
collagen and perfusing over whole blood or plasma free blood supplemented with VWF. 
To determine the optimal collagen source to use with the Ibidi slides, five collagen 
sources that are routinely used in our laboratory were selected (Table 8.1). Ibidi slides 
were coated with these collagens at 100µg/ml and a control channel coated with BSA. 
Plasma free blood supplemented with 10µg/ml pdVWF was then perfused over for 
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5mins at 1500s-1 and the extent of VWF mediated platelet capture measured as the 
percentage surface covered by labelled platelets. Firstly, validating the specificity of the 
assay, no platelet binding was detected in a control channel coated with BSA only 
(Figure 8.7a). In addition, no platelet attachment was observed in the absence of VWF. 
Of the five collagens tested, only two were able to capture platelets via VWF (Figure 
8.7a,b). These were Sigma type III collagen and Southern Biosceinces type III collagen, 
both derived from human placenta. While the Sigma collagen, demonstrated platelet 
capture, the coating appeared to be non-uniform, as opposed to the SB collagen which 
coated the surface evenly and gave good VWF mediated platelet captured.  
Finally the coating concentration of collagen type III was tested. The manufacturer’s 
protocol for the Ibidi VI slides recommended using collagen at a concentration of 
300µg/ml.  Nonetheless, I have detected similar number of captured platelets on slides 
coated with 300 and 100µg/ml of SB type collagen III (Figure 8.7c) implying the 100 
µg/ml of collagen is sufficient to saturate the surface. On the basis of presented data, in 
subsequent experiments, flow slides were coated with Southern Biosciences collagen 
type III at a concentration of 100µg/ml. 
 
Source Preparation Collagen type Supplier 
Human 
Trypsin digestion from 
human placenta 
III Sigma 
Human 
Trypsin digestion from 
human placenta 
I Sigma 
Human 
Pepsin digestion from 
human placenta 
III 
Southern 
Biosciences 
Rat Rat tail I Invitrogen 
Bovine Unspecified I Invitrogen 
Table 8.1 Collagen sources tested 
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Figure 8.7 Determination of optimal collagen source for the flow assay 
(A) Individual frames from videos recorded after 3 minutes of flow assay in which 
labelled platelets with VWF were passed over collagen coated slides at a shear rate of 
1500s-1.Platelet attachment was only detected for type III collagen from Sigma and 
Southern Biosciences (SB). (B) 5 types of collagen (Table 8.1) were immobilised onto 
flow slides at a concentration of 300µg/ml). Labelled platelets reconstituted with 
erythrocytes and 10μg/ml of VWF were passed over at a shear rate of 1500s-1 for 4 
minutes, and the number of  adherent platelets was measured. The greatest platelet 
adhesion was detected for SB Type III collagen, followed by type III sigma collagen. 
Other types of collagen failed to support VWF mediated platelet adhesion. No binding 
was detected for surface coated with BSA (control). (C)  Platelet adhesion to collagen 
type III was than compared at coating concentration of 100 and 300µg/ml. The SB type 
III collagen showed similar VWF mediated platelet binding at both coating 
concentrations unlike Sigma type III which exhibited reduced platelet binding at 
100μg/ml 
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8.4 Kinetics and mechanics of platelet interaction with immobilised 
VWF-D’A3: method optimisation and data analysis  
8.4.1 Platelet capture 
Once the coating conditions were optimised, I investigated the ability of immobilised 
VWF-D’A3 to capture platelets at a range of shear rates (200 to 2000s-1 corresponding 
to low and high shear stresses respectively). Briefly, slides were coated with VWF-
D’A3 at a saturating concentration of 30µg/ml for 1 hour, blocked with BSA and 
washed with PBS prior to use. Fluorescently labelled platelets were re-suspended with 
erythrocytes and Hepes-Tyrodes buffer and perfused for 4 minutes at a given shear rate 
to allow adequate time for initial platelet interaction. Real-time movies of ~20sec for 
three separate fields of view were captured at a frame rate of ~20fps. Image J was used 
to determine the number of platelets captured via a series of steps outlined in Figure 8.8. 
Required video clips were saved as ‘avi’ files, and subsequently processed with 
VirtualDub to separate the movies into individual frames. In the case of platelet 
attachment measurements, three subsequent frames were saved and then processed 
using ImageJ software. Firstly, a minimal intensity Z-projection was performed to stack 
the three frames. This stacks objects that have remained stationary over the duration of 
the three frames and removes background noise and non-stationary objects, thus only 
platelets that had remained attached over three frames (0.15sec) would remain and any 
non-attached platelets or moving objects close to the surface would be removed from 
the composite image. Platelets were then counted using the “nucleus counter” function 
supplied with the ImageJ “particle analysis” plug-in. This works by selecting objects 
with intensity higher than the average background threshold intensity. The process was 
repeated for 3 different fields of view and the average number of attached platelets 
calculated for each shear rate. 
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1. Video files were first processed by the VirtualDub which allows viewing movies 
frame by frame. Required frames were selected and saved. These were then opened in 
Image J program. 
 
2. Firstly Z-stack function was used to select an image with only platelets that remained 
residual for the duration of 3 frames (0.15s)  
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3. The number of platelets in the created image was calculated using a Particle analysis 
Plugin. The Nucleus counter function was selected where the minimal and maximal size 
of particles to be counted was determined and the ‘Otsu’ threshold method was applied. 
Each platelet counted by the program was outlined in purple and assigned a number.  
Among other parameters, platelet count was presented in a table (red arrow). In 
addition, it was possible to manually deselect particles that did not correspond to 
platelets and add platelets that the program had overlooked.  
Figure 8.8 A step by step diagram showing and explaining the individual stages 
used to count the number of platelets bound to D’A3-VWF 
 
Platelet attachment to wtD’A3 at a range of shear rates is illustrated in Figure 8.9.  In 
keeping with previous studies, the number of interacting platelets increased as function 
of shear rate. It is clear that when the shear rate increases from 400 to 1000s-1 a greater 
number of bound plates is detected, while only a slight increase in platelet binding is 
observed when the shear rate is further increased to 2000s-1. The specificity of 
interaction was demonstrated by the inability of platelets to adhere to BSA coated slides 
(Figure 8.9). Unexpectedly, in contrast to previously reports, more bound platelets were 
detected at 200s-1 compared to 400s-1, however at the lower shear rate it was noted that 
the flow appeared uneven and almost pulsatile. This reflected the inability of the 
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available syringe pump to accurately pump at this shear rate: therefore 400s-1 was the 
minimal shear rate that could be accurately used in subsequent experiments. 
 
Figure 8.9 Shear rate dependence of platelet adhesion to wtD’A3-VWF 
Purified fluorescently labelled platelets were perfused over slide surface coated with 
30µg/ml of wtD’A3 at shear rates ranging from 200 to 2000s-1 for 4 minutes. The 
images were taken after that time and 3 different fields of view on the slides were 
recorded. The number of platelets that remained stationary for the duration of 3 frames 
(0.15s) as a function of shear rates was determined. Values are SEM of three separate 
experiments. As expected, increased platelet binding to immobilised D’A3 was 
observed with increasing shear rates. No platelet attachment was detected on surface 
coated with BSA only.  
 
8.4.2 Platelet rolling velocities  
The GPIbα-A1 interaction cannot support irreversible platelet adhesion but allows 
tethering and translocation which slows the platelet velocity, allowing establishment of 
additional bonds through other receptors on activated platelets. Importantly, when 
analysing platelet attachment to wtD’A3 I observed that platelet interaction with 
immobilised protein appears as a continuous translocation. Interacting platelets moved 
in the direction of flow, albeit at a markedly reduced velocity relative to freely flowing 
platelets. Since this translocation occurred in a “stop-start” manner it can therefore be 
described as rolling.  Consequently I proceeded to analyse platelet rolling velocities at a 
variety of shear stresses. As described previously, video clips saved as ‘avi’ files, were 
subsequently processed with VirtualDub. For platelet rolling assays, longer movies 
comprising approximately 50 successive frames were created. Next the rolling 
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velocities were measured by tracking individual platelets    frame-by-frame at intervals 
of 0.05s, and the velocity was calculated using the ImageJ plug-in MtrackJ.  This 
measures the distance in pixels an object travels over time. The microscope was 
calibrated so that 1 pixel corresponded to a distance of 0.64μm. The time that one 
platelet spent continuously moving while maintaining contact with the VWF coated 
surface is defined as the rolling duration, and rolling velocity was calculated from the 
distance that the platelet translocated during this period (Figure 8.10). Approximately 
25-40 platelets were tracked in 3 random fields of view, and 3 separate experimental 
runs were completed for each flow rate. 
 
 
 
 
 
 
 
Next page- 
Figure 8.10 Platelet rolling velocities measurement using Image J 
A fragmented movie consisting of 53 frames was used to determined platelet rolling 
velocities on immobilised wtD’A3. (A) Selected platelet translocation was tracked 
frame by frame. Start and end point were manually marked on respective frames 
(coloured lines on the picture) using a MtrackJ plug-in. Information regarding the frame 
duration was inserted and function ‘measure tracks’ was selected (B) Among other 
information Image J determined mean rolling velocities (red box) of selected platelets 
from the distance that they translocated depending on the time that the translocation has 
taken. Distance was measured in pixels per second, which was then converted manually 
to μm per second. Using a calibration slide it was determined that 1 pixel in the movie 
corresponded to 0.64 μm.  
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The mean rolling velocities for platelets perfused over wtD’A3 (in µm per second) were 
plotted against shear rate and illustrated in Figure 8.11. In agreement with previously 
published data, a biphasic velocity curve was observed.335 This is characteristic for the 
flow dependent interaction of GPIbα with the A1 domain involving the formation of 
‘catch and slip’ bonds. As the shear rate increased from 400 to 1000s-1 platelet 
translocation velocity decreased from ~12μm/s to ~7μm/s (catch regime). Once the 
shear rate was raised to 2000s-1 rolling speed increased back to 12μm/s (slip regime). 
 
Figure 8.11 Shear rate depended platelets rolling velocity on wtD’A3-VWF 
VWF-D’A3 was coated onto a flow slide at a saturating concentrations of 30µg/ml and 
labelled platelets with erythrocytes were perfused over at shear rates ranging from 400 
to  2000s-1 for 4 minutes. Movies were recorded after this time and rolling velocities 
were measured by tracking an individual platelet frame by frame at an interval of 0.05s, 
in the direction of flow and mean velocity was determined by Image J. The data are 
mean ±SEM of 3 independent experiments. Platelets rolling velocities first decreased 
with increasing shear rate until 1000s-1 and then increased when shear rate increased to 
a value of 2000s-1.  
 
To determine the influence of A1 domain density on platelet rolling velocities, slides 
were coated with varying concentrations of either FL-VWF or wtD’A3 at a shear rate of 
1000s-1. The velocity of platelets decreased by ~50% when the concentration of 
immobilised FL-VWF was increased from 10 to 25µg/ml (Figure 8.12a). No significant 
difference in translocation speed was observed on slides coated with 25, 50, 100µg/ml , 
presumably because at 25µg/ml the surface was saturated with FL-VWF. Similarly, in 
the case of wtD’A3 the fastest platelet rolling was detected on slides coated with the 
lowest concentration of protein (20µg/ml), and the velocity decreased appreciably with 
 217 
increasing concentrations of protein (Figure 8.12b). When the surface was saturated 
with wtD’A3 (>30µg/ml) cells exhibited similar lowest translocation velocities. The 
presented results show that the surface density of VWF and its A1 domain influence 
platelet rolling velocities. 
A 
 
B 
 
Figure 8.12 Comparison of platelets rolling velocities on various concentrations of 
immobilised FL-VWF and D’A3 at a shear stress of 1000s-1 
Platelets were perfused over slide surface coated with various concentrations of FL-
VWF (A) or wtD’A3 (B) at shear rate of 1000s-1 for 4 minutes. Movies were recorded 
after this time and rolling velocities were measured by tracking an individual platelet 
frame by frame at an interval of 0.05s, in the direction of (A) platelets exhibited highest 
rolling velocities on the surfaces coated with 10µg/ml of FL-wtVWF, when the slides 
were saturated with VWF (>25µg/ml) platelet translocated notably slower.(B) The 
fastest platelet rolling was observed when wtD’A3 was immobilised at 5µg/ml, and 
velocity decreased with increasing concentration of immobilised protein, with the 
slowest value reached at the saturating concentrations of wtD’A3 (>30µg/ml) 
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8.4.3 Dissociation rate constant  
The interaction between platelet receptor GPIbα and the A1 domain of VWF has a fast 
association and fast dissociation rate. To estimate the GPIbα-A1 disassociation rate   
(koff ) in the presence of shear stress, flow slides were coated with 2μg/ml VWF-D’A3 
and purified labelled platelets and RBC perfused over the surface as increasing shear 
rates.  
The coating concentration of 2µg/ml was selected because it allowed spatial separation 
of D’A3 domains and I have observed that it was the highest concentration at which no 
platelet rolling or other forms of translocation occurred. This condition limited the 
possibility of multiple bond formation and allowed the determination of single GPIbα-
A1 bond lifetimes at various shear rates. A transient tether was defined as a flowing 
platelet that suddenly arrested, without evidence of translocation and then resumed a 
velocity equivalent to that of a non-interacting platelet. Only one tethering event per 
platelet (in the field of view) was counted during the observation period. The duration 
of tethers was determined by recording images at a rate of 22 frames per second and 
measuring the length of time each platelet remained bound to the surface. Recorded 
movies were opened in VirtualDub to separate the movie sequences into individual 
frames and the number and length of individual transient tethering events was 
determined manually. On average, 150 tethering events were measured to determine the 
koff in each independent experimental run. The dissociation rate constants were then 
determined by plotting the natural logarithm of the number of platelets that interacted as 
a function of duration of tethering (Figure 8.13a). For first-order dissociation kinetics, 
the resultant plot is a straight line, and the slope of the line = -koff.  As an example, bond 
lifetimes between VWF-D’A3 and platelets at a shear rate of 1000s-1 are illustrated on 
Figure 8.13a. The negative slope of the straight line was calculated as 8.7s-1 and the R2 
value of 0.99 indicated a good linear relationship between the natural log of the number 
of tethering events and the duration of the events. Analogous measurements were 
performed at the shear rates of 400, 600 and 2000s-1. Average wtD’A3-GPIbα 
dissociation rates values are listed in the Figure 8.13b. The lowest koff value was 
determined at a shear rate of 400s-1, it was slightly higher at shear rates of 600 and 
1000s-1 and then increased at 2000s-1. However the changes in koff were minimal, 
indicating that the wtD’A3-GPIbα bond lifetime was similar across the shear range 
tested. 
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B 
Shear rate (s-1) Dissociation rate constant - Koff (s-1) 
400 6.7 ± 1.3 
600 7.1 ± 1.1 
1000 7.1 ±1.4 
2000 9.2 ± 1.6 
 
Figure 8.13 Kinetics of dissociation of transiently tethered platelets from wtD’A3 
Labelled platelets were perfused over flow slides coated with 2µg/ml coating 
concentration of wtD’A3, the lowest concentration capable of supporting adhesion to 
assure occurrence of only transient tethering events. Disassociation rate constants were 
estimated at various wall shear stresses and based on the duration of transient tether 
events for approximately 150 platelets. (A) Representative experiment for wtD’A3 
variant at a shear rate of 1000s-1 The natural logarithm of the number of platelets that 
interacted as a function of time that platelet remained attached was plotted in Excel. The 
plot was a straight line whose slope corresponded to -koff . (B) Disassociation rates 
values for the tether bond between GPIbα- and wtD’A3 at range of shear rates (400-
1000s-1).  
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8.4.4 Transient tethering  
Finally, the number of transient tethering events occurring over a set time frame at 
increasing shear rates was calculated. The number of transient tethering events is 
indicative of VWF-GPIbα association rate. Platelets were perfused over slides coated 
with low concentration of wtD’A3 at a range of shear rates (400-1000s-1) and the 
number of interacting platelets over 5 seconds counted. As shown in Figure 8.14 the 
number of tether events was the highest at the shear rate of 600s-1 and subsequently 
decreased with increasing shear rate, with very few events taking place at 2000s-1. 
Moreover, a high number of platelet tethering events was observed at a lower shear rate 
of 400s-1. These experiments demonstrate that increase in the shear rate promotes 
transient tethering but over a certain threshold value it then has a negative effect.  
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Figure 8.14 Shear rate dependence of  transient platelet tethering on flow slides 
coated with wtD’A3 
Labelled platelets were perfused over slides coated with 2µg/ml of wtD’A3- VWF 
fragment at shear rates ranging from 400 to 2000s-1. The number of platelets that 
transiently tethered during 5 s observation period was quantified for 3 different fields of 
view for 3 independent experiments. 
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8.5 Desialylated wtVWF interaction with platelets under shear stress 
8.5.1 Platelet adhesion and rolling  
As presented in the previous chapter, the removal of sialic acid from VWF O-linked 
glycans enhanced the ability of VWF to bind to GPIbα in the presence of ristocetin. 
Therefore the flow assay was used to determine if VWF sialic acid also affected the 
interaction under shear stress conditions. As shown above, platelet capture on 
immobilised wtD’A3 increased with increasing shear stress. Interestingly, for 
desialylated wtD’A3 (+Neu-wtD’A3) the number of captured platelets at 400 and 600s-1 
was considerably increased compared to wtD’A3. However, at 1000 and 2000s-1 platelet 
capture was similar for both wild type and neuraminidase treated protein (Figure 8.15). 
 
Figure 8.15 Platelets attachment to wtD’A3 and desialylated wtD’A3 under shear 
stress 
Purified platelets were perfused over slide surface coated with 30µg/ml wtD’A3 and 
desialylated wtD’A3 (+Neu wtD’A3) at shear rates ranging from 200 to 2000 s-1 for 4 
minutes. The number of platelets that remained stationery for the duration of 3 frames 
(0.15s) on the indicated substrates as a function of shear rates was determined. 
0.4x0.3mm  
 
From observation of the real time interaction of platelets with Neu-wtD’A3 it was 
apparent that at the lower shear rates platelets appeared to move slower across the VWF 
surface when compared to platelets interacting with wtD’A3, therefore rolling velocities 
were calculated. As with wtVWF-D’A3, a biphasic shear dependent velocity curve was 
observed, albeit with smaller changes in rolling velocity (Figure 8.16). Significantly, at 
400 and 600s-1, platelets rolled slower over Neu-wtD’A3, (~16 μm/s) compared to 
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wtVWF-D’A3, (~9μm/s), where as similar rolling velocities were determined at 1000 
and 2000s-1 (Figure 8.16). 
 
Figure 8.16 Platelet rolling on wtD’A3 and desialylated wtD’A3 
wtD’A3 and  desialylated wtD’A3  (+Neu wtD’A3) were coated at a saturating 
concentrations of 30µg/ml and platelets with erythrocytes were passed over at shear 
rates ranging from 400 to  2000s-1 for 4 minutes. Rolling velocities were measured by 
tracking individual platelets frame by frame at an interval of 0.05s, in the direction of 
flow and mean velocity was calculated by Image J. Approximately 25-40 platelets were 
tracked in 3 random fields of views, and 3 separate experimental runs were completed 
for each flow rate. Mean ±SEM shown. 
 
8.5.2 Transient tethering  
Since at the lower shear rates Neu-wtD’A3 bound greater numbers of platelets and 
slowed the decreased the platelet rolling velocity the kinetics of the interaction were 
investigated. To limit the possibility of multiple bond formation and to ensure that only 
transient tethering events take place, the concentration of immobilised proteins was low 
(2μg/ml). Initially, the number of transient tethering events occurring in specified time 
at a given shear rate was quantified as described in section 1.4.2. As shown on Figure 
8.17 at all shear values tested, the number of platelets transiently tethering was similar 
for wtD’A3 and Neu-wtD’A3. Moreover as previously described, the number of tether 
events decreased with increasing shear rate.  
 223 
 
Figure 8.17 Shear dependence of transient tethering between platelets and wtD’A3 
and desialylated wtD’A3 
Platelets were perfused over slides coated with 2µg/ml of wtD’A3 and desialylated 
D’A3 (+Neu-D’A3) at shear rates ranging from 400 to 2000s-1. The number of platelets 
that transiently tethered to the substrate was quantified for 3 different fields of view 
(0.4x0.3mm) for 3 independent experiments during 5s of flow. Both wtD’A3 and Neu-
D’A3 participated in equivalent number of tethering events across the shear rates range 
tested.  
 
Finally, I determined the GPIbα-A1 bond lifetime and quantified the dissociation rate 
constant under shear stress (as described in detail in section 3.4.3)..The values of the 
dissociation rate constant, Koff were calculated for both wtD’A3 and Neu-wtD’A3 at 
shear rates ranging from 400 to 2000s-1. As demonstrated in Table 8.2 I established that 
under all shear rates tested, koff values for GPIbα binding to wtD’A3 and Neu-wtD’A3 
were comparable. This data suggests that removal of sialic acid from VWF does not 
alter GPIbα-A1 bond dissociation under the shear stress rates tested.  
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Shear rate (s-1) 
                                koff 
  400s-1        600 s-1     1000 s-1      2000 s-1 
wtD’A3 6.7 ±1.3 7.1 ±1.1 7.1 ±1.4 9.2 ±1.6 
+Neu wtD’A3 6.7 ±1 7.4 ±1.2 6.6 ±1.1 8.6 ±1.1 
Table 8.2 Disassociation rate constants for the tether bond between GPIbα- and 
wtD’A3 and desialyated wtD’A3 
Estimation of the Koff values for the GPIbα VWF tether bond was based on the duration 
of transient tether events. Experiments were conducted for wtD’A3 and desialylated 
wtD’A3 (+Neu-wtD’A3) at coating concentrations supporting only transient tethering 
events (2μg/ml) under a range of shear rates. Similar dissociation rates were estimated 
for platelet interaction with both immobilised wtD’A3 and Neu-wtD’A3 under shear 
stress.(p>0.05) 
 
8.6 Platelet accumulation and rolling on wtD’A3 and O-linked 
glycosylation variants 
In the plate based ELISA assay the T1255A, Clus1 and DC variants all exhibited 
increased sensitivity to ristocetin mediated GPIbα binding, while the T1468A variant 
demonstrated decreased binding. I have therefore investigated if these mutations have a 
similar effect on the interaction with GPIbα under flow conditions. Firstly, the ability of 
platelets to accumulate and translocate on VWF O-glycosylation variants was compared 
to that of wild type VWF. The assays were performed under a range of shear rates from 
400 to 2000s-1 using slides saturated with wild type and mutated D’A3 proteins.  
Initially, platelet attachment to the immobilised and T1255A and the Clus1 variants 
double cluster variant (DC-D’A3) was examined. Interestingly when compared to wild 
type protein, the T1255A-D’A3 single glycosylation variant and Clus1-D’A3 and DC-
D’A3 showed similar capability to binding platelets at shear rates up to 1000s-1, and 
decreased platelet capture at the shear rate of 2000s-1(Figure 8.18). Importantly, 
similarly to wild type protein, wtD’A3 variants exhibited a shear dependent increase in 
platelet binding, except at 2000s-1 where the number of platelets bound to the D’A3 
glycosylation variants decreased.   
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Figure 8.18 Comparison of platelets attachment to immobilised Clus1-, 1255- , DC-
D’A3 variants and wtD’A3 under flow 
Purified platelets were perfused over immobilised wtD’A3, T1255A-D’A3, Clus1-D’A3 
and DC-D’A3 at shear rates ranging from 400 to 2000 s-1 for 4 minutes. The number of 
platelets that remained stationery for the duration of 3 frames (0.15s) on the indicated 
substrates as a function of shear rates was determined. At the shear rates up to 1000s-1 
platelet accumulation on the T1255A-, Clus1- and DC-D’A3, variants was similar to 
wtD’A3. At 2000s-1 less platelet binding was observed on immobilised variants. 
 
Subsequently, platelet rolling velocities were determined for platelets translocating over 
T1255A-, Clus1- and DC-D’A3 variants, and compared to wtD’A3. As shown in Figure 
8.19 platelets rolling over D’A3 glycosylation variants generally followed a biphasic 
shear dependent pattern similar to wtD’A3. However at all shear rates tested the rolling 
velocity was significantly higher for the T1255A-, Clus1 and DC variants. This 
indicates that platelets translocate faster over VWF molecules lacking O-linked glycan 
chains. Interestingly at 600s-1 platelets had higher rolling velocities on the cluster 1 
variant compared to the T1255A and DC variants.  
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Figure 8.19 Platelets translocation velocities on the immobilised T1255A-D’A3 and 
Clus1-D’A3 O-linked glycosylation variant under flow 
Translocation velocities were measured by tracking an individual platelet frame by 
frame at an interval of 0.05s, in the direction of flow. Mean translocation velocities 
(µm/s-1) were calculated by ImageJ at indicated wall shear stresses. Platelets 
translocation velocities were notably higher on both immobilised T1255A-, Clus1- and 
DC-D’A3 variant when compared to wtD’A3 at all shear rates tested. 
 
In the plate binding assay the T1468A variant showed reduced sensitivity to ristocetin 
mediated GPIbα binding and platelet aggregation. To investigate if this was due to an 
altered interaction with ristocetin or a true effect on GPIbα binding, the interaction of 
platelets with VWF-D’A3-T1468A was investigated under flow. As demonstrated in 
Figure 8.20a under all flow rates tested the number of bound platelets was similar on 
immobilised T1468A-D’A3 compared to wtD’A3. Furthermore, mean platelet rolling 
velocities were calculated and plotted against the shear rate. The velocity curves for 
both wtD’A3 and T1468A-D’A3 have the same biphasic shape. Platelets rolled with the 
same speed on immobilised T148A-D’A3 as on wtD’A3 under shear rates from 400 to 
2000s-1 (Figure 8.20b). These results indicate that removal of O-glycan chain from 
position T1468 has no influence on the ability of bound VWF to mediate platelet 
capture and subsequent translocation.  
 
 
 227 
 
Figure 8.20 The impact of the T1468A mutation on platelet attachment and 
translocation in flow 
Labelled platelets were perfused over immobilised wtD’A3 and the T1468A –D’A3 
variant for 4 minutes under flow rates from 400 to 2000s-1. (A) After that time the 
number of attached platelets in the field of view (0.5x0.4) was counted at indicated 
shear rates for both substrates. The platelet accumulation was the same on wtD’A3 and 
T1468A-D’A3. (B) Mean platelet rolling velocities were measured and plotted against 
shear rates. Platelets translocated with the same speed on immobilised wtD’A3 and the 
T148A-D’A3 glycosylation variant. Values shown here are mean ± SEM of 3 separate 
experiments, with ~30-40 platelets analysed for each shear rate in each experiments.  
 
In addition, it was necessary to compare the platelet interaction with the VWF variants 
present in D’A3 and full length VWF. For that purpose, I have determined platelet 
attachment to immobilised full length wtVWF as well as T1255A, Cluster 1 and the 
double cluster variants under shear rates from 400 to 2000s-1. Firstly the number of 
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platelets attached increased with increasing shear rates for wtVWF and all mutated 
proteins (Figure 8.21). Correspondingly to the results obtained with immobilised D’A3 
variants, platelets bound similarly to wtVWF as to T1255A-Clus1 and DC-VWF 
variants when exposed to shear rates up to 1000s-1. Also similar platelet attachment was 
observed for full length wtVWF and glycosylation variants at the shear rate 2000s-1. 
This is in contrast to when D’A3 fragment were used, as at the shear rate of 2000s-1 the 
T1255A-Clus1 and DC-variants exhibited decreased binding when compared to wild 
type protein. 
 
Figure 8.21 Comparison of platelet attachment to immobilised full length Clus1-, 
1255- DC-VWF variants and wtVWF 
Purified platelets were perfused over immobilised wtVWF, T1255A, Cluster 1 and 
double cluster at shear rates ranging from 400 to 2000 s-1 for 4 minutes. The number of 
platelets that remained stationery for the duration of 3 frames (0.15s) on the indicated 
substrates as a function of shear rates was determined. At all the shear rates tested 
platelet accumulation on VWF variants was similar to that of wtVWF.  
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8.7 The influence of VWF O-linked glycosylation on the kinetics of 
GPIbα-A1 tether bond  
The interaction between platelet receptor GPIbα and the A1 domain of VWF has a fast 
association and fast dissociation rate. The increased platelet rolling velocity on 
immobilised T1255A-, Clus1- and DC-D’A3 variants is suggestive of altered kinetics of 
the receptor-ligand bond. For that reason the influence of the O-linked glycan mutants 
on the rate of bond formation and bond dissociation rates under various shear stress 
rates was investigated. To directly measure the kinetic parameters, I have analysed the 
formation and dissociation of transient adhesive events between platelets and D’A3 
proteins coated at low site density to limit multiple bond formation. 
8.7.1 Dissociation rate 
The duration of transient tethers on each immobilised D’A3 variant was measured under 
shear rates ranging from 400 to 1000s-1. When the initiation of tethering was 
synchronised to t=0, transient tethers were seen to dissociate with first order kinetics. 
The log transformed data fitted into a single straight line with a high correlation 
coefficient and the slope of the regression line corresponded to the dissociation 
constant.  A representative graph depicting the distribution of interaction times for 
approximately 150 transient tethering events that occurred between platelets and DC-
D’A3 at various shear rates is shown in Figure 8.22. The same analysis was applied to 
wtD’A3 and T1255A-, Clus1-D’A3 variants in three separate experiments and the Koff 
values at respective shear rates are gathered in Table 8.3. No major difference between 
the koff values at shear rates between 200 and 2000s-1 was detected for any of the 
proteins. Importantly, the dissociation rates appeared quite similar for wtD’A3 and all 
the variants tested. Based on this results it appears that the increased rolling velocity 
seen with the VWF O-linked glycan variants is not due to increased dissociation of the 
GPIbα-A1 bond. 
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Figure 8.22 Kinetics of dissociation of transiently tethered platelets on DC-D’A3  
Disassociation rate constants were estimated at various wall shear stresses using a 
2µg/ml coating concentration of recombinant protein. Kinetics of transient tethering 
between platelets and DC-D’A3 variant at a shear rates of 400, 600 and 1000s-1 is 
demonstrated as an example. The natural logarithm of the number of tethering events 
was plotted against the duration of tethering and the negative slope of the lines is the 
koff.. Disassociation rate values at each shear rate are indicated. (R2 values were ~0.9) 
 
 
Shear rate (s-1) 
                                koff 
  400s-1         600 s-1       1000 s-1         2000 s-1 
wtD’A3 6.7±1.3 7.1 ±1.1 7.1 ±1.4 9.2 ±1.6 
DC-D’A3 5.4±0.9 4.7±0.6 5.7±0.9 3.7 ±0.4 
T1255-D’A3 6.6±0.1 6.6±0.8 6±0.2 7.4 ±1.7 
Clus1-D’A3 5.5±1.0 6.4 ±1.2 5.1 ±0.5 7.5 ±1.6 
T1468A 5.9±0.9 6.9±0.8 6.9±0.9 7.9±1.5 
Table 8.3 Disassociation rates values for the tether bond between GPIbα- and wild 
type and mutated D’A3 
Estimation of the Koff values for the GPIbα -VWF tether bond was based on the duration 
of transient tether events. Experiments were conducted for wtD’A3 and D’A3 O-linked 
glycosylation variants at coating concentrations supporting only transient tethering 
events (2μg/ml) under a range of shear rates. Similar dissociation rates were estimated 
for platelet interaction with both immobilised wtD’A3 and mutated-D’A3. Values 
shown here are SEM of 3 separate experiments. Calculated p values between koff 
between mutants and shear rates were above 0.05. 
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8.7.2 Transient tethering rate  
Firstly the effect of the T1255A, Clus1- and DC- mutations on the flow dependent 
transient tethering of platelets to immobilised D’A3 was investigated. Briefly, platelets 
were perfused over VWF at a range of shear rates for 3 minutes and the number and 
behaviour of interacting platelets was determined as a function of the bulk concentration 
of D’A3 absorbed on the slides. As before, the formation of platelet tethers with 
wtD’A3 was inversely correlated with shear rate, with decreasing numbers of tethers 
formed as the shear rate increased.(Figure 8.23) Interestingly, the number of transient 
tethers formed on the T1255A, Clus 1 and DC variants was greatly decreased at all 
shear rates, with the T1255A and Clus 1 variants only able to tether minimal numbers of 
platelets and the DC variant able to support marginally more tethering events at all shear 
rates compared to the T1255A and Clus1 variants. (Figure 8.23) The specificity of this 
adhesive event was demonstrated by the inability of platelets to interact with BSA 
coated surface under all flow conditions tested. 
 
Figure 8.23 Platelet tethering to immobilised wtD’A3 and D’A3 glycosylation 
variants as a function of shear rate 
Platelets were perfused over slides coated with 2µg/ml of wtD’A3 and T1255A-, 
Clus1,and DC D’A3 glycosylation variants at shear rates ranging from 200 to 5000s-1 
for 3 minutes. The graph shows the number of platelets that transiently tethered to each 
substrate at a given shear rate, during 5 seconds at 3 different fields of view 
(0.4x0.3mm). Values are shown as SEM of three experiments at each protein 
concentration tested. The number of transient tethering events was markedly lower on 
immobilised T1255A, Clus1 and DC variants than on wild type protein at all shear rates 
except 2000s-1. 
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8.7.3 Effect of coating concentration on platelet adhesion to VWF-D’A3 
Since the analysed VWF O-linked glycan variants had faster rolling velocity it was 
hypothesised that this could be the result of a decrease in the bond lifetime and 
therefore, would result in alteration of the Koff for the interaction. However, as shown, 
the calculated Koff values for the T1255A, Clus1 and DC variants were all similar to 
wtD’A3 indicating that the Koff was unaltered, and therefore the difference in rolling 
velocity could not be attributed to a decrease in bond lifetime. Intriguingly, as also 
shown, at low coating concentrations, the T1255A, Clus1 and DC variants were 
significantly less efficient than wild type protein at supporting transient tethering 
events, however when flow slides were saturated with these proteins they were able to 
effectively capture platelets. It was therefore hypothesised that when coated below 
saturating concentrations, the mutant VWF molecules were less efficient at capturing 
platelets. To test this hypothesis, separate flow channels were coated with increasing 
concentrations of either wild type D’A3 or T1255A-D’A3 and platelets perfused over at 
1500s-1.The number of platelets interacting and the type of interaction (i.e. transient 
tethering, rolling) were compared at each protein concentration. (Figure 8.24) At a 
coating concentration of 2µg/ml, transient tether formation was the only type of 
interaction observed on either T1255A-D’A3 or wtD’A3, with significantly more 
tethers seen on wtD’A3 compared to T1255A-D’A3. At 3ug/ml, more platelets tethered 
to wtD’A3 with a small proportion being rolling events. However, only a few tethering 
events were observed on T1255A-D’A3. At 7 and 15µg/ml, more platelets interacted 
with wtD’A3 and the proportion of rolling events increased. In contrast at 7 and 
15µg/ml, although more platelets were observed to tether to T1255A-D’A3, the number 
of events was still less than for wtD’A3, and furthermore very few rolling events were 
observed. It was only at 30µg/ml that T1255A-D’A3 was able to support platelet rolling 
and capture platelets to the same extent as wtD’A3 
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Figure 8.24Interaction of platelets with various concentrations of wtD’A3 and T1255A-D’A3 
Flow slides were coated with wtD’A3 (top panels) and T1255-D’A3 (bottom panels) at concentrations from 2 to 30µg/ml (as indicated), and 
labelled platelets were perfused at 1500s-1 for 4 minutes. At the lowest coating concentration of 2µg/ml transient tethering (yellow arrows) was 
the only type of interaction between platelets and immobilised wtD’A3 and T1255A-D’A3. When the concentration increased to 3µg/ml the 
wtD’A3 supported significantly more interaction than the T1255A, majority of which could be described as platelet rolling (pink arrows). With 
increasing wtD’A3 concentration, an increasing number of tethers resulted in rolling. The T1255A-D’A3 was unable to mediate platelet 
translocation until it was immobilised at a concentration of 30µg/ml. Platelets flowing near the surface, but not binding were visible as a white 
smear (green arrows).  
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Since the number of tethering events was notably lower on immobilised T1255A, Clus1 
and DC-D’A3 variants than on the wtD’A3, it was necessary to verify whether O-
glycosylation variant were coated on the slide to the same extent, and remained attached 
after subject to hydrodynamic flow. To this end, after incubation with protein, slides 
were washed; blocked and HEPES/Tyrodes buffer was perfused for 4 minutes at the 
shear rate of 1500s-1. Then proteins were stripped from the slide surface and subject to 
SDS-PAGE under reducing conditions followed by WB and immunostaining with anti-
c-myc antibodies. As demonstrated in Figure 8.25 same amount of protein was detected 
in each well, suggesting that both wtD’A3 and D’A3 variants were present on the flow 
slides in equal amounts and were not removed  by shear stress.  
 
Figure 8.25 Western Blot analysis of the wtD’A3 and mutated D’A3 fragments 
coated on a flow slide surface 
wtD’A3 and T1255A, Clus-1, and DC-D’A3 glycosylation variants were removed from 
the slide surface, reduced and subject to SDS-PAGE under reducing conditions and 
blotted. Detection of D’A3 was carried out the using anti-c-myc antibodies. The same 
signal was detected in each lane, implying the same amount of D’A3 was present.  
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8.8 Comparison of platelet translocation pattern over immobilised 
wtD’A3 and O-glycosylation variants 
On closer inspection of the recorded movies of platelet rolling, it was observed that 
platelets did not appear to translocate across the T1255A, Clus1 and DC variants in the 
same way when compared to wtD’A3. While platelets moved in a smooth and 
consistent manner across wtD’A3, the translocation across the mutant D’A3 surfaces 
appeared less uniform and more erratic. To investigate this further, 35 individual frames 
from selected movies were stacked using the maximal intensity Z-projection function in 
ImageJ to assess the movement of individual platelets over the duration of the 35 
frames.  
As illustrated in Figure 8.26, on surfaces coated with the O-glycosylation variants, 
platelets appeared to “jump”, as gaps are visible between points of binding when 
subsequent movie frames are analysed. In the case of interaction wtD’A3 platelets 
stopped more often, indicating that the distance between bonds and therefore 
presumably between available A1 domains, was shorter. 
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Figure 8.26 Platelet translocation pattern on immobilised wtD’A3 and T1255-, 
Cluster1- and DC-D’A3 glycosylation variants 
Purified platelets were perfused over wtD’A3, T1255A-D’A3, Clus1-D’A3 and DC-D’A3 
immobilised (at a concentration of 30μg/ml) at shear rates of 1000 s-1 for 4 minutes after 
that time movies were recorded. 35 subsequent frames were superimposed (~1.75s) to track 
the translocation of individual platelets. Examples of platelets translocation paths on wild 
type and mutated proteins are shown.  It is clear that platelets roll uniformly on the surface 
coated with wtD’A3. In contrast platelets translocate less consistently and smoothly on 
immobilised glycosylation variants and appear to jump rather than roll as indicated by the 
larger gaps between points of platelets attachment. (Images were acquired at x20 
magnification and analysed following x3 zoom in ImageJ) 
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8.9 Influence of O-linked glycosylation variants on VWF mediated 
platelet adhesion to collagen  
Removal of the O-linked glycan from position T1255 or the entire N-terminal glycan 
cluster or all O-linked glycans clustered around the A1 domain resulted in altered 
interaction with platelets. However these experiments were performed using D’A3 
fragments immobilised on to flow slides. While this is more physiological than static 
assays used to examine VWF function, in vivo platelets bind to VWF that is 
immobilised on collagen surfaces under high shear stress. Therefore to analyse further 
the effect of the O-linked glycan variants on VWF platelet capture function, flow assays 
were performed in which flow slides were coated with collagen and these were perfused 
with plasma free blood supplemented with wild type FL-VWF or its variants.  
The number of bound platelets was determined every 0.5min of perfusion and the 
results were expressed as a percentage of the collagen surface covered. Firstly, no 
significant collagen binding was detected when platelets without VWF or with the type 
2M-VWD variant (G1324S-VWF) were used, confirming the specificity of the 
interaction (Figure 8.27). The amount of binding increased with perfusion time for 
wtVWF and the O-glycosylation variants. As demonstrated in Figure 8.27, after 0.5min 
of flow notable platelet binding was observed in the presence of T1255A- and Clus1-
VWF, whilst only a minimal binding occurred in the presence of wtVWF. Increased 
T1255A and Clus1-VWF mediated platelet capture to collagen was observed at time 
points between 2-5 minutes when compared to wtVWF, with approximately 10% more 
surface covered in the presence of glycosylation variants. Surprisingly, these data 
indicate that the removal of O-linked glycans from the position T1255 or the entire N-
terminal glycan cluster results in enhanced platelet capture to collagen type III under 
high shear rate of 1500s-1.  
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Figure 8.27 Platelet adhesion to collagen type III in the presence of wtVWF and 
VWF glycosylation variants 
Labelled platelets with wtVWF and VWF variants were perfused over collagen type III 
coated surface at shear rate of 1500s-1. The number of bound platelets was expressed as 
the percentage of surface coverage and plotted against time after the start of perfusion. 
No significant collagen binding was detected when platelets without VWF (noVWF) or 
with type 2M-VWD variant (1324-VWF) were used. The amount of captured platelets 
was higher in the presence of T1255- and Clus1-VWF than in the presence of wtVWF. 
Mean ± SEM 
 
8.10 Discussion 
It is apparent from the previous chapter that the O-linked glycans clustered around the 
VWF A1 domain alter VWF sensitivity to ristocetin mediated GPIbα binding. However, 
these assays do not accurately reflect how the interaction occurs in vivo, due to the 
requirement of an artificial modulator and the absence of flow.  To study the VWF-
GPIbα interaction in a more physiological setting I have optimised an in vitro flow 
based assay system to assess the VWF-platelet interaction in real time under shear stress 
which closely mimics blood flow.   
In this project flow assays were performed using purified and fluorescently labelled 
platelets and washed erythrocytes. Since only the interaction between the platelet 
receptor GPIbα and the VWF-A1 domain was investigated, platelet activation was 
inhibited by the addition of prostaglandin E1, apyrase and EDTA. Platelet isolation and 
labelling involved a series of centrifugations and it was important to keep buffers and 
platelets at room temperature and be very slow and careful when re-suspending the 
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platelets to minimise activation. In addition, I have observed that the presence of 
erythrocytes is essential to observe platelet adhesion to immobilised VWF under flow. 
This finding is in agreement with previous data showing that  in the presence of 
erythrocytes, shear enhances radial transport of platelets to the surface due to shear 
induced tumbling of erythrocytes.348,522 Under flow, especially high shear, erythrocytes 
tend to move towards the centre of the vessel pushing platelets towards the vascular 
wall creating a near-wall platelet excess.523 Interestingly, it has been previously shown 
that platelet adhesion to VWF coated slides under high shear rate (1500 s-1) is still 
efficient even when the platelet count was reduced by up to 90% further confirming the 
importance of erythrocytes.523 Importantly I have determined that erythrocytes had to be 
washed four times in order to remove any residual VWF. Subsequently I have optimised 
coating conditions for VWF and collagen. The type III collagen from Southern 
Biosciences immobilised overnight at a concentration of 100µg/ml was identified as the 
most suitable for the flow assays. Furthermore, the concentrations of VWF-D’A3 and 
FL-VWF required to saturate the slide surface and which would support platelet 
attachment and rolling were determined. In addition a coating concentration of VWF-
D’A3 that would support only transient tethering events was established. 
In the majority of the assays described in this project a fragment of VWF comprising of 
D’ to A3 domains was used as it allowed me to study the kinetics of the bond formation 
between platelet GPIbα and the VWF-A1 domain, which would not be feasible if 
multimeric VWF was used. In the majority of previously published studies, the isolated 
A1 domain expressed in E.coli was used to study the kinetics of the VWF-GPIbα bond 
formation.  It was assumed that the isolated A1 domain would perform in the flow assay 
identically as full length VWF. This assumption is based on the studies which have 
shown that under shear flow platelet attachment to a surface saturated with immobilised 
bacterial A1 or a  glycosylated VWF fragment containing the A1 domain and part of the 
D3 domain (residues 1208-1496) was comparable to multimeric VWF.524,285 However, 
in these studies only platelet attachment was evaluated, which provides little insight into 
the biomechanical properties of the GPIb-VWF-A1 bond. Therefore a more detailed 
analysis such as platelet rolling and kinetic analysis of bond formation is necessary 
before a direct comparison can be made. Using static assays I have demonstrated that O-
linked glycans flanking the A1 domain modulate VWF-GPIbα binding. In previous 
studies, domains neighbouring the A1 domain have been implicated in modulating its 
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accessibility. The D’D3 domains and N-terminal A1 domain flanking region have an 
inhibitory effect on GPIbα binding137,138 and it has also been suggested that the A2 
domain interacts with the A1 domain.286   Based on these data, the D’A3 fragment was 
chosen for the flow experiments, as in contrast to the isolated A1 domain, it 
encompasses structural elements that may influence GPIbα binding in multimeric VWF.  
It has been well documented that GPIbα mediates platelet attachment and translocation 
of platelets on immobilised VWF in vitro. I have confirmed this observation by 
examining the interaction of platelets with immobilised full length VWF and D’A3-
VWF. Initially, the effect of increasing shear rate (400 to 2000s-1) on platelet attachment 
and rolling on immobilised wtD’A3 was investigated. The specificity of this interaction 
was demonstrated by inability of platelets to adhere to surface coated with BSA. 
Platelets were able to bind to immobilised wtD’A3 in a shear dependent manner, 
however since the A1-GPIbα interaction cannot support irreversible adhesion, they 
translocated in the direction of flow, albeit at a markedly reduced velocity relative to 
freely flowing platelets. In accordance with previously published studies1 platelet 
rolling velocities were dependent on the shear rate, with a biphasic velocity curve at 
shear rates between 400 and 2000s-1. I have observed that with increasing shear rates 
platelets rolled more slowly due to increasing bond-lifetimes (catch bond) until a 
threshold shear rate value was reached. A further increase in the shear rate caused faster 
platelet rolling (slip bond). The shear stress dependent bond formation between platelet 
GPIbα and the VWF-A1 domain has been previously documented and is similar to that 
of selectins with their glycoconjugate ligands which mediate leukocyte rolling on 
inflamed vascular surfaces.525 The force applied on the bond initially increases and the 
bond lifetime increases (catch bond) until a maximal value is reached and then as the 
force increases further, bond lifetimes decreases (slip bond).526 Platelet attachment and 
rolling experiments were performed under conditions that support multiple bond 
formation at a time between platelet and VWF-A1 domains, and as such, provide 
limited insight into the biomechanical properties of the GPIbα-A1 bond. To gain insight 
into the kinetics of transient tether events between platelets and wtD’A3 under flow 
conditions, protein was immobilised at a concentration that limited multiple bond 
formation. Initially, shear rate dependence of transient tethering was examined. It is 
well established that tether formation is related to shear rate and therefore is limited by 
the time that the receptor and ligand are in proximity to one another, rather than by the 
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force exerted on forming bonds.332 It has been shown for selectin-ligand bond formation 
that the initial increase in shear rate increases the collision probability and allows it to 
overcome a repulsive barrier.353,355 However, above a certain threshold shear rate, the 
tether formation becomes limited by the time that the receptor and ligand are in 
proximity to one another. Similarly, the GPIbα-A1 tether bond formation requires a 
critical level of hydrodynamic flow to initiate adhesion and an increase in shear rate 
promotes bond formation up to a point where shear rate becomes the limiting factor. In 
accordance with these studies I have observed that as the flow rates increased, the 
number of platelet-wtD’A3 transient tethering events increased until a shear rate of 
600s-1 was reached. Above that point the number of platelet-wtD’A3 tethering events 
started to decrease and at shear rates above 5000s-1 no transient tethering was observed.  
Transient tethers are the smallest unit of adhesive interaction observed in shear flow, 
and have a distribution of bond lifetimes that obey first order dissociation kinetics. 
333,354,527,528 The wtD’A3 platelet tether time distribution followed first-order 
dissociation kinetics implying we have indeed looked at single bond formation. Based 
on the bond lifetimes, the dissociation rate constants of transient tethers were calculated 
at a range of shear rates (400-2000s-1). The koff values for wtD’A3 appear to fall in to 
the same order of magnitude as reported in the literature, although previously obtained 
dissociation rates were determined for tethers between the isolated A1 domain-platelet 
interaction and at lower shear rates (up to approximately 200s-1).262 To our knowledge 
this is the first time the dissociation rate values for the GPIbα-VWF-A1 interaction 
under condition of medium and high shear stress have been derived. Interestingly no 
apparent differences were detected in the koff values across the shear range tested (400-
2000s-1). The viscosity of plasma is approximately 5 fold higher that blood preparations 
used in this study. In the future a HEPES-TYRODES buffer supplemented with Ficoll 
to increase viscosity is going to be used. This may help to resolve changes in bond 
lifetime across the ranges of shear rates that were previously reported, and observe the 
influence of shear stress values on bond lifetimes. So far I have only modified the shear 
stress by increasing the shear rate values; however by increasing those I am also 
decreasing the probability of bond formation, which could mean that the effect of 
increasing force on the bond will not be observed, as the bond will not be formed in the 
first place. By increasing the viscosity we increase the shear stress therefore increase the 
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force acting on a bond and in result the bond lifetime and dissociation rate but not the 
velocity of blood and probability of bond formation. 
In addition, I have observed that the shear rates that supported the maximal number of 
platelet-wtD’A3 tethering events, were lower than the shear rates at which platelet 
attachment was maximal and rolling velocity was the slowest. I propose that the force 
acting on an entire platelet is the same in both experiments, however in platelet 
adhesion and rolling experiments the force acting on the platelet is distributed among 
several bonds, thus the force acting on an individual bond is decreased. In the platelet 
transient tethering experiments, the entire force acting on a platelet is loaded onto a 
single GPIbα-VWFA1 bond. When the surface is saturated with VWF, multiple bonds 
mediate platelet adhesion and rolling, which could reduce the force on individual bonds 
below the levels that produce the catch and slip bond transition. At low shear stresses, 
bond lifetimes are too short to support rolling and platelet attachment that would be 
long enough to be measured in the experiments performed in this project. However low 
shear rates are large enough to mediate platelets transient tethering. 
8.10.1 The influence of O-linked glycans on platelet interaction with immobilised 
D’A3-VWF under various shear rates  
With the flow assays optimised, I investigated the influence of O-linked glycosylation 
on VWF-platelet interactions under hydrodynamic shear stress. To begin with, I 
investigated the properties of the T1468A variant which exhibited decreased sensitivity 
to ristocetin mediated GPIbα binding in the plate assay and diminished ability to 
support platelets aggregation in the VWF:RCo assay. I have shown that platelet 
adhesion and platelet rolling velocities on the slide surface densely coated with 
T1468A-D’A3 are comparable to that on immobilised wtD’A3 at all shear rates tested. 
Furthermore, the transient tethering rate and dissociation rate constant of bonds formed 
between GPIbα and T1468A-D’A3 were similar to that of GPIbα-wtD’A3. These results 
indicate that the decreased GPIbα binding observed for T1468A variant under static 
conditions was likely due to distorted interaction with ristocetin not GPIbα. As 
discussed in the previous chapter the T1468 glycosylation site resides in one of the 
regions implicated in ristocetin binding, therefore removal of the glycan chain might 
directly affect ristocetin binding or ristocetin effect on VWF-A1 domain 
conformation.288,290  
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It has been previously suggested that ristocetin dependent assays may not entirely 
reliable in assessing VWF function.516 Significantly decreased ristocetin dependent 
platelet binding was observed for VWF from patients with the type 2M-P1467S 
mutation or individuals with the D1472H polymorphism even though they had no 
bleeding phenotype. Conversely VWF containing those mutations exhibited normal 
GPIbα binding when the assay was performed under shear conditions or static 
conditions in an assay that did not require presence of ristocetin (using GPIbα with gain 
of function mutations).516,529 The discrepancy in the binding studies performed 
dependent and independently of ristocetin was attributed by the authors to altered 
ristocetin binding.  
Subsequently the flow assay was employed to examine platelet interaction with the O-
linked glycosylation variants that exhibited increased sensitivity to ristocetin mediated 
GPIbα. The T1255A- Clus1- and DC-D’A3 variants exhibited a generally similar ability 
to mediate platelet capture as wtD’A3 at the shear rates up to 1000s-1, however 
decreased platelet capture was observed at 2000s-1. Interestingly the calculated platelet 
rolling velocities showed that platelets translocated faster on all three immobilised O-
linked glycosylation variants than on wild type protein at all shear rates tested. 
Interestingly, the Cluster 1 showed higher rolling velocity then the other two variants at 
a shear rate of 600s-1. This has been observed several times however an adequate 
explanation cannot be determined for this observation. Importantly, platelet rolling 
velocity curves followed a biphasic pattern, implying that removal of O-linked glycans 
does not affect the ability of VWF to form catch and slip bonds with GPIbα. The rolling 
velocity is thought to depend on the bond lifetime and dissociation rate constant. 
However, platelet rolling also relies on the efficiency at which primary transient tethers 
transform into stable tethers by forming new bonds at the front edge of the platelets as 
previous bonds in the rear edge dissociate.   
To further elucidate the differences in rolling I have attempted to characterise the 
kinetics of tether bonds for mutated proteins. Unexpectedly, I have shown that there is 
no significant difference in the dissociation rate values for bonds formed between 
platelets and T1255A, Clus1 and DC-D’A3 when compared to wtD’A3 under all flow 
conditions tested. This finding implies that the difference in platelet rolling observed for 
these O-glycosylation variants is caused by reasons other than the change in bond 
dissociation under shear stress.  Subsequently, I have shown that immobilised T1255A-, 
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Clus1- and DC-D’A3 variants support notably lower numbers of transient tethering 
events when compared to wtD’A3 at the shear rates between 400 and 1000s-1.  This 
finding shows that a proportion of immobilised D’A3 variants are unable to bind GPIbα 
under shear stress therefore the probability of bond formation is lower, which suggests 
that the accessibility of GPIbα binding sites is limited in the absence of O-glycans. This 
finding is intriguing since the immobilised glycosylation variants were able to 
effectively capture platelets when flow slides were saturated with protein. It can be 
proposed that this dissimilarity is due to the concurrent GPIbα-A1 bonds being formed 
between individual platelet and densely immobilised D’A3, whereas transient tethering 
engages an individual A1 domain and GPIbα receptor. It can be hypothesised that when 
the surface is saturated with D’A3, the distance between A1 domains is significantly 
smaller; therefore individual platelets can interact with more than one A1 domain, thus 
allowing adhesion even if a proportion of GPIbα binding sites are not available. 
Corroborating this hypothesis I have shown that the number of bound platelets was 
similar for wtD’A3 and T1255A-D’A3 only when both were coated at saturating 
conditions allowing multivalent contacts to form due to clustering of A1 domains. 
Furthermore it was observed that T1255A-D’A3 had to be immobilised at 
concentrations ten times higher than wtD’A3 in order to support platelet rolling.  
In view of the fact that the bond dissociation rates were comparable for wtD’A3 and the 
T1255A, Cluster 1 and DC D’A3 variants, the faster platelet rolling on the O-
glycosylation variants has to be attributed to decreased accessibility of their GPIbα 
binding sites. I propose that since a proportion of GPIbα binding sites are unavailable as 
indicated by the reduced number of transient tethering events taking place (figure C,D) 
the distance between the A1 domains that a translocating platelet can bind to is 
increased. Thus transloacting platelets pause less often on the VWF variants (B) than on 
wild type protein (A) and appear to cover a larger distance during the same time, which 
is reflected in a higher platelet translocation velocity. When analysing movies of platelet 
translocation frame by frame it is becomes apparent that platelet translocation on 
immobilised wtD’A3 appears as consistent and smooth rolling. In contrast platelet 
translocation over immobilised T1255A-, Cluster1 and DC-D’A3 variants appears less 
continuous, more erratic and platelet appear to ‘jump’ as well as roll.  
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Figure 8.28 Illustration of proposed pattern of platelet translocation and transient 
tethering on immobilised wtD’A3 and the T1255A, Clus1 and DC glycosylation 
variants under shear stress 
Graphic representation of platelet rolling on a slide surface saturated with wtD’A3 (A) 
and T1255A-, Clus1 or DC-D’A3 variants (B) under shear stress. (A) All the GPIbα 
binding sites of the wtD’A3 are available, therefore platelets bind and pause more often, 
rolling consistently. (B) A proportion of GPIbα binding sites of the O-glycosylation 
variants is non-accessible, therefore platelets bind and pause less often which allows 
them to cover a larger distance in a shorter space of time, which is reflected by faster 
translocation velocity. Similarly if more of GPIbα binding sites are available in the 
wtD’A3 (C) than glycosylation variants (D) platelet transiently tether more often on 
immobilised wtD’A3  than the T1255A-, Clus1 or DC-D’A3 variants under conditions 
of  shear stress.  
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To further elucidate this hypothesis I have investigated platelet rolling velocities on    
FL-VWF and wtD’A3 coated at different concentrations. Platelets rolled faster on the 
lowest concentration of protein immobilised and slower when the surface was saturated 
with the protein. Moreover, I have shown that platelets roll faster on a surface saturated 
with immobilised FL-VWF (15.2±0.5μm/s) than wtD’A3 (9.7±0.2μm/s). These results 
further support the concept that the shorter the distance between A1 domains the more 
frequently platelets can bind and pause, which results in slower translocation velocity. 
The dependence of rolling velocity on the density of potential interaction sites has been 
previously demonstrated by Fredrickson et al., in a study using mammalian cells 
expressing GPIbα and immobilised VWF.530 Cells with a lower GPIbα receptor density 
rolled significantly faster than cells with medium or high density of GPIbα. Importantly, 
the number of interacting cells was independent of receptor density. In addition it was 
observed that GPIbα expressing cells rolled on immobilised VWF notably faster when 
VWF was coated at low concentrations.530 
Finally, the other O-glycosylation variants were able to interact with platelets under 
shear stress in a similar manner as wtD’A3. Importantly, the Cluster 2 variant exhibited 
unaltered interaction with platelets suggesting that the differences in GPIbα binding 
observed for the double cluster variant is only due to the absence of glycans on the N-
terminal side of the A1 domain.  
On the basis of the presented data, I propose that removal of O-linked glycans from the 
N-terminal side of the A1 domain can induce a change in the conformation of VWF 
D’A3. As a result the accessibility of the GPIbα binding site in the A1 domain becomes 
limited, at least when the D’A3 protein is immobilised on the slide surface and exposed 
to shear stress. As discussed in chapter 3, O-linked glycans are positioned in close 
proximity to the peptide backbone, which facilitates close interaction between the sugar 
and protein, and clustering of glycans can further amplify this effect.400,502 O-linked 
glycans are known to provide rigidity to peptide backbones and stabilize otherwise 
flexible regions, thus stabilising protein conformation.439 Glycans introduce steric 
hindrance, and the polypeptide they are attached to can adopt a rigid, extended 
conformation.438-445 The removal of O-linked glycan(s) from the N-terminal A1 flanking 
region may change its flexibility, and allow VWF to adopt a more tightly folded 
conformation, limiting the exposure of the A1 domain. Furthermore, the absence of O-
linked glycans may allow formation of nonspecific interactions between A1 and 
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neighbouring domains, possibly increasing shielding by D’D3 domain, and as a result, 
altering the accessibility of the GPIbα binding site. 
8.10.2 Sialic acid effect on VWF-platelet interaction under conditions of shear 
flow 
In the static assay removal of sialic acid residues from VWF resulted in increased 
sensitivity to ristocetin mediated GPIbα binding. In the present study I have therefore 
investigated the ability of desialylated VWF to interact with platelet receptor GPIbα 
under various shear rates. Firstly I demonstrated that both sialylated and desialylated 
proteins were able to support the same number of transient tethering events. Moreover 
the GPIbα-A1 dissociation rate constants were similar for both proteins at all shear rates 
tested. Seemingly contradictory, the number of bound platelets was higher for the 
desialylated D’A3 when proteins were immobilised at saturated concentrations under 
shear rates up to 1000s-1 but no difference was observed at higher shear rates. 
Furthermore platelets rolled with markedly slower velocities on immobilised 
desialylated D’A3 when compared to sialylated D’A3 at shear rates up to 1000s-1. 
Even though a similar number of primary transient tethering events were supported by 
desialylated D’A3 and sialylated D’A3, I propose that the number of primary tethering 
events that transform into rolling events was higher on surface saturated with 
desialylated D’A3. This hypothesis could explain why the calculated number of 
attached platelets was greater on the desialylated wtD’A3 compared to sialylated 
wtD’A3 when proteins were immobilised at saturating concentrations, but not when 
they were coated at low concentrations and only transient tethering events were 
measured.  
I hypothesise that the slower platelet rolling velocity on desialylated wtD’A3 could be a 
result of increased affinity of platelets that are already tethered to VWF when terminal 
sialic acid residues are absent from the protein. The ability of platelets to interact with 
the next available GPIbα binding site could increase when VWF is devoid of sialic acid.  
Consequently rolling platelets bound to more A1 domains and paused more frequently. 
Therefore over a given time period platelets translocated over a shorter distance than if 
they were rolling on sialylated D’A3, even though the actual bond lifetime was 
unaltered. The molecular mechanism of this effect of sialic acid residues is not clear. 
GPIbα contains a negatively charged aspartate and glutamate residues and sulphated 
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tyrosines295,297 (which are also present in the recombinant GPIbα fragment used in the 
static assays) as well as a highly glycosylated mucin stalk. It has been previously 
demonstrated that inhibiting the sulfaation of GPIbα reduced ristocetin dependent VWF 
binding.297 It could be hypothesised that removal of terminal sialic acid residues which 
confer a negative charge to glycans505 from VWF promote electrostatic interaction of 
VWF with GPIbα under lower shear stress and static conditions. Interestingly, the 
difference in platelet adhesion and rolling occurs until a certain shear rate value     
(1000s-1). It can be assumed that after this point shear stress becomes the crucial factor 
that limiting GPIbα-A1 bond formation and platelet translocation, and conformational 
changes that occur in GPIb and VWF structure are more important that an electrostatic 
interaction between the proteins. An increase in GPIbα binding was also observed 
following removal of sialic acid in the static assay in the presence of ristocetin, further 
confirming increased affinity of desialylated VWF towards GPIbα.  
8.10.3 Platelets interaction with collagen in the presence of VWF under high shear 
stress the role of O-linked glycans 
In the experiments discussed above VWF was immobilised directly onto the flow slides, 
while this is more physiological than static assays used to examine VWF function, it is 
perhaps not a true reflection of platelet-VWF interactions in vivo where platelets bind to 
VWF that is immobilised on collagen surfaces under high shear stress. For that reason I 
have also investigated platelet capture to slides coated with collagen in the presence of 
wild type FL-VWF or T1255A and Cluster 1 variants. Experiments were performed 
under high shear stress (1500s-1) to prevent platelet binding directly to collagen. 
Moreover, since both platelet and collagen binding depend on VWF multimeric content, 
I ensured that purified VWF samples of the same multimeric composition were used. 
Surprisingly the number of platelets captured to collagen via T1255A or Cluster1 was 
greater than platelet capture mediated by the wtVWF. These results imply that the 
removal of O-linked glycans from the N-terminal side of the A1 domain has a different 
effect on the ability of VWF to interact with platelets when VWF is immobilised 
directly on the slide to when it is bound to collagen. The observed difference might be 
either to an increased ability of collagen bound VWF variants to capture platelets or e a 
consequence of increased ability of these mutants to bind to collagenunder shear stress. 
However it appears from the static assays and preliminary flow experiments performed 
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towards the end of the study that is not the case, as both variant showed normal collagen 
binding however is more studies are needed to confirm this.  
Based on the presented data, it can be hypothesised that the effect of VWF O-linked 
glycans on platelet binding under shear stress is dependent on the way VWF is attached 
to the slide surface. VWF adheres to collagen mainly via its A3 domain and putatively 
via A1 domain; direct binding to the slide surface is possibly less uniform and might 
involve several domains. Currently, it is not apparent how diverse methods of VWF 
immobilisation affect its conformation. Moreover, shear stress could potentially exert 
different effects on immobilised VWF depending on the way it has been captured. It has 
been previously demonstrated that the hydrophobicity of the surface can influence the 
structure of immobilised VWF. On a hydrophilic mica surface VWF appears in more 
extended structure, while on a hydrophobic surface VWF adopts a more compact coiled 
structure, thought to resemble VWF in solution.93  In this study a hydrophobic plastic 
surface was used; therefore the immobilisation should not influence the conformation of 
D’A3 domains. It has been previously shown that surface immobilised VWF may 
undergo a conformational change under the influence of high shear stress and acquire an 
elongated structure rather than a loosely coiled structure observed under static 
conditions.89,90 However a change in the overall (molecular) shape does need not induce 
a conformational transition in the A1 domain. Following absorption on the slide the 
tight globular conformation of the D’-A3 domains might still be retained whilst the C-
terminal domains might undergo elongation. Indeed tapping force atomic force 
microscopy (TM-AFM) studies demonstrated that VWF multimers and dimers 
immobilised on hydrophobic mica surfaces consist of intramolecular repeat units of 
globular and stretched domains.94 Moreover, the overall structural change in VWF 
exposed to shear before immobilisation did not cause a significant change in the 
diameter of its globular repeat units.94  
It has also been previously demonstrated that the structural conformation of the isolated 
VWF-A1 domain changes when it binds to collagen.132 The presence of O-linked 
glycans might influence this change in conformation; for example their absence could 
provide more flexibility to VWF A domains structure so that they are more prone to 
unfolding. The isolated A1 domain is able to interact with collagen and bind platelets 
but in the presence of other domains, the interaction of VWF-A3 domain with collagen 
is essential to mediate platelet attachment.134 It has been shown that the binding of VWF 
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to collagen via the A3 domain induces a conformational change in VWF, exposing its 
cryptic A1 collagen binding site.134 I hypothesise that when VWF is bound to collagen, 
O-linked glycans influence the ability of the A1 domain to interact with the A2 and A3 
domains and to participate in the shielding effect of D’D3 domains on the A1 domain. 
Moreover the absence of O-linked glycans could result in destabilisation of the 
A1A2A3 tridomain complex. This destabilisation can augment the effect that collagen 
binding via the A3 domains has on the exposure of A1 domain and its GPIbα binding 
site under shear stress 
Importantly, platelet adhesion to collagen under high shear stress depends on the 
presence of both soluble and collagen bound VWF, whereas in the experiments where 
VWF is immobilised directly onto the slides surface no soluble VWF is present. It has 
been previously demonstrated that under shear stress the additional inter-molecular 
interaction between VWF domains of both soluble and collagen bound VWF facilitate 
formation of a VWF network, which anchors circulating platelets.95,164,362 It can be 
hypothesised that the removal of O-linked glycans could enhance this VWF self-
association under shear stress, resulting in increased platelet capture. 
It has been shown that under static conditions ristocetin mediated VWF self-aggregation 
can also take place.531 It has been suggested that ristocetin induces large conformational 
changes that disrupt the multiple domain interactions that occur within globular VWF. 
Ristocetin binding to VWF possibly alters domain interactions within a VWF monomer, 
thereby allowing inter-domain interactions between different VWF molecules that 
contribute to the formation of aggregates. Since I have observed increased ristocetin 
dependent platelet capture for the T1255A- Cluster 1 and DC cluster in my static GPIbα 
binding assay it could be tentatively suggested that the absence of O-linked glycans 
might increase the efficiency of ristocetin mediated VWF self-aggregation which could 
result in increased GPIbα binding. This hypothesis is however unlikely as the 
concentration of ristocetin used in the previously published study was three times higher 
than the highest concentration I have used in the static assay   
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In summary, I have demonstrated that the T1255A, Cluster 1 and double cluster variants 
have a distorted ability to interact with platelets in the presence of hydrodynamic shear 
stress. Importantly however, the effect of the glycans on GPIbα binding depends on the 
manner in which VWF is immobilised. Previous studies investigating the interaction of 
platelets with VWF under flow conditions have demonstrated that the initial, and 
crucial, tethering and translocation of platelets is mediated by the GPIbα receptor 
interaction with the A1 domain, whereas firm adhesion requires binding by integrin 
αIIbβ3 of activated platelets.245 In view of the presented data it is clear that GPIbα 
binding to VWF is a complex event and distinct structural characteristic can control the 
ability to establish stable bonds or to initiate platelets tethering.  The results presented in 
this chapter emphasise the importance of immobilisation method on receptor-ligand 
interaction under shear flow. Moreover, it is the first time the role and kinetic effects of 
O-linked glycans on platelet binding under shear stress has been studied and my results 
could be important in understanding the fundamental mechanism of platelets tethering 
and rolling.  
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9 CONCLUSION AND FUTURE DIRECTIONS  
Glycosylation is a co- and post-translational modification that involves the covalent 
attachment of carbohydrate structures to the protein backbone and has been shown to be 
crucial for the expression and functioning of many eukaryotic proteins. The two major 
types of glycans produced by eukaryotic cells are N- and O-linked glycans. While the 
former has been extensively studied, fewer data exist regarding the function of O-linked 
glycosylation. Mucin type O-linked glycosylation is well known to support the structure 
and function of mucin proteins on endothelial cell surfaces, by assisting in tissue 
hydration, protecting cells against stress and pathogen infection and altering 
accessibility of the peptide backbone to proteases therefore protecting it from 
degradation.1-3 O-linked glycans have been shown to mediate specific functions such as 
regulating the serum half-life of chemokines and hormones and also to mediate 
intracellular trafficking of proteins as well as signalling and interaction with     
receptors.4-10 However O-linked oligosaccharides can also have a general nonspecific 
effect on the properties of proteins.  O-glycans are suggested to influence the secondary, 
tertiary, and quaternary structure of the folded protein by introducing steric hindrance, 
and causing the polypeptide to which they are attached to adopt a rigid, extended 
conformation.11-18 For example, it has been shown that ovine submaxillary mucine 
(OSM) has an elongated filamentous conformation, however following removal of       
O-glycans it assumes a globular conformation.19 There are not many examples of 
studies on proteins with isolated mucin type glycans. It has been shown that a single O-
linked glycan on human granulocyte colony stimulating factor contributes to stability of 
the glycoprotein by suppressing polymerisation and conformational change of the 
protein, allowing it to keep its biological activity.20 Clusters of O-linked glycans are 
located in the hinge regions of immunoglobulins IgD and IgA, where up to 6 O-linked 
glycans chains can be present.21-23   O-linked glycans in these hinge regions have been 
shown to mediate binding of  IgA and IgD to a lectin binding site on T-lymphocytes in 
vitro.22,24Abnormalities in IgA O-glycosylation have been implicated in diseases such as 
Sjogren’s syndrome and IgA nephropathy (IgAN).25-27 In IgAN, patients have  
abnormalities in glycan biosynthesis which can results in the exposure of GalNAc 
residues22,28-30 Aberrantly glycosylated IgA molecules have a tendency to self aggregate 
as the exposed GalNAc residues are recognised by anti-IgG or IgA antibodies, leading 
to the formation of large circulating immune complexes that deposit in the kidney and 
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activate Complement.31-33 In addition, IgA molecules lacking terminal Gal residues 
have increased affinity for the extracellular matrix components fibronectin and collagen 
type IV, as shown by studies in vitro.34,35  
VWF is a large multimeric plasma glycoprotein that plays a crucial role in haemostasis 
by mediating platelet capture to thrombogenic surfaces under conditions of high shear 
stress.36 A considerable proportion (18.7%) of the molecular mass of VWF is comprised 
of N- and O- linked oligosaccharides.37 Based on previous studies, VWF contains 16 N-
linked and 10 O-linked glycosylation sites.37 VWF N-glycans have been studied 
extensively and their roles in VWF dimerisation, intracellular processing and storage as 
well as susceptibility to ADAMTS13 proteolysis have been well established38-42 In 
contrast, prior to this study, only limited data were available on the function of VWF O-
linked glycans. 
Currently there are very few approaches available to study the role of O-linked glycans. 
Firstly, one might compare the properties of the native glycoprotein to the 
enzymatically deglycosylated counterpart. In the case of N-linked glycans this is 
possible by the use of PNGase-F which removes whole N-linked glycan chains from the 
peptide or protein. Unfortunately there is not an equivalent enzyme that allows the 
removal of entire O-linked glycan chains. Instead, monosaccharides have to be removed 
by a series of exoglycosidases until only the Galβ(1-3)GalNAc core remains attached to 
the serine or threonine residues. In the case of VWF, the glycans initially would have to 
be desialyated which would also mean removal of terminal sialic acid residues from the 
N-linked glycans, and therefore could confound any functional results. Subsequently the 
enzyme O-glycanase (endo-α-N-acetylgalactosaminidase) could be used to remove the 
core 1 structures with no modification of the serine or threonine residues. However, O-
glycanase cannot recognise core 2 structures and since VWF contains core 2 structures 
this approach could not be used. 
Alternatively, VWF could be expressed in the  ldlD-CHO cell line, which cannot 
incorporate either Gal or GalNAc into carbohydrate chains when provided with medium 
lacking this sugars.43 This cell line was however not available for this study and 
furthermore the entire proteome of these cells would lack O-linked glycans with 
unpredictable secondary effects. 
 254 
As mentioned above VWF contains 10 O-glycosylation sites, eight of which are 
clustered around the A1 domain, therefore it has been suggested they might be part of 
mechanisms regulating the exposure of the GPIbα binding site.44 To date, the published 
data regarding the role of O-glycans in platelet binding is partial and often 
contradictory. VWF devoid of O-linked glycans demonstrated decreased ristocetin 
mediated platelet binding and normal binding potential in the presence of botrocetin.45 
On the other hand, the A1 domain lacking glycans at the N-terminal side exhibited 
increased platelet aggregatory potential in the presence of ristocetin.46 Previous studies 
have demonstrated that VWF expressed in ldlD-CHO cells lacking O-linked glycans 
was secreted normally and had unaltered multimeric structure and heparin and collagen 
binding. 
In an attempt to further characterise the function of VWF O-glycans, individual and 
multiple mutations (threonine/serine into alanine) were made to O-linked glycan sites to 
prevent addition of oligosaccharides. The variants consisted of ten single point 
mutations (T1248A, T1248A, T1255A, S1263A, T1468A, T1477A, S1486A, T1679A 
and T1679A and T2298A) and three types of cluster variants created by mutating all of 
the 4 sites either side of the A1 domain (cluster 1 and cluster 2) or all 8 sites around the 
A1 domain (double cluster). Mutated proteins were then expressed in HEK293T cells 
and characterised. Firstly, in keeping with a preceding study, I have demonstrated that 
absence of O-linked glycans does not influence VWF expression or secretion.45 
Furthermore all the variants had normal multimeric composition and an ability to bind 
collagens type I and III similar to that of recombinant wild type protein. The absence of 
O-linked glycans did not influence the binding between VWF and heparin or isolated 
bacterial A2 domain.  
9.1 Susceptibility to ADAMTS13 proteolysis 
Next, I have analysed the susceptibility of VWF variants to ADAMTS13 proteolysis 
and binding. Firstly, I have shown than the S1486A, Cluster 2 and double cluster 
variants were proteolysed slower than wtVWF both in the presence of urea and under 
the pseudo-shear stress generated using a bench top vortex mixer.47 Based on the fact 
that O-linked glycans are known to provide rigidity to peptide backbones11-15 I 
hypothesised that removal of O-glycans from the linker region between the A1 and the 
A2 domain may increase its flexibility. Change in the flexibility of the linker region 
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could alter any potential interactions between the A1 and the A2 domains, consequently 
altering the accessibility of the ADAMTS13 cleavage site. Furthermore, I also 
hypothesised that the O-glycans may participate in stabilising the extended 
conformation of VWF, allowing efficient exposure of the ADAMTS13 cleavage site. 
Interestingly, the VWF S1486A, Clus2 and DC variants immobilised on a microtitre 
plate (therefore in at least a partially elongated confirmation) bound ADAMTS13 with 
similar affinity to wtVWF. Intriguingly, the mutations that resulted in decreased 
susceptibility to ADAMTS13 proteolysis, enhanced binding of VWF to ADAMTS13 in 
solution. I suggested that a change in the local conformation of the VWF A1A2A3 
domains, due to removal of glycans, may have a downstream effect and alter the 
exposure of other domains and the binding sites they encompass. To further confirm 
this effect, and determine kinetic parameters of the interaction, binding will be 
investigated in further detail using surface plasmon resonance analysis. Ultimately, to 
confirm the effect of O-linked glycans on VWF proteolysis by ADAMTS13 it will be 
necessary to adapt the flow assays to analyse ADAMTS13 cleavage under conditions of 
physiological shear stress. Blood outgrowth endothelial cells (BOECs) isolated from a 
dog with VWD type 3 will be used to create an EC model of VWF expression. BOECs 
will be seeded onto flow slides and transfected with VWF variants; provided they can 
form WPBs the cell will be stimulated with histamine. ADAMTS13 cleavage of UL-
VWF released from WPBs will be analysed under high shear stress.  
9.2 VWF interaction with platelet GPIbα – the role of O-linked 
glycans  
Platelet adhesion at sites of vascular injury contributes to the arrest of bleeding, and at 
high shear stress this interaction is dependent on the interaction between VWF and the 
platelet receptor GPIbα. A major aim of this project was to establish the influence of O-
linked glycans on the VWF-GPIbα interaction. To facilitate this I developed a plate 
based ELISA method to analyse the interaction of VWF with a recombinant fragment of 
GPIbα in the presence of ristocetin and optimised an in vitro flow assay to study 
platelet-VWF interactions under conditions of flow. 
The data presented in this thesis extends previous observations which demonstrated that 
the O-linked glycans attached to residues T1248 and T1256 negatively modulated the 
ristocetin dependent platelet binding to COS-7 cell anchored A1 domains in the 
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presence of ristocetin.46  Firstly I have shown that the T1255A, Cluster 1 and DC 
variants have significantly increased sensitivity to ristocetin mediated GPIbα binding 
and platelet agglutination. The effect was evidenced both as a higher overall binding to 
GPIbα, and binding to GPIbα at a lower concentration than required by wtVWF.  
In vivo, platelets bind to VWF under conditions of physiological blood flow, thus the 
plate binding assay is limited by the requirement for ristocetin and the absence of shear 
stress. To explore and define the mechanics and kinetics of the VWF-GPIbα interaction 
and investigate the influence of O-linked glycans on this interaction under shear stress, 
which closely mimics conditions in the blood flow, I have optimised and employed an 
in vitro flow based assay system. Images of fluorescently labelled platelet motion over 
surfaces coated with a D’A3-VWF fragment or collagen coated with FL-VWF were 
visualised under a microscope equipped with a camera and recorded during flow 
experiments at a range of fluid shear rates (400-2000s-1). Firstly I measured the number 
of platelets interacting with saturated surfaces and platelet rolling velocities on wtD’A3 
and D’A3 glycosylation variants. I have demonstrated that platelets bound transiently to 
both wtD’A3 and glycosylation variants in a generally similar, shear dependent manner. 
Moreover platelet rolling velocities on all proteins tested followed a biphasic curve, as 
the platelets rolling velocity firstly decreased with increasing shear and then after a 
certain point started to increase with increasing shear rate, indicating catch and slip 
transition. Interestingly, when compared to wtVWF the T1255A-, Cluster 1- and DC-
D’A3 supported faster platelet rolling at the shear rates between 400 and 2000s-1. 
Subsequently I have analysed the kinetics of GPIbα-VWF bond formation. It has been 
observed that the rate of transient platelet tethering is notably decreased on immobilised 
T1255A-, Clus 1- and DC-D’A3 variants. Interestingly the dissociation rate is the same 
for bonds formed between GPIbα and wild type as well as mutated D’A3.  
These results imply that faster platelet translocation on glycosylation variants is not due 
to shortening in the lifetime of the GPIbα-A1 bond, but is related to the reduced ability 
of the VWF variants to support platelet tethering. The exact nature of this change has 
not yet been elucidated, however based on the obtained results I hypothesise that 
removal of O-linked glycans from the N-terminal O-linked glycan cluster results in 
reduced accessibility of the GPIbα binding site when VWF is immobilised directly onto 
the flow slide and exposed to shear stress. Furthermore since a proportion of GPIbα 
binding sites is inaccessible the distance between potential binding sites is increased. As 
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a result platelets translocate on the slide surface irregularly and jump rather than roll, 
therefore they move further in a given time. 
In all these experiments VWF was captured directly onto the flow slides: even though it 
is a standard approach used in flow studies and allows us to study kinetic parameters of 
the GPIbα-A1 interaction, it may not be a true reflection of the platelet-VWF interaction 
in vivo where platelets bind to VWF that is captured to collagen surfaces under flow. 
For that reason I have also investigated platelet capture to slides coated with collagen in 
the presence of FL-VWF under high shear stress. Surprisingly I have shown that platelet 
capture to collagen was higher in the presence of T1255A- and Cluster 1 VWF than 
wtVWF. The increase platelet capture would not be correlated directly to the multimeric 
size as all glycosylation variants have identical multimer distribution to the wild type 
protein. Moreover they exhibit similar affinity for collagen under static conditions. The 
difference in binding could be related to the altered ability of VWF variants to bind to 
collagen under flow. It has been proposed that the VWF-A1 domain contains a cryptic 
collagen binding site which aids the capture of VWF to collagen under high shear 
stress.48 The O-linked glycan variants could potentially cause greater exposure of this 
site or may enhance its function under flow conditions. Further work will be needed to 
develop an assay to directly determine VWF-collagen binding function under shear 
stress that can then be used to determine if VWF O-linked glycans alter collagen 
binding under flow conditions. Alternatively, I hypothesise that increased platelet 
capture in the presence of T1255A and Cluster 1 variants could be attributable to the 
influence of O-linked glycans on VWF self-assembly under high shear stress on 
collagen surface. It has been previously demonstrated that that upon application of high 
shear forces VWF multimers and self-assemble to form “spider web” like structures 
which facilitates capture of flowing platelets.49-51  Moreover, as recently shown, the 
formation of macro-aggregates (VWF self-assembly) may also be induced by VWF 
binding of ristocetin. In order to further examine this hypothesis additional studies are 
going to be devised. The amount of VWF bound to collagen as well as its multimeric 
structure will have to be compared. Studies under static conditions correlate well with 
studies where platelet capture by VWF variants immobilised on collagen was 
investigated under high shear stress.  Conversely these studies provide different results 
than the studies under shear flow where platelet interactions with D’A3-VWF 
immobilised directly on the slide surface were studied. This observation must be 
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examined with respect to the various differences between the flow assays such as the 
size and multimerisation of the VWF constructs used and the method of VWF 
immobilisation, as well as the presence of soluble VWF. In the assays where VWF was 
immobilised directly onto a slide surface a fragment of VWF encompassing the D’-A3 
domains was used while the experiment using collagen coated slides involved the full 
length multimeric VWF. Domains after the A3 domain might influence the accessibility 
of the GPIbα binding site, for instance it has been previously shown that a peptide 
directed against the region between A3 and D4 domains inhibited VWF binding to 
collagen type I.52 In addition, the length of VWF molecule might affect its 
conformational stability and unfolding under shear stress. Moreover, the extent of 
conformational changes caused by VWF immobilisation directly on the slide surface or 
caused by VWF binding to collagen has not been fully clarified. Importantly, in the 
assays involving collagen coated slides, the soluble VWF has the potential to bind to 
collagen and to also self-associate. In the future platelet capture to collagen will be 
analysed at other shear rates and also platelet capture under flow with VWF 
immobilised on the slide and present in solution will be investigated to determine if 
VWF O-linked glycans affect self-association in the absence of collagen. 
Considering the number of possible differences between the two flow assays, i.e. 
collagen coated slides or VWF coated slides, it is not surprising that the effects of O-
linked glycans on VWF-platelet interactions differ. Importantly both assays provide 
unique information and parameters regarding the mechanism of the VWF-GPIbα 
interaction. Both assays complement each other, and the results highlight the need for 
varied approaches when studying the effects and mechanism of VWD mutations. 
Significantly the results presented in this thesis emphasise the importance of using 
VWF expressed in mammalian cells. Most of the previous studies on VWF-platelet 
interactions have been limited to experiments using isolated bacterial A1 domain. This 
study clearly indicates that the O-glycosylation status of VWF strongly influences 
properties of VWF and its interaction with various ligands. In future studies, especially 
when designing pro- or anti-thrombotic therapies it will be important to consider the 
influence of VWF glycans on its function. For example, several companies are 
producing recombinant VWF and it will be crucial to determine that the glycan chains 
present on these molecules do not drastically alter VWF function. The GPIbα plate 
binding assay correlates well with the current laboratory assay used in the diagnosis of 
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VWD; the VWF:RCo, nevertheless, both assays are dependent on the presence of 
ristocetin and not laminar flow, which is not a physiological situation, even though it 
has been previously suggested that interaction with ristocetin closely mimics changes 
induced by flow.53 Aggregation in the VWF:RCo is evaluated with platelets in 
suspension and the absence of interactions with immobilised substrates, as such the 
assay does not provide an accurate assessment on in vivo function. Alternatively, a cone 
and plate viscometer can be used to generate shear stress to measure VWF mediated 
platelet aggregation, however the fluid dynamic parameters are poorly defined and 
again may not truly reflect in vivo shear stress. 
In contrast, in flow assays, platelet adhesion and aggregation involve the transition from 
free flow to arrest on a surface. The other disadvantage is the fact that the VWF:RCo 
assay has a high coefficient of variation and may display abnormal results due to 
polymorphism or mutations in the VWF ristocetin binding regions.54,55 In this study the 
removal of the glycan from the threonine localised in the ristocetin binding site 
(T1468A) resulted in the diminished GPIbα binding in the static assay and platelet 
aggregation, however the mutated protein was able to support platelet binding under 
shear stress, in the absence of ristoecetin. Based on the results from the flow assay I 
attributed decreased GPIbα binding by the T1468A mutants in the static assay to an 
abnormal interaction with ristocetin rather than GPIbα. Interestingly, a plate based 
GPIbα binding assay has been recently described where a novel gain of function GPIbα 
mutant was used to eliminate the need for ristocetin.  As part of my future work I plan 
to generate this mutant and use it to analyse binding of the VWF O-linked glycans 
variants. 
9.3 VWF O-linked glycans as stabilisers of linker regions  
Overall, based on the results presented in this thesis it can be hypothesised that the 
interaction between VWF domains is stabilised and modulated by the presence of the O-
linked glycans. Removal of all or specific O-glycan chains from the linker regions can 
destabilise the A1A2A3 tri-domain structure and result in a reduced interaction between 
the three domains. In addition the absence of O-linked glycans could alter the shielding 
of the A1 domain by the D’D3 domains56 or even more distal domains.  The altered 
interface between the A1A2A3 domains induces changes in their interaction with 
ligands such as GPIbα and ADAMTS13. It appears that the glycans clustered at the C-
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terminal side of the A1 domain influence VWF interaction with ADAMTS13, whilst O-
glycans clustered at the N-terminal side of the A1 domain strongly control its 
interaction with platelet receptor GPIbα. The O-linked glycans might mediate this effect 
by number of mechanisms. It is known that due to steric hindrance introduced by the O-
glycans, glycosylated protein backbones adopt a stiff extended conformation.11-15 I 
propose that VWF O-glycans provide rigidity to the proline rich and flexible linker 
regions and thereby influence the position of the VWF domains towards each other and 
as a result the accessibility of various binding sites. As discussed, I hypothesise that O-
glycans in the A1-A2 linker region stabilise the interaction of those domains as well as 
allowing VWF to more readily adopt an extended conformation when unfolding, 
therefore reducing residual interactions which could hinder its interaction with 
ADAMTS13. It has been previously demonstrated that isolated bacterial A2 domain 
interacts with the A1 domain and it may block the VWF-GPIbα interaction in the native 
protein.57 Moreover, it has been demonstrated that binding of FVIII and platelets to 
VWF accelerates proteolytic cleavage of VWF by ADAMTS13 under mechanically 
induced fluid shear stress.58-60 The interplay between platelet binding and ADAMTS13 
cleavage may play a role in regulating plasma multimer distribution under flow 
conditions and glycans might be a part of this mechanism. Recent data using  small 
angle neutron scattering (SANS) spectroscopy to study VWF dynamics in response to 
shear flow, suggests that fluid shear forces may be able to maintain structural alterations 
at the domain level of VWF in solution which may then augment the A1 domain 
binding function and the A2 domain proteolysis rate.61  Based on results presented in 
this thesis I propose that O-linked glycans are an important part of that mechanism.  
It has been previously shown that the D’D3 domains shield the GPIb binding site in the 
A1 domain.56 It has been also demonstrated that the GPIbα binding site remains cryptic 
in  a fragment of VWF starting at 1238; thus including only part of the D3 domain.62,63 
Moreover the N-terminal flanking regions of the A1 domain (1260-1271) and the C-
terminal region of the D3 domain (1204-1259) shield the GPIbα binding site, while the 
peptides derived from these regions inhibited ristocetin-induced binding of purified 
VWF to platelets.44 In addition it was demonstrated that the shorter the D3-A1 linker 
region the greater the ability of VWF to bind platelet in the presence of ristocetin.64 
From those studies it appears that the A1 domain N-terminal flanking region is an 
important determinant of the availability of the A1 domain for GPIbα. Based on the 
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obtained results, I postulate that the O-linked glycans clustered in the D3-A1 linker 
region are crucial modifiers of the linker region function as they can determine its 
rigidity and as result accessibility of the A1 domain.   
Interestingly the local changes may have an allosteric effect; rearrangement of the 
VWF-A domains complex can propagate to the other end of the protein influencing, for 
instance, ADAMTS13 binding or more complex aspect of VWF function such as self 
association. To my knowledge the data presented in this thesis is one of very few 
studies that demonstrate that linker regions between domains of glycoproteins can be 
stabilised by only a small number of O-linked oligosaccharide chains, and the flexibility 
of linker regions has a significant influence on the function of the entire protein.  
9.4 Structure of VWF O-linked glycans 
Prior to the start of this project the only structural study suggested that O-glycome is 
heterogeneous but only a single major structure desialylated core 1 was identified.65 A 
detailed analysis of the plasma derived VWF O-glycom has been published to facilitate 
characterisation of VWF O-linked glycans function.66 Since in this project recombinant 
VWF was used it was necessary to compare its O-glycome to that of plasma VWF. In 
collaboration with Dr. K.Canis, by performing mass spectrometry analysis on purified 
recombinant VWF I have demonstrated that plasma derived and recombinant VWF 
present  similar O-glycan structures, with both core 1 and core 2 structures present. The 
desialylated core 1 was shown to be the major moiety and also tri-sialylated core 1 
glycans were detected. In contrast to pdVWF no tetrasialylated core 1 or ABH antigen-
containing core 2 glycans were detected. Identification of the disialosyl motif (two sialic 
acid residues linked together) is particularly interesting as it requires a particular sialyl-
transferase activity usually known to synthesise polysialic acid structures. The fact that 
HEK293T cells produce this unusual moiety on VWF O-glycans implies a direct 
importance for VWF structure and function. The disialosyl motif is recognised by 
SIGLEC 7 (sialic acid binding Immunoglobulin-like lectin 7) which is expressed in 
abundance on natural killer (NK) cells.67 I therefore propose that that VWF O-glycans 
might be able to interact with SIGLECs which are a family of sialic acid-binding 
receptors, expressed on the cells of hematopoietic origin.68 Indeed recently an abstract 
was published on a study which identified one murine and six human SIGLEC-family 
members (including SIGLEC7) as novel partners for pdVWF.69 Moreover the VWF-
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SIGLEC interaction was shown to be mediated by sialic acid residues present on VWF 
glycans. In addition, the majority of identified structures terminated in sialic acid 
residues which confer a negative charge and therefore might be an important element of 
O-glycans’ influence on the rigidity of the A1 domain flanking regions as discussed 
above. Current data clearly demonstrates that N-glycans modulate the interaction 
between VWF and ADAMTS13. The ABO antigens influence VWF susceptibility to 
ADAMTS13 proteolysis.70 It was recently shown that a very small proportion of         
O-linked glycans also present ABH antigens they also might participate in mediating 
this a effect.  
It is fascinating that individual glycan chains at specific sites have an impact on VWF 
function comparable to the removal of entire clusters. The differences in binding 
observed for the single glycosylation variants T1255A and S1486A are similar to that 
obtained with the respective cluster variants, which could suggest that the observed 
effects result from loss of single O-linked carbohydrate attachment sites rather that a 
cumulative response to the loss of several O-glycans. It has been previously suggested 
that the glycosylation of different sites takes place in a specific order and can be 
influenced by steric hindrance of neighbouring glycosylation sites.71,72 However, to date 
we have not been able to ascertain whether mutation of a given O-linked glycosylation 
site of VWF affects glycosylation of nearby residues. It would have been useful to 
characterise the composition of O-linked oligosaccharides at specific sites. Regrettably, 
due to proximity of the O-glycosylation sites within the clusters it will not be possible to 
determine occupancy of individual sites, however we will attempt to characterise 
separately the two clusters. In order to perform the structural analysis of glycans clusters 
peptides carrying O-linked glycans have to be isolated, which is technically difficult. To 
aid this process I am currently performing studies with the Click-iT™ O-GalNAc 
enzymatic labelling system (Invitrogen). Briefly O-linked glycan containing proteins 
expressed in HEK293T cells are metabolically labelled by incorporating an azide 
modified sugar in to the glycan structure on the newly synthesised proteins. This is 
performed by incubating cultured VWF cDNA transfected cells with modified GalNac 
sugar–GalNAz. Recombinant VWF is then purified using both ion-exchange and 
heparin-Sepharose chromatography. VWF containing the modified sugar is then 
detected using the Click-iT detection kit where the GalNAz sugar is tagged with 
biotinylated alkyne. Next VWF is digested with trypsin and O-linked glycans 
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containing peptides purified using Streptavidin affinity chromatography. Isolated 
glycopeptides will be then analysed by mass spectrometry. 
9.5 Sialic acid and VWF function 
Another aspect of VWF O- and N-glycans is the presence of terminal sialic acid 
residues. Sialylation was shown to protect VWF from ADAMTS13 proteolysis but it 
was demonstrated that this effect is mediated primarily by sialic acid presented on the 
N-linked glycans.73 Desialylated VWF was previously shown to support enhanced 
platelet adhesion in flow assays which was confirmed in this study.74,75 I have also 
demonstrated that desialylation  (treatment with neuraminidase) of VWF increased its 
sensitivity to ristocetin mediated GPIbα binding and I have attributed this effect to 
absence of terminal sialic acid residues from the O-linked glycans. Moreover it is 
reasonable to suggest that negatively charged sialic acid residues participate in the effect 
of O-linked glycans clustered in the A1-A2 linker region on VWF’s interaction with 
ADAMTS13. In addition, I have demonstrated that the neuraminidase treated (Neu)-
D’A3-VWF supports increased platelet attachment and slower platelet rolling up to a 
shear rate of   1000s-1. Conversely it does not alter the GPIbα-A1 bond dissociation rate 
or probability of transient tethering events taking place. The mechanism of increased 
binding exhibited by Neu-D’A3 has not been fully elucidated, however as discussed in 
the previous chapter I propose that removal of sialic acid residues increases the 
electrostatic interaction between VWF and GPIbα for the platelets that are already 
tethered to the D’A3 coated surface, as a result more primary transient tethering events 
are transformed into rolling events.  
9.6 Role of VWF O-linked glycans in vivo  
Additional studies are ongoing to further specify the physiological implications of VWF 
O-linked glycans. The relationship between VWF proteolysis and clearance has not yet 
been fully established. Animal models used to investigate the clearance of VWF have 
returned conflicting results.76-80 It has been previously suggested that VWF levels are 
associated with variations in the presence of the sialylated T-antigen.81 Moreover we 
have detected that  a small proportion of plasma VWF O-linked glycans carry ABO 
blood group antigens66 which is interesting because the ABO-carbohydrate structures 
are implicated in regulating VWF plasma levels and clearance.82-84 In the view of this 
data is seems feasible that O-linked glycans might influence VWF clearance. In 
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collaboration with Dr James O’Donnell (Trinity College, Dublin) I am performing 
studies to determine the effect of the O-linked variants on VWF clearance using the 
VWF-/- murine model. In addition the VWF-/- mouse will also be used to investigate the 
role of O-linked glycans on VWF function in vivo. The murine and human VWF 
sequences differ to some extent (86% identity); moreover one putative glycosylation 
site is different in murine VWF as it contains a serine residue in position 1262 instead 
of position 1263 which is glycosylated in humans. Importantly human VWF has 
impaired capacity to support murine platelet adhesion and murine VWF-A1 supports 
limited binding of human platelets.85 Thus in order to study VWF function in the murine 
model I have created murine VWF O-linked glycosylation variants. In collaboration 
with Prof K Vanhoorelbeke, (KU Leuven, Belgium) the vector pcDNA6-VWF was 
injected hydrodynamically into the murine tail vein for in vivo expression of murine 
VWF. In these preliminary experiments a reduced platelet count was observed 
following expression of the T1262A variant and a slight increase in bleeding time was 
observed with the T1255A variant(Figure 9.1).  However, expression levels of all the 
injected variants were quite low To increase VWF levels the experiments are going to 
be repeated using the vector pBS-HCRHPi-MCS with liver-specific expression cassette, 
which allows for high level hepatic gene expression.86 As before, platelets and VWF 
levels as well as bleeding time will be measured for mice with wtVWF and VWF 
glycosylation variants and thrombus formation will be investigated. 
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Figure 9.1 Platelet numbers and bleeding time after VWF gene transfer in VWF 
deficient mice 
Hydrodynamic gene transfer was performed as described previously in VWF deficient 
mice strain.86,87 (A) Mice were bled 48 hours after gen transfers in order to evaluate 
VWF expression, and platelet count. Reduced platelet count was observed for mice with 
T1262A-VWF variant present. (B) Function of mutated VWF was assessed by 
measuring a tail clipping bleeding time. Increased bleeding tine was detected for the 
T1262A-VWF variant when compared with wtVWF, however since the VWF levels 
were very low the bleeding time is not very informative. (All experiments were 
performed in accordance with protocols by the Institutional Animal Care and Use 
Committee of the K.U. Leuven, Belgium).   
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I have made several observations that highlight the role of O-linked glycans in 
mediating VWF function and have also raised a number of questions that require further 
investigation. Several experiments are already in progress that will enable me to obtain 
even further insight into the mechanism by which VWF function is modulated by its O-
linked glycans. 
In conclusion the work presented in this thesis clearly demonstrates important roles for 
VWF O-linked glycans in mediating different aspects of VWF function. While the O-
linked glycans chains presented on VWF do not affect the expression, secretion, 
multimerisation or collagen and heparin binding functions of VWF, they have profound 
effects on the susceptibility of VWF to ADAMTS13 cleavage and the interaction of 
VWF with platelets. These effects appear to, certainly in part, be attributed to the O-
linked glycans stabilising the conformation of the VWF molecule, particularly the linker 
regions either side of the A1 domain. These data not only demonstrate a critical role for 
O-linked glycans in mediating VWF function but also confirm the importance of O-
linked glycosylation as a major determinant of protein structure and function.  
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APPENDICES 
APPENDIX A - Buffers and solutions 
10 X DNA loading buffer 
0.125% (w/v) xilene cyanol, 0.125% (w/v) bromophenol blue, 0.625% SDS (w/v), 20% 
(v/v) glycerol 
10 X TBE buffer 
0.89 M Tris-borate (pH 8.3), 20 mM EDTA. Prior to use, this was diluted to 1 x TBE 
buffer with purified water 
TE buffer 
10 mM Tris (pH 8.0), 1 mM EDTA 
SDS-PAGE Electrophoresis buffer 
25 mM Tris-HCl (pH 8.3) 192 mM glycine and 0.1% (w/v) SDS 
2 x Protein Loading buffer 
150 mM Tris-HCl (pH 6.8), 20% (v/v) glycerol, 4% (w/v) SDS, 0.125% (w/v) 
bromophenol blue 
Transfer buffer 
25 mM Tris-HCl (pH 8.3), 192 mM glycine, 20% (v/v) methanol 
PBS buffer 
Dissolve 5 PBS tablets (Sigma) to 1 litre of distilled H2O 
LB (Luria-Bertani) broth 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCl 
LB agar 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCl, 1.5% bacto-
agar 
(The components of each medium are dissolved in ultra-pure water and autoclaved) 
 
 
 
 298 
APPENDIX B – Oligonucleotide primers 
Primer Sequnce (5’-3’) 
T1248A fwd GGTGGTGCCTCCCGCAGATGCCCCGGTG 
T1248A rev CACCGGGGCATCTGCGGGAGGCACCACC 
T1255A fwd CCGGGTGAGCCCCGCCACTCTGTATGTGGAGGACATC 
T1255A rev GATGTCCTCCACATCAAGAGTGGCGGGGCTCACCCGG 
T1256A fwd GTGAGCCCCGCCGCTCTGTATGTGG 
T1256A rev CCACATACAGAGCGGCGGGGCTCAC 
S12623A fwd GTATGTGGAGGACATCGCGGAACCGCCGTTGC 
S1263A rev GCAACGGCGGTTCCGCGATGTCCTCCACATAC 
T1468A fwd GCCCCTCCTCCTGCTCTGCCCCCC 
T1468A rev GGGGGGGCAGAGCAGGAGGAGGGG 
T1477A fwd CATGGCACAAGTCGCTGTGGGCCCGG 
T1477A rev CCGGGCCCTCAGCGACTAGTGCCATG 
S1486A fwd CTCTTGGGGGTTGCGACCCTGGGG 
S1486A rev GCCCCAGGCTCGCAACCCCCAAGA 
T1487A fwd CTTGGGGGTTTCGGCCCTGGGGCCCAAG 
T1487A rev CTTGGGCCCCAGGGCCGAAACCCCCAAG 
C3 fwd CCCGGTGAGCCCCGCCACTCTGTATGTG 
C3 rev CACATACAGAGTGGCGGGGCTCACCGGG 
C4 fed GGTGAGCCCCGCCGCTCTGTATGTGGAG 
C4 rev CTCCACATACAGAGCGGCGGGGCTCACC 
C6 fwd CATGGCACAAGTCGCTGTGGGCCCG 
C6 rev CCGGGCCCACAGCGACTTGTGCCATG 
C7 fwd CTCTTGGGGGTTGCGGCCCTGGGGC 
C7 rev GCCCCAGGGCCGCAACCCCCAAGAG 
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T1679A fed CTGCAGATCCCCGCCTCTCCCCAT 
T1679A rev ATGGGAGAGGGCGGGGATCTGCAG 
T2298A fed CAGCCCTGCCCCGCGGCCAAAGCTC 
T2298A rev GAGCTTTGGCCGCGGGGCAGGGCTG 
G1324S fwd GGAGTACCACGACAGCTCCCACGCCTAC 
G1324S rev GTAGGCGTGGGAGCTGTCGTGGTACTC 
GPIbá clone fwd ATAAGCTTGATATCGAATTCATGCCTCTCCTCCTCTTGCT 
GPIbá clone rev GTGGATCCCCCGGGCTGCAGACGCACCTTATCGCCCTCA 
GPIbá insert fwd CTGAGGGCGATAAGGTGCGTGAACAAAAACTCATCTCAG 
GPIbá insert rev GTGGATCCCCCGGGCTGCAGTCAATGGTGATGGTGATGAT 
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